{"209a97a430972fa5ec93be1ffbfe58d6690fe418": [["T A G G E D H 1 INTRODUCTIONT A G G E D E N DCoronavirus disease-2019 (COVID- 19) , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was discovered in late 2019.", [["COVID- 19", "CHEMICAL", 71, 80], ["acute respiratory syndrome coronavirus", "DISEASE", 101, 139], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 94, 141], ["SARS-CoV-2", "ORGANISM", 143, 153], ["N DCoronavirus disease-2019 (COVID- 19", "SPECIES", 42, 80], ["severe acute respiratory syndrome coronavirus", "SPECIES", 94, 139], ["SARS-CoV-2", "SPECIES", 143, 153], ["A G G E D H", "TEST", 2, 13], ["INTRODUCTIONT", "TEST", 16, 29], ["A G G E D E N DCoronavirus disease", "PROBLEM", 30, 64], ["COVID", "TEST", 71, 76], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 94, 139], ["SARS-CoV", "TEST", 143, 151], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory syndrome", "OBSERVATION", 107, 127]]], ["1 In January 2020, details about the disease were still unknown making public health decisions challenging.", [["the disease", "PROBLEM", 33, 44]]], ["By early March, the disease spread rapidly with the number of cases increasing by 1000-fold and the World Health Organization (WHO) declaring a pandemic on March 11, 2020.", [["the disease spread", "PROBLEM", 16, 34], ["disease", "OBSERVATION", 20, 27], ["spread", "OBSERVATION_MODIFIER", 28, 34], ["rapidly", "OBSERVATION_MODIFIER", 35, 42]]], ["[2] [3] [4] By April 20, there were 2.42 million confirmed cases and 166 235 deaths and by May 4, 2020 there were 3.58 million cumulative confirmed cases and 250 687 deaths due to COVID-19 globally.", [["deaths", "DISEASE", 77, 83], ["deaths", "DISEASE", 166, 172], ["COVID", "TEST", 180, 185]]], ["8 It was estimated that approximately 20% of COVID-19 cases were severe or critical 8 and that COVID-19 had a globally estimated average fatality rate of 3%; however, rates varied by country.", [["COVID", "TEST", 45, 50], ["COVID", "TEST", 95, 100]]], ["8 For example, on May 5, 2020 the observed case-fatality ratio for the United Kingdom was 15%, while for the Netherlands it was 12.6%, Brazil was 6.9%, and the United States (US) was 5.9%.", [["Brazil", "TEST", 135, 141]]], ["9 The rapid spread of COVID-19 has had tremendous impact but especially on healthcare resources and personnel around the world.", [["COVID-19", "CHEMICAL", 22, 30], ["COVID", "TEST", 22, 27], ["rapid", "OBSERVATION_MODIFIER", 6, 11], ["spread", "OBSERVATION_MODIFIER", 12, 18], ["tremendous", "OBSERVATION_MODIFIER", 39, 49], ["impact", "OBSERVATION_MODIFIER", 50, 56]]], ["8, 10, 11 During the early phase of the COVID-19 pandemic, health care providers faced difficult situations screening for this high-threat pathogen while caring for those who were infected and trying to mitigate spread of the virus.", [["this high-threat pathogen", "PROBLEM", 122, 147], ["the virus", "PROBLEM", 222, 231]]], ["Measures to control the novel disease created additional burdens on the health and social care systems.", [["the novel disease", "PROBLEM", 20, 37]]], ["8 Medical providers and first responders faced difficult life and death decisions in the midst of a severe supply shortage at the same time that they were putting their own lives at risk.", [["death", "DISEASE", 66, 71]]], ["To protect the health of the community, all people around the world were asked to join together in solidarity to fight COVID-19 using various measures.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["various measures", "TREATMENT", 134, 150]]], ["4, 8, 10, 12, 13 Along with other health professionals, chiropractic practitioners (ie, doctors of chiropractic (DC), chiropractors) faced unknown territory as they navigated health care in the context of unprecedented governmental restrictions and public health responses.T A G G E D H 1 INTRODUCTIONT A G G E D E N DChiropractic is a recognized and licensed health care profession in many world regions.", [["DC", "ANATOMY", 113, 115], ["T", "SPECIES", 273, 274], ["chiropractic (DC)", "TREATMENT", 99, 116], ["A G G E D H", "TREATMENT", 275, 286], ["A G G E D E N DChiropractic", "TREATMENT", 303, 330]]], ["14 Each country, state, or province has its own regulations for the chiropractic profession.", [["the chiropractic profession", "TREATMENT", 64, 91]]], ["However, depending on preceding historical and social factors, local regulations and scopes of practice vary.", [["local regulations", "TREATMENT", 63, 80]]], ["[15] [16] [17] As of 2017, the World Federation of Chiropractic (WFC) estimates that there are nearly 104 000 chiropractors in the world.", [["Chiropractic (WFC)", "TREATMENT", 51, 69]]], ["18 Patients typically have direct access to chiropractors and do not require a referral to receive chiropractic care.", [["Patients", "ORGANISM", 3, 11], ["Patients", "SPECIES", 3, 11], ["chiropractic care", "TREATMENT", 99, 116]]], ["Chiropractors often function as primary contact practitioners (ie, in some areas this is known as portal of entry) and work at the primary level in healthcare.", [["portal", "ANATOMY", 98, 104]]], ["16, 17, 19, 20 Chiropractors are part of the healthcare workforce and collaborate with other providers to deliver the safest and most effective care possible to their patients and the public.", [["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175]]], ["21, 22 One view of chiropractic is that it \"is one of the healing professions dedicated to conservative and natural methods of health care and recognizes the body's innate ability to heal.\" 22 Chiropractic primarily focuses on physiological and biomechanical aspects of health, including spinal, musculoskeletal, and neurological components, but also includes consideration of psychological, social, and environmental relationships, which is congruent with the biopsychosocial model of care.", [["body", "ANATOMY", 158, 162], ["spinal", "ANATOMY", 288, 294], ["neurological", "ANATOMY", 317, 329], ["spinal, musculoskeletal, and neurological components", "DISEASE", 288, 340], ["body", "ORGANISM_SUBDIVISION", 158, 162], ["spinal", "ANATOMICAL_SYSTEM", 288, 294], ["health care", "TREATMENT", 127, 138], ["spinal, musculoskeletal, and neurological components", "PROBLEM", 288, 340], ["spinal", "ANATOMY", 288, 294], ["musculoskeletal", "ANATOMY", 296, 311]]], ["[23] [24] [25] [26] It has been suggested that chiropractic care \"offers potential for cost\u00c0effective management of neuromusculoskeletal disorders.\" 16 Thus, chiropractors may contribute to reducing the global burden of back and neck pain.", [["neuromusculoskeletal", "ANATOMY", 116, 136], ["back", "ANATOMY", 220, 224], ["neck", "ANATOMY", 229, 233], ["neuromusculoskeletal disorders", "DISEASE", 116, 146], ["back and neck pain", "DISEASE", 220, 238], ["[23] [24] [25] [26]", "SIMPLE_CHEMICAL", 0, 19], ["back", "ORGANISM_SUBDIVISION", 220, 224], ["neck", "ORGANISM_SUBDIVISION", 229, 233], ["chiropractic care", "TREATMENT", 47, 64], ["cost\u00c0effective management", "TREATMENT", 87, 112], ["neuromusculoskeletal disorders", "PROBLEM", 116, 146], ["back and neck pain", "PROBLEM", 220, 238], ["global", "OBSERVATION_MODIFIER", 203, 209], ["burden", "OBSERVATION", 210, 216], ["back", "ANATOMY", 220, 224], ["neck", "ANATOMY", 229, 233]]], ["[25] [26] [27] [28] [29] According to the WHO Guidelines on Basic Training and Safety in Chiropractic, chiropractic \"is one of the most popularly used forms of manual therapy.\" 16 The chiropractic profession is known for high rates of patient satisfaction and a hands-on approach to care.", [["[25] [26] [27] [28", "SIMPLE_CHEMICAL", 0, 18], ["patient", "ORGANISM", 235, 242], ["patient", "SPECIES", 235, 242], ["Basic Training", "TREATMENT", 60, 74], ["manual therapy", "TREATMENT", 160, 174]]], ["20, [30] [31] [32] [33] [34] People seek out chiropractic care for a variety of reasons, but commonly for musculoskeletal concerns, such as back and neck pain.", [["back", "ANATOMY", 140, 144], ["neck", "ANATOMY", 149, 153], ["back and neck pain", "DISEASE", 140, 158], ["[30] [31] [32] [33", "SIMPLE_CHEMICAL", 4, 22], ["back", "ORGANISM_SUBDIVISION", 140, 144], ["neck", "ORGANISM_SUBDIVISION", 149, 153], ["chiropractic care", "TREATMENT", 45, 62], ["musculoskeletal concerns", "PROBLEM", 106, 130], ["back and neck pain", "PROBLEM", 140, 158], ["back", "ANATOMY", 140, 144], ["neck", "ANATOMY", 149, 153], ["pain", "OBSERVATION", 154, 158]]], ["17, 35, 36 The median 12-month utilization of chiropractic services has been estimated to be 9.1% globally.", [["chiropractic services", "TREATMENT", 46, 67]]], ["37 Therefore, due to its common use, taking a closer look at this health profession in the context of response to the COVID-19 pandemic is warranted.T A G G E D H 1 INTRODUCTIONT A G G E D E N DPandemics create challenging circumstances for all health care providers.", [["T", "SPECIES", 149, 150], ["the COVID", "TREATMENT", 114, 123], ["A G G E D H", "TREATMENT", 151, 162], ["A G G E D E N DPandemics", "TREATMENT", 179, 203]]], ["Regulations for physical distancing and other measures to control the spread of COVID-19 has disrupted daily life and routine health care practices.", [["COVID-19", "CHEMICAL", 80, 88], ["physical distancing", "TREATMENT", 16, 35], ["other measures", "TREATMENT", 40, 54]]], ["10 Clinical practice is especially challenging for those professionals who routinely use their hands as a part of their assessment and treatment for managing patients.", [["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["their assessment", "TEST", 114, 130], ["treatment", "TREATMENT", 135, 144]]], ["Therefore, the purpose of this qualitative report is to describe actions by an international sample of practicing chiropractors during the early stages of the COVID-19 pandemic.T A G G E D H 1 METHODST A G G E D E N DThis is a qualitative, narrative research study using chronological, story-oriented reporting.", [["T", "SPECIES", 177, 178], ["the COVID", "TEST", 155, 164], ["A G G E D H", "TEST", 179, 190], ["narrative research study", "TEST", 240, 264]]], ["38 Because qualitative research is focused on the perceptions and experiences of people, 39 we used a qualitative-constructivist approach to understand chiropractic practice during the COVID-19 pandemic as described by the participants.", [["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87], ["participants", "SPECIES", 223, 235], ["chiropractic practice", "TREATMENT", 152, 173]]], ["This approach strives to understand the complexities of experience from the point of view of the participant.", [["participant", "SPECIES", 97, 108]]], ["41 This descriptive report includes chiropractors' actions during the early COVID-19 pandemic between the dates of April 20 to May 4, 2020.", [["chiropractors' actions", "TREATMENT", 36, 58]]], ["As far as the first author was aware, none of the chiropractors reporting actions taken in their practices had regular communications with one another (except KS and CL who are married).", [["CL", "MULTI-TISSUE_STRUCTURE", 166, 168]]], ["It was presumed that practitioners in each location acted independently in their actions and responses to the pandemic.", [["the pandemic", "PROBLEM", 106, 118]]], ["Anyone who was invited but declined or did not respond was excluded from this report.T A G G E D H 1 METHODST A G G E D E N DThe role of the researcher is an integrated part of qualitative research.", [["T", "SPECIES", 85, 86]]], ["39 The constructivist approach typically utilizes broad and general questions to capture the richness of the participants' experiences and how each navigates the cultural and social influences on their lives.", [["participants", "SPECIES", 109, 121]]], ["39 Accordingly, each participant was asked to answer 2 open-ended questions with a limitation of 500 words: (1) provide a description of the public health response to COVID-19 in their local area and (2) provide a brief synopsis of actions that they took in their chiropractic practices in response to COVID-19.", [["COVID-19", "CHEMICAL", 302, 310], ["participant", "SPECIES", 21, 32], ["COVID", "TEST", 167, 172], ["COVID", "TEST", 302, 307]]], ["All contributors reviewed the full manuscript for accuracy and approved the final contents.", [["accuracy", "TEST", 50, 58]]], ["43 For this report, we followed the Standards for Reporting Qualitative Research according to O'Brien et al. 44 This was not an experimental study.", [["an experimental study", "TEST", 125, 146]]], ["No private health information was included, and each participant consented and contributed as an author; thus, no ethics review was sought.T A G G E D H 1 METHODST A G G E D E N DEighteen chiropractors representing 17 locations in 11 countries participated.", [["T", "SPECIES", 139, 140], ["A G G E D E N DEighteen chiropractors", "TREATMENT", 164, 201]]], ["Their location, number of chiropractors in their country, and number of confirmed cases of COVID-19 are represented in figure 1 .", [["COVID-19", "DNA", 91, 99], ["COVID", "TEST", 91, 96]]], ["5, 6, 14 The following summaries from the individual chiropractic practitioners describe their locations and how each responded to the COVID-19 crisis.California, USAOn January 26, 2020, the first case of COVID-19 in California was reported.", [["COVID-19", "CHEMICAL", 205, 213], ["the COVID", "TEST", 131, 140], ["COVID", "TEST", 205, 210]]], ["45 Following this, the first known fatality in the US occurred in Northern California on February 6.", [["fatality", "OBSERVATION", 35, 43]]], ["46 The Governor of California declared a state of emergency and a statewide stay-at-home order on March 19 47 when the number of confirmed COVID-19 cases in California exceeded 1000.", [["COVID", "TEST", 139, 144]]], ["48 Businesses were closed unless they were considered to be part of the critical infrastructure, such as healthcare.", [["infrastructure", "OBSERVATION", 81, 95]]], ["49 Some California counties issued requirements for all citizens to wear face coverings when they were in proximity to anyone other than family members.", [["face coverings", "TREATMENT", 73, 87]]], ["50 Bart Green.", [["Green", "GENE_OR_GENE_PRODUCT", 8, 13]]], ["Services provided at this location include primary medical care, behavioral health, physical therapy, acupuncture, nutritional counseling, optometry, and chiropractic.", [["primary medical care", "TREATMENT", 43, 63], ["physical therapy", "TREATMENT", 84, 100], ["acupuncture", "TREATMENT", 102, 113], ["nutritional counseling", "TREATMENT", 115, 137]]], ["We serve an ethnically diverse population with an international demographic.", [["ethnically", "OBSERVATION_MODIFIER", 12, 22], ["diverse", "OBSERVATION_MODIFIER", 23, 30]]], ["This patient population frequently travels domestically and internationally for business or family visits, particularly to Southern and Eastern Asia.California, USAIn the health center, I normally use standard infection control measures, 51 such as wiping down treatment tables with antiseptic cleaners in between patient visits, hand washing before and after each patient encounter, and regular office hygiene and safety protocols, as recommended by The Joint Commission.", [["hand", "ANATOMY", 330, 334], ["infection", "DISEASE", 210, 219], ["patient", "ORGANISM", 5, 12], ["patient", "ORGANISM", 314, 321], ["patient", "ORGANISM", 365, 372], ["patient", "SPECIES", 5, 12], ["patient", "SPECIES", 314, 321], ["patient", "SPECIES", 365, 372], ["standard infection control measures", "TREATMENT", 201, 236], ["antiseptic cleaners", "TREATMENT", 283, 302], ["hand washing", "TREATMENT", 330, 342], ["safety protocols", "TREATMENT", 415, 431], ["infection", "OBSERVATION", 210, 219], ["Joint", "ANATOMY", 455, 460]]], ["52 In the first week of March, when the COVID-19 outbreak was increasing in prevalence and spreading in distribution in California, infection control measures were enhanced to additionally include wiping down door handles, seat arm rests, and other frequently touched areas in between each patient visit.", [["infection", "DISEASE", 132, 141], ["patient", "ORGANISM", 290, 297], ["patient", "SPECIES", 290, 297], ["the COVID", "TEST", 36, 45], ["outbreak", "PROBLEM", 49, 57], ["infection control measures", "TREATMENT", 132, 158], ["seat arm rests", "TREATMENT", 223, 237], ["increasing", "OBSERVATION_MODIFIER", 62, 72], ["spreading", "OBSERVATION_MODIFIER", 91, 100], ["distribution", "OBSERVATION_MODIFIER", 104, 116], ["California", "OBSERVATION_MODIFIER", 120, 130], ["infection", "OBSERVATION", 132, 141]]], ["As recommended by WHO and the US Centers for Disease Control and Prevention, we began to practice physical distancing between patients and between staff members.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["Disease Control", "TREATMENT", 45, 60]]], ["53, 54 Patients were asked screening questions before scheduling and when checking in for an appointment.", [["Patients", "ORGANISM", 7, 15], ["Patients", "SPECIES", 7, 15]]], ["Only 1 patient was allowed in the reception area at a time; others waited outside of the health center.California, USAIn response to the state mandated stay-at-home order, other providers at the health center and I transitioned from in-office visits to telehealth encounters.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14]]], ["Patients scheduled for in-office appointments were called and invited to reschedule to telehealth visits at their discretion.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Telehealth patient visits were done using a secure video platform that was integrated within the electronic health record.", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["a secure video platform", "TEST", 42, 65]]], ["Both new patient consultations and follow-up visits were conducted.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["new", "OBSERVATION_MODIFIER", 5, 8]]], ["Many of the exam procedures that were normally done in the health center were done through videoconferencing through verbal instruction or by having the patient mimic what I was doing.", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["the exam procedures", "TEST", 8, 27]]], ["This approach was also used for home exercises.", [["home exercises", "TREATMENT", 32, 46]]], ["Video visits allowed me to spend more time on patient education and my patients seemed to like this format.", [["patient", "ORGANISM", 46, 53], ["patients", "ORGANISM", 71, 79], ["patient", "SPECIES", 46, 53], ["patients", "SPECIES", 71, 79], ["patient education", "TREATMENT", 46, 63]]], ["No patients presenting during this time had any severe health problems requiring referral.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["any severe health problems", "PROBLEM", 44, 70], ["severe", "OBSERVATION_MODIFIER", 48, 54]]], ["Thus far, patients have provided positive feedback about the use of video visits.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Many expressed gratitude that they were able to receive care remotely and avoid community exposure to coronavirus.Arkansas, USAOn March 11, 2020, the first case of COVID-19 was confirmed in Arkansas.", [["coronavirus", "DISEASE", 102, 113], ["coronavirus", "ORGANISM", 102, 113], ["coronavirus", "PROBLEM", 102, 113], ["COVID", "TEST", 164, 169]]], ["The Arkansas Department of Health recommended that patient care that could be safely postponed be rescheduled to a future date.", [["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58]]], ["The following criteria were recommended by the Department of Health to determine if a patient should be rescheduled: (1) temperature of 100.4\u2070 F or greater, cough, or other symptoms of COVID-19; (2) aged 65 years or older; (3) immunocompromised and/ or had chronic disease; or (4) returned from international travel within the past 14 days.", [["cough", "DISEASE", 157, 162], ["chronic disease", "DISEASE", 257, 272], ["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["temperature", "TEST", 121, 132], ["cough", "PROBLEM", 157, 162], ["other symptoms", "PROBLEM", 167, 181], ["immunocompromised", "PROBLEM", 227, 244], ["chronic disease", "PROBLEM", 257, 272], ["greater", "OBSERVATION_MODIFIER", 148, 155], ["cough", "OBSERVATION", 157, 162], ["chronic", "OBSERVATION_MODIFIER", 257, 264], ["disease", "OBSERVATION", 265, 272]]], ["Strict adherence to universal precautions were recommended to minimize disease transmission.", [["universal precautions", "TREATMENT", 20, 41], ["disease transmission", "PROBLEM", 71, 91]]], ["It was thought that by rescheduling patients, DCs could contribute to preventing community spread and preserving the limited supply of personal protective equipment (PPE) that was critical for frontline healthcare personnel responding to this pandemic.ARTICLE IN PRESSThe Arkansas Department of Health recommended that chiropractic offices consider several prevention measures.", [["DCs", "ANATOMY", 46, 49], ["patients", "ORGANISM", 36, 44], ["DCs", "CELL", 46, 49], ["DCs", "CELL_TYPE", 46, 49], ["patients", "SPECIES", 36, 44], ["community spread", "PROBLEM", 81, 97], ["personal protective equipment", "TREATMENT", 135, 164], ["chiropractic offices", "TREATMENT", 319, 339], ["several prevention measures", "TREATMENT", 349, 376]]], ["56 The first was to remove items such as magazines and children's toys from patient waiting areas.", [["children", "ORGANISM", 55, 63], ["patient", "ORGANISM", 76, 83], ["children", "SPECIES", 55, 63], ["patient", "SPECIES", 76, 83]]], ["It also advised that a single sign-in sheet per patient be used or to sanitize digital sign-in screens and styluses after each patient used them.", [["patient", "ORGANISM", 48, 55], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 48, 55], ["patient", "SPECIES", 127, 134], ["digital sign", "TEST", 79, 91]]], ["Sanitizing exam tables and rooms after each patient encounter was recommended.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["Sanitizing exam tables", "TEST", 0, 22]]], ["Patients and staff were asked to practice social distancing in the waiting room, patients were encouraged to wait in their cars until called in for appointments, or that an alternative waiting room procedure be offered to patients.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 222, 230], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 222, 230], ["procedure", "TREATMENT", 198, 207]]], ["Respiratory etiquette and hand hygiene were advised for all employees.", [["hand", "ANATOMY", 26, 30], ["hand", "ORGANISM_SUBDIVISION", 26, 30]]], ["The Department also recommended that clinic staff perform routine environmental cleaning.ARTICLE IN PRESSKaren Konarski-Hart.", [["routine environmental cleaning", "TREATMENT", 58, 88]]], ["Many of my patients are employed in the local healthcare system and also are caretakers of family members.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["During the first weeks of the outbreak, many people with possible COVID symptoms presented at healthcare facilities.", [["COVID", "DISEASE", 66, 71], ["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["COVID symptoms", "PROBLEM", 66, 80]]], ["Health and government officials discouraged the use of emergency or urgent care facilities except for medical necessity.ARTICLE IN PRESSDuring that time, many patients who presented to my office with acute musculoskeletal concerns did not want to go to a medical facility for fear of COVID-19 exposure.", [["COVID-19", "CHEMICAL", 284, 292], ["COVID-19", "CHEMICAL", 284, 292], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["urgent care facilities", "TREATMENT", 68, 90], ["acute musculoskeletal concerns", "PROBLEM", 200, 230], ["COVID", "TEST", 284, 289], ["musculoskeletal", "ANATOMY", 206, 221]]], ["I saw an increase in patients who were caregivers for their families.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["increase", "OBSERVATION_MODIFIER", 9, 17]]], ["They often had symptoms of mental stress because of the additional duties of protecting and caring for their loved ones during the pandemic.", [["symptoms", "PROBLEM", 15, 23], ["mental stress", "PROBLEM", 27, 40]]], ["Signs and symptoms of stress included new onset of muscle spasms, headaches, or temporomandibular joint issues.", [["muscle", "ANATOMY", 51, 57], ["temporomandibular", "ANATOMY", 80, 97], ["muscle spasms", "DISEASE", 51, 64], ["headaches", "DISEASE", 66, 75], ["temporomandibular joint issues", "DISEASE", 80, 110], ["muscle", "ORGAN", 51, 57], ["temporomandibular joint", "MULTI-TISSUE_STRUCTURE", 80, 103], ["stress", "PROBLEM", 22, 28], ["muscle spasms", "PROBLEM", 51, 64], ["headaches", "PROBLEM", 66, 75], ["temporomandibular joint issues", "PROBLEM", 80, 110], ["muscle", "ANATOMY", 51, 57], ["spasms", "OBSERVATION", 58, 64], ["temporomandibular joint", "ANATOMY", 80, 103]]], ["For some patients, their desire for social contact, conversation and reassurance seemed as great as the need for treatment for their musculoskeletal symptoms.", [["musculoskeletal", "ANATOMY", 133, 148], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["reassurance", "TREATMENT", 69, 80], ["treatment", "TREATMENT", 113, 122], ["their musculoskeletal symptoms", "PROBLEM", 127, 157]]], ["Patients who were sheltering in place and no longer had social contact from their churches or social groups commented on how happy they were to see and talk face-to-face with another person during their treatment visits.ARTICLE IN PRESSMy practice normally offers random urine drug sampling for professionals who are in a program to maintain their license.", [["urine", "ANATOMY", 271, 276], ["Patients", "ORGANISM", 0, 8], ["urine", "ORGANISM_SUBSTANCE", 271, 276], ["Patients", "SPECIES", 0, 8], ["person", "SPECIES", 183, 189]]], ["However, because of the fear of COVID-19 exposure, I saw an increase in these clients.", [["COVID-19", "CHEMICAL", 32, 40], ["COVID", "PROBLEM", 32, 37], ["increase", "OBSERVATION_MODIFIER", 60, 68]]], ["We asked patients COVID screening questions when they called for an appointment.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["If they were suspected of having a COVID infection, they were referred to the medical center for screening and testing.", [["COVID infection", "DISEASE", 35, 50], ["a COVID infection", "PROBLEM", 33, 50], ["screening and testing", "TEST", 97, 118], ["infection", "OBSERVATION", 41, 50]]], ["Patients were expected to enter the clinic alone unless they needed assistance.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["I met them wearing a gown and mask, walked them directly to the treatment room and walked them directly out after treatment.", [["a gown and mask", "TREATMENT", 19, 34], ["treatment", "TREATMENT", 114, 123]]], ["Any forms were filled out by me in the treatment room so there was minimal sharing of pens or clipboards.", [["minimal", "OBSERVATION_MODIFIER", 67, 74]]], ["We kept patient appointments scheduled apart from each another to avoid contact between patients.", [["patient", "ORGANISM", 8, 15], ["patients", "ORGANISM", 88, 96], ["patient", "SPECIES", 8, 15], ["patients", "SPECIES", 88, 96]]], ["The treatment room had all smooth surfaces, and chair and treatment table arm rests were wrapped with disposable plastic film, which made wipe downs and spraying easier between appointments.", [["The treatment room", "TREATMENT", 0, 18], ["chair and treatment table arm rests", "TREATMENT", 48, 83], ["disposable plastic film", "TREATMENT", 102, 125]]], ["Paper napkins were inserted in the facepiece crease and patients were gowned.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Paper napkins", "TREATMENT", 0, 13]]], ["I washed my hands before and after treatment and used sanitizing gel within the patients' view.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["treatment", "TREATMENT", 35, 44], ["sanitizing gel", "TREATMENT", 54, 68]]], ["I also sprayed and wiped the table so the patients witnessed that the surfaces were clean.Oregon, USAThe governor of Oregon increased restrictions as a response to COVID-19 starting on March 12, 2020.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["Oregon increased restrictions", "TREATMENT", 117, 146], ["COVID", "TEST", 164, 169], ["clean", "OBSERVATION", 84, 89]]], ["57 Restrictions included closing schools for 2 weeks and limiting gatherings to less than 250 people.", [["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100]]], ["On March 17, school closures were extended for 4 more weeks, gatherings were limited to less than 25 people, and all restaurants and bars were closed.", [["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["school closures", "TREATMENT", 13, 28]]], ["On March 23, a mandatory shelterin-place order banned all non-essential travel.", [["a mandatory shelterin", "TREATMENT", 13, 34], ["non-essential travel", "OBSERVATION", 58, 78]]], ["58 Health care was considered an essential service and DCs were included as essential healthcare providers.", [["DCs", "ANATOMY", 55, 58], ["DCs", "CELL", 55, 58], ["DCs", "CELL_TYPE", 55, 58]]], ["On March 19, the governor prohibited any non-essential (ie, non-life-threatening) healthcare procedures that required the use of PPE, to conserve PPE for critical care.", [["healthcare procedures", "TREATMENT", 82, 103], ["PPE", "TREATMENT", 129, 132], ["critical care", "TREATMENT", 154, 167]]], ["My chiropractic practice includes 6 DCs (ie, 4 general chiropractic practitioners and 2 chiropractic pediatric specialists.)", [["DCs", "ANATOMY", 36, 39], ["DCs", "CELL_TYPE", 36, 39], ["My chiropractic practice", "TREATMENT", 0, 24]]], ["To address the community's concerns about the COVID-19 pandemic, my staff and I communicated with patients about the extra safety measures we are took to protect their health.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["the extra safety measures", "TREATMENT", 113, 138]]], ["These procedures were posted on the office web page, office Facebook (Menlo Park, CA) page, and emailed to each patient.", [["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119]]], ["Since much remained to be discovered about COVID-19, I continued to monitor the latest developments and modified procedures as new information warranted.Oregon, USAMy goal was to provide chiropractic care that contributed to patients' well-being in an office that had low risk for infection.", [["infection", "DISEASE", 281, 290], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 225, 233], ["modified procedures", "TREATMENT", 104, 123], ["chiropractic care", "TREATMENT", 187, 204], ["infection", "PROBLEM", 281, 290], ["infection", "OBSERVATION", 281, 290]]], ["To this end, a hospital-grade air purification system was installed on the office HVAC units.", [["a hospital-grade air purification system", "TREATMENT", 13, 53], ["air purification", "OBSERVATION", 30, 46]]], ["This system uses an ozone and hydroperoxides oxidation technology to eradicate 99.9% of all airborne and surface pathogens capable of eradicating the droplets of a sneeze at a 3 feet distance.", [["surface", "ANATOMY", 105, 112], ["ozone", "CHEMICAL", 20, 25], ["hydroperoxides", "CHEMICAL", 30, 44], ["sneeze", "DISEASE", 164, 170], ["ozone", "CHEMICAL", 20, 25], ["hydroperoxides", "CHEMICAL", 30, 44], ["ozone", "SIMPLE_CHEMICAL", 20, 25], ["hydroperoxides", "SIMPLE_CHEMICAL", 30, 44], ["an ozone", "TREATMENT", 17, 25], ["hydroperoxides oxidation technology", "TREATMENT", 30, 65]]], ["We instituted additional protocols to further limit exposure.", [["additional protocols", "TREATMENT", 14, 34]]], ["Patients were screened to identify if they were ill or were exposed to anyone ill when they scheduled an appointment and were screened again when they arrived at the office.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["For pediatric patients, we asked that only 1 parent or caregiver attend the visit and that siblings who were not being treated be left home.Oregon, USAOnce patients arrived, they were asked to remain in their cars until their treatment room was cleaned and ready, at which time they received a call from the receptionist, who opened the front door for them.", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 156, 164]]], ["Upon entering, patients were asked to clean their hands with hand sanitizer located on the front counter or with soap and water in the reception area bathroom.", [["hand", "ANATOMY", 61, 65], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["hand sanitizer", "TREATMENT", 61, 75]]], ["The receptionists controlled the flow of patients so that only 1 patient was in the reception area at a time.", [["patients", "ORGANISM", 41, 49], ["patient", "ORGANISM", 65, 72], ["patients", "SPECIES", 41, 49], ["patient", "SPECIES", 65, 72]]], ["In the treatment room, I wore a mask and took the patient's temperature before commencing with the history.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["a mask", "TREATMENT", 30, 36]]], ["Any patient with a fever was asked to go home and re-schedule once they were well.", [["fever", "DISEASE", 19, 24], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a fever", "PROBLEM", 17, 24]]], ["Patients were provided with COVID-19 information if needed.Oregon, USAUpon leaving the treatment room, if no one else was in the reception area, patients re-scheduled at the front desk.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 145, 153], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 145, 153], ["COVID", "TREATMENT", 28, 33]]], ["We instituted a modified method for payment in which the patient inserted and removed their own card into and from the card reader, and the receptionist completed the payment transaction.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["payment", "TREATMENT", 36, 43]]], ["Alternatively, patients had the choice of returning immediately to their cars and then calling from their car to re-schedule, receive charges, and provide credit card information over the phone.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["Once the treatment was complete, surfaces touched by the patient were disinfected, such as treatment tables and door handles.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["the treatment", "TREATMENT", 5, 18], ["treatment tables", "TREATMENT", 91, 107]]], ["At the beginning and end of every day, and hourly during the day, bathrooms and other common areas were disinfected.", [["bathrooms", "TREATMENT", 66, 75], ["disinfected", "OBSERVATION", 104, 115]]], ["As a result, we increased the length of each treatment visit to accommodate the extra time required and to keep patient overlap inside the office to a minimum.Oregon, USAMy patients expressed gratitude for creating a safe environment in the clinic.", [["patient", "ORGANISM", 112, 119], ["patients", "ORGANISM", 173, 181], ["patient", "SPECIES", 112, 119], ["patients", "SPECIES", 173, 181]]], ["I feel it is my responsibility as a health care provider to continue to provide the care my patients consider essential to their health.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100]]], ["I and the others in my clinic strive to do this in an environment that protects the health of our patients, our staff, and the community in which we all live.Missouri, USAThe Missouri Governor issued a stay-at-home order on April 6, 2020 that remained in effect until May 3 with the county of St Louis extending the deadline for an indefinite period of time.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106]]], ["60 In the State of Missouri, DCs are considered essential healthcare workers as outlined in the US Department of Homeland Security memorandum on identification of essential critical infrastructure.", [["DCs", "ANATOMY", 29, 32], ["DCs", "CELL", 29, 32], ["DCs", "CELL_TYPE", 29, 32], ["essential", "OBSERVATION_MODIFIER", 163, 172], ["critical", "OBSERVATION_MODIFIER", 173, 181], ["infrastructure", "OBSERVATION", 182, 196]]], ["61 Additionally, the Missouri Chiropractic Physicians Association made a statement to encourage DCs to make an educated decision about what is best for their patients, their practice, and their loved ones with their decision to continue seeing patients.", [["DCs", "ANATOMY", 96, 99], ["DCs", "CELL", 96, 99], ["patients", "ORGANISM", 158, 166], ["patients", "ORGANISM", 244, 252], ["DCs", "CELL_TYPE", 96, 99], ["patients", "SPECIES", 158, 166], ["patients", "SPECIES", 244, 252]]], ["63 Chiropractic providers work closely with the veteran's primary medical provider and complimentary and integrated health teams in an effort to improve quality of life, function, and self-management strategies.Missouri, USAStarting on April 1, 2020, all health care at this location focused on emergent and urgent care.", [["self-management strategies", "TREATMENT", 184, 210], ["emergent and urgent care", "TREATMENT", 295, 319]]], ["Many of the providers either shifted to inpatient care or screening stations while at the same time providing telehealth for their other patients.", [["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145]]], ["To reduce the risk of exposure to patients, my inperson visits were converted to telehealth visits.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["64 For those veterans who were unable to connect via VA video connect, we called them by telephone.Missouri, USADuring chiropractic telehealth visits, I took health histories, completed a limited examination, and provided patients with appropriate education, exercise, ergonomic recommendations, lifestyle instruction, and reassurance/ compassion.", [["veterans", "ORGANISM", 13, 21], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 222, 230], ["a limited examination", "TEST", 186, 207], ["lifestyle instruction", "TREATMENT", 296, 317]]], ["Patient recommendations included simple movement activities, directionally preferred exercises, selfmobilizations, nutritional guidance, and overall lifestyle changes to help them self-manage their conditions.", [["Patient", "SPECIES", 0, 7], ["simple movement activities", "TREATMENT", 33, 59], ["selfmobilizations", "TREATMENT", 96, 113], ["nutritional guidance", "TREATMENT", 115, 135]]], ["During these visits, I was able to link veterans to a variety of Whole Health virtual offerings, which included information to maintain healthy living with complimentary and integrated health self-management strategies including mindfulness, meditation, nutrition, coaching and peer support, and videos on yoga, tai chi, acupressure, postural advice, and nutritional support.", [["meditation", "TREATMENT", 242, 252], ["nutrition", "TREATMENT", 254, 263], ["peer support", "TREATMENT", 278, 290], ["yoga", "TREATMENT", 306, 310], ["acupressure", "TREATMENT", 321, 332], ["postural advice", "TREATMENT", 334, 349], ["nutritional support", "TREATMENT", 355, 374]]], ["Veterans indicated a high level of satisfaction with these modalities and self-management strategies.", [["these modalities", "TREATMENT", 53, 69], ["self-management strategies", "TREATMENT", 74, 100]]], ["However, veterans expressed their appreciation for the telehealth care that I was able to provide during the pandemic.Texas, USAOn March 12, 2020, a public health disaster due to COVID-19 was declared in Dallas County.", [["COVID", "TEST", 179, 184]]], ["65 On March 19, Dallas County, Texas Judge Clay Jenkins issued more restrictive requirements with earlier interventions than at the state level jurisdiction to mitigate transmission.", [["earlier interventions", "TREATMENT", 98, 119], ["more restrictive", "OBSERVATION_MODIFIER", 63, 79]]], ["66 The Texas Governor issued an executive order closing schools, limiting statewide gatherings to less than 10 people, limiting food and beverage operations to carry-out/delivery, and closure of nonessential businesses.", [["people", "ORGANISM", 111, 117], ["people", "SPECIES", 111, 117], ["delivery", "TREATMENT", 170, 178]]], ["67 Dallas County was put under shelterin-place orders until April 30, 2020 where Dallas County residents were advised that tiered openings of businesses would occur incrementally, dependent on county capacity for testing and tracing of positive cases.", [["testing", "TEST", 213, 220], ["tracing", "TEST", 225, 232], ["positive cases", "PROBLEM", 236, 250]]], ["Health care operations, which included chiropractic practices, were deemed as essential businesses, where employees and patients were required to wear masks to cover the mouth and nose.", [["mouth", "ANATOMY", 170, 175], ["nose", "ANATOMY", 180, 184], ["patients", "ORGANISM", 120, 128], ["mouth", "ORGANISM_SUBDIVISION", 170, 175], ["nose", "ORGANISM_SUBDIVISION", 180, 184], ["patients", "SPECIES", 120, 128], ["chiropractic practices", "TREATMENT", 39, 61], ["masks", "TREATMENT", 151, 156], ["mouth", "ANATOMY", 170, 175], ["nose", "ANATOMY", 180, 184]]], ["Homemade coverings, bandanas, and scarves were permissible.Texas, USAThe Texas Board of Chiropractic Examiners confirmed chiropractic care as an essential service.", [["bandanas", "TREATMENT", 20, 28], ["chiropractic care", "TREATMENT", 121, 138]]], ["68 The Texas Board of Chiropractic Examiners issued guidelines on appropriateness of chiropractic care through April 30 that stated, \"Licensees should only provide essential chiropractic services for patients with current or recurrent complaints of pain or disability which adversely affects the patient's ability to engage in the essential activities of daily living or work, or adversely affects the patient's quality of life, and with anticipation of material improvement under chiropractic care.\" 69 As of May 1, updated orders included that licensed chiropractors could provide wellness care but, \"should continue to adhere to safety and prevention best practices specified in the most current advice from the Centers for Disease Control.\" 70 William Foshee.", [["pain", "DISEASE", 249, 253], ["disability", "DISEASE", 257, 267], ["patients", "ORGANISM", 200, 208], ["patient", "ORGANISM", 296, 303], ["patient", "ORGANISM", 402, 409], ["patients", "SPECIES", 200, 208], ["patient", "SPECIES", 296, 303], ["patient", "SPECIES", 402, 409], ["chiropractic care", "TREATMENT", 85, 102], ["pain", "PROBLEM", 249, 253], ["disability", "PROBLEM", 257, 267], ["chiropractic care", "TREATMENT", 481, 498], ["Disease Control", "TREATMENT", 727, 742]]], ["My chiropractic practice is in Dallas, Texas, which is a city of 1.345 million people.", [["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85]]], ["My patients often begin care with a musculoskeletal complaint and transition to wellness care depending on patient preferences.", [["patients", "ORGANISM", 3, 11], ["patient", "ORGANISM", 107, 114], ["patients", "SPECIES", 3, 11], ["patient", "SPECIES", 107, 114], ["a musculoskeletal complaint", "PROBLEM", 34, 61], ["wellness care", "TREATMENT", 80, 93]]], ["Many of my patients are ethnic minority.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["I regularly treat patients who primarily speak Spanish.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["I also serve a large portion of the sexual minority population, which is represented by those whose sexual identity, orientation or practices differ from the majority, such as lesbian, gay, bisexual, or transgender.", [["large", "OBSERVATION_MODIFIER", 15, 20]]], ["71 I also have a small, solo practice where my patients are almost exclusively sexual minorities.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["small", "OBSERVATION_MODIFIER", 17, 22]]], ["I limit patients in my solo practice to active care.Texas, USADuring the early response to COVID-19, clinic intake procedures included screening patients for fever, symptomatology, and travel history.", [["fever", "DISEASE", 158, 163], ["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 145, 153], ["COVID", "TEST", 91, 96], ["screening patients", "TEST", 135, 153], ["fever", "PROBLEM", 158, 163], ["symptomatology", "PROBLEM", 165, 179]]], ["Assessment and treatment were limited to individuals who denied international or out-ofstate travel in the previous 2 weeks, infection or known contact with a person experiencing COVID-19, and history of fever, cough, shortness of breath, dysgeusia, or hyposmia in the previous 2 weeks.", [["infection", "DISEASE", 125, 134], ["fever", "DISEASE", 204, 209], ["cough", "DISEASE", 211, 216], ["shortness of breath", "DISEASE", 218, 237], ["dysgeusia", "DISEASE", 239, 248], ["hyposmia", "DISEASE", 253, 261], ["person", "SPECIES", 159, 165], ["Assessment", "TEST", 0, 10], ["treatment", "TREATMENT", 15, 24], ["infection", "PROBLEM", 125, 134], ["fever", "PROBLEM", 204, 209], ["cough", "PROBLEM", 211, 216], ["shortness of breath", "PROBLEM", 218, 237], ["dysgeusia", "PROBLEM", 239, 248], ["hyposmia", "PROBLEM", 253, 261], ["infection", "OBSERVATION", 125, 134], ["fever", "OBSERVATION", 204, 209]]], ["All of this information was noted in patient records.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44]]], ["Prospective and existing patients were delayed care for 2-weeks or until their responses were compatible with the screening requirements.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["I disinfected the treatment table between patients and sanitized frequently touched surfaces.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["the treatment table", "TREATMENT", 14, 33]]], ["I asked patients to wait in their cars until the time of treatment.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["treatment", "TREATMENT", 57, 66]]], ["Alcohol-based hand sanitizer and tissues were available in all spaces accessible to patients.", [["hand", "ANATOMY", 14, 18], ["tissues", "ANATOMY", 33, 40], ["Alcohol", "CHEMICAL", 0, 7], ["Alcohol", "SIMPLE_CHEMICAL", 0, 7], ["tissues", "TISSUE", 33, 40], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["tissues", "ANATOMY", 33, 40]]], ["There were no other items for patients to touch, as pens were sanitized between patients and all other material, magazines, and water cooler were removed.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 80, 88], ["magazines", "TREATMENT", 113, 122], ["water cooler", "TREATMENT", 128, 140], ["no other", "UNCERTAINTY", 11, 19]]], ["Spinal manipulation was limited to prone and instrument assisted techniques to better control the direction and velocity of forced expiratory projection.Texas, USANew and existing patients presented with musculoskeletal complaints such as radiculopathy, tension pattern headache, posture induced musculoskeletal pain from working at home, injuries related to home improvement projects, and exacerbations of chronic or ongoing complaints.", [["Spinal", "ANATOMY", 0, 6], ["musculoskeletal", "ANATOMY", 204, 219], ["musculoskeletal", "ANATOMY", 296, 311], ["musculoskeletal complaints", "DISEASE", 204, 230], ["radiculopathy", "DISEASE", 239, 252], ["headache", "DISEASE", 270, 278], ["musculoskeletal pain", "DISEASE", 296, 316], ["injuries", "DISEASE", 339, 347], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["Spinal manipulation", "TREATMENT", 0, 19], ["instrument assisted techniques", "TREATMENT", 45, 75], ["musculoskeletal complaints", "PROBLEM", 204, 230], ["radiculopathy", "PROBLEM", 239, 252], ["tension pattern headache", "PROBLEM", 254, 278], ["posture induced musculoskeletal pain", "PROBLEM", 280, 316], ["injuries", "PROBLEM", 339, 347], ["chronic or ongoing complaints", "PROBLEM", 407, 436], ["musculoskeletal", "ANATOMY", 204, 219], ["radiculopathy", "OBSERVATION", 239, 252], ["tension pattern", "OBSERVATION", 254, 269], ["musculoskeletal", "ANATOMY", 296, 311], ["chronic", "OBSERVATION_MODIFIER", 407, 414]]], ["I noticed that patients seemed to be more sensitive and had a lower pain tolerance, possibly due to the additional mental stress because of the pandemic.New York, USANew York (NY) state was an epicenter of the US COVID-19 pandemic.", [["pain", "DISEASE", 68, 72], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["a lower pain tolerance", "PROBLEM", 60, 82], ["the additional mental stress", "PROBLEM", 100, 128], ["the pandemic", "PROBLEM", 140, 152], ["the US COVID", "TEST", 206, 218], ["pandemic", "PROBLEM", 222, 230]]], ["72 This guidance allowed chiropractic practices to remain open.", [["chiropractic practices", "TREATMENT", 25, 47]]], ["The impact of COVID-19 varied widely throughout the state.", [["COVID-19", "DNA", 14, 22], ["COVID", "TREATMENT", 14, 19]]], ["Many chiropractors in NY voluntarily closed their practices out of service to public health, patient protection, or due to risks to providers/staff.", [["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100]]], ["For those practices that remained open, emergency chiropractic services included management of urgent and necessary neuromusculoskeletal conditions to avoid overwhelming emergency care settings.", [["emergency chiropractic services", "TREATMENT", 40, 71], ["management", "TREATMENT", 81, 91], ["urgent and necessary neuromusculoskeletal conditions", "TREATMENT", 95, 147]]], ["When face to face care was not possible, an executive order allowed NY chiropractors to provide telemedicine services so that patients could access clinical advice in self-care, home exercise, ergonomics, nutrition, and stress management.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["telemedicine services", "TREATMENT", 96, 117], ["home exercise", "TREATMENT", 178, 191], ["nutrition", "TREATMENT", 205, 214], ["stress management", "TREATMENT", 220, 237]]], ["75 This included office staff with patient contact and clinical providers.", [["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42]]], ["Beginning on April 17, the general public was required to wear protective masks whenever they were in public and could not social distance; attending an office visit fit this description.", [["protective masks", "TREATMENT", 63, 79]]], ["During that time, patients who received wellness and supportive care were advised to delay care until the crisis passed.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["supportive care", "TREATMENT", 53, 68], ["the crisis", "PROBLEM", 102, 112]]], ["For some patients needing supportive care and who would have severe progression of symptoms, care was delivered judiciously.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["supportive care", "TREATMENT", 26, 41], ["severe progression of symptoms", "PROBLEM", 61, 91], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["progression", "OBSERVATION_MODIFIER", 68, 79]]], ["The practice operated at a small fraction of normal volume, with most care provided to essential front-line workers, such as those in healthcare, first responders, and other essential business functions.", [["normal volume", "OBSERVATION", 45, 58]]], ["Acute and urgent musculoskeletal conditions were triaged and managed with an emphasis on self-care so patients could recover while maximizing their ability to remain at home.New York, USAPatients were scheduled with extra time between visits to minimize patient-to-patient contact in the reception area.", [["patients", "ORGANISM", 102, 110], ["patient", "ORGANISM", 254, 261], ["patient", "ORGANISM", 265, 272], ["patients", "SPECIES", 102, 110], ["patient", "SPECIES", 254, 261], ["patient", "SPECIES", 265, 272], ["Acute and urgent musculoskeletal conditions", "PROBLEM", 0, 43], ["self-care", "TREATMENT", 89, 98], ["musculoskeletal", "ANATOMY", 17, 32]]], ["Increased time between visits also provided opportunity for a thorough disinfecting of all treatment surfaces and equipment and periodic disinfecting of commonly contacted surfaces such as countertops and doorknobs.", [["all treatment surfaces", "TREATMENT", 87, 109], ["equipment", "TREATMENT", 114, 123]]], ["Steps were taken to reduce or eliminate exchanges between patients and staff.New York, USAI noticed an increase in repetitive strain injuries.", [["injuries", "DISEASE", 133, 141], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["repetitive strain injuries", "PROBLEM", 115, 141], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["repetitive strain", "OBSERVATION_MODIFIER", 115, 132], ["injuries", "OBSERVATION", 133, 141]]], ["Workfrom-home orders for non-essential workers throughout NY state led many people to use makeshift home office arrangements.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82]]], ["An often less than ideal ergonomic environment seemed to contribute to increased reporting of postural and repetitive strain injuries.", [["injuries", "DISEASE", 125, 133], ["postural and repetitive strain injuries", "PROBLEM", 94, 133]]], ["Therefore, I found that advice for home office ergonomics was helpful for patients.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82]]], ["Further, social isolation as well as fear and anxiety around both the infectious and financial aspects of COVID-19 heightened patients' needs for psychosocial interventions.New York, USATo address patient concerns, we worked to establish procedures for managing disease symptoms or exposures.", [["anxiety", "DISEASE", 46, 53], ["patients", "ORGANISM", 126, 134], ["patient", "ORGANISM", 197, 204], ["patients", "SPECIES", 126, 134], ["patient", "SPECIES", 197, 204], ["social isolation", "TREATMENT", 9, 25], ["anxiety", "PROBLEM", 46, 53], ["psychosocial interventions", "TREATMENT", 146, 172], ["managing disease symptoms", "PROBLEM", 253, 278], ["infectious", "OBSERVATION", 70, 80]]], ["We gathered state and national resources to provide patients with accurate and actionable information.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["We provided access to home resources including yoga and meditation apps or Internet sites, home exercise options, and financial resources.Ontario, CanadaOn April 11, 2020, Canada implemented the COVID-19 Emergency Response Act, enabling government to make sweeping changes for the protection of the public.", [["home resources", "TREATMENT", 22, 36], ["yoga", "TREATMENT", 47, 51], ["meditation apps", "TREATMENT", 56, 71], ["home exercise options", "TREATMENT", 91, 112], ["sweeping changes", "TREATMENT", 256, 272]]], ["78 Chiropractors were required to close their offices, except for limited weekly hours for treating only patients with urgent musculoskeletal needs.", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["urgent musculoskeletal needs", "TREATMENT", 119, 147]]], ["On March 24, closures of public places followed.", [["closures of public places", "TREATMENT", 13, 38]]], ["79 Self-isolation, social distancing, frequent hand-washing, working from home, the use of cloth masks when shopping for groceries were implemented.", [["hand", "ANATOMY", 47, 51], ["cloth masks", "TREATMENT", 91, 102]]], ["The chiropractic regulatory authorities enabled chiropractors to provide telehealth visits, outlining standards for virtual practice.", [["virtual practice", "TREATMENT", 116, 132]]], ["All chiropractic patients were notified by phone that in-person visits were not allowed.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["However, care continued through telehealth visits provided on a ministry of health supported platform enabling both audio and visual interactivity, depending on the patient's available technology.Ontario, CanadaThrough virtual visits, patients reported their concerns, progress, demonstrated prescribed exercises and ranges of motion, performed functional tests, and received instructions for exercises.", [["patient", "ORGANISM", 165, 172], ["patients", "ORGANISM", 235, 243], ["patient", "SPECIES", 165, 172], ["patients", "SPECIES", 235, 243], ["functional tests", "TEST", 345, 361]]], ["Chiropractic care included providing reassurance, advice (such as pacing strategies, pain coping techniques), and COVID-19 prevention education.", [["pain", "DISEASE", 85, 89], ["Chiropractic care", "TREATMENT", 0, 17], ["pacing strategies", "TREATMENT", 66, 83], ["pain coping techniques", "TREATMENT", 85, 107], ["COVID", "TREATMENT", 114, 119]]], ["Collaboration with patients' medical physicians, pharmacists, or other health team members was facilitated through the electronic medical record or by phone.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["New patients with urgent musculoskeletal complaints were screened by telephone and provided with advice and education as indicated.", [["musculoskeletal", "ANATOMY", 25, 40], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["urgent musculoskeletal complaints", "PROBLEM", 18, 51], ["musculoskeletal", "ANATOMY", 25, 40]]], ["If these patients requested an in-person visit, they were referred to a local, collaborating chiropractor who provided this care.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["this care", "TREATMENT", 119, 128]]], ["We monitored patients who used telehealth to better understand the musculoskeletal conditions that may have resulted from isolation due to COVID-19.Ontario, CanadaThis practice serves the inner city of Toronto, reaching the poorest and most vulnerable populations in Ontario.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["telehealth", "TREATMENT", 31, 41], ["the musculoskeletal conditions", "PROBLEM", 63, 93], ["COVID", "TEST", 139, 144], ["most vulnerable", "OBSERVATION_MODIFIER", 236, 251]]], ["We identified individuals who were vulnerable or high risk for severe COVID-19 impact and contacted them by phone to see how they were doing and to linked them with people and resources.", [["COVID", "DISEASE", 70, 75], ["people", "ORGANISM", 165, 171], ["people", "SPECIES", 165, 171], ["severe COVID", "PROBLEM", 63, 75]]], ["Over 4700 of the patients in our clinic database met the criteria for this initiative.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["By keeping people informed and feeling connected to their health team, particularly for seniors and low-income quintile patients, we hoped to minimize the impact of the COVID-19 pandemic on their physical and mental health.Alberta, CanadaAlberta Canada's first case of COVID-19 was reported on March 5, 2020.", [["people", "ORGANISM", 11, 17], ["patients", "ORGANISM", 120, 128], ["people", "SPECIES", 11, 17], ["patients", "SPECIES", 120, 128], ["the COVID", "TEST", 165, 174]]], ["83 Alberta's public health response included restricting mass gatherings to fewer than 15 people, restricting visitation to health and senior care facilities, canceling international travel, and closing schools and non-essential businesses, facilities, and services.", [["people", "SPECIES", 90, 96], ["restricting mass", "PROBLEM", 45, 61], ["mass", "OBSERVATION", 57, 61]]], ["84 Citizens were strongly encouraged by the government to stay at home, abide by social distancing rules, do frequent handwashing, and wear masks in public spaces.Alberta, CanadaEffective March 23, the Alberta College and Association of Chiropractors (ACAC) suspended mobile visits (ie, any visit that does not take place in a clinical environment) and strongly recommended that chiropractors only engage in urgent care.", [["urgent care", "TREATMENT", 408, 419]]], ["On March 27, the Chief Medical Officer of Health of the Government of Alberta ordered the closure of close contact businesses, including chiropractic services, with the exception of urgent, critical, and emergency care.", [["chiropractic services", "TREATMENT", 137, 158]]], ["86 Kent Stuber.", [["Stuber", "OBSERVATION", 8, 14]]], ["Instead, I provide chiropractic care at the patient's location.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["chiropractic care", "TREATMENT", 19, 36]]], ["After mobile visits were suspended, I communicated with my patients and updated them on practice status by telephone, text messaging, videoconference, or e-mail.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67]]], ["I advised patients to continue their active care plans for their musculoskeletal conditions, to be active on a daily basis, and to engage in mental health self-care, such as relaxation or meditation exercises.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["meditation exercises", "TREATMENT", 188, 208]]], ["I maintained contact with patients to provide ongoing encouragement and follow-up.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["Patients who required urgent care were referred to local chiropractors for in-person care.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["urgent care", "TREATMENT", 22, 33]]], ["Patients with stress, depression, anxiety, or grief were referred to mental health services for counselling.Alberta, CanadaCaterina Lerede.", [["stress, depression", "DISEASE", 14, 32], ["anxiety", "DISEASE", 34, 41], ["grief", "DISEASE", 46, 51], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["stress", "PROBLEM", 14, 20], ["depression", "PROBLEM", 22, 32], ["anxiety", "PROBLEM", 34, 41], ["grief", "PROBLEM", 46, 51]]], ["My chiropractic practice is in a multiprofessional clinic, which includes other providers who are in the fields of physical therapy, massage therapy, and naturopathic medicine.", [["physical therapy", "TREATMENT", 115, 131], ["massage therapy", "TREATMENT", 133, 148], ["naturopathic medicine", "TREATMENT", 154, 175]]], ["I saw patients with pain and disability who were unable to self-manage any longer.", [["pain", "DISEASE", 20, 24], ["disability", "DISEASE", 29, 39], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["pain", "PROBLEM", 20, 24]]], ["Patients who met the criteria for an urgent, critical, or emergency visit were scheduled for an in-person visit.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["If they did not meet the criteria, I provided home care options.", [["home care options", "TREATMENT", 46, 63]]], ["If patients met the criteria, they were screened for signs or symptoms of COVID-19 or for any risks of possible exposure.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["symptoms", "PROBLEM", 62, 70], ["COVID", "TEST", 74, 79]]], ["Patients who passed screening criteria were booked for an appointment; any who did not were referred to public health services for evaluation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["evaluation", "TEST", 131, 141]]], ["I contacted patients to provide advice and encouragement.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Steps to reduce exposure risk to patients and staff included disinfection of all examination and treatment surfaces and instruments between all patients, and social distancing.", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 144, 152], ["disinfection", "TREATMENT", 61, 73], ["all examination", "TEST", 77, 92], ["treatment surfaces", "TREATMENT", 97, 115], ["instruments", "TREATMENT", 120, 131]]], ["For example, we reduced the number of chairs and increased the distance between them in the waiting room.Alberta, CanadaWe staggered appointments to minimize risk of patient exposure in passing and installed a plexiglass shield at the front desk between the receptionist and the patients.Queensland, AustraliaDuring that time, the Australian federal and state governments enacted restrictions including closing of international and state borders, closing of \"non-essential\" businesses, restrictions on gatherings, strict physical distancing, and orders to stay at home.", [["patient", "ORGANISM", 166, 173], ["patients", "ORGANISM", 279, 287], ["patient", "SPECIES", 166, 173], ["patients", "SPECIES", 279, 287], ["a plexiglass shield", "TREATMENT", 208, 227], ["reduced", "OBSERVATION_MODIFIER", 16, 23]]], ["Inconsistency in state and federal rules meant we ceased all remedial massage therapy.Queensland, AustraliaScott Charlton.", [["Inconsistency in state and federal rules", "PROBLEM", 0, 40], ["all remedial massage therapy", "TREATMENT", 57, 85]]], ["My practice consists of myself, a massage therapist, and 3 administrative and rehabilitation support staff.", [["a massage therapist", "TREATMENT", 32, 51]]], ["We are located on the edge of the city of Ipswich, approximately 30 miles from Brisbane, the capital city of Queensland.", [["edge", "OBSERVATION_MODIFIER", 22, 26], ["capital", "OBSERVATION_MODIFIER", 93, 100]]], ["My practice is in between a small city and rural area, serving both those nearby and from surrounding rural communities.", [["small", "OBSERVATION_MODIFIER", 28, 33]]], ["I restricted my practice to patients with acute pain and actively discouraged at-risk populations from attending.", [["acute pain", "DISEASE", 42, 52], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["acute pain", "PROBLEM", 42, 52]]], ["All patients were screened for whether they recently participated in overseas travel, had close contact with confirmed cases and if they had any flu like symptoms.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["any flu like symptoms", "PROBLEM", 141, 162]]], ["All staff in the practice completed and were certified in the department of health online COVID-19 infection control training.", [["infection", "DISEASE", 99, 108], ["infection control training", "TREATMENT", 99, 125]]], ["88 Large signs were posted before and at the entry to the practice outlining the clinic procedures.", [["the clinic procedures", "TREATMENT", 77, 98], ["Large", "OBSERVATION_MODIFIER", 3, 8], ["signs", "OBSERVATION", 9, 14]]], ["Hand sanitizer was provided in various stations throughout the clinic.", [["Hand sanitizer", "TREATMENT", 0, 14]]], ["The lack of reliable supply of basic cleaning products led me to use a specialist dental sanitizer that was effective against COVID-19.", [["basic cleaning products", "TREATMENT", 31, 54], ["a specialist dental sanitizer", "TREATMENT", 69, 98], ["COVID", "TEST", 126, 131]]], ["We sanitized all surfaces in treatment rooms and all touch points in the clinic between each patient.Queensland, AustraliaAppointments were modified to ensure strict physical distancing.", [["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["AustraliaAppointments", "TREATMENT", 113, 134], ["surfaces", "OBSERVATION_MODIFIER", 17, 25]]], ["Physical distancing rules in businesses evolved at that time to limit the number of people within a premise or a meeting room to no more than 1 per 4 square meters.", [["people", "ORGANISM", 84, 90], ["people", "SPECIES", 84, 90]]], ["89 My office size permitted 22 people at any given time, though we elected to allow a maximum of 8 including staff.", [["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37]]], ["We removed most seating and provided measured compliant distances to reduce potential patient exposure.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93]]], ["We removed all magazines and pamphlets as well as all toys, books, and furniture from the children's area.", [["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98]]], ["All patients and staff were temperature scanned, observed for signs of being unwell and asked screening questions by the chiropractor in addition to administrative staff on each visit.Queensland, AustraliaThe advice from the Australian government and WHO was that PPE was in limited supply and should be reserved for front-line workers either with symptoms or treating those with symptoms.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["being unwell", "PROBLEM", 71, 83], ["front-line workers", "TREATMENT", 317, 335], ["symptoms", "PROBLEM", 348, 356], ["symptoms", "PROBLEM", 380, 388]]], ["11, 13, 54, 90 For this reason, we elected not to use face masks at all times.", [["face masks", "TREATMENT", 54, 64]]], ["Masks were available for patients to use or have me use if requested.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["I modified history taking to be at a minimum 2 meter distance from the patient.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78]]], ["Examination and treatment procedures were modified to minimize droplet transmission wherever possible.Queensland, AustraliaIn my practice, we serve a portion of a lower socioeconomic population including many older patients and those with mental health illness.", [["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["Examination", "TEST", 0, 11], ["treatment procedures", "TREATMENT", 16, 36], ["droplet transmission", "TEST", 63, 83], ["mental health illness", "PROBLEM", 239, 260]]], ["For those at likely higher risk due to COVID-19 (eg, elderly, immunocompromised), we actively provided outreach by calling and advising patients not to attend unless their need was particularly urgent.", [["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["COVID", "TEST", 39, 44], ["immunocompromised", "PROBLEM", 62, 79]]], ["I provided patients with regular electronic communications including updates on government recommendations and the approaches being used to help keep the clinic safe.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19]]], ["I offered phone and telehealth consultations to patients as a means of easing their anxiety and answering any concerns.Hampshire, United KingdomIn late January 2020, SARS-CoV-2 first arrived in the United Kingdom (UK) carried by returning travelers.", [["anxiety", "DISEASE", 84, 91], ["SARS", "DISEASE", 166, 170], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["SARS-CoV", "SPECIES", 166, 174], ["their anxiety", "PROBLEM", 78, 91]]], ["New laws were introduced (The Health Protection (Coronavirus) Regulations 2020) in March, which provided the Government with powers to control movement of potentially infected individuals.", [["The Health Protection (Coronavirus) Regulations", "TREATMENT", 26, 73], ["potentially infected individuals", "PROBLEM", 155, 187], ["infected", "OBSERVATION", 167, 175]]], ["92 In the second week of March, anyone with a new continuous cough or a fever was told to self-isolate for 7 days and vulnerable groups (ie, aged over 70, or with certain medical conditions or other risk factors) were advised to self-isolate at home.", [["cough", "DISEASE", 61, 66], ["fever", "DISEASE", 72, 77], ["a new continuous cough", "PROBLEM", 44, 66], ["a fever", "PROBLEM", 70, 77], ["cough", "OBSERVATION", 61, 66]]], ["Elective hospital activity was stopped and schools were closed, other than where needed to look after children who were considered vulnerable or children of key workers.", [["children", "ORGANISM", 102, 110], ["children", "ORGANISM", 145, 153], ["children", "SPECIES", 102, 110], ["children", "SPECIES", 145, 153], ["Elective hospital activity", "TREATMENT", 0, 26]]], ["93 Places where people might gather, such as non-food shops, pubs and cinemas, were shut down.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22], ["pubs", "ANATOMY", 61, 65]]], ["94 Work began at several large venues in key locations to convert them into temporary hospitals to provide an additional 10 000 specialist beds.Hampshire, United KingdomChiropractic clinics were considered exempt from closure.", [["closure", "TREATMENT", 218, 225], ["closure", "OBSERVATION", 218, 225]]], ["Since the enacting of emergency information technology system protocols within the clinic we had remote access to patients' electronic health records.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122]]], ["This meant whilst conducting a full schedule of telehealth consultations 5 days a week, I was able to isolate with my family and, along with others in the population, leave home only for 1 period of exercise a day and 1 shopping trip a week.Hampshire, United KingdomMany members of the chiropractic profession in the UK responded to the Health Protection (Coronavirus) Regulations by exploring new ways to engage with and support their patients.", [["patients", "ORGANISM", 436, 444], ["patients", "SPECIES", 436, 444]]], ["I created a support group using Slack (Slack Technologies, San Francisco, CA, USA) to help chiropractors in the UK learn about how to set up practice for remote consultations, including the technology and differences in the way consultations are conducted including the care that can be provided and the way we communicate.Bahia, BrazilAs of April 28, 2020, Brazil had the second largest number of people infected with coronavirus in North and South America, second to the US.", [["coronavirus", "DISEASE", 419, 430], ["people", "ORGANISM", 398, 404], ["people", "SPECIES", 398, 404], ["coronavirus", "PROBLEM", 419, 430], ["largest", "OBSERVATION_MODIFIER", 380, 387], ["coronavirus", "OBSERVATION", 419, 430]]], ["98 The first confirmed COVID-19 case in Brazil was on February 26, 2020.", [["COVID", "TEST", 23, 28]]], ["99 The first COVID-19 related death in Brazil was on March 17.", [["death", "DISEASE", 30, 35]]], ["Telehealth consultations were provisionally accepted and recommended as an important tool to assist patients.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108]]], ["103 The use of face masks was mandatory for any worker in direct contact with the public.", [["face masks", "TREATMENT", 15, 25]]], ["Due the lack of surgical masks available, double layer cloth homemade individual masks were considered acceptable by the ministry of health.", [["surgical masks", "TREATMENT", 16, 30], ["double layer cloth homemade individual masks", "TREATMENT", 42, 86]]], ["People were to wash their hands for 20 seconds or use hand sanitizer (70% alcohol).", [["hand", "ANATOMY", 54, 58], ["alcohol", "CHEMICAL", 74, 81], ["alcohol", "CHEMICAL", 74, 81], ["People", "ORGANISM", 0, 6], ["hand", "ORGANISM_SUBDIVISION", 54, 58], ["alcohol", "SIMPLE_CHEMICAL", 74, 81], ["People", "SPECIES", 0, 6], ["hand sanitizer", "TREATMENT", 54, 68]]], ["People were not to share personal items (eg, towels, tableware, glasses).", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Places where people may crowd were closed (eg, shopping malls, gyms, stores, clubs, and restaurants that now only work in a delivery basis) Essential services such as health, food industry, transportation, and others were allowed to remain open.Bahia, BrazilMarcelo Botelho.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19]]], ["On March 29, the first reported COVID-19 related death in my state (Bahia) was at this hospital.", [["death", "DISEASE", 49, 54]]], ["I continued to see patients who had ongoing treatment needs and who were in severe pain but avoided new patient admissions.", [["pain", "DISEASE", 83, 87], ["patients", "ORGANISM", 19, 27], ["patient", "ORGANISM", 104, 111], ["patients", "SPECIES", 19, 27], ["patient", "SPECIES", 104, 111], ["ongoing treatment needs", "TREATMENT", 36, 59], ["severe pain", "PROBLEM", 76, 87]]], ["To increase the efficacy of transmission prevention, the following measures were implemented in my clinic: Face mask use was mandatory for myself, all staff members and other health care providers in the hospital.", [["transmission prevention", "TREATMENT", 28, 51], ["Face mask", "TREATMENT", 107, 116]]], ["All patients were asked to wear face masks.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["face masks", "TREATMENT", 32, 42]]], ["If the patient presented without a mask, the clinic provided a mask.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["a mask", "TREATMENT", 33, 39], ["a mask", "TREATMENT", 61, 67]]], ["Patients were asked to use hand sanitizer when arriving and before leaving the clinic.", [["hand", "ANATOMY", 27, 31], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["hand sanitizer", "TREATMENT", 27, 41]]], ["Patients were informed, by cell phone message, about relevant information regarding prevention and relevant updates.", [["cell", "ANATOMY", 27, 31], ["Patients", "ORGANISM", 0, 8], ["cell", "CELL", 27, 31], ["Patients", "SPECIES", 0, 8]]], ["These messages included the need to inform the clinic of suspected symptoms prior of clinical attendance, and to reschedule their appointments for a later date if it was the case.", [["suspected symptoms", "PROBLEM", 57, 75]]], ["I modified the treatment schedule to have patient appointments at doublespaced intervals to avoid contact between patients.", [["patient", "ORGANISM", 42, 49], ["patients", "ORGANISM", 114, 122], ["patient", "SPECIES", 42, 49], ["patients", "SPECIES", 114, 122], ["the treatment schedule", "TREATMENT", 11, 33]]], ["In between patient visits, my staff and I carefully cleaned the treatment tables with 70% alcohol, and also chairs, desk and any other surfaces the patient may have contacted.", [["alcohol", "CHEMICAL", 90, 97], ["alcohol", "CHEMICAL", 90, 97], ["patient", "ORGANISM", 11, 18], ["alcohol", "SIMPLE_CHEMICAL", 90, 97], ["patient", "ORGANISM", 148, 155], ["patient", "SPECIES", 11, 18], ["patient", "SPECIES", 148, 155]]], ["Full clinic cleaning with antiseptic material was done every 4 hours.Gauteng, South AfricaOn March 15, 2020, the South African (SA) leadership declared a state of disaster due to COVID-19.", [["antiseptic material", "TREATMENT", 26, 45], ["COVID", "TEST", 179, 184]]], ["105 The regulations governing the state of disaster dictated only essential services could continue, including emergency medical treatment.Gauteng, South AfricaDuring that time, SA had comparatively few cases, few deaths, and large numbers of people who recovered from COVID-19.", [["deaths", "DISEASE", 214, 220], ["COVID-19", "CHEMICAL", 269, 277], ["people", "ORGANISM", 243, 249], ["people", "SPECIES", 243, 249], ["emergency medical treatment", "TREATMENT", 111, 138], ["COVID", "TEST", 269, 274], ["large", "OBSERVATION_MODIFIER", 226, 231]]], ["Because of the reduced demand on the health care system, SA was able to secure PPE, ventilators, and test kits.", [["the reduced demand", "PROBLEM", 11, 29], ["ventilators", "TREATMENT", 84, 95], ["test kits", "TEST", 101, 110], ["reduced", "OBSERVATION_MODIFIER", 15, 22]]], ["The National Department of Health had set up community test centers and secured 60 vehicles for mobile screening particularly in high risk areas such as townships.", [["mobile screening", "TEST", 96, 112]]], ["The National Institute for Communicable Diseases (NICD) monitored the COVID-19 pandemic in SA.", [["the COVID", "TEST", 66, 75]]], ["106 Although there were some areas that did not have enough PPE or sufficient testing facilities, this was minimal.", [["minimal", "OBSERVATION_MODIFIER", 107, 114]]], ["The gap that needed attention was relief funding.", [["relief funding", "TREATMENT", 34, 48]]], ["Chiropractors in SA were only allowed to register as sole proprietors, but the relief funding for such sole proprietors was extremely limited.", [["the relief funding", "TREATMENT", 75, 93], ["such sole proprietors", "TREATMENT", 98, 119]]], ["There were relief funds for registered businesses, however, with little to no relief funding for practitioners, there was a concern that many would not be able to practice once the lockdown was lifted.", [["relief", "OBSERVATION_MODIFIER", 11, 17]]], ["Registered businesses only had the option of loans, but no chiropractor was able to register as a business.Gauteng, South AfricaAll registered health care providers, including chiropractors, were permitted to consult emergency patients.", [["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235]]], ["Those essential to the COVID\u221219 pandemic (ie, the front-line staff for screening, testing, and treating) were permitted to be at work.", [["screening", "TEST", 71, 80], ["testing", "TEST", 82, 89]]], ["Chiropractors were permitted to consult in person only for patients with emergencies (eg, the patient may lose life or limb, or seriously deteriorate, if they did not receive intervention).", [["limb", "ANATOMY", 119, 123], ["patients", "ORGANISM", 59, 67], ["patient", "ORGANISM", 94, 101], ["limb", "ORGANISM_SUBDIVISION", 119, 123], ["person", "SPECIES", 43, 49], ["patients", "SPECIES", 59, 67], ["patient", "SPECIES", 94, 101], ["intervention", "TREATMENT", 175, 187], ["limb", "ANATOMY", 119, 123]]], ["To see patients, all health care providers required a permit as issued by their regulatory authority.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["Malpractice insurance and medical aid administrators were mobilized to bring policy in line with the amended regulations.Gauteng, South AfricaThe Chiropractic Association of South Africa (CASA) issued an advisory to its members to adhere to the regulations and to close their practices.", [["medical aid administrators", "TREATMENT", 26, 52]]], ["Chiropractors were informed that they were allowed only to consult with patients with emergency conditions and to adhere to strict PPE protocol.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["strict PPE protocol", "TREATMENT", 124, 143]]], ["The CASA initiated a series of webinars, to educate chiropractors on the topics of COVID-19 as well as telehealth, and a presentation on the increase and change in hygiene protocol which needs to be followed.", [["COVID", "TREATMENT", 83, 88], ["change in hygiene protocol", "TREATMENT", 154, 180]]], ["These courses allowed practitioners to gain continuing education credits at that time.Gauteng, South AfricaKendrah L Da Silva.", [["continuing education credits", "TREATMENT", 44, 72]]], ["I use the Medici platform (Medici Technologies, LLC, Austin, TX, USA) to participate in telehealth consultations with my patients.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["LLC", "ANATOMY", 48, 51]]], ["Most patients expressed that they wished to wait for the face-to-face consult once the lockdown orders have been removed.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Patients who participated in telehealth visits responded positively about the encounter and many experienced a reduction in their chief complaint, such as pain.Gauteng, South AfricaBefore the lockdown was implemented, when I was seeing patients with face-to-face visits, I put out hand sanitizer for the patients.", [["hand", "ANATOMY", 281, 285], ["pain", "DISEASE", 155, 159], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 236, 244], ["hand", "ORGANISM_SUBDIVISION", 281, 285], ["patients", "ORGANISM", 304, 312], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 304, 312], ["pain", "PROBLEM", 155, 159]]], ["I have always sanitized before each patient, and handwashing after each patient.", [["patient", "ORGANISM", 36, 43], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 36, 43], ["patient", "SPECIES", 72, 79]]], ["Therefore, these practices continued.", [["these practices", "TREATMENT", 11, 26]]], ["I wore a surgical mask and a coat, which was washed at the end of each day.", [["a surgical mask", "TREATMENT", 7, 22], ["a coat", "TREATMENT", 27, 33]]], ["Most patients at that time wore their own masks.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["All touch surfaces were sanitized between patients.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50]]], ["Patients were booked with sanitization gaps in between.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["sanitization gaps", "TEST", 26, 43]]], ["I informed my patients through electronic communications.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Information sent to patients originated from the South African COVID\u221219 response, the WFC, and CASA.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["For patients needing more personal attention, I helped by telephone or by video teleconsultations.Amsterdam, NetherlandsStarting March 16, 2020, on orders of the Dutch government, schools, day care centers and restaurants closed, and working from home was encouraged.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["107 A week later, government leaders announced a partial lockdown to allow hospitals to cope with increasing presentations of patients with COVID-19 and to allow a level of herd immunity to develop.", [["patients", "ORGANISM", 126, 134], ["herd", "ORGANISM_SUBDIVISION", 173, 177], ["patients", "SPECIES", 126, 134], ["COVID", "TREATMENT", 140, 145]]], ["108 In the Netherlands, chiropractic is an unregulated profession.", [["unregulated", "OBSERVATION_MODIFIER", 43, 54], ["profession", "OBSERVATION", 55, 65]]], ["However, patients do not need a referral to see a chiropractor.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["109 On March 23, the Netherlands National Institute for Public Health and the Environment (ie, known as Rijksinstituut voor Volksgezondheid en Milieu (RIVM)) increased public protection and limited health care provision for hands-on and para-medical professions.", [["Rijksinstituut voor Volksgezondheid en Milieu (RIVM)", "TREATMENT", 104, 156], ["increased public protection", "TREATMENT", 158, 185]]], ["110, 111 On April 15, the Netherlands Chiropractors Association (NCA) aided clarification that chiropractors were allowed to treat severe cases using PPE measures.", [["PPE measures", "TREATMENT", 150, 162]]], ["Thus, chiropractic care was opened back up, \"in exceptional cases if the patient has a medical indication for this, the care cannot be given remotely or cannot be postponed and the practitioner during the treatment can comply with all advice from RIVM regarding personal protective equipment.\" 111 On April 29, the RIVM changed the regulations again, resulting in chiropractors and other alternative care providers to be limited to only telehealth visits through May 11.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["chiropractic care", "TREATMENT", 6, 23]]], ["My patients have predominantly chronic and complex concerns with a variety of co-morbidities.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["predominantly", "OBSERVATION_MODIFIER", 17, 30], ["chronic", "OBSERVATION_MODIFIER", 31, 38]]], ["Following the governmental regulations, I saw patients with severe symptoms from March 16 to 23, which was followed by not seeing patients between March 23 and April 15.", [["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 130, 138], ["severe symptoms", "PROBLEM", 60, 75]]], ["Between April 15 and 29, I saw patients again.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["I was very selective to which patients I saw since the risk of patients contracting the COVID-19 could potentially increase when patients were traveling to and from the appointment.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 129, 137]]], ["To answer their questions and concerns, I offered email consultations for my patients.Amsterdam, NetherlandsWhen I was seeing patients, as per the NCA hygiene standards, I wore an N95 mask, gloves, and a shirt exclusively for seeing patients.", [["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 233, 241], ["an N95 mask", "TREATMENT", 177, 188], ["gloves", "TREATMENT", 190, 196]]], ["Patients were asked to wash their hands thoroughly when they entered my clinic.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["My chiropractic table was outfitted with disposable layers for each patient.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75]]], ["The chiropractic table and surfaces that were touched were cleaned.", [["The chiropractic table", "TREATMENT", 0, 22], ["surfaces", "OBSERVATION_MODIFIER", 27, 35]]], ["After the visit, I cleaned the door handles as patients exited.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["I indicated in the patient clinical record the level of urgency of the patient's concern and the hygiene measures provided.", [["patient", "ORGANISM", 19, 26], ["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 19, 26], ["patient", "SPECIES", 71, 78], ["urgency", "PROBLEM", 56, 63], ["the hygiene measures", "TREATMENT", 93, 113]]], ["Three days after the treatment I emailed the patients to ascertain how they responded to chiropractic care and if they developed any symptoms of COVID-19.SingaporeOn January 23, 2020, the first case of the COVID-19 infection infiltrated the shores of Singapore.", [["COVID-19", "CHEMICAL", 206, 214], ["infection", "DISEASE", 215, 224], ["COVID-19", "CHEMICAL", 145, 153], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["the treatment", "TREATMENT", 17, 30], ["chiropractic care", "TREATMENT", 89, 106], ["any symptoms", "PROBLEM", 129, 141], ["COVID", "TEST", 145, 150], ["the COVID", "TEST", 202, 211], ["infection", "PROBLEM", 215, 224], ["infection", "OBSERVATION", 215, 224]]], ["113 Prior to that, the government was already keeping a close eye on the spread of disease at ground zero, Wuhan, China as the number of Chinese travelers for leisure and business to Singapore, hit 3.6 million visits in 2019.", [["eye", "ANATOMY", 62, 65], ["eye", "ORGAN", 62, 65], ["disease", "PROBLEM", 83, 90]]], ["114 Hence, it was not a matter of if the disease would reach the shores of Singapore, but a matter of when.", [["the disease", "PROBLEM", 37, 48], ["disease", "OBSERVATION", 41, 48]]], ["On April 7, 2020, the government implemented restraints to contain the spread of the disease.", [["restraints", "TREATMENT", 45, 55], ["the disease", "PROBLEM", 81, 92], ["disease", "OBSERVATION", 85, 92]]], ["115 Jobs that the government deemed as non-essential were required to cease and people to work from home.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86]]], ["Even though we were disappointed, chiropractors abided by the Ministry of Health's decision that they should remain closed at that time.SingaporeTerrance B.K. Yap.", [["Yap", "PROTEIN", 159, 162]]], ["Prior to closing my clinic on April 7, I took the proper hygiene measures such as social distancing, wearing a face mask, and temperature reading for all staff and patients.", [["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["the proper hygiene measures", "TREATMENT", 46, 73], ["a face mask", "TREATMENT", 109, 120]]], ["The air was regularly sanitized and clinic equipment disinfected after each patient.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["air", "OBSERVATION", 4, 7]]], ["Additionally, patients were required to answer and sign a travel declaration at every visit, enabling contact tracing if necessary.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Patients were to rest at home or seek medical attention if they had flu symptoms.", [["flu", "DISEASE", 68, 71], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["flu symptoms", "PROBLEM", 68, 80]]], ["These preventive measures were to safeguard patients and staff as well as to assure the public.Athens, GreeceOn February 26, 2020, COVID-19 first appeared in Greece.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["COVID", "TEST", 131, 136]]], ["116 Through early March, state authorities issued precautionary guidelines and recommendations were implemented locally to include the closure of schools and the suspension of cultural and sports events in the affected geographical regions.", [["the closure of schools", "TREATMENT", 131, 153]]], ["On March 10, with 89 confirmed cases and no deaths yet in the country, the government suspended the operation of all educational institutions nationwide 117 and on March 13 all parades, cafes, bars, restaurants, museums, shopping centers, and sports facilities in the country were closed.", [["deaths", "DISEASE", 44, 50]]], ["119 Following this, the government announced a series of financial support measuring 10 billion Euros to support the economy, including chiropractors.", [["financial support", "TREATMENT", 57, 74]]], ["120 On March 23, restriction on all non-essential citizen movement throughout Greece was imposed.", [["non-essential", "OBSERVATION_MODIFIER", 36, 49], ["citizen movement", "OBSERVATION", 50, 66]]], ["These measures were considered among the most proactive and strict in Europe and were reported by international press as the reason behind slowing the spread of the disease and having kept the number of deaths among the lowest in Europe.", [["deaths", "DISEASE", 203, 209], ["the disease", "PROBLEM", 161, 172], ["disease", "OBSERVATION", 165, 172]]], ["122, 123 Chiropractic practices had not been asked to shut down by the authorities.", [["Chiropractic practices", "TREATMENT", 9, 31]]], ["However, on March 15, due to the lack of chiropractic legislation, regulation, and malpractice insurance, the Hellenic Chiropractors' Association recommended that its' members enact a complete shutdown of chiropractic practices in the name of public safety.", [["chiropractic legislation", "TREATMENT", 41, 65], ["chiropractic practices", "TREATMENT", 205, 227]]], ["In the absence of any recognition and or communication between the health care authorities and the chiropractic profession, it was prioritized to act responsibly and take no unnecessary risks in contributing to the spread of the disease.Athens, GreeceVasileios S Gkolfinopoulos.", [["the disease", "PROBLEM", 225, 236], ["disease", "OBSERVATION", 229, 236]]], ["Before closing and since March 2, my office was operating with strict precaution measures in place in the form of: spacing out of appointments; repetitive disinfection of all surfaces during the day; toilet disinfection after each use; hand sanitizer available in the reception area and treatment rooms; use of mask and gloves by practitioner; thorough disinfection of treatment benches before and after every treatment.", [["hand", "ANATOMY", 236, 240], ["strict precaution measures", "TREATMENT", 63, 89], ["toilet disinfection", "TREATMENT", 200, 219], ["hand sanitizer", "TREATMENT", 236, 250], ["mask", "TREATMENT", 311, 315], ["gloves", "TREATMENT", 320, 326], ["treatment benches", "TREATMENT", 369, 386]]], ["Patients were screened by telephone and if they exhibited any known symptoms of COVID-19 they were advised to stay at home.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["any known symptoms", "PROBLEM", 58, 76]]], ["These included advice on selfcare, reassurance, psychological support, ergonomics, recommendations for diet/supplements, and rehabilitative exercises.Bucaramanga, ColombiaOn March 6, 2020, the first 3 COVID-19 cases were reported in Colombia.", [["selfcare", "TREATMENT", 25, 33], ["reassurance", "TREATMENT", 35, 46], ["psychological support", "TREATMENT", 48, 69], ["diet/supplements", "TREATMENT", 103, 119], ["rehabilitative exercises", "TREATMENT", 125, 149]]], ["125 Health workers initially were only allowed to work if they worked with concerns related to COVID-19 patients.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112]]], ["Adults could exercise outside while practicing social distancing during early morning.", [["Adults", "ORGANISM", 0, 6], ["Adults", "SPECIES", 0, 6]]], ["Air and ground transportation were restricted only for passengers.Bucaramanga, ColombiaGabriel Quintero.", [["Bucaramanga", "TREATMENT", 66, 77], ["ground transportation", "OBSERVATION", 8, 29]]], ["My chiropractic practice is in the city of Bucaramanga.", [["My chiropractic practice", "TREATMENT", 0, 24]]], ["When the outbreak started, I followed increased safety procedures in my practice, which included increased hand washing, wearing a mask, and no hand shaking to welcome patients.", [["hand", "ANATOMY", 107, 111], ["hand", "ANATOMY", 144, 148], ["hand", "ORGANISM_SUBDIVISION", 107, 111], ["hand", "ORGANISM_SUBDIVISION", 144, 148], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["increased hand washing", "TREATMENT", 97, 119], ["a mask", "TREATMENT", 129, 135], ["hand shaking", "PROBLEM", 144, 156], ["washing", "OBSERVATION", 112, 119]]], ["Since that time, I informed my patients via telehealth using WhatsApp (Menlo Park, California) and e-mail to stay home following government orders.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["I provided patients with important information in response to COVID-19.", [["COVID-19", "CHEMICAL", 62, 70], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["COVID", "TEST", 62, 67]]], ["I advised them about improving posture, maintaining lumbar support when sitting, especially for those who are working at home.", [["lumbar", "ANATOMY", 52, 58], ["lumbar", "ORGANISM_SUBDIVISION", 52, 58], ["lumbar support", "TREATMENT", 52, 66], ["lumbar", "ANATOMY", 52, 58]]], ["I educated them about using an orthopedic pillow when in bed, proper hydration, good nutrition, decreasing refined sugar intake, and proper breathing methods.", [["sugar", "CHEMICAL", 115, 120], ["sugar", "SIMPLE_CHEMICAL", 115, 120], ["an orthopedic pillow", "TREATMENT", 28, 48], ["proper hydration", "TREATMENT", 62, 78], ["proper breathing methods", "TREATMENT", 133, 157]]], ["For those who had musculoskeletal complaints, I provided recommendations depending on their need, such as information about ice, exercise, and stretching.", [["musculoskeletal complaints", "PROBLEM", 18, 44]]], ["I emphasized the importance of mobility since sedentary life has negative consequences for the spine and general health.Bucaramanga, ColombiaI have a general practice that normally sees about 40 patients per day, 5 days a week.", [["spine", "ANATOMY", 95, 100], ["spine", "MULTI-TISSUE_STRUCTURE", 95, 100], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["spine", "ANATOMY", 95, 100], ["Colombia", "OBSERVATION", 133, 141]]], ["If a test was positive and the person was asymptomatic, that person stayed home isolated in quarantine until the next COVID-19 test was negative.", [["person", "SPECIES", 31, 37], ["person", "SPECIES", 61, 67], ["a test", "TEST", 3, 9], ["asymptomatic", "PROBLEM", 42, 54], ["the next COVID", "TEST", 109, 123]]], ["If positive and symptomatic, the person would have been hospitalized for treatment.", [["person", "SPECIES", 33, 39], ["positive", "PROBLEM", 3, 11], ["symptomatic", "PROBLEM", 16, 27], ["treatment", "TREATMENT", 73, 82], ["symptomatic", "OBSERVATION_MODIFIER", 16, 27]]], ["No more than 4 patients were scheduled per hour in the clinic, each patient participated with disinfection and temperature measurement when entering the clinic.", [["patients", "ORGANISM", 15, 23], ["patient", "ORGANISM", 68, 75], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 68, 75], ["disinfection", "TREATMENT", 94, 106], ["temperature measurement", "TEST", 111, 134]]], ["Patients wore masks.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Areas of contact by the patient, such as treatment tables and areas in the reception room, were disinfected after each patient.Izmir, TurkeyThe first cases of COVID-19 in the Eastern Mediterranean and Middle East region was reported on February 19, 2020 in _ Iran.", [["COVID-19", "CHEMICAL", 159, 167], ["patient", "ORGANISM", 24, 31], ["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 24, 31], ["patient", "SPECIES", 119, 126], ["treatment tables", "TREATMENT", 41, 57], ["COVID", "TEST", 159, 164], ["contact", "OBSERVATION", 9, 16], ["Middle", "ANATOMY_MODIFIER", 201, 207]]], ["127 The first case of COVID-19 in Turkey was detected on March 11.", [["COVID", "TEST", 22, 27]]], ["128 Since then, the Turkish authorities took systematic measures to control the spread of the coronavirus.", [["coronavirus", "DISEASE", 94, 105], ["coronavirus", "ORGANISM", 94, 105], ["systematic measures", "TREATMENT", 45, 64], ["the coronavirus", "PROBLEM", 90, 105]]], ["The office of the Deputy Prime Ministry and Ministry of Foreign Affairs of the Turkish Republic of Northern Cyprus extended a partial curfew and travel ban to try to mitigate the spread of the disease.", [["a partial curfew", "TREATMENT", 124, 140], ["the disease", "PROBLEM", 189, 200], ["Foreign Affairs", "OBSERVATION", 56, 71], ["disease", "OBSERVATION", 193, 200]]], ["129 All people who were infected were sent to a designated hospital for testing, treatment, and observation under quarantine guidelines for 14 days.", [["people", "ORGANISM", 8, 14], ["people", "SPECIES", 8, 14], ["testing", "TEST", 72, 79], ["treatment", "TREATMENT", 81, 90]]], ["There was a partial curfew on leaving home during the weekdays and a complete curfew on weekends.", [["partial", "OBSERVATION_MODIFIER", 12, 19]]], ["All museums, archaeological sites and public gathering places, including cafes, parks, swimming pools, barber shops and sports centers were closed.", [["museums", "OBSERVATION", 4, 11], ["archaeological sites", "OBSERVATION", 13, 33]]], ["Restaurants were closed except for takeaway or delivery services.", [["delivery services", "TREATMENT", 47, 64]]], ["All individuals were to wear cloth face coverings in supermarkets and workplaces as well as in all forms of transportation including private vehicles with at least 2 persons inside.", [["persons", "SPECIES", 166, 173], ["cloth face coverings", "TREATMENT", 29, 49]]], ["Local authorities could put in place additional COVID-19 restrictions with little or no advanced notice.", [["additional COVID", "TREATMENT", 37, 53]]], ["My office was closed except for 1 day of the week to support patients with noncomplicated, acute spine pain causing daily disability.", [["spine", "ANATOMY", 97, 102], ["pain", "DISEASE", 103, 107], ["disability", "DISEASE", 122, 132], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["acute spine pain", "PROBLEM", 91, 107], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["spine", "ANATOMY", 97, 102]]], ["One of my priorities was to care for health care providers working in local hospitals caring for patients with COVID-19.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105]]], ["Patient communication in my office was by telephone.", [["Patient", "SPECIES", 0, 7]]], ["I recommended home care, such as exercises.", [["home care", "TREATMENT", 14, 23]]], ["When caring for patients in person, the patients were required to have government issued N-95 face masks.", [["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 16, 24], ["person", "SPECIES", 28, 34], ["patients", "SPECIES", 40, 48], ["face masks", "TREATMENT", 94, 104]]], ["Patients were required to take off their shoes outside of the office.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["We provided surgical overshoes for patients.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["surgical overshoes", "TREATMENT", 12, 30]]], ["Patients were required to thoroughly wash their hands before entering the chiropractic treatment space.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the chiropractic treatment space", "TREATMENT", 70, 102]]], ["Chiropractic tables were sanitized between each patient visit.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["Chiropractic tables", "TREATMENT", 0, 19]]], ["Patients were provided with standard government issued flyers with public health information for how to keep themselves and their family clean and sanitized.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The hazards of smoking and positives of not smoking were shared extensively.", [["smoking", "CHEMICAL", 15, 22], ["smoking", "CHEMICAL", 44, 51]]], ["Patients were directed to the WHO and Turkish health ministry updates for information and advised to stay away from social media news agencies on the matter to prevent the spread of misinformation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Any patients who showed signs of anxiety or panic were given reassurance and empathy.", [["anxiety", "DISEASE", 33, 40], ["panic", "DISEASE", 44, 49], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["anxiety", "PROBLEM", 33, 40], ["panic", "PROBLEM", 44, 49], ["empathy", "PROBLEM", 77, 84]]], ["As a policy of my clinic, I always have shown empathy to the urgent needs of my patients and the public.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88]]], ["Those in economic hardship have always been dealt with humanely.T A G G E D H 1 DISCUSSIONT A G G E D E N DAs far as the authors are aware, this is the first published report that describes individual chiropractic practitioners' experiences and responses to the COVID-19 pandemic.", [["T", "SPECIES", 64, 65], ["the COVID", "TEST", 258, 267]]], ["This study was based on a constructivist and naturalistic position and each practitioner was bound by their local regulations; therefore, some degree of variation was expected.", [["This study", "TEST", 0, 10], ["variation", "OBSERVATION_MODIFIER", 153, 162]]], ["The experiences represented here, as of May 4, ranged from the country with the greatest number of confirmed cases of COVID-19 to other countries with fewer cases.", [["COVID", "TEST", 118, 123]]], ["This sample covers all 7 WFC regions (ie, African, Asian, Eastern Mediterranean, European, Latin American, North American, and Pacific) and provides insights into measures being taken by chiropractors around the world during the COVID-19 pandemic.T A G G E D H 1 DISCUSSIONT A G G E D E N DAs demonstrated in this sample, chiropractors work in a variety of settings, 17 each of which may have an influence on responses during a disaster or pandemic.", [["D E N", "CHEMICAL", 283, 288], ["T", "SPECIES", 247, 248], ["This sample", "TEST", 0, 11], ["the COVID", "TEST", 225, 234], ["A G G E D E N DAs", "TREATMENT", 275, 292], ["pandemic", "PROBLEM", 440, 448]]], ["17 Each work environment has its own unique requirements for day-to-day operations, but these may be especially different when facing a natural disaster or pandemic.T A G G E D H 1 DISCUSSIONT A G G E D E N DFor the chiropractors who practiced in solo practice, they assumed responsibility for the function of the office, including patient care, communications, and sanitation.", [["patient", "ORGANISM", 332, 339], ["patient", "SPECIES", 332, 339], ["T", "SPECIES", 165, 166], ["pandemic", "PROBLEM", 156, 164]]], ["In other settings, chiropractors worked with other health professionals, such as medical providers, physical therapists, acupuncturists, massage therapists, or other health providers.", [["massage therapists", "TREATMENT", 137, 155]]], ["However, hospitals had their own regulations in addition to local government regulations, such as for infection control and which providers on the workforce may continue care face-to-face.", [["infection", "DISEASE", 102, 111], ["local government regulations", "TREATMENT", 60, 88], ["infection control", "TREATMENT", 102, 119]]], ["Thus, those in more integrated practice settings or hospitals may have had more resources but needed to consider additional policies and mandates that resulted from the more complex infrastructure.T A G G E D H 1 DISCUSSIONT A G G E D E N DThemes were observed among these independent reports.", [["T", "SPECIES", 197, 198], ["A G G E D E N DThemes", "TREATMENT", 225, 246], ["complex", "OBSERVATION_MODIFIER", 174, 181], ["infrastructure", "OBSERVATION", 182, 196]]], ["They took great efforts to protect the health of their staff, patients, and the public.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["Others continued to see patients in their clinic complying with public health regulations.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["public health regulations", "TREATMENT", 64, 89]]], ["Many modified their practices by increasing the use of available technology to reach patients who needed care.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93]]], ["And, many focused their care to serve front-line health care workers, who were responsible for taking care of patients who were acutely sick with COVID-19.T A G G E D H 1 DISCUSSIONT A G G E D E N DAnother theme was responsiveness.", [["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["COVID", "TEST", 146, 151]]], ["Each practitioner responded to unique timelines, government regulations, and regional restrictions as COVID-19 increased in prevalence.", [["government regulations", "TREATMENT", 49, 71], ["COVID", "TEST", 102, 107]]], ["Despite these challenges, these chiropractors complied with local regulations and health boards and adhered to the recommendations of global and national bodies, such as WHO and the Centers for Disease Control and Prevention.", [["global and national bodies", "TREATMENT", 134, 160], ["Disease Control", "TREATMENT", 194, 209]]], ["They monitored changes in regulations and modified their practices to be compliant.T A G G E D H 1 DISCUSSIONT A G G E D E N DAnother theme was the application of person-centered care, which is when a practitioner has respect for patients' preferences and values and provides them with information to help decide when to seek care and when to engage in self-care.", [["patients", "ORGANISM", 230, 238], ["person", "SPECIES", 163, 169], ["patients", "SPECIES", 230, 238], ["T", "SPECIES", 83, 84]]], ["26 The chiropractors communicated with their patients about the pandemic situation, including what care was available, how to access care, and other helpful health information about COVID-19.", [["COVID-19", "CHEMICAL", 182, 190], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["COVID", "TEST", 182, 187]]], ["They viewed their patients' needs from their patients' points of view, such as reducing potential exposure within the clinic and in other environments, such as traveling to and from the clinic or while waiting for their appointments.T A G G E D H 1 DISCUSSIONT A G G E D E N DTheir observations were congruent with the biopsychosocial model.", [["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 45, 53], ["T", "SPECIES", 233, 234], ["A G G E D E N DTheir observations", "TREATMENT", 261, 294]]], ["In addition to the typical physical concerns that patients present to for chiropractic care, such as neck and back pain, the chiropractors observed that the pandemic likely resulted in their patients experiencing increased mental health concerns and physical signs and symptoms due to stress.", [["neck", "ANATOMY", 101, 105], ["neck and back pain", "DISEASE", 101, 119], ["patients", "ORGANISM", 50, 58], ["neck", "ORGANISM_SUBDIVISION", 101, 105], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 191, 199], ["chiropractic care", "TREATMENT", 74, 91], ["neck and back pain", "PROBLEM", 101, 119], ["increased mental health concerns", "PROBLEM", 213, 245], ["physical signs and symptoms", "PROBLEM", 250, 277], ["stress", "PROBLEM", 285, 291], ["neck", "ANATOMY", 101, 105], ["back", "ANATOMY", 110, 114]]], ["The association of mental health and musculoskeletal pain and dysfunction is an important part of the biopsychosocial model of health care.", [["musculoskeletal", "ANATOMY", 37, 52], ["musculoskeletal pain", "DISEASE", 37, 57], ["mental health", "PROBLEM", 19, 32], ["musculoskeletal pain", "PROBLEM", 37, 57], ["dysfunction", "PROBLEM", 62, 73], ["musculoskeletal", "ANATOMY", 37, 52], ["pain", "OBSERVATION", 53, 57]]], ["26 These observations of mental health symptoms and the COVID-19 pandemic are congruent with the observations of WHO.", [["mental health symptoms", "PROBLEM", 25, 47], ["the COVID", "TEST", 52, 61]]], ["131 These chiropractors demonstrated collaborative behaviors.", [["collaborative behaviors", "OBSERVATION", 37, 60]]], ["Those in solo practice who did not offer in-person visits, referred patients to other practitioners.", [["patients", "ORGANISM", 68, 76], ["person", "SPECIES", 44, 50], ["patients", "SPECIES", 68, 76]]], ["26 In summary, even though most of the participants were in different countries or types of practices, their responses were relatively consistent.", [["participants", "ORGANISM", 39, 51], ["participants", "SPECIES", 39, 51]]], ["They abided by national and WHO recommendations and they adopted innovative strategies to maintain connectivity with patients through a people-centered, integrated, and collaborative approach.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["people", "SPECIES", 136, 142], ["innovative strategies", "TREATMENT", 65, 86]]], ["They described that providing care was especially challenging when the evidence needed to make decisions and local regulations continued to change.", [["local regulations", "TREATMENT", 109, 126]]], ["They focused first on serving their patients, including front-line healthcare personnel, and continued to monitor the COVID-19 situation and responded accordingly as new regulations and information became available.T A G G E D H 1 LIMITATIONST A G G E D E N DEach practitioner's report was limited in length.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["T", "SPECIES", 215, 216], ["the COVID", "TEST", 114, 123]]], ["Thus, a detailed recount of each practitioner's operating procedures during the early phase of the COVID-19 pandemic was not possible.", [["the COVID", "TEST", 95, 104]]], ["This report is limited to the individuals who responded during a 2-week period in the early months of the COVID-19 pandemic.", [["the COVID", "TEST", 102, 111], ["pandemic", "PROBLEM", 115, 123]]], ["The invitation list of providers was created by the primary author without the knowledge or input of the other coauthors thus, the participants reflects the bias of this author.", [["participants", "SPECIES", 131, 143]]], ["There may be non-responder bias since those who did not reply were not included.", [["non-responder bias", "PROBLEM", 13, 31], ["may be", "UNCERTAINTY", 6, 12], ["non-responder bias", "OBSERVATION", 13, 31]]], ["Regulations have likely changed since the time of capture of this information.T A G G E D H 1 CONCLUSIONT A G G E D E N DAlthough the chiropractors in this report practice in different cities and countries, their compliance with changing local regulations, concern for staff and patient safety, and peoplecentered responses were consistent.", [["patient", "ORGANISM", 279, 286], ["patient", "SPECIES", 279, 286], ["T", "SPECIES", 78, 79], ["A G G E D E N DAlthough the chiropractors", "TREATMENT", 106, 147]]], ["They did outreach and communicated with patients and they observed increased stress and mental health issues.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["increased stress and mental health issues", "PROBLEM", 67, 108]]], ["They recognized and abided by changing governmental regulations and they adopted innovative strategies to communicate with and provide care for patients.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152]]], ["This sample covers all 7 WFC regions (i.e., African, Asian, Eastern Mediterranean, European, Latin American, North American, and Pacific) and provides insights into measures being taken by chiropractors during the early stages of the COVID-19 pandemic.", [["This sample", "TEST", 0, 11], ["the COVID", "TEST", 230, 239]]], ["This information may assist the chiropractic profession as it prepares for different scenarios as new information about this disease evolves.Practical ApplicationsChiropractic practitioners in this sample demonstrated patient-centered behaviors to serve their patients, including front-line healthcare personnel They modified their practices to comply with unique timelines, government regulations, and regional restrictions.", [["patient", "ORGANISM", 218, 225], ["patients", "ORGANISM", 260, 268], ["patient", "SPECIES", 218, 225], ["patients", "SPECIES", 260, 268], ["this disease evolves", "PROBLEM", 120, 140], ["Chiropractic practitioners", "TREATMENT", 163, 189]]], ["They reported increasing sanitation measures and modified patient interactions to reduce spread of the contagion.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["increasing sanitation measures", "TREATMENT", 14, 44], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["sanitation", "OBSERVATION", 25, 35]]], ["They monitored the COVID-19 situation and responded accordingly as new regulations and information became available.", [["the COVID", "TEST", 15, 24]]], ["They modified practice and patient encounters to include telehealth.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34]]]], "PMC7315971": [["IntroductionIn December 2019, a novel coronavirus caused a cluster of cases of severe pneumonia in Wuhan, China.", [["coronavirus", "DISEASE", 38, 49], ["pneumonia", "DISEASE", 86, 95], ["coronavirus", "ORGANISM", 38, 49], ["a novel coronavirus", "PROBLEM", 30, 49], ["severe pneumonia", "PROBLEM", 79, 95], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["pneumonia", "OBSERVATION", 86, 95]]], ["The World Health Organization (WHO) has since named the disease \u201ccoronavirus disease 2019\u201d (COVID-19) and the etiologic agent \u201csevere acute respiratory syndrome-coronavirus-2\u201d (SARS-CoV-2).", [["coronavirus disease", "DISEASE", 65, 84], ["acute respiratory syndrome", "DISEASE", 134, 160], ["COVID-19", "CELL", 92, 100], ["-coronavirus", "SPECIES", 160, 172], ["the disease \u201ccoronavirus disease", "PROBLEM", 52, 84], ["COVID", "TEST", 92, 97], ["severe acute respiratory syndrome", "PROBLEM", 127, 160], ["coronavirus", "TEST", 161, 172], ["SARS", "TEST", 177, 181], ["CoV", "TEST", 182, 185], ["coronavirus disease", "OBSERVATION", 65, 84], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["respiratory syndrome", "OBSERVATION", 140, 160]]], ["On January 30, 2020, the first human-to-human transmission of this infection was confirmed, and the WHO declared COVID-19 a Public Health Emergency of Concern.", [["infection", "DISEASE", 67, 76], ["human", "ORGANISM", 31, 36], ["human", "ORGANISM", 40, 45], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 40, 45], ["this infection", "PROBLEM", 62, 76], ["infection", "OBSERVATION", 67, 76]]], ["By March 2020, there were more than 400,000 recorded cases of COVID-19 worldwide, prompting the WHO to declare a global pandemic.[1]", [["COVID", "TEST", 62, 67], ["a global pandemic", "PROBLEM", 111, 128]]]], "0e07a59dda6552d13bf7695d605f7baa983c23e8": [["IntroductionH1N1 influenza A was first described in humans in April 2009 [1] .", [["influenza A", "DISEASE", 17, 28], ["H1N1 influenza A", "ORGANISM", 12, 28], ["humans", "ORGANISM", 52, 58], ["H1N1 influenza", "SPECIES", 12, 26], ["humans", "SPECIES", 52, 58], ["humans", "SPECIES", 52, 58], ["IntroductionH1N1 influenza A", "PROBLEM", 0, 28]]], ["This disease which was known to affect pigs was noted to have become established in human patients in Mexico and subsequently seen to spread to Southern California and thus worldwide.", [["pigs", "ORGANISM", 39, 43], ["human", "ORGANISM", 84, 89], ["patients", "ORGANISM", 90, 98], ["pigs", "SPECIES", 39, 43], ["human", "SPECIES", 84, 89], ["patients", "SPECIES", 90, 98], ["pigs", "SPECIES", 39, 43], ["human", "SPECIES", 84, 89], ["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12]]], ["The Centres for Disease Control and Prevention in the US subsequently confirmed that this new H1N1 strain (S-OIV) contained a number of unique segments that had not been previously identified in either humans or animals [2] .IntroductionThe WHO has reported 506,770 confirmed cases of H1N1 and 15,174 deaths at the end of January 2010 [3] .", [["H1N1", "DISEASE", 285, 289], ["deaths", "DISEASE", 301, 307], ["S-OIV", "ORGANISM", 107, 112], ["humans", "ORGANISM", 202, 208], ["humans", "SPECIES", 202, 208], ["humans", "SPECIES", 202, 208], ["Disease Control", "TREATMENT", 16, 31], ["the US", "TEST", 50, 56], ["this new H1N1 strain (S-OIV)", "PROBLEM", 85, 113], ["H1N1", "PROBLEM", 285, 289], ["new", "OBSERVATION_MODIFIER", 90, 93], ["H1N1", "OBSERVATION", 94, 98]]], ["This illness has become a global pandemic and by November 2009 the critical illness burden of H1N1 was known, with 30 patients per million of population admitted to intensive care units (ICU) [4] .IntroductionIreland has been significantly affected by this global pandemic with 4,586 cases confirmed since April/May 2009, with 26 deaths [5] .", [["H1N1", "DISEASE", 94, 98], ["deaths", "DISEASE", 330, 336], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["H1N1", "PROBLEM", 94, 98], ["H1N1", "OBSERVATION", 94, 98]]], ["The main burden of the illness is reported in the urban centres of Health Service Executive (HSE) South, HSE West and HSE East.", [["illness", "DISEASE", 23, 30], ["main", "OBSERVATION_MODIFIER", 4, 8], ["burden", "OBSERVATION_MODIFIER", 9, 15], ["illness", "OBSERVATION", 23, 30]]], ["80% of cases in Ireland have been reported in those under 35 years.IntroductionThe characteristic clinical features of this illness are still emerging due to the relative short time period since first discovery of the virus.", [["this illness", "PROBLEM", 119, 131], ["the virus", "PROBLEM", 214, 223], ["virus", "OBSERVATION", 218, 223]]], ["Symptoms of seasonal influenza such as cough, malaise, fever and gastrointestinal upset remain common hallmarks of H1N1 infection, however, confusion, dehydration and persistent pyrexia has also been reported.", [["gastrointestinal", "ANATOMY", 65, 81], ["influenza", "DISEASE", 21, 30], ["cough", "DISEASE", 39, 44], ["fever", "DISEASE", 55, 60], ["gastrointestinal upset", "DISEASE", 65, 87], ["H1N1 infection", "DISEASE", 115, 129], ["confusion", "DISEASE", 140, 149], ["dehydration", "DISEASE", 151, 162], ["pyrexia", "DISEASE", 178, 185], ["gastrointestinal", "ORGAN", 65, 81], ["Symptoms", "PROBLEM", 0, 8], ["seasonal influenza", "PROBLEM", 12, 30], ["cough", "PROBLEM", 39, 44], ["malaise", "PROBLEM", 46, 53], ["fever", "PROBLEM", 55, 60], ["gastrointestinal upset", "PROBLEM", 65, 87], ["H1N1 infection", "PROBLEM", 115, 129], ["confusion", "PROBLEM", 140, 149], ["dehydration", "PROBLEM", 151, 162], ["persistent pyrexia", "PROBLEM", 167, 185], ["seasonal", "OBSERVATION_MODIFIER", 12, 20], ["influenza", "OBSERVATION", 21, 30], ["gastrointestinal", "ANATOMY", 65, 81], ["H1N1", "OBSERVATION_MODIFIER", 115, 119], ["infection", "OBSERVATION", 120, 129], ["persistent", "OBSERVATION_MODIFIER", 167, 177], ["pyrexia", "OBSERVATION", 178, 185]]], ["Patients with underlying chronic illnesses and those under 2 years and over 65 have been noted as highrisk groups and the majority of hospitalisations occur in these subgroups [6] .", [["chronic illnesses", "DISEASE", 25, 42], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["underlying chronic illnesses", "PROBLEM", 14, 42], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["illnesses", "OBSERVATION", 33, 42]]], ["Pregnant women and those with asthma were also noted to be high risk.IntroductionComplications of H1N1 that often lead to death include rapidly progressive pneumonia, acute respiratory distress syndrome (ARDS) and multi-organ failure [7, 8] .", [["respiratory", "ANATOMY", 173, 184], ["multi-organ", "ANATOMY", 214, 225], ["asthma", "DISEASE", 30, 36], ["H1N1", "DISEASE", 98, 102], ["death", "DISEASE", 122, 127], ["pneumonia", "DISEASE", 156, 165], ["acute respiratory distress syndrome", "DISEASE", 167, 202], ["ARDS", "DISEASE", 204, 208], ["multi-organ failure", "DISEASE", 214, 233], ["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["asthma", "PROBLEM", 30, 36], ["H1N1", "PROBLEM", 98, 102], ["death", "PROBLEM", 122, 127], ["rapidly progressive pneumonia", "PROBLEM", 136, 165], ["acute respiratory distress syndrome", "PROBLEM", 167, 202], ["ARDS", "PROBLEM", 204, 208], ["multi-organ failure", "PROBLEM", 214, 233], ["H1N1", "OBSERVATION", 98, 102], ["rapidly", "OBSERVATION_MODIFIER", 136, 143], ["progressive", "OBSERVATION_MODIFIER", 144, 155], ["pneumonia", "OBSERVATION", 156, 165], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["respiratory distress syndrome", "OBSERVATION", 173, 202], ["ARDS", "OBSERVATION", 204, 208], ["multi-organ", "ANATOMY", 214, 225], ["failure", "OBSERVATION", 226, 233]]], ["Similar to seasonal influenza, bacterial superinfection can lead to a significantly increased mortality rate [9] .IntroductionOver the past year, much has been published on the epidemiology and complications of this illness, with mortality rates reported of 7-14%, and ICU admission rates of 25% [10] .", [["influenza", "DISEASE", 20, 29], ["bacterial superinfection", "DISEASE", 31, 55], ["seasonal influenza", "PROBLEM", 11, 29], ["bacterial superinfection", "PROBLEM", 31, 55], ["a significantly increased mortality rate", "PROBLEM", 68, 108], ["this illness", "PROBLEM", 211, 223], ["mortality rates", "TEST", 230, 245], ["seasonal", "OBSERVATION_MODIFIER", 11, 19], ["influenza", "OBSERVATION", 20, 29], ["bacterial superinfection", "OBSERVATION", 31, 55]]], ["The incidence of renal insufficiency and renal failure is not well described.", [["renal", "ANATOMY", 17, 22], ["renal", "ANATOMY", 41, 46], ["renal insufficiency", "DISEASE", 17, 36], ["renal failure", "DISEASE", 41, 54], ["renal", "ORGAN", 17, 22], ["renal", "ORGAN", 41, 46], ["renal insufficiency", "PROBLEM", 17, 36], ["renal failure", "PROBLEM", 41, 54], ["renal", "ANATOMY", 17, 22], ["insufficiency", "OBSERVATION", 23, 36], ["renal", "ANATOMY", 41, 46], ["failure", "OBSERVATION", 47, 54]]], ["The most significant biochemical abnormalities associated with this illness have been transiently raised liver enzymes, and sporadic cases of rhabdomyolysis [11] .IntroductionThis study aims to highlight the common renal manifestations of H1N1 as seen in the Irish national tertiary referral centre for renal disease.MethodsThis was a retrospective cohort study of all patients who were admitted to our institution with clinical and/or virological evidence of H1N1 infection from July to November 2009.MethodsPatients were tested for H1N1 using standardised nasal/ throat swabs which were subsequently analysed using Centers for Disease Control (CDC)/Health Protection Surveillance Centre based primers [12] .", [["liver", "ANATOMY", 105, 110], ["renal", "ANATOMY", 215, 220], ["renal", "ANATOMY", 303, 308], ["nasal", "ANATOMY", 558, 563], ["rhabdomyolysis", "DISEASE", 142, 156], ["H1N1", "DISEASE", 239, 243], ["renal disease", "DISEASE", 303, 316], ["H1N1 infection", "DISEASE", 460, 474], ["liver", "ORGAN", 105, 110], ["renal", "ORGAN", 215, 220], ["renal", "ORGAN", 303, 308], ["patients", "ORGANISM", 369, 377], ["nasal", "ORGANISM_SUBDIVISION", 558, 563], ["liver enzymes", "PROTEIN", 105, 118], ["patients", "SPECIES", 369, 377], ["The most significant biochemical abnormalities", "PROBLEM", 0, 46], ["this illness", "PROBLEM", 63, 75], ["liver enzymes", "TEST", 105, 118], ["rhabdomyolysis", "PROBLEM", 142, 156], ["This study", "TEST", 175, 185], ["the common renal manifestations", "PROBLEM", 204, 235], ["H1N1", "PROBLEM", 239, 243], ["renal disease", "PROBLEM", 303, 316], ["a retrospective cohort study", "TEST", 333, 361], ["H1N1 infection", "PROBLEM", 460, 474], ["MethodsPatients", "TREATMENT", 502, 517], ["H1N1", "PROBLEM", 534, 538], ["standardised nasal/ throat swabs", "TREATMENT", 545, 577], ["Disease Control", "TREATMENT", 629, 644], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["biochemical", "OBSERVATION_MODIFIER", 21, 32], ["abnormalities", "OBSERVATION", 33, 46], ["rhabdomyolysis", "OBSERVATION", 142, 156], ["common renal", "ANATOMY", 208, 220], ["manifestations", "OBSERVATION", 221, 235], ["H1N1", "OBSERVATION", 239, 243], ["renal", "ANATOMY", 303, 308], ["disease", "OBSERVATION", 309, 316], ["H1N1", "OBSERVATION", 460, 464], ["throat", "ANATOMY", 565, 571]]], ["This is performed using real-time reverse transcriptase PCR, the most sensitive and specific method of diagnosis [13] .", [["reverse transcriptase", "PROTEIN", 34, 55], ["transcriptase PCR", "TEST", 42, 59]]], ["All testing was performed at the National Virus Reference Laboratory, at University College Dublin.MethodsAll patients who were thought to have H1N1 infection were highlighted by the attending clinical nurse manager or physician to the hospital pandemic/infection control team.", [["H1N1 infection", "DISEASE", 144, 158], ["infection", "DISEASE", 254, 263], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["All testing", "TEST", 0, 11], ["H1N1 infection", "PROBLEM", 144, 158], ["infection", "OBSERVATION", 149, 158], ["infection", "OBSERVATION", 254, 263]]], ["Subsequent swab results, gender, and age were noted.", [["swab", "ANATOMY", 11, 15], ["Subsequent swab results", "TEST", 0, 23]]], ["The admission pathway of these patients was also logged, including admission length, location of care, and discharge dates.MethodsA patient was deemed to have H1N1 influenza when they exhibited symptoms, and a positive or weakly positive viral swab result, as defined by the European Union (EU) Commission document of 30th April 2009 [14] .MethodsA subsequent standardised data collection protocol was created recording age, sex and biochemical values (sodium, potassium, urea and creatinine) at admission, discharge and peak values.", [["influenza", "DISEASE", 164, 173], ["sodium", "CHEMICAL", 453, 459], ["potassium", "CHEMICAL", 461, 470], ["urea", "CHEMICAL", 472, 476], ["creatinine", "CHEMICAL", 481, 491], ["sodium", "CHEMICAL", 453, 459], ["potassium", "CHEMICAL", 461, 470], ["urea", "CHEMICAL", 472, 476], ["creatinine", "CHEMICAL", 481, 491], ["patients", "ORGANISM", 31, 39], ["patient", "ORGANISM", 132, 139], ["sodium", "SIMPLE_CHEMICAL", 453, 459], ["potassium", "SIMPLE_CHEMICAL", 461, 470], ["urea", "SIMPLE_CHEMICAL", 472, 476], ["creatinine", "SIMPLE_CHEMICAL", 481, 491], ["patients", "SPECIES", 31, 39], ["patient", "SPECIES", 132, 139], ["H1N1 influenza", "PROBLEM", 159, 173], ["symptoms", "PROBLEM", 194, 202], ["a positive or weakly positive viral swab result", "PROBLEM", 208, 255], ["sodium", "TEST", 453, 459], ["potassium", "TEST", 461, 470], ["urea", "TEST", 472, 476], ["creatinine", "TEST", 481, 491], ["peak values", "TEST", 521, 532]]], ["Urinalysis was also recorded when available.MethodsMedical records of all H1N1-positive patients were then obtained to ascertain outcomes and interventions, including management of acute kidney injury, intensive care stay and need for renal replacement therapy.ResultsFrom 1st July to 31st November 2009, 378 patients were tested for H1N1 using nasal/throat swabs, of which 32 were positive.", [["kidney", "ANATOMY", 187, 193], ["renal", "ANATOMY", 235, 240], ["nasal", "ANATOMY", 345, 350], ["acute kidney injury", "DISEASE", 181, 200], ["H1N1", "DISEASE", 334, 338], ["H1N1", "ORGANISM", 74, 78], ["patients", "ORGANISM", 88, 96], ["kidney", "ORGAN", 187, 193], ["renal", "ORGAN", 235, 240], ["patients", "ORGANISM", 309, 317], ["nasal", "ORGANISM_SUBDIVISION", 345, 350], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 309, 317], ["Urinalysis", "TEST", 0, 10], ["interventions", "TREATMENT", 142, 155], ["management", "TREATMENT", 167, 177], ["acute kidney injury", "PROBLEM", 181, 200], ["renal replacement therapy", "TREATMENT", 235, 260], ["H1N1", "PROBLEM", 334, 338], ["nasal/throat swabs", "TEST", 345, 363], ["acute", "OBSERVATION_MODIFIER", 181, 186], ["kidney", "ANATOMY", 187, 193], ["injury", "OBSERVATION", 194, 200], ["renal", "ANATOMY", 235, 240], ["replacement", "OBSERVATION", 241, 252], ["throat", "ANATOMY", 351, 357]]], ["Two more patients were subsequently diagnosed as having H1N1 despite negative PCR.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["H1N1", "PROBLEM", 56, 60]]], ["This represents 1.1% of all patients who tested positive during this time period in the Republic of Ireland.ResultsThe median age of patients with H1N1 admitted to Beaumont hospital was 28.5, with a range of 9-62 years.", [["H1N1", "DISEASE", 147, 151], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 133, 141], ["H1N1", "PROBLEM", 147, 151]]], ["The majority of patients were Caucasian, of Irish ethnicity (89%) with the remainder being Eastern European and Asian (Table 1) .ResultsSymptoms alerting healthcare staff to the presence of H1N1 included; cough, GI upset, fever, malaise and headache.", [["H1N1", "DISEASE", 190, 194], ["cough", "DISEASE", 205, 210], ["fever", "DISEASE", 222, 227], ["headache", "DISEASE", 241, 249], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["H1N1", "PROBLEM", 190, 194], ["cough", "PROBLEM", 205, 210], ["GI upset", "PROBLEM", 212, 220], ["fever", "PROBLEM", 222, 227], ["malaise", "PROBLEM", 229, 236], ["headache", "PROBLEM", 241, 249], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["GI", "ANATOMY", 212, 214]]], ["Ten patients (29.4%) had underlying medical conditions.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["underlying medical conditions", "PROBLEM", 25, 54]]], ["The most prevalent comorbidity was hypertension or ischaemic heart disease.", [["heart", "ANATOMY", 61, 66], ["hypertension", "DISEASE", 35, 47], ["ischaemic heart disease", "DISEASE", 51, 74], ["heart", "ORGAN", 61, 66], ["hypertension", "PROBLEM", 35, 47], ["ischaemic heart disease", "PROBLEM", 51, 74], ["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["hypertension", "OBSERVATION", 35, 47], ["ischaemic", "OBSERVATION_MODIFIER", 51, 60], ["heart", "ANATOMY", 61, 66], ["disease", "OBSERVATION", 67, 74]]], ["None of the patients who tested positive were over 65 or under 2.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["None of the patients were known to be pregnant.ResultsThe average creatinine of those admitted was 99 lmol/l, and peak values throughout admission ranged from 11 to 610.", [["creatinine", "CHEMICAL", 66, 76], ["creatinine", "CHEMICAL", 66, 76], ["patients", "ORGANISM", 12, 20], ["creatinine", "SIMPLE_CHEMICAL", 66, 76], ["patients", "SPECIES", 12, 20], ["The average creatinine", "TEST", 54, 76], ["peak values", "TEST", 114, 125]]], ["Eleven patients (32%) developed acute kidney injury as defined by the RIFLE criteria [15] (creatinine range 120-610 lmol/l).", [["kidney", "ANATOMY", 38, 44], ["acute kidney injury", "DISEASE", 32, 51], ["creatinine", "CHEMICAL", 91, 101], ["creatinine", "CHEMICAL", 91, 101], ["patients", "ORGANISM", 7, 15], ["kidney", "ORGAN", 38, 44], ["patients", "SPECIES", 7, 15], ["acute kidney injury", "PROBLEM", 32, 51], ["the RIFLE criteria", "TEST", 66, 84], ["creatinine", "TEST", 91, 101], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["kidney", "ANATOMY", 38, 44], ["injury", "OBSERVATION", 45, 51]]], ["Four of these patients subsequently required renal replacement therapy, representing 11% of all patients admitted.", [["renal", "ANATOMY", 45, 50], ["patients", "ORGANISM", 14, 22], ["renal", "ORGAN", 45, 50], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 96, 104], ["renal replacement therapy", "TREATMENT", 45, 70], ["renal", "ANATOMY", 45, 50], ["replacement therapy", "OBSERVATION", 51, 70]]], ["Seven further patients developed acute kidney injury that responded to volume resuscitation.ResultsAll patients who required renal replacement therapy were admitted to the intensive care unit, and received either continuous veno-veno haemodiafiltration or intermittent haemodialysis.", [["kidney", "ANATOMY", 39, 45], ["renal", "ANATOMY", 125, 130], ["acute kidney injury", "DISEASE", 33, 52], ["patients", "ORGANISM", 14, 22], ["kidney", "ORGAN", 39, 45], ["patients", "ORGANISM", 103, 111], ["renal", "ORGAN", 125, 130], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 103, 111], ["acute kidney injury", "PROBLEM", 33, 52], ["volume resuscitation", "TREATMENT", 71, 91], ["renal replacement therapy", "TREATMENT", 125, 150], ["continuous veno-veno haemodiafiltration", "TREATMENT", 213, 252], ["intermittent haemodialysis", "TREATMENT", 256, 282], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["kidney", "ANATOMY", 39, 45], ["injury", "OBSERVATION", 46, 52], ["volume resuscitation", "OBSERVATION", 71, 91], ["renal", "ANATOMY", 125, 130], ["replacement", "OBSERVATION", 131, 142]]], ["These patients required an average of 22 days of renal replacement therapy (10-52 days), and those that were successfully discharged recovered full renal function.ResultsRenal dysfunction was attributed to acute tubular necrosis in the context of coexistent sepsis in all patients who required renal replacement therapy and in four of those that did not need dialysis.", [["renal", "ANATOMY", 49, 54], ["renal", "ANATOMY", 148, 153], ["Renal", "ANATOMY", 170, 175], ["tubular", "ANATOMY", 212, 219], ["renal", "ANATOMY", 294, 299], ["Renal dysfunction", "DISEASE", 170, 187], ["acute tubular necrosis", "DISEASE", 206, 228], ["sepsis", "DISEASE", 258, 264], ["patients", "ORGANISM", 6, 14], ["renal", "ORGAN", 49, 54], ["renal", "ORGAN", 148, 153], ["Renal", "ORGAN", 170, 175], ["tubular", "ORGAN", 212, 219], ["patients", "ORGANISM", 272, 280], ["renal", "ORGAN", 294, 299], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 272, 280], ["renal replacement therapy", "TREATMENT", 49, 74], ["Renal dysfunction", "PROBLEM", 170, 187], ["acute tubular necrosis", "PROBLEM", 206, 228], ["coexistent sepsis", "PROBLEM", 247, 264], ["renal replacement therapy", "TREATMENT", 294, 319], ["dialysis", "TREATMENT", 359, 367], ["renal", "ANATOMY", 49, 54], ["replacement", "OBSERVATION", 55, 66], ["renal", "ANATOMY", 148, 153], ["Renal", "ANATOMY", 170, 175], ["dysfunction", "OBSERVATION", 176, 187], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["tubular", "ANATOMY_MODIFIER", 212, 219], ["necrosis", "OBSERVATION", 220, 228], ["coexistent", "OBSERVATION_MODIFIER", 247, 257], ["sepsis", "OBSERVATION", 258, 264], ["renal", "ANATOMY", 294, 299], ["replacement", "OBSERVATION", 300, 311]]], ["Two patients were found to have pre-renal acute kidney injury secondary to hypovolemia and renin angiotensin aldosterone blockade.ResultsFive patients required admission to ICU (14.7%) for management of multi-organ failure, and the average length of stay was 30 days, with a range of 20-60 days.", [["kidney", "ANATOMY", 48, 54], ["multi-organ", "ANATOMY", 203, 214], ["acute kidney injury", "DISEASE", 42, 61], ["hypovolemia", "DISEASE", 75, 86], ["angiotensin aldosterone", "CHEMICAL", 97, 120], ["multi-organ failure", "DISEASE", 203, 222], ["aldosterone", "CHEMICAL", 109, 120], ["patients", "ORGANISM", 4, 12], ["kidney", "ORGAN", 48, 54], ["renin angiotensin aldosterone", "GENE_OR_GENE_PRODUCT", 91, 120], ["patients", "ORGANISM", 142, 150], ["multi-organ", "ORGAN", 203, 214], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 142, 150], ["pre-renal acute kidney injury", "PROBLEM", 32, 61], ["hypovolemia", "PROBLEM", 75, 86], ["renin angiotensin aldosterone blockade", "TREATMENT", 91, 129], ["management", "TREATMENT", 189, 199], ["multi-organ failure", "PROBLEM", 203, 222], ["pre-renal", "OBSERVATION", 32, 41], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["kidney", "ANATOMY", 48, 54], ["injury", "OBSERVATION", 55, 61], ["hypovolemia", "OBSERVATION", 75, 86], ["angiotensin aldosterone blockade", "OBSERVATION", 97, 129], ["multi-organ", "ANATOMY", 203, 214], ["failure", "OBSERVATION", 215, 222], ["average", "OBSERVATION_MODIFIER", 232, 239], ["length", "OBSERVATION_MODIFIER", 240, 246]]], ["All of these patients required ventilatory and inotropic support.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["ventilatory", "TREATMENT", 31, 42], ["inotropic support", "TREATMENT", 47, 64], ["inotropic support", "OBSERVATION", 47, 64]]], ["One patient died of complications of H1N1 infection.", [["H1N1 infection", "DISEASE", 37, 51], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["H1N1 infection", "PROBLEM", 37, 51], ["H1N1", "OBSERVATION_MODIFIER", 37, 41], ["infection", "OBSERVATION", 42, 51]]], ["One patients required extra corporeal membrane oxygenation (ECMO) therapy and was transferred to another institution.ConclusionWe report on a specific cohort of the Irish population who were admitted with H1N1 infection, and document the complications of this illness, concentrating largely on renal manifestations of the illness.", [["corporeal membrane", "ANATOMY", 28, 46], ["renal", "ANATOMY", 294, 299], ["H1N1 infection", "DISEASE", 205, 219], ["patients", "ORGANISM", 4, 12], ["corporeal membrane", "MULTI-TISSUE_STRUCTURE", 28, 46], ["renal", "ORGAN", 294, 299], ["patients", "SPECIES", 4, 12], ["extra corporeal membrane oxygenation", "TREATMENT", 22, 58], ["ECMO) therapy", "TREATMENT", 60, 73], ["H1N1 infection", "PROBLEM", 205, 219], ["this illness", "PROBLEM", 255, 267], ["the illness", "PROBLEM", 318, 329], ["infection", "OBSERVATION", 210, 219], ["renal", "ANATOMY", 294, 299], ["illness", "OBSERVATION", 322, 329]]], ["As can be seen above, these patients had severe illnesses as a result of H1N1, and a significant proportion required ICU admission (14%).ConclusionThe group of patients described above do not fit into the previously labelled high-risk age groups, i.e. those over 65 and under 2.", [["H1N1", "DISEASE", 73, 77], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 160, 168], ["severe illnesses", "PROBLEM", 41, 57], ["H1N1", "PROBLEM", 73, 77], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["illnesses", "OBSERVATION", 48, 57]]], ["A larger study published in the New England Journal of Medicine in November 2009 described approximately 10% of patients in these groups.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["A larger study", "TEST", 0, 14], ["larger", "OBSERVATION_MODIFIER", 2, 8]]], ["Similarly, in that study 7% of patients were pregnant females, compared to no known pregnant patients in our group.", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 93, 101], ["that study", "TEST", 14, 24]]], ["Our hospital is not attached to a maternity/women's hospital unlike those in the study mentioned above.ConclusionIn contrast to most previous studies, our patients had a low rate of underlying medical problems (29%) compared to an average national rate of 42.7% and international rate of approximately 70%.ConclusionThe renal manifestations of this illness are poorly described internationally, the majority of studies concentrate on ICU admission rates and clinical epidemiology.", [["renal", "ANATOMY", 320, 325], ["women", "ORGANISM", 44, 49], ["patients", "ORGANISM", 155, 163], ["renal", "ORGAN", 320, 325], ["women", "SPECIES", 44, 49], ["patients", "SPECIES", 155, 163], ["the study", "TEST", 77, 86], ["previous studies", "TEST", 133, 149], ["underlying medical problems", "PROBLEM", 182, 209], ["an average national rate", "TEST", 228, 252], ["international rate", "TEST", 266, 284], ["this illness", "PROBLEM", 344, 356], ["renal", "ANATOMY", 320, 325], ["manifestations", "OBSERVATION", 326, 340]]], ["This paper highlights the significant rates of acute kidney injury associated with this new virus.", [["kidney", "ANATOMY", 53, 59], ["acute kidney injury", "DISEASE", 47, 66], ["kidney", "ORGAN", 53, 59], ["acute kidney injury", "PROBLEM", 47, 66], ["this new virus", "PROBLEM", 83, 97], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["kidney", "ANATOMY", 53, 59], ["injury", "OBSERVATION", 60, 66], ["virus", "OBSERVATION", 92, 97]]], ["The high rates of acute kidney injury, and high rates of patients requiring renal replacement therapy noted here further emphasises the significant healthcare burden associated with this disease.", [["kidney", "ANATOMY", 24, 30], ["renal", "ANATOMY", 76, 81], ["acute kidney injury", "DISEASE", 18, 37], ["kidney", "ORGAN", 24, 30], ["patients", "ORGANISM", 57, 65], ["renal", "ORGAN", 76, 81], ["patients", "SPECIES", 57, 65], ["acute kidney injury", "PROBLEM", 18, 37], ["renal replacement therapy", "TREATMENT", 76, 101], ["the significant healthcare burden", "PROBLEM", 132, 165], ["this disease", "PROBLEM", 182, 194], ["high", "OBSERVATION_MODIFIER", 4, 8], ["rates", "OBSERVATION_MODIFIER", 9, 14], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["kidney", "ANATOMY", 24, 30], ["injury", "OBSERVATION", 31, 37], ["high", "OBSERVATION_MODIFIER", 43, 47], ["renal", "ANATOMY", 76, 81], ["replacement", "OBSERVATION", 82, 93], ["significant", "OBSERVATION_MODIFIER", 136, 147]]], ["It has been well described that a significant cause of mortality in these patients is multi-organ failure in the context of sepsis.", [["multi-organ", "ANATOMY", 86, 97], ["multi-organ failure", "DISEASE", 86, 105], ["sepsis", "DISEASE", 124, 130], ["patients", "ORGANISM", 74, 82], ["multi-organ", "ORGAN", 86, 97], ["patients", "SPECIES", 74, 82], ["multi-organ failure", "PROBLEM", 86, 105], ["sepsis", "PROBLEM", 124, 130], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["mortality", "OBSERVATION", 55, 64], ["multi-organ", "ANATOMY", 86, 97], ["failure", "OBSERVATION", 98, 105], ["sepsis", "OBSERVATION", 124, 130]]], ["It is not unexpected that the most common cause of acute kidney injury in the patients described above was acute tubular necrosis in the setting of sepsis.ConclusionThe results presented above show a significantly higher rate of ICU admission (14%) when compared nationally (8%).", [["kidney", "ANATOMY", 57, 63], ["tubular", "ANATOMY", 113, 120], ["acute kidney injury", "DISEASE", 51, 70], ["acute tubular necrosis", "DISEASE", 107, 129], ["sepsis", "DISEASE", 148, 154], ["kidney", "ORGAN", 57, 63], ["patients", "ORGANISM", 78, 86], ["tubular", "MULTI-TISSUE_STRUCTURE", 113, 120], ["patients", "SPECIES", 78, 86], ["acute kidney injury", "PROBLEM", 51, 70], ["acute tubular necrosis", "PROBLEM", 107, 129], ["sepsis", "PROBLEM", 148, 154], ["not unexpected", "UNCERTAINTY", 6, 20], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["kidney", "ANATOMY", 57, 63], ["injury", "OBSERVATION", 64, 70], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["tubular", "OBSERVATION_MODIFIER", 113, 120], ["necrosis", "OBSERVATION", 121, 129], ["sepsis", "OBSERVATION", 148, 154]]], ["Mortality rates were similar in the above study (2%) to those published nationally.", [["Mortality rates", "TEST", 0, 15], ["the above study", "TEST", 32, 47]]], ["This is lower than rates published internationally, 7-10%.ConclusionThis study highlights the significant health care burden associated with this illness, and for the first time addresses the common renal manifestations of the illness.", [["renal", "ANATOMY", 199, 204], ["renal", "ORGAN", 199, 204], ["This study", "TEST", 68, 78], ["the illness", "PROBLEM", 223, 234], ["lower", "OBSERVATION_MODIFIER", 8, 13], ["significant", "OBSERVATION_MODIFIER", 94, 105], ["renal", "ANATOMY", 199, 204], ["illness", "OBSERVATION", 227, 234]]]], "8bfbc6f5441984ce3f8b49d8722c158c9ee19793": [["IntroductionIn 2003, an atypical and highly contagious pneumonia, severe acute respiratory syndrome (SARS), caused a global health crisis.", [["pneumonia", "DISEASE", 55, 64], ["acute respiratory syndrome", "DISEASE", 73, 99], ["SARS", "DISEASE", 101, 105], ["highly contagious pneumonia", "PROBLEM", 37, 64], ["severe acute respiratory syndrome", "PROBLEM", 66, 99], ["a global health crisis", "PROBLEM", 115, 137], ["atypical", "OBSERVATION_MODIFIER", 24, 32], ["highly", "OBSERVATION_MODIFIER", 37, 43], ["contagious", "OBSERVATION_MODIFIER", 44, 54], ["pneumonia", "OBSERVATION", 55, 64], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory syndrome", "OBSERVATION", 79, 99], ["global", "OBSERVATION_MODIFIER", 117, 123], ["health crisis", "OBSERVATION", 124, 137]]], ["After a worldwide intensive investigation, a specific novel form of human coronavirus (CoV), denoted SARS-CoV, was identified as the pathogenic agent behind this epidemic (Peiris et al. 2004) .", [["human coronavirus", "DISEASE", 68, 85], ["human", "ORGANISM", 68, 73], ["coronavirus", "ORGANISM", 74, 85], ["CoV", "ORGANISM", 87, 90], ["SARS-CoV", "ORGANISM", 101, 109], ["human", "SPECIES", 68, 73], ["coronavirus", "SPECIES", 74, 85], ["human coronavirus", "SPECIES", 68, 85], ["CoV", "SPECIES", 87, 90], ["SARS-CoV", "SPECIES", 101, 109], ["a worldwide intensive investigation", "TEST", 6, 41], ["human coronavirus", "PROBLEM", 68, 85]]], ["The maturation and production of the infectious progeny of SARS-CoV involves proteolytic processing of the virus polyproteins by a main protease (Mpro) (also called 3CLpro because of its 3 0 -proximal chymotrypsin-like catalytic domain) and a papain-like protease (PLpro).IntroductionThis chapter summarizes the present knowledge of the structure and function of the SARS-CoV Mpro protein.", [["SARS", "DISEASE", 59, 63], ["SARS-CoV", "ORGANISM", 59, 67], ["Mpro", "GENE_OR_GENE_PRODUCT", 146, 150], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 201, 213], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 243, 263], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 367, 380], ["virus polyproteins", "PROTEIN", 107, 125], ["protease", "PROTEIN", 136, 144], ["Mpro", "PROTEIN", 146, 150], ["3CLpro", "PROTEIN", 165, 171], ["chymotrypsin", "PROTEIN", 201, 213], ["catalytic domain", "PROTEIN", 219, 235], ["papain-like protease", "PROTEIN", 243, 263], ["PLpro", "PROTEIN", 265, 270], ["SARS-CoV Mpro protein", "PROTEIN", 367, 388], ["SARS-CoV", "SPECIES", 59, 67], ["SARS-CoV", "SPECIES", 367, 375], ["SARS", "PROBLEM", 59, 63], ["CoV", "PROBLEM", 64, 67], ["the virus polyproteins", "TREATMENT", 103, 125], ["a main protease", "TREATMENT", 129, 144], ["3CLpro", "TREATMENT", 165, 171], ["proximal chymotrypsin", "TREATMENT", 192, 213], ["a papain-like protease (PLpro)", "TREATMENT", 241, 271], ["the SARS", "PROBLEM", 363, 371], ["CoV Mpro protein", "TREATMENT", 372, 388], ["infectious", "OBSERVATION_MODIFIER", 37, 47]]], ["Particular attention is paid to the quaternary structure of this protease, as the catalytically active form of this enzyme is a dimer.", [["protease", "PROTEIN", 65, 73], ["enzyme", "PROTEIN", 116, 122], ["dimer", "PROTEIN", 128, 133], ["this protease", "TREATMENT", 60, 73], ["this enzyme", "TEST", 111, 122]]], ["The structure and function of PLpro is also touched upon briefly.", [["PLpro", "GENE_OR_GENE_PRODUCT", 30, 35], ["PLpro", "PROTEIN", 30, 35], ["function", "OBSERVATION_MODIFIER", 18, 26]]], ["The current state of play in anti-SARS drug development strategies that target Mpro is discussed in the chapter following (Chap.", [["Mpro", "GENE_OR_GENE_PRODUCT", 79, 83]]], ["9).Molecular Biology of the SARS-CoV PolyproteinsThe genomic organization of SARS-CoV is similar to that of other coronaviruses, but phylogenetic analysis and sequence comparisons of the viral proteins indicate that SARS-CoV is in fact different from any of the previously characterized viruses of this type (Tanner et al. 2003; Eickmann et al. 2003) .", [["SARS", "DISEASE", 28, 32], ["SARS", "DISEASE", 77, 81], ["SARS", "DISEASE", 216, 220], ["SARS-CoV", "ORGANISM", 77, 85], ["SARS-CoV", "ORGANISM", 216, 224], ["SARS-CoV Polyproteins", "PROTEIN", 28, 49], ["viral proteins", "PROTEIN", 187, 201], ["SARS-CoV", "SPECIES", 28, 36], ["SARS-CoV", "SPECIES", 77, 85], ["SARS-CoV", "SPECIES", 216, 224], ["the SARS", "PROBLEM", 24, 32], ["CoV Polyproteins", "PROBLEM", 33, 49], ["SARS-CoV", "PROBLEM", 77, 85], ["other coronaviruses", "PROBLEM", 108, 127], ["phylogenetic analysis", "TEST", 133, 154], ["the viral proteins", "TEST", 183, 201], ["SARS-CoV", "PROBLEM", 216, 224], ["SARS", "OBSERVATION", 77, 81], ["coronaviruses", "OBSERVATION", 114, 127], ["SARS", "OBSERVATION", 216, 220], ["viruses", "OBSERVATION", 287, 294]]], ["Coronaviruses are enveloped positive-sense, single-strand RNA viruses.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["Coronaviruses", "PROBLEM", 0, 13]]], ["The genome length of SARS-CoV is around 30,000 nucleotides and its replicase gene encodes two overlapping polyproteins, polyprotein 1a (pp1a) (486 kDa) and polyprotein 1ab (1a + 1b) (790 kDa) ( Fig. 8.1a ).", [["SARS", "DISEASE", 21, 25], ["nucleotides", "CHEMICAL", 47, 58], ["SARS-CoV", "ORGANISM", 21, 29], ["polyprotein 1a", "GENE_OR_GENE_PRODUCT", 120, 134], ["pp1a", "GENE_OR_GENE_PRODUCT", 136, 140], ["polyprotein 1ab (1a + 1b", "GENE_OR_GENE_PRODUCT", 156, 180], ["SARS-CoV", "DNA", 21, 29], ["replicase gene", "DNA", 67, 81], ["polyproteins", "PROTEIN", 106, 118], ["polyprotein 1a", "PROTEIN", 120, 134], ["pp1a", "PROTEIN", 136, 140], ["486 kDa", "PROTEIN", 143, 150], ["SARS-CoV", "SPECIES", 21, 29], ["SARS-CoV", "PROBLEM", 21, 29], ["nucleotides", "TREATMENT", 47, 58], ["two overlapping polyproteins", "PROBLEM", 90, 118], ["polyprotein 1a", "TREATMENT", 120, 134], ["polyprotein", "TREATMENT", 156, 167], ["length", "OBSERVATION_MODIFIER", 11, 17]]], ["These polyproteins are extensively cleaved by the internally encoded SARS-CoV proteases, Mpro and PLpro.Molecular Biology of the SARS-CoV PolyproteinsThe 33.8-kDa Mpro plays a major role in the proteolytic processing of the virion polyproteins and cleaves pp1a at seven sites and pp1b at four sites ( Fig. 8.1a ).", [["SARS", "DISEASE", 129, 133], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 69, 77], ["Mpro", "GENE_OR_GENE_PRODUCT", 89, 93], ["PLpro", "GENE_OR_GENE_PRODUCT", 98, 103], ["SARS-CoV", "ORGANISM", 129, 137], ["Mpro", "GENE_OR_GENE_PRODUCT", 163, 167], ["pp1a", "GENE_OR_GENE_PRODUCT", 256, 260], ["pp1b", "GENE_OR_GENE_PRODUCT", 280, 284], ["SARS-CoV proteases", "PROTEIN", 69, 87], ["Mpro", "PROTEIN", 89, 93], ["PLpro", "PROTEIN", 98, 103], ["SARS-CoV Polyproteins", "PROTEIN", 129, 150], ["33.8-kDa Mpro", "PROTEIN", 154, 167], ["virion polyproteins", "PROTEIN", 224, 243], ["pp1a", "PROTEIN", 256, 260], ["pp1b", "PROTEIN", 280, 284], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV", "SPECIES", 129, 137], ["These polyproteins", "PROBLEM", 0, 18], ["CoV proteases", "TREATMENT", 74, 87], ["Mpro", "TREATMENT", 89, 93], ["PLpro", "TREATMENT", 98, 103], ["the SARS", "TEST", 125, 133], ["CoV Polyproteins", "TEST", 134, 150], ["the virion polyproteins", "TREATMENT", 220, 243], ["polyproteins", "OBSERVATION", 6, 18], ["virion polyproteins", "OBSERVATION", 224, 243]]], ["The 35-kDa protease PLpro cleaves pp1a at three sites.", [["PLpro", "GENE_OR_GENE_PRODUCT", 20, 25], ["pp1a", "GENE_OR_GENE_PRODUCT", 34, 38], ["35-kDa protease", "PROTEIN", 4, 19], ["PLpro", "PROTEIN", 20, 25], ["pp1a", "PROTEIN", 34, 38], ["The 35-kDa protease PLpro cleaves pp1a", "TREATMENT", 0, 38]]], ["These autoprocessing reactions result in the maturation of 16 nonstructural proteins (nsp), including those that are common to the replication of plus-strand RNA viruses: the RNA-dependent RNA polymerase at nsp12 and helicase at nsp13.", [["nsp", "GENE_OR_GENE_PRODUCT", 86, 89], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 175, 203], ["nsp12", "GENE_OR_GENE_PRODUCT", 207, 212], ["nsp13", "GENE_OR_GENE_PRODUCT", 229, 234], ["16 nonstructural proteins", "PROTEIN", 59, 84], ["nsp", "PROTEIN", 86, 89], ["plus-strand RNA viruses", "RNA", 146, 169], ["RNA-dependent RNA polymerase", "PROTEIN", 175, 203], ["nsp12", "PROTEIN", 207, 212], ["helicase", "PROTEIN", 217, 225], ["nsp13", "PROTEIN", 229, 234], ["These autoprocessing reactions", "PROBLEM", 0, 30], ["16 nonstructural proteins (nsp)", "PROBLEM", 59, 90], ["strand RNA viruses", "PROBLEM", 151, 169], ["the RNA", "TEST", 171, 178], ["dependent RNA polymerase", "PROBLEM", 179, 203], ["helicase at nsp13", "TREATMENT", 217, 234], ["RNA viruses", "OBSERVATION", 158, 169]]], ["The Mpro and PLpro enzymes are themselves located at nsp5 and nsp3, respectively.Molecular Biology of the SARS-CoV PolyproteinsThese proteases are involved in the viral life cycle, the maturation of the precapsid, and in the production of infectious virions.", [["virions", "ANATOMY", 250, 257], ["SARS", "DISEASE", 106, 110], ["Mpro", "GENE_OR_GENE_PRODUCT", 4, 8], ["PLpro enzymes", "GENE_OR_GENE_PRODUCT", 13, 26], ["nsp5", "GENE_OR_GENE_PRODUCT", 53, 57], ["nsp3", "GENE_OR_GENE_PRODUCT", 62, 66], ["Mpro and PLpro enzymes", "PROTEIN", 4, 26], ["nsp5", "PROTEIN", 53, 57], ["nsp3", "PROTEIN", 62, 66], ["SARS-CoV Polyproteins", "PROTEIN", 106, 127], ["proteases", "PROTEIN", 133, 142], ["SARS-CoV", "SPECIES", 106, 114], ["The Mpro and PLpro enzymes", "TEST", 0, 26], ["nsp3", "TEST", 62, 66], ["the SARS", "PROBLEM", 102, 110], ["CoV Polyproteins", "PROBLEM", 111, 127], ["These proteases", "PROBLEM", 127, 142], ["infectious virions", "PROBLEM", 239, 257], ["infectious", "OBSERVATION", 239, 249]]], ["Viral protease inhibitors would thus be predicted to have great clinical potential in the treatment of the associated infectious diseases (Krausslich and Wimmer 1988; Tong 2002) .", [["infectious diseases", "DISEASE", 118, 137], ["Viral protease inhibitors", "TREATMENT", 0, 25], ["the associated infectious diseases", "PROBLEM", 103, 137], ["infectious", "OBSERVATION", 118, 128]]], ["The structurefunction relationship of these proteases has therefore received much recent attention in the search for an effective anti-SARS-CoV agent Yang et al. 2005; Wei et al. 2006; Lai et al. 2006; Liang 2006; Bartlam et al. 2008 ).Three-Dimensional Structure of the SARS-CoV Main ProteaseMpro was the first of the SARS-CoV proteins to have its three-dimensional structure solved by crystallography ( Fig. 8 .2) (Yang et al. 2003; Bartlam et al. 2005 Bartlam et al. , 2007 .", [["SARS", "DISEASE", 271, 275], ["SARS-CoV", "ORGANISM", 271, 279], ["proteases", "PROTEIN", 44, 53], ["SARS-CoV proteins", "PROTEIN", 319, 336], ["SARS-CoV", "SPECIES", 271, 279], ["SARS-CoV", "SPECIES", 319, 327], ["these proteases", "PROBLEM", 38, 53], ["the SARS", "TEST", 267, 275], ["the SARS", "PROBLEM", 315, 323], ["CoV proteins", "TREATMENT", 324, 336], ["SARS", "OBSERVATION", 271, 275]]], ["This protease is a homodimer in which the two subunits are arranged perpendicularly to each other (Fig. 8.3a) .", [["protease", "PROTEIN", 5, 13], ["homodimer", "PROTEIN", 19, 28], ["This protease", "TREATMENT", 0, 13], ["a homodimer", "TREATMENT", 17, 28]]], ["Each protomer of SARS-CoV Mpro comprises 13 strands and 11 helices distributed among three distinct structural domains.", [["SARS", "DISEASE", 17, 21], ["SARS-CoV", "ORGANISM", 17, 25], ["SARS-CoV Mpro", "DNA", 17, 30], ["structural domains", "PROTEIN", 100, 118], ["SARS-CoV", "SPECIES", 17, 25], ["SARS", "PROBLEM", 17, 21], ["CoV Mpro", "TREATMENT", 22, 30], ["SARS", "OBSERVATION", 17, 21], ["distinct", "OBSERVATION_MODIFIER", 91, 99], ["structural domains", "OBSERVATION", 100, 118]]], ["The first two domains (residues 8-101 for domain I and 102-184 for domain II) have an antiparallel b-barrel structure, which has a folding scaffold similar to other viral chymotrypsin-like proteases (Anand et al. 2002; Hegyi et al. 2002; Ziebuhr et al. 2003) .", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 171, 183], ["domain I and 102-184", "PROTEIN", 42, 62], ["domain II", "PROTEIN", 67, 76], ["antiparallel b-barrel structure", "PROTEIN", 86, 117], ["viral chymotrypsin-like proteases", "PROTEIN", 165, 198], ["residues", "TEST", 23, 31], ["domain I", "TEST", 42, 50], ["an antiparallel b-barrel structure", "PROBLEM", 83, 117], ["a folding scaffold", "PROBLEM", 129, 147], ["other viral chymotrypsin", "PROBLEM", 159, 183], ["viral chymotrypsin", "OBSERVATION", 165, 183]]], ["Each subunit also has its own substrate binding site with a His41-Cys145 catalytic dyad located at the interface between domains I and II.", [["His41", "CHEMICAL", 60, 65], ["Cys", "CHEMICAL", 66, 69], ["substrate binding site", "PROTEIN", 30, 52], ["His41-Cys145 catalytic dyad", "PROTEIN", 60, 87], ["domains I and II", "PROTEIN", 121, 137], ["a His41", "TEST", 58, 65]]], ["However, unlike chymotrypsin, the active site of SARS-CoV Mpro contains a catalytic cysteinyl residue instead of a seryl residue.", [["cysteinyl", "CHEMICAL", 84, 93], ["cysteinyl", "CHEMICAL", 84, 93], ["seryl", "CHEMICAL", 115, 120], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 16, 28], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 49, 57], ["chymotrypsin", "PROTEIN", 16, 28], ["SARS-CoV Mpro", "PROTEIN", 49, 62], ["SARS-CoV", "SPECIES", 49, 57], ["unlike chymotrypsin", "PROBLEM", 9, 28], ["SARS", "PROBLEM", 49, 53], ["CoV Mpro", "TREATMENT", 54, 62], ["a catalytic cysteinyl residue", "PROBLEM", 72, 101], ["a seryl residue", "PROBLEM", 113, 128], ["chymotrypsin", "OBSERVATION", 16, 28], ["active", "OBSERVATION_MODIFIER", 34, 40], ["SARS", "OBSERVATION", 49, 53], ["catalytic cysteinyl residue", "OBSERVATION", 74, 101]]], ["III folds into a structure that is indistinguishable from the intact chymotrypsin-like fold but is enzymatically inactive (Chang et al. 2007 ).", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 69, 81], ["chymotrypsin", "PROTEIN", 69, 81], ["III folds into a structure", "PROBLEM", 0, 26], ["the intact chymotrypsin-like fold", "PROBLEM", 58, 91], ["intact", "OBSERVATION_MODIFIER", 62, 68], ["chymotrypsin", "OBSERVATION", 69, 81], ["enzymatically", "OBSERVATION_MODIFIER", 99, 112], ["inactive", "OBSERVATION_MODIFIER", 113, 121]]], ["The extra domain III of SARS-CoV Mpro increases the structural stability of the catalytic domain.", [["SARS", "DISEASE", 24, 28], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 24, 37], ["extra domain III", "PROTEIN", 4, 20], ["SARS-CoV Mpro", "PROTEIN", 24, 37], ["catalytic domain", "PROTEIN", 80, 96], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "PROBLEM", 24, 28], ["CoV Mpro", "PROBLEM", 29, 37], ["stability", "OBSERVATION_MODIFIER", 63, 72], ["catalytic domain", "OBSERVATION", 80, 96]]], ["This may be achieved by increasing the folding rate of domains I and II, which would thus increase the overall stability of the protein.", [["I and II", "PROTEIN", 63, 71], ["may be", "UNCERTAINTY", 5, 11]]], ["Furthermore, domain III is related to the quaternary structure of Mpro, which has important functional implications for this enzyme. .", [["Mpro", "GENE_OR_GENE_PRODUCT", 66, 70], ["domain III", "PROTEIN", 13, 23], ["Mpro", "PROTEIN", 66, 70], ["enzyme", "PROTEIN", 125, 131], ["this enzyme", "TEST", 120, 131], ["quaternary structure", "OBSERVATION", 42, 62]]], ["Domains I (blue) and II (green) constitute a chymotrypsin-like folding scaffold with a catalytic dyad comprising His41 and Cys145 (alanine in 1Z1J) shown using a bond-and-ball model (red).", [["alanine", "CHEMICAL", 131, 138], ["His41", "CHEMICAL", 113, 118], ["Cys145", "CHEMICAL", 123, 129], ["alanine", "CHEMICAL", 131, 138], ["I (blue)", "GENE_OR_GENE_PRODUCT", 8, 16], ["His41", "SIMPLE_CHEMICAL", 113, 118], ["Cys145", "AMINO_ACID", 123, 129], ["alanine", "AMINO_ACID", 131, 138], ["I (blue) and II", "PROTEIN", 8, 23], ["chymotrypsin-like folding scaffold", "PROTEIN", 45, 79], ["catalytic dyad", "PROTEIN", 87, 101], ["His41", "PROTEIN", 113, 118], ["Cys145", "PROTEIN", 123, 129], ["1Z1J", "PROTEIN", 142, 146], ["Domains I (blue) and II (green)", "PROBLEM", 0, 31], ["a chymotrypsin-like folding scaffold", "PROBLEM", 43, 79], ["His41", "TEST", 113, 118], ["Cys145 (alanine in 1Z1J", "TREATMENT", 123, 146], ["a bond", "TEST", 160, 166]]], ["This catalytic domain is linked to an extra domain III (red) by a long loop (yellow).", [["catalytic domain", "PROTEIN", 5, 21], ["extra domain III", "PROTEIN", 38, 54], ["red", "PROTEIN", 56, 59], ["This catalytic domain", "PROBLEM", 0, 21], ["a long loop (yellow", "PROBLEM", 64, 83]]], ["The N-finger (magenta) of subunit A protrudes into the active site region of subunit B, which is shown in gray. (b) Structural analysis of Mpro.", [["B", "GENE_OR_GENE_PRODUCT", 85, 86], ["Mpro", "GENE_OR_GENE_PRODUCT", 139, 143], ["N-finger (magenta)", "PROTEIN", 4, 22], ["subunit A", "PROTEIN", 26, 35], ["active site region", "PROTEIN", 55, 73], ["subunit B", "PROTEIN", 77, 86], ["Mpro", "PROTEIN", 139, 143], ["The N-finger (magenta)", "TREATMENT", 0, 22], ["Structural analysis", "TEST", 116, 135], ["finger", "ANATOMY", 6, 12], ["active", "OBSERVATION", 55, 61]]], ["The primary amino acid sequence is displayed along with secondary structural elements, crystallographic contact, and hydropathy.", [["amino acid", "CHEMICAL", 12, 22], ["amino acid", "CHEMICAL", 12, 22], ["amino acid", "AMINO_ACID", 12, 22], ["The primary amino acid sequence", "TEST", 0, 31], ["secondary structural elements", "PROBLEM", 56, 85], ["hydropathy", "PROBLEM", 117, 127], ["secondary structural elements", "OBSERVATION", 56, 85]]], ["Panel (a) was generated using MacPymol (DeLano 2002) and panel (b) with ENDscript (Gouet et al. 2003)Quaternary Structure of the SARS-CoV Main ProteaseA coronavirus Mpro (from transmissible gastroenteritis virus) was the first viral protease shown to be dimeric, both in its crystal form and in solution (Anand et al. 2002) .", [["MacPymol", "CHEMICAL", 30, 38], ["SARS", "DISEASE", 129, 133], ["Mpro", "CHEMICAL", 165, 169], ["transmissible gastroenteritis", "DISEASE", 176, 205], ["SARS-CoV", "ORGANISM", 129, 137], ["ProteaseA coronavirus Mpro", "ORGANISM", 143, 169], ["transmissible gastroenteritis virus", "ORGANISM", 176, 211], ["viral protease", "PROTEIN", 227, 241], ["coronavirus", "SPECIES", 153, 164], ["transmissible gastroenteritis virus", "SPECIES", 176, 211], ["SARS-CoV Main ProteaseA coronavirus", "SPECIES", 129, 164], ["transmissible gastroenteritis virus", "SPECIES", 176, 211], ["MacPymol (DeLano", "TREATMENT", 30, 46], ["the SARS", "PROBLEM", 125, 133], ["CoV Main ProteaseA coronavirus Mpro", "TREATMENT", 134, 169], ["transmissible gastroenteritis virus", "PROBLEM", 176, 211], ["the first viral protease", "PROBLEM", 217, 241], ["SARS", "OBSERVATION", 129, 133]]], ["Significantly, SARS-CoV Mpro also exists as a dimer in solution (Chou et al. 2004 ) and both its N-and C-terminal residues are involved in dimer formation.", [["SARS", "DISEASE", 15, 19], ["N", "CHEMICAL", 97, 98], ["C", "CHEMICAL", 103, 104], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 15, 23], ["SARS-CoV Mpro", "PROTEIN", 15, 28], ["dimer", "PROTEIN", 46, 51], ["N-and C-terminal residues", "PROTEIN", 97, 122], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["terminal residues", "PROBLEM", 105, 122]]], ["The N-terminal finger (N-finger, containing residues 1-7) of subunit A extends from domain I toward domain III and forms intensive interactions with subunit B. The side chain of Arg4 at the N-finger fits into a pocket of subunit B and forms a salt bridge with Glu290 that constitutes one of the major interactions between the two subunits (Chou et al. 2004 ).", [["Arg4", "CHEMICAL", 178, 182], ["Glu290", "CHEMICAL", 260, 266], ["Arg4", "CHEMICAL", 178, 182], ["N", "CHEMICAL", 190, 191], ["Glu290", "CHEMICAL", 260, 266], ["subunit A", "GENE_OR_GENE_PRODUCT", 61, 70], ["Arg4", "GENE_OR_GENE_PRODUCT", 178, 182], ["Glu290", "SIMPLE_CHEMICAL", 260, 266], ["N-terminal finger (N-finger, containing residues 1-7", "PROTEIN", 4, 56], ["subunit A", "PROTEIN", 61, 70], ["domain I", "PROTEIN", 84, 92], ["domain III", "PROTEIN", 100, 110], ["subunit B.", "PROTEIN", 149, 159], ["side chain", "PROTEIN", 164, 174], ["Arg4", "PROTEIN", 178, 182], ["N-finger", "PROTEIN", 190, 198], ["subunit B", "PROTEIN", 221, 230], ["Glu290", "PROTEIN", 260, 266], ["The N-terminal finger (N-finger, containing residues", "TREATMENT", 0, 52], ["a pocket of subunit B", "TREATMENT", 209, 230], ["a salt bridge", "TREATMENT", 241, 254], ["Glu290", "TREATMENT", 260, 266], ["N-terminal", "ANATOMY_MODIFIER", 4, 14], ["finger", "ANATOMY", 15, 21], ["finger", "ANATOMY", 25, 31]]], ["In addition, the subunit interfacial region of the enzyme contains many hydrophobic interactions and hydrogen bonds (Fig. 8.3b ).", [["hydrogen", "CHEMICAL", 101, 109], ["subunit interfacial region", "PROTEIN", 17, 43], ["enzyme", "PROTEIN", 51, 57], ["the enzyme", "TEST", 47, 57], ["hydrogen bonds (Fig.", "TEST", 101, 121], ["interfacial", "ANATOMY_MODIFIER", 25, 36], ["many", "OBSERVATION_MODIFIER", 67, 71], ["hydrophobic interactions", "OBSERVATION", 72, 96], ["hydrogen bonds", "OBSERVATION", 101, 115]]], ["The interactions between the N-terminus and the other monomer play an important role in maintaining the active site integrity of the dimer (Lin et al. 2008; Chen et al. 2008b; Zhong et al. 2008) .", [["N", "CHEMICAL", 29, 30], ["N-terminus", "PROTEIN", 29, 39], ["dimer", "PROTEIN", 133, 138], ["the N-terminus", "TREATMENT", 25, 39]]], ["Importantly, the dimeric form of SARS-CoV Mpro is the biologically functional form of this enzyme (Anand et al. 2002; Shi et al. 2008 ) and dissociation of the subunits yields enzymatically inactive monomers (Shi et al. 2004; Fan et al. 2004; Chang et al. 2007) .Quaternary Structure of the SARS-CoV Main ProteaseThe functional role of the N-terminus and C-terminus of Mpro has been evaluated by truncation and mutation studies.", [["SARS", "DISEASE", 33, 37], ["SARS", "DISEASE", 291, 295], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 33, 46], ["Protease", "GENE_OR_GENE_PRODUCT", 305, 313], ["Mpro", "GENE_OR_GENE_PRODUCT", 369, 373], ["SARS-CoV Mpro", "PROTEIN", 33, 46], ["SARS-CoV Main Protease", "PROTEIN", 291, 313], ["N-terminus", "PROTEIN", 340, 350], ["C-terminus", "PROTEIN", 355, 365], ["Mpro", "PROTEIN", 369, 373], ["SARS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 291, 299], ["SARS", "PROBLEM", 33, 37], ["this enzyme", "TEST", 86, 97], ["the SARS", "PROBLEM", 287, 295], ["CoV Main Protease", "TREATMENT", 296, 313], ["mutation studies", "TEST", 411, 427], ["SARS", "OBSERVATION", 291, 295]]], ["Both N-terminal and C-terminal regions are involved in the activity of this enzyme as well as in its dimerization.", [["C", "CHEMICAL", 20, 21], ["N-terminal and C-terminal regions", "PROTEIN", 5, 38], ["enzyme", "PROTEIN", 76, 82], ["Both N-terminal and C-terminal regions", "PROBLEM", 0, 38], ["this enzyme", "TEST", 71, 82], ["N-terminal", "OBSERVATION_MODIFIER", 5, 15], ["terminal", "ANATOMY_MODIFIER", 22, 30], ["regions", "ANATOMY_MODIFIER", 31, 38]]], ["N-terminal truncation of the whole N-finger results in almost complete loss of enzymatic activity (Hsu et al. 2005b) .", [["N", "CHEMICAL", 0, 1], ["N-finger", "PROTEIN", 35, 43], ["terminal truncation", "PROBLEM", 2, 21], ["terminal", "OBSERVATION_MODIFIER", 2, 10], ["truncation", "OBSERVATION", 11, 21], ["finger", "ANATOMY", 37, 43], ["enzymatic activity", "OBSERVATION", 79, 97]]], ["Critical N-terminal amino acid residues to Arg4 and C-terminal to Gln299 have been identified as those involved in dimerization, thus generating the correct conformation of the active site (Hsu et al. 2005b; Lin et al. 2008 ).", [["amino acid", "CHEMICAL", 20, 30], ["amino acid", "CHEMICAL", 20, 30], ["Arg4", "CHEMICAL", 43, 47], ["C", "CHEMICAL", 52, 53], ["amino acid", "AMINO_ACID", 20, 30], ["Arg4", "GENE_OR_GENE_PRODUCT", 43, 47], ["Gln299", "GENE_OR_GENE_PRODUCT", 66, 72], ["N-terminal amino acid residues", "PROTEIN", 9, 39], ["Arg4", "PROTEIN", 43, 47], ["C-terminal", "PROTEIN", 52, 62], ["Gln299", "PROTEIN", 66, 72], ["Critical N-terminal amino acid residues", "PROBLEM", 0, 39], ["Arg4", "TEST", 43, 47], ["C-terminal to Gln299", "PROBLEM", 52, 72], ["N-terminal", "OBSERVATION_MODIFIER", 9, 19], ["amino acid residues", "OBSERVATION", 20, 39], ["active", "OBSERVATION_MODIFIER", 177, 183]]], ["The C-terminal helical domain interacts with the active site of another protomer in the dimer and switches the enzyme molecule from the inactive form to the active form (Shi et al. 2004 ).", [["C-terminal helical domain", "PROTEIN", 4, 29], ["dimer", "PROTEIN", 88, 93], ["enzyme molecule", "PROTEIN", 111, 126], ["inactive form", "PROTEIN", 136, 149], ["The C-terminal helical domain interacts", "PROBLEM", 0, 39], ["active", "OBSERVATION_MODIFIER", 157, 163]]], ["Hsu et al. (2005a) have proposed an autocleavage mechanism, which explains the dimeric nature of the mature enzyme.Enzyme Activity-Assay for the SARS-CoV Main ProteaseThe hydrolytic activity of Mpro can be assayed by its ability to cleave a peptide substrate.", [["Mpro", "CHEMICAL", 194, 198], ["Protease", "GENE_OR_GENE_PRODUCT", 159, 167], ["Mpro", "SIMPLE_CHEMICAL", 194, 198], ["mature enzyme", "PROTEIN", 101, 114], ["Mpro", "PROTEIN", 194, 198], ["SARS-CoV", "SPECIES", 145, 153], ["Enzyme Activity", "TEST", 115, 130], ["the SARS", "PROBLEM", 141, 149], ["CoV Main Protease", "TREATMENT", 150, 167], ["a peptide substrate", "TREATMENT", 239, 258]]], ["A procedure to separate the substrate and product peptides by high performance liquid chromatography has now been developed ).", [["A procedure", "TREATMENT", 0, 11], ["the substrate and product peptides", "TREATMENT", 24, 58], ["high performance liquid chromatography", "TREATMENT", 62, 100]]], ["The reaction is monitored by the formation of products peaks from the substrate peak and this method is thus very useful in the identification of cleaved peptide products.", [["The reaction", "PROBLEM", 0, 12], ["cleaved peptide products", "TREATMENT", 146, 170]]], ["However, this procedure is very labor-intensive and thus not suitable for high throughput screening protocols.Enzyme Activity-Assay for the SARS-CoV Main ProteaseVarious fluorescence-based methods have also been developed for Mpro in which the enzyme activity can be assayed using an internally quenched fluorogenic , and the interacting amino acid residues are shown by residue conservation.", [["amino acid", "CHEMICAL", 338, 348], ["amino acid", "CHEMICAL", 338, 348], ["Mpro", "SIMPLE_CHEMICAL", 226, 230], ["amino acid", "AMINO_ACID", 338, 348], ["SARS-CoV", "SPECIES", 140, 148], ["this procedure", "TREATMENT", 9, 23], ["very labor", "PROBLEM", 27, 37], ["high throughput screening protocols", "TREATMENT", 74, 109], ["Enzyme Activity", "TEST", 110, 125], ["the SARS", "PROBLEM", 136, 144], ["CoV Main ProteaseVarious fluorescence", "TREATMENT", 145, 182], ["Mpro", "TREATMENT", 226, 230], ["an internally quenched fluorogenic", "PROBLEM", 281, 315], ["the interacting amino acid residues", "TREATMENT", 322, 357], ["very", "OBSERVATION_MODIFIER", 27, 31], ["labor", "OBSERVATION", 32, 37]]], ["The width of the substrate peptide (e.g., ortho-aminobenzoic acid-peptide-2,4-dinitrophenyl amide) (Chou et al. 2004 ).", [["ortho-aminobenzoic acid-peptide-2,4-dinitrophenyl amide", "CHEMICAL", 42, 97], ["ortho-aminobenzoic acid-peptide-2,4-dinitrophenyl amide", "CHEMICAL", 42, 97], ["ortho-aminobenzoic acid-peptide-2,4-dinitrophenyl amide", "SIMPLE_CHEMICAL", 42, 97], ["the substrate peptide", "TEST", 13, 34], ["ortho", "TEST", 42, 47], ["-aminobenzoic acid-peptide", "TREATMENT", 47, 73], ["dinitrophenyl amide", "TREATMENT", 78, 97], ["width", "OBSERVATION_MODIFIER", 4, 9]]], ["Enhanced fluorescence due to cleavage of the peptide can be monitored at 420 nm with excitation at 362 nm using a luminescence spectrometer.", [["Enhanced fluorescence", "PROBLEM", 0, 21], ["the peptide", "TREATMENT", 41, 52], ["a luminescence spectrometer", "TREATMENT", 112, 139]]], ["For precise quantitation, a calibration curve under identical conditions should be constructed with equal amounts of hydrolytic products.Enzyme Activity-Assay for the SARS-CoV Main ProteaseAlternatively, colorimetric methods (e.g., p-nitroanilide-peptide based assays) have been adopted for use in an Mpro assay ).", [["p-nitroanilide", "SIMPLE_CHEMICAL", 232, 246], ["SARS-CoV", "SPECIES", 167, 175], ["precise quantitation", "TEST", 4, 24], ["a calibration curve", "TEST", 26, 45], ["hydrolytic products", "TREATMENT", 117, 136], ["Enzyme Activity", "TEST", 137, 152], ["the SARS", "PROBLEM", 163, 171], ["CoV Main ProteaseAlternatively", "TREATMENT", 172, 202], ["colorimetric methods", "TREATMENT", 204, 224], ["p-nitroanilide-peptide", "TREATMENT", 232, 254]]], ["The chromophore p-nitroanilide has a known absorbance that is conductive to quantitation.", [["p-nitroanilide", "CHEMICAL", 16, 30], ["p-nitroanilide", "CHEMICAL", 16, 30], ["chromophore p-nitroanilide", "SIMPLE_CHEMICAL", 4, 30], ["The chromophore p-nitroanilide", "TREATMENT", 0, 30], ["a known absorbance", "PROBLEM", 35, 53], ["absorbance", "OBSERVATION", 43, 53], ["conductive", "OBSERVATION", 62, 72]]], ["In addition, colorimetric assay methods do not require inner filter effect corrections, which are essential for fluorimetric assays, and photometric devices are less expensive.Enzyme Activity-Assay for the SARS-CoV Main ProteaseFluorimetric analysis is generally at least 10-fold more sensitive than a colorimetric-based assay.", [["SARS-CoV", "SPECIES", 206, 214], ["colorimetric assay methods", "TEST", 13, 39], ["inner filter effect corrections", "TREATMENT", 55, 86], ["fluorimetric assays", "TEST", 112, 131], ["photometric devices", "TREATMENT", 137, 156], ["Enzyme Activity", "TEST", 176, 191], ["the SARS", "TEST", 202, 210], ["CoV Main ProteaseFluorimetric analysis", "TEST", 211, 249], ["a colorimetric-based assay", "TEST", 300, 326], ["filter", "OBSERVATION", 61, 67]]], ["However, its intrinsic insensitivity is in fact a distinct advantage of using colorimetric analysis for Mpro.", [["Mpro", "CHEMICAL", 104, 108], ["Mpro", "SIMPLE_CHEMICAL", 104, 108], ["colorimetric analysis", "TEST", 78, 99], ["Mpro", "TREATMENT", 104, 108]]], ["In the case of Mpro activity, to confirm a direct correlation between the quaternary structure of the protease and its enzyme activity, a method that can simultaneously monitor protein dissociation and enzyme inactivation is highly desirable.", [["Mpro", "GENE_OR_GENE_PRODUCT", 15, 19], ["Mpro", "PROTEIN", 15, 19], ["protease", "PROTEIN", 102, 110], ["enzyme", "PROTEIN", 119, 125], ["the protease", "TREATMENT", 98, 110], ["protein dissociation", "PROBLEM", 177, 197], ["enzyme inactivation", "PROBLEM", 202, 221]]], ["Analytical ultracentrifugation with a band-forming centerpiece is ideal for this task (Harding and Rowe 1996) .", [["Analytical ultracentrifugation", "TREATMENT", 0, 30], ["a band-forming centerpiece", "TREATMENT", 36, 62]]], ["The substrate is diluted in buffer and loaded into the ultracentrifuge cell.", [["cell", "ANATOMY", 71, 75], ["cell", "CELL", 71, 75], ["ultracentrifuge cell", "CELL_LINE", 55, 75], ["The substrate", "TREATMENT", 0, 13], ["ultracentrifuge cell", "OBSERVATION", 55, 75]]], ["Deuterium oxide, sucrose, or glycerol can be used to increase the density of this substrate solution.", [["Deuterium oxide", "CHEMICAL", 0, 15], ["sucrose", "CHEMICAL", 17, 24], ["glycerol", "CHEMICAL", 29, 37], ["Deuterium oxide", "CHEMICAL", 0, 15], ["sucrose", "CHEMICAL", 17, 24], ["glycerol", "CHEMICAL", 29, 37], ["Deuterium oxide", "SIMPLE_CHEMICAL", 0, 15], ["sucrose", "SIMPLE_CHEMICAL", 17, 24], ["glycerol", "SIMPLE_CHEMICAL", 29, 37], ["Deuterium oxide", "TREATMENT", 0, 15], ["sucrose", "TREATMENT", 17, 24], ["glycerol", "TREATMENT", 29, 37], ["this substrate solution", "TREATMENT", 77, 100]]], ["The band-forming centerpiece has small drilled-out holes to accommodate the enzyme solution, which is separated from the substrate before the application of the centrifugal force.", [["The band-forming centerpiece", "TREATMENT", 0, 28], ["small drilled-out holes", "TREATMENT", 33, 56], ["the enzyme solution", "TREATMENT", 72, 91], ["small", "OBSERVATION_MODIFIER", 33, 38], ["drilled", "OBSERVATION_MODIFIER", 39, 46], ["centrifugal force", "OBSERVATION", 161, 178]]], ["Upon commencing centrifugation, the enzyme solution, which is less dense than the substrate solution, will form a thin layer on top of the separation column.", [["centrifugation", "TREATMENT", 16, 30], ["the enzyme solution", "TEST", 32, 51], ["the substrate solution", "TREATMENT", 78, 100], ["less", "OBSERVATION_MODIFIER", 62, 66], ["dense", "OBSERVATION_MODIFIER", 67, 72], ["thin", "OBSERVATION_MODIFIER", 114, 118], ["layer", "OBSERVATION_MODIFIER", 119, 124], ["separation column", "OBSERVATION", 139, 156]]], ["The enzymatic reaction will start at the bound interface.", [["The enzymatic reaction", "PROBLEM", 0, 22], ["enzymatic reaction", "OBSERVATION", 4, 22]]], ["During ultracentrifugation, the separation of monomer and dimer bands can be monitored by UV absorption, whereas the enzyme activity levels can be assessed by the absorption at 405 nm if p-nitroanilide-peptide is used.", [["p-nitroanilide-peptide", "CHEMICAL", 187, 209], ["p-nitroanilide", "CHEMICAL", 187, 201], ["p-nitroanilide-peptide", "SIMPLE_CHEMICAL", 187, 209], ["ultracentrifugation", "TREATMENT", 7, 26], ["the separation of monomer and dimer bands", "TREATMENT", 28, 69], ["the enzyme activity levels", "TEST", 113, 139], ["p-nitroanilide-peptide", "TREATMENT", 187, 209]]], ["The advantage of then using a colorimetric detector is that the k cat value of Mpro is low enough to allow large amounts of protein to be used.", [["Mpro", "SIMPLE_CHEMICAL", 79, 83], ["Mpro", "PROTEIN", 79, 83], ["a colorimetric detector", "TREATMENT", 28, 51], ["the k cat value", "TEST", 60, 75], ["large amounts of protein", "TREATMENT", 107, 131]]], ["If fluorogenic substrates are used, the sensitivity of enzymatic reaction will be such that the protein levels may be below the threshold of detection.Enzyme Activity-Assay for the SARS-CoV Main ProteaseThe Mpro protease is an ideal model for the analysis of the correlation between quaternary structure and enzyme activity (Barrila et al. 2006; Shi and Song 2006) .", [["Protease", "GENE_OR_GENE_PRODUCT", 195, 203], ["Mpro protease", "GENE_OR_GENE_PRODUCT", 207, 220], ["Mpro protease", "PROTEIN", 207, 220], ["SARS-CoV", "SPECIES", 181, 189], ["fluorogenic substrates", "TEST", 3, 25], ["enzymatic reaction", "PROBLEM", 55, 73], ["the protein levels", "TEST", 92, 110], ["Enzyme Activity", "TEST", 151, 166], ["the SARS", "PROBLEM", 177, 185], ["CoV Main Protease", "TREATMENT", 186, 203], ["The Mpro protease", "TREATMENT", 203, 220], ["the analysis", "TEST", 243, 255]]], ["This is due partly to the fact that it is a relatively simple dimeric system and that it has only a moderate catalytic efficiency.", [["a relatively simple dimeric system", "PROBLEM", 42, 76], ["a moderate catalytic efficiency", "PROBLEM", 98, 129], ["moderate", "OBSERVATION_MODIFIER", 100, 108], ["catalytic efficiency", "OBSERVATION", 109, 129]]], ["To date, no activity has been detected for the Mpro monomer.Catalytic Mechanism of the SARS-CoV Main ProteaseSARS-CoV Mpro cleaves pp1a at 11 sites containing the canonical Leu-Gln-#-(Ala/Ser) sequence (Fig. 8.1b) .", [["SARS", "DISEASE", 87, 91], ["Ala", "CHEMICAL", 184, 187], ["Ser", "CHEMICAL", 188, 191], ["Mpro", "GENE_OR_GENE_PRODUCT", 47, 51], ["Mpro", "GENE_OR_GENE_PRODUCT", 118, 122], ["pp1a", "GENE_OR_GENE_PRODUCT", 131, 135], ["Ser", "AMINO_ACID", 188, 191], ["Mpro monomer", "PROTEIN", 47, 59], ["Mpro", "PROTEIN", 118, 122], ["pp1a", "PROTEIN", 131, 135], ["canonical Leu-Gln-#-(Ala/Ser) sequence", "DNA", 163, 201], ["SARS-CoV Main ProteaseSARS-CoV", "SPECIES", 87, 117], ["the SARS", "PROBLEM", 83, 91], ["Mpro cleaves pp1a", "TREATMENT", 118, 135], ["Ala/Ser) sequence", "TREATMENT", 184, 201], ["Fig.", "TEST", 203, 207], ["SARS", "OBSERVATION", 87, 91]]], ["The first step in this process involves binding of the substrate at the enzyme active center, which forms a Michaelis complex.", [["Michaelis complex", "GENE_OR_GENE_PRODUCT", 108, 125], ["Michaelis complex", "PROTEIN", 108, 125], ["a Michaelis complex", "PROBLEM", 106, 125], ["Michaelis complex", "OBSERVATION", 108, 125]]], ["An electrostatic trigger mediated by Cys145 at the susceptible peptide bond initiates the chemical reaction.", [["Cys145", "CHEMICAL", 37, 43], ["Cys145", "CHEMICAL", 37, 43], ["Cys145", "SIMPLE_CHEMICAL", 37, 43], ["the chemical reaction", "PROBLEM", 86, 107], ["electrostatic", "OBSERVATION", 3, 16], ["chemical reaction", "OBSERVATION", 90, 107]]], ["Acylation of the sulfhydryl group of this cysteine results in a covalent link between the C-terminal moiety of the substrate and the SH group and the release of the N-terminal moiety (Fig. 8.4a) .", [["sulfhydryl", "CHEMICAL", 17, 27], ["cysteine", "CHEMICAL", 42, 50], ["sulfhydryl", "CHEMICAL", 17, 27], ["cysteine", "CHEMICAL", 42, 50], ["C", "CHEMICAL", 90, 91], ["SH", "CHEMICAL", 133, 135], ["sulfhydryl", "SIMPLE_CHEMICAL", 17, 27], ["cysteine", "AMINO_ACID", 42, 50], ["C-terminal moiety", "PROTEIN", 90, 107], ["N-terminal moiety", "PROTEIN", 165, 182], ["Acylation", "TREATMENT", 0, 9], ["the sulfhydryl", "TREATMENT", 13, 27], ["this cysteine", "TREATMENT", 37, 50], ["terminal", "ANATOMY_MODIFIER", 92, 100]]], ["Finally, deacylation and release of the C-terminal moiety completes the reaction (Solowiej et al. 2008) .Catalytic Mechanism of the SARS-CoV Main ProteaseThe -SH group of Cys145 is ion-paired with a nearby histidine residue (His41).", [["SARS", "DISEASE", 132, 136], ["Cys145", "CHEMICAL", 171, 177], ["histidine", "CHEMICAL", 206, 215], ["C", "CHEMICAL", 40, 41], ["SH", "CHEMICAL", 159, 161], ["Cys145", "CHEMICAL", 171, 177], ["histidine", "CHEMICAL", 206, 215], ["Protease", "GENE_OR_GENE_PRODUCT", 146, 154], ["Cys145", "GENE_OR_GENE_PRODUCT", 171, 177], ["His41", "AMINO_ACID", 225, 230], ["C-terminal moiety", "PROTEIN", 40, 57], ["SARS-CoV Main Protease", "PROTEIN", 132, 154], ["SARS-CoV", "SPECIES", 132, 140], ["deacylation", "TREATMENT", 9, 20], ["the C-terminal moiety", "TREATMENT", 36, 57], ["the reaction", "PROBLEM", 68, 80], ["the SARS", "PROBLEM", 128, 136], ["CoV Main Protease", "TREATMENT", 137, 154], ["a nearby histidine residue", "PROBLEM", 197, 223], ["SARS", "OBSERVATION", 132, 136], ["histidine residue", "OBSERVATION", 206, 223]]], ["This forms the catalytic dyad (Cys145-His41), which differs from most serine proteases that have a catalytic Ser-His-Asp triad in their active sites.", [["Cys145-His41", "CHEMICAL", 31, 43], ["serine", "CHEMICAL", 70, 76], ["Ser-His-Asp", "CHEMICAL", 109, 120], ["Cys145-His41", "GENE_OR_GENE_PRODUCT", 31, 43], ["catalytic dyad", "PROTEIN", 15, 29], ["His41", "PROTEIN", 38, 43], ["serine proteases", "PROTEIN", 70, 86], ["catalytic Ser-His-Asp triad", "PROTEIN", 99, 126], ["most serine proteases", "PROBLEM", 65, 86], ["Asp triad", "PROBLEM", 117, 126], ["active sites", "OBSERVATION", 136, 148]]], ["In Mpro, a stable water molecule occupies the Asp position of the typical serine protease triad and this molecule might play a role in stabilizing the imidazolium ring during catalysis .", [["imidazolium", "CHEMICAL", 151, 162], ["Asp", "CHEMICAL", 46, 49], ["serine", "CHEMICAL", 74, 80], ["imidazolium", "CHEMICAL", 151, 162], ["Mpro", "SIMPLE_CHEMICAL", 3, 7], ["Asp", "AMINO_ACID", 46, 49], ["serine", "AMINO_ACID", 74, 80], ["Mpro", "PROTEIN", 3, 7], ["Asp position", "PROTEIN", 46, 58], ["serine protease triad", "PROTEIN", 74, 95], ["the typical serine protease triad", "PROBLEM", 62, 95], ["the imidazolium ring during catalysis", "TREATMENT", 147, 184], ["stable", "OBSERVATION_MODIFIER", 11, 17], ["water molecule", "OBSERVATION", 18, 32], ["Asp position", "OBSERVATION_MODIFIER", 46, 58]]], ["Mutations at the catalytic dyad residues (H41A and C145A) almost completely abolish enzymatic activity and these mutant enzymes exist exclusively as dimers Chang et al. 2007 ).", [["catalytic dyad residues", "PROTEIN", 17, 40], ["mutant enzymes", "PROTEIN", 113, 127], ["Mutations at the catalytic dyad residues", "PROBLEM", 0, 40], ["these mutant enzymes", "TEST", 107, 127]]], ["However, mutation of Cys145 to Ser results in a partially active enzyme.", [["Cys145", "CHEMICAL", 21, 27], ["Ser", "CHEMICAL", 31, 34], ["Cys145", "AMINO_ACID", 21, 27], ["Ser", "AMINO_ACID", 31, 34], ["enzyme", "PROTEIN", 65, 71]]], ["These results are consistent with the notion that in the chemical mechanism underlying Mpro activity, His41 acts as a general base during the deacylation step and that the catalytic dyad involving Cys145 and His41 is left uncharged Solowiej et al. 2008) .Catalytic Mechanism of the SARS-CoV Main ProteaseThe rate-limiting step for Mpro hydrolysis is the covalent deacylation step.", [["His41", "CHEMICAL", 102, 107], ["SARS", "DISEASE", 282, 286], ["Mpro", "CHEMICAL", 331, 335], ["Cys", "CHEMICAL", 197, 200], ["His41", "CHEMICAL", 208, 213], ["Mpro", "CHEMICAL", 331, 335], ["Mpro", "GENE_OR_GENE_PRODUCT", 87, 91], ["His41", "GENE_OR_GENE_PRODUCT", 102, 107], ["Cys145", "AMINO_ACID", 197, 203], ["His41", "AMINO_ACID", 208, 213], ["Protease", "GENE_OR_GENE_PRODUCT", 296, 304], ["Mpro", "SIMPLE_CHEMICAL", 331, 335], ["Mpro", "PROTEIN", 87, 91], ["His41", "PROTEIN", 102, 107], ["catalytic dyad", "PROTEIN", 172, 186], ["SARS-CoV Main Protease", "PROTEIN", 282, 304], ["SARS-CoV", "SPECIES", 282, 290], ["the deacylation step", "TREATMENT", 138, 158], ["Cys", "TEST", 197, 200], ["the SARS", "PROBLEM", 278, 286], ["CoV Main Protease", "TREATMENT", 287, 304], ["The rate", "TEST", 304, 312], ["Mpro hydrolysis", "TREATMENT", 331, 346], ["the covalent deacylation step", "TREATMENT", 350, 379], ["consistent with", "UNCERTAINTY", 18, 33], ["left", "ANATOMY_MODIFIER", 217, 221], ["SARS", "OBSERVATION", 282, 286]]], ["There is a close correlation here between the kinetic parameters and subunit dissociation constant.", [["subunit dissociation", "PROBLEM", 69, 89], ["subunit dissociation", "OBSERVATION", 69, 89]]], ["Mpro subunit dissociation affects catalysis but not substrate binding (Lin et al. 2008) .", [["Mpro", "GENE_OR_GENE_PRODUCT", 0, 4], ["Mpro subunit", "PROTEIN", 0, 12], ["Mpro subunit dissociation affects catalysis", "PROBLEM", 0, 43], ["dissociation", "OBSERVATION", 13, 25]]], ["Molecular dynamic simulations have also demonstrated an asymmetric dimer and inactivation of the enzyme after dissociation Chen et al. 2006; Zheng et al. 2007) .", [["enzyme", "PROTEIN", 97, 103], ["Molecular dynamic simulations", "TEST", 0, 29], ["an asymmetric dimer", "PROBLEM", 53, 72], ["the enzyme", "TEST", 93, 103], ["asymmetric dimer", "OBSERVATION", 56, 72]]], ["Crystal structures of the monomeric Mpro provide direct structural evidence for the catalytic incompetence of the dissociated monomer (Chen et al. 2008a; Shi et al. 2008 ).Catalytic Mechanism of the SARS-CoV Main ProteaseAn association-activation-catalysis-dissociation mechanism has been proposed for Mpro enzyme activity control .", [["SARS", "DISEASE", 199, 203], ["Mpro", "GENE_OR_GENE_PRODUCT", 36, 40], ["ProteaseAn", "GENE_OR_GENE_PRODUCT", 213, 223], ["Mpro enzyme", "GENE_OR_GENE_PRODUCT", 302, 313], ["monomeric Mpro", "PROTEIN", 26, 40], ["Mpro enzyme", "PROTEIN", 302, 313], ["the catalytic incompetence", "PROBLEM", 80, 106], ["the SARS", "PROBLEM", 195, 203], ["dissociation mechanism", "PROBLEM", 257, 279], ["Mpro enzyme activity control", "TREATMENT", 302, 330]]], ["The catalytically competent conformation in one protomer is induced only upon dimer formation.", [["catalytically", "OBSERVATION_MODIFIER", 4, 17], ["competent conformation", "OBSERVATION", 18, 40]]], ["Under physiological conditions, Mpro exists as an asymmetric dimer that might have a half-site acylation-deacylation catalytic cycle; i.e., when one subunit is in the active acylated form, the other is in the deacylated form.", [["Mpro", "GENE_OR_GENE_PRODUCT", 32, 36], ["Mpro", "PROTEIN", 32, 36], ["an asymmetric dimer", "PROBLEM", 47, 66], ["a half-site acylation", "TREATMENT", 83, 104], ["asymmetric dimer", "OBSERVATION", 50, 66], ["deacylated", "OBSERVATION", 209, 219]]], ["The dimer is the essential functional unit of this protease that regulates catalytic turnover.Catalytic Mechanism of the SARS-CoV Main ProteaseThe proposed flip-flop mechanism for Mpro is shown in Fig. 8 .4b, which may account for the kinetics and structural information available for this enzyme.", [["SARS", "DISEASE", 121, 125], ["Protease", "GENE_OR_GENE_PRODUCT", 135, 143], ["Mpro", "SIMPLE_CHEMICAL", 180, 184], ["dimer", "PROTEIN", 4, 9], ["protease", "PROTEIN", 51, 59], ["SARS-CoV Main Protease", "PROTEIN", 121, 143], ["Mpro", "PROTEIN", 180, 184], ["enzyme", "PROTEIN", 290, 296], ["SARS-CoV", "SPECIES", 121, 129], ["this protease", "TREATMENT", 46, 59], ["the SARS", "PROBLEM", 117, 125], ["CoV Main Protease", "TREATMENT", 126, 143], ["The proposed flip-flop mechanism", "TREATMENT", 143, 175], ["this enzyme", "TEST", 285, 296], ["SARS", "OBSERVATION", 121, 125], ["flip", "OBSERVATION", 156, 160], ["may account for", "UNCERTAINTY", 215, 230]]], ["The two subunits are used alternately in acylation and deacylation reactions whereby binding at subunit A induces the deacylation at subunit B and vice versa.", [["subunit A", "PROTEIN", 96, 105], ["subunit B", "PROTEIN", 133, 142], ["The two subunits", "TREATMENT", 0, 16], ["acylation and deacylation reactions", "TREATMENT", 41, 76], ["the deacylation", "TREATMENT", 114, 129]]], ["Mpro is thus proposed to be regulated by negative cooperativity.", [["Mpro", "CHEMICAL", 0, 4], ["Mpro", "GENE_OR_GENE_PRODUCT", 0, 4], ["Mpro", "PROTEIN", 0, 4], ["negative cooperativity", "OBSERVATION", 41, 63]]], ["Only one of the two subunits is catalytically active at any one time and the two subunits thus exist in an alternate active-inactive cycle.", [["catalytically", "OBSERVATION_MODIFIER", 32, 45], ["active", "OBSERVATION", 46, 52], ["inactive cycle", "OBSERVATION", 124, 138]]], ["Substrate binding at one subunit induces the deacylation of the otherStructure and Function of the SARS-CoV Papain-Like ProteaseIn addition to Mpro, SARS-CoV expresses a papain-like protease (PLpro) that cleaves polyprotein 1a at three sites harboring the canonical Leu-(Lys/Asn)-Gly-Gly-#-(Ala/Lys) sequence (Fig. 8.1b) .", [["Leu", "CHEMICAL", 266, 269], ["Lys", "CHEMICAL", 271, 274], ["Asn", "CHEMICAL", 275, 278], ["Gly", "CHEMICAL", 284, 287], ["Ala", "CHEMICAL", 291, 294], ["Lys", "CHEMICAL", 295, 298], ["SARS-CoV", "ORGANISM", 99, 107], ["Mpro", "GENE_OR_GENE_PRODUCT", 143, 147], ["SARS-CoV", "ORGANISM", 149, 157], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 170, 190], ["PLpro", "GENE_OR_GENE_PRODUCT", 192, 197], ["polyprotein 1a", "GENE_OR_GENE_PRODUCT", 212, 226], ["SARS-CoV Papain", "PROTEIN", 99, 114], ["ProteaseIn", "PROTEIN", 120, 130], ["Mpro", "PROTEIN", 143, 147], ["CoV", "DNA", 154, 157], ["papain-like protease", "PROTEIN", 170, 190], ["PLpro", "PROTEIN", 192, 197], ["polyprotein 1a", "PROTEIN", 212, 226], ["SARS-CoV", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 149, 157], ["Substrate binding", "PROBLEM", 0, 17], ["the SARS", "PROBLEM", 95, 103], ["CoV Papain", "TREATMENT", 104, 114], ["a papain", "TREATMENT", 168, 176], ["protease (PLpro)", "TREATMENT", 182, 198], ["polyprotein 1a", "TREATMENT", 212, 226], ["Ala/Lys) sequence", "TREATMENT", 291, 308], ["Fig.", "TEST", 310, 314], ["canonical Leu", "OBSERVATION", 256, 269]]], ["The tertiary structure of PLpro reveals a distant relationship to the papain family of cysteine proteases (Ratia et al. 2006) .", [["cysteine", "CHEMICAL", 87, 95], ["PLpro", "GENE_OR_GENE_PRODUCT", 26, 31], ["papain", "GENE_OR_GENE_PRODUCT", 70, 76], ["cysteine", "AMINO_ACID", 87, 95], ["PLpro", "PROTEIN", 26, 31], ["papain family", "PROTEIN", 70, 83], ["cysteine proteases", "PROTEIN", 87, 105], ["cysteine proteases", "TREATMENT", 87, 105], ["tertiary", "OBSERVATION_MODIFIER", 4, 12]]], ["The catalytic triad of this enzyme (Cys112-His273-Asp287) also has a broad range of pH optima that is characteristic of the thiolate-imidazolium ion pair that exists also in other papain-like cysteine proteases (Storer and M\u00e9nard 1994; Han et al. 2005) .Structure and Function of the SARS-CoV Papain-Like ProteaseThe functional unit of PLpro is a monomer comprising four structural domains (Fig. 8.5) .", [["Cys112-His273-Asp287", "CHEMICAL", 36, 56], ["thiolate-imidazolium", "CHEMICAL", 124, 144], ["SARS", "DISEASE", 284, 288], ["PLpro", "CHEMICAL", 336, 341], ["Cys112-His273-Asp287", "CHEMICAL", 36, 56], ["thiolate", "CHEMICAL", 124, 132], ["imidazolium", "CHEMICAL", 133, 144], ["cysteine", "CHEMICAL", 192, 200], ["thiolate-imidazolium ion", "SIMPLE_CHEMICAL", 124, 148], ["PLpro", "GENE_OR_GENE_PRODUCT", 336, 341], ["papain", "PROTEIN", 180, 186], ["cysteine proteases", "PROTEIN", 192, 210], ["SARS-CoV Papain-Like Protease", "PROTEIN", 284, 313], ["PLpro", "PROTEIN", 336, 341], ["structural domains", "PROTEIN", 371, 389], ["SARS-CoV", "SPECIES", 284, 292], ["this enzyme", "TEST", 23, 34], ["Cys112", "TEST", 36, 42], ["Asp", "TEST", 50, 53], ["pH optima", "PROBLEM", 84, 93], ["the thiolate-imidazolium ion pair", "TREATMENT", 120, 153], ["the SARS", "TEST", 280, 288], ["CoV Papain", "TREATMENT", 289, 299], ["PLpro", "TREATMENT", 336, 341], ["a monomer", "TREATMENT", 345, 354], ["broad", "OBSERVATION_MODIFIER", 69, 74], ["pH optima", "OBSERVATION", 84, 93]]], ["A zinc atom is bound at the finger domain and the active site is located at the interface of the palm and thumb domains.", [["zinc", "CHEMICAL", 2, 6], ["zinc", "CHEMICAL", 2, 6], ["zinc atom", "SIMPLE_CHEMICAL", 2, 11], ["palm", "ORGANISM_SUBDIVISION", 97, 101], ["finger domain", "PROTEIN", 28, 41], ["active site", "PROTEIN", 50, 61], ["palm and thumb domains", "PROTEIN", 97, 119], ["A zinc atom", "PROBLEM", 0, 11], ["zinc atom", "OBSERVATION", 2, 11], ["bound", "OBSERVATION_MODIFIER", 15, 20], ["finger", "ANATOMY", 28, 34], ["active", "OBSERVATION_MODIFIER", 50, 56], ["site", "OBSERVATION", 57, 61], ["interface", "ANATOMY_MODIFIER", 80, 89], ["palm", "ANATOMY", 97, 101], ["thumb", "ANATOMY", 106, 111]]], ["A special feature of PLpro is its ubiquitin-like domain, and indeed SARS-CoV PLpro has been shown to possess deubiquitination activity (Barretto et al. 2005; Lindner et al. 2005 Lindner et al. , 2007 .", [["PLpro", "GENE_OR_GENE_PRODUCT", 21, 26], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 68, 76], ["PLpro", "PROTEIN", 21, 26], ["ubiquitin-like domain", "PROTEIN", 34, 55], ["SARS-CoV PLpro", "PROTEIN", 68, 82], ["SARS-CoV", "SPECIES", 68, 76], ["CoV PLpro", "TREATMENT", 73, 82]]], ["This dualfunctional role makes PLpro another viable target for the development of anti-SARS drugs.Structure and Function of the SARS-CoV Papain-Like ProteaseThiocarbonyl-containing analogs (6-mercaptopurine and 6-thioguanine) have been demonstrated to be PLpro active site-directed compounds ) that bind with high affinity, block the essential sulfhydryl group after binding, and thereby prevent subunit acylation and block enzyme activity.", [["ProteaseThiocarbonyl", "CHEMICAL", 149, 169], ["6-mercaptopurine", "CHEMICAL", 190, 206], ["6-thioguanine", "CHEMICAL", 211, 224], ["sulfhydryl", "CHEMICAL", 344, 354], ["ProteaseThiocarbonyl", "CHEMICAL", 149, 169], ["6-mercaptopurine", "CHEMICAL", 190, 206], ["6-thioguanine", "CHEMICAL", 211, 224], ["sulfhydryl", "CHEMICAL", 344, 354], ["PLpro", "SIMPLE_CHEMICAL", 31, 36], ["anti-SARS drugs", "SIMPLE_CHEMICAL", 82, 97], ["SARS-CoV Papain-Like ProteaseThiocarbonyl-containing analogs", "SIMPLE_CHEMICAL", 128, 188], ["6-mercaptopurine", "SIMPLE_CHEMICAL", 190, 206], ["6-thioguanine", "SIMPLE_CHEMICAL", 211, 224], ["PLpro", "SIMPLE_CHEMICAL", 255, 260], ["sulfhydryl", "SIMPLE_CHEMICAL", 344, 354], ["SARS-CoV", "SPECIES", 128, 136], ["anti-SARS drugs", "TREATMENT", 82, 97], ["the SARS", "TEST", 124, 132], ["CoV Papain", "TREATMENT", 133, 143], ["ProteaseThiocarbonyl-containing analogs", "TREATMENT", 149, 188], ["mercaptopurine", "TREATMENT", 192, 206], ["thioguanine", "TREATMENT", 213, 224], ["high affinity", "PROBLEM", 309, 322], ["block the essential sulfhydryl group", "TREATMENT", 324, 360], ["subunit acylation", "TREATMENT", 396, 413], ["block enzyme activity", "PROBLEM", 418, 439]]], ["These thiopurine compounds are currently used clinically to treat children with acute lymphoblastic or myeloblastic leukemia (Pui and Evans 1998; Elion 1989) and the adverse toxicities of these drugs are well documented.", [["lymphoblastic", "ANATOMY", 86, 99], ["myeloblastic leukemia", "ANATOMY", 103, 124], ["thiopurine", "CHEMICAL", 6, 16], ["acute lymphoblastic or myeloblastic leukemia", "DISEASE", 80, 124], ["toxicities", "DISEASE", 174, 184], ["thiopurine", "CHEMICAL", 6, 16], ["thiopurine", "SIMPLE_CHEMICAL", 6, 16], ["children", "ORGANISM", 66, 74], ["acute lymphoblastic", "CANCER", 80, 99], ["myeloblastic leukemia", "CANCER", 103, 124], ["children", "SPECIES", 66, 74], ["These thiopurine compounds", "TREATMENT", 0, 26], ["acute lymphoblastic or myeloblastic leukemia", "PROBLEM", 80, 124], ["the adverse toxicities", "PROBLEM", 162, 184], ["these drugs", "TREATMENT", 188, 199], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["lymphoblastic", "OBSERVATION", 86, 99], ["myeloblastic leukemia", "OBSERVATION", 103, 124]]], ["These thiopurine analogs are important potential lead compounds for the development of anti-SARS-CoV agents in the near future.ConclusionsThe maturation of SARS-CoV involves two viral proteases, Mpro and PLpro.", [["thiopurine", "CHEMICAL", 6, 16], ["SARS", "DISEASE", 156, 160], ["thiopurine", "CHEMICAL", 6, 16], ["thiopurine analogs", "SIMPLE_CHEMICAL", 6, 24], ["anti-SARS-CoV", "ORGANISM", 87, 100], ["SARS-CoV", "ORGANISM", 156, 164], ["Mpro", "GENE_OR_GENE_PRODUCT", 195, 199], ["PLpro", "GENE_OR_GENE_PRODUCT", 204, 209], ["viral proteases", "PROTEIN", 178, 193], ["Mpro", "PROTEIN", 195, 199], ["PLpro", "PROTEIN", 204, 209], ["anti-SARS-CoV", "SPECIES", 87, 100], ["SARS-CoV", "SPECIES", 156, 164], ["These thiopurine analogs", "TREATMENT", 0, 24], ["potential lead compounds", "TREATMENT", 39, 63], ["anti-SARS", "TREATMENT", 87, 96], ["CoV agents", "TREATMENT", 97, 107], ["SARS", "PROBLEM", 156, 160], ["two viral proteases", "TREATMENT", 174, 193], ["Mpro", "TREATMENT", 195, 199], ["PLpro", "TREATMENT", 204, 209]]], ["Mpro has a Cys145-His41 catalytic dyad at its active center with His41 acting as a general base.", [["Mpro", "CHEMICAL", 0, 4], ["Cys145", "CHEMICAL", 11, 17], ["His41", "CHEMICAL", 65, 70], ["Mpro", "GENE_OR_GENE_PRODUCT", 0, 4], ["Cys145", "GENE_OR_GENE_PRODUCT", 11, 17], ["His41", "SIMPLE_CHEMICAL", 65, 70], ["Mpro", "PROTEIN", 0, 4], ["Cys145-His41 catalytic dyad", "PROTEIN", 11, 38], ["His41", "PROTEIN", 65, 70], ["base", "ANATOMY_MODIFIER", 91, 95]]], ["In addition, the functional unit of Mpro is a dimer and there is a close correlation between dimer formation and catalytic activity.", [["Mpro", "GENE_OR_GENE_PRODUCT", 36, 40], ["Mpro", "PROTEIN", 36, 40], ["dimer", "PROTEIN", 46, 51], ["catalytic activity", "OBSERVATION", 113, 131]]], ["A flip-flop mechanism is proposed for Mpro in which its two subunits are alternately used in acylation and deacylation steps.", [["Mpro", "SIMPLE_CHEMICAL", 38, 42], ["Mpro", "PROTEIN", 38, 42], ["A flip-flop mechanism", "TREATMENT", 0, 21], ["Mpro", "TREATMENT", 38, 42]]], ["The subunit interfacial region of the main protease is an ideal target for rational drug design in the future treatment of SARS-CoV.", [["SARS-CoV", "DISEASE", 123, 131], ["SARS-CoV", "ORGANISM", 123, 131], ["subunit interfacial region", "PROTEIN", 4, 30], ["protease", "PROTEIN", 43, 51], ["SARS-CoV", "SPECIES", 123, 131], ["rational drug design", "TREATMENT", 75, 95], ["SARS", "PROBLEM", 123, 127], ["interfacial", "OBSERVATION_MODIFIER", 12, 23], ["main protease", "ANATOMY", 38, 51]]], ["Inhibitors of PLpro are also potential avenues for developing anti-SARS therapies.ConclusionsAcknowledgment This work was supported by the National Science Council, ROC.", [["PLpro", "GENE_OR_GENE_PRODUCT", 14, 19], ["anti-SARS", "CANCER", 62, 71], ["PLpro", "PROTEIN", 14, 19], ["Inhibitors", "TREATMENT", 0, 10], ["PLpro", "TREATMENT", 14, 19], ["developing anti-SARS therapies", "TREATMENT", 51, 81]]], ["2FE8) is shown in rainbow colors from the N-terminus (blue) to C-terminus (red).", [["2FE8", "CHEMICAL", 0, 4], ["N", "CHEMICAL", 42, 43], ["C", "CHEMICAL", 63, 64], ["2FE8", "PROTEIN", 0, 4], ["N-terminus", "PROTEIN", 42, 52], ["C-terminus", "PROTEIN", 63, 73], ["red", "PROTEIN", 75, 78]]], ["The catalytic triad (Cys112-His273-Asp287) and the Zn atom are highlighted using a sphere model. (b) Amino acid sequence and other structural annotations.", [["Cys112-His273-Asp287", "CHEMICAL", 21, 41], ["Zn", "CHEMICAL", 51, 53], ["Cys112-His273-Asp287", "CHEMICAL", 21, 41], ["Zn", "CHEMICAL", 51, 53], ["Amino acid", "CHEMICAL", 101, 111], ["Zn atom", "SIMPLE_CHEMICAL", 51, 58], ["Amino acid", "AMINO_ACID", 101, 111], ["catalytic triad", "PROTEIN", 4, 19], ["Asp287", "PROTEIN", 35, 41], ["Zn atom", "PROTEIN", 51, 58], ["The catalytic triad", "TEST", 0, 19], ["Cys112", "TEST", 21, 27], ["the Zn atom", "TEST", 47, 58], ["a sphere model", "TREATMENT", 81, 95], ["Amino acid sequence", "TEST", 101, 120]]], ["The key for these structural features of PLpro is shown below the panel.", [["PLpro", "SIMPLE_CHEMICAL", 41, 46], ["PLpro", "PROTEIN", 41, 46]]], ["Panel (a) was generated using MacPymol (DeLano 2002) and panel (b) with PdbSum (Laskowski et al. 2005)", [["MacPymol (DeLano", "TREATMENT", 30, 46]]]], "604397da653890b54d4af23b45adab3365e1f042": [["IntroductionRift Valley fever virus (RVFV) belongs to genus Phlebovirus of the family Bunyaviridae, and is a mosquito-borne zoonotic pathogen which causes Rift Valley fever (RVF).", [["IntroductionRift Valley fever", "DISEASE", 0, 29], ["Bunyaviridae", "DISEASE", 86, 98], ["zoonotic pathogen", "DISEASE", 124, 141], ["Rift Valley fever", "DISEASE", 155, 172], ["RVF", "DISEASE", 174, 177], ["IntroductionRift Valley fever virus", "ORGANISM", 0, 35], ["RVFV", "ORGANISM", 37, 41], ["Bunyaviridae", "ORGANISM", 86, 98], ["Rift Valley fever", "ORGANISM", 155, 172], ["fever virus", "SPECIES", 24, 35], ["Rift Valley fever", "SPECIES", 155, 172], ["IntroductionRift Valley fever virus", "SPECIES", 0, 35], ["RVFV", "SPECIES", 37, 41], ["Rift Valley fever (RVF", "SPECIES", 155, 177], ["Valley fever virus", "PROBLEM", 17, 35], ["Bunyaviridae", "TREATMENT", 86, 98], ["a mosquito-borne zoonotic pathogen", "PROBLEM", 107, 141], ["Rift Valley fever (RVF", "PROBLEM", 155, 177]]], ["RVF is characterized by an acute febrile illness, hemorrhagic fever, neurological disorder or blindness in humans [1, 2, 3, 4] .", [["neurological", "ANATOMY", 69, 81], ["RVF", "DISEASE", 0, 3], ["febrile illness", "DISEASE", 33, 48], ["hemorrhagic fever", "DISEASE", 50, 67], ["neurological disorder", "DISEASE", 69, 90], ["blindness", "DISEASE", 94, 103], ["humans", "ORGANISM", 107, 113], ["humans", "SPECIES", 107, 113], ["RVF", "SPECIES", 0, 3], ["humans", "SPECIES", 107, 113], ["RVF", "PROBLEM", 0, 3], ["an acute febrile illness", "PROBLEM", 24, 48], ["hemorrhagic fever", "PROBLEM", 50, 67], ["neurological disorder", "PROBLEM", 69, 90], ["blindness in humans", "PROBLEM", 94, 113], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["febrile", "OBSERVATION_MODIFIER", 33, 40], ["illness", "OBSERVATION", 41, 48], ["hemorrhagic", "OBSERVATION_MODIFIER", 50, 61], ["fever", "OBSERVATION", 62, 67], ["blindness", "OBSERVATION", 94, 103]]], ["In ruminants, RVFV induces a high rate of abortion or fetal malformation as well as lethal hepatitis in newborn lambs [5] .", [["fetal", "ANATOMY", 54, 59], ["RVFV", "DISEASE", 14, 18], ["abortion", "DISEASE", 42, 50], ["fetal malformation", "DISEASE", 54, 72], ["hepatitis", "DISEASE", 91, 100], ["RVFV", "ORGANISM", 14, 18], ["fetal", "ORGAN", 54, 59], ["RVFV", "SPECIES", 14, 18], ["RVFV", "PROBLEM", 14, 18], ["a high rate of abortion", "PROBLEM", 27, 50], ["fetal malformation", "PROBLEM", 54, 72], ["lethal hepatitis in newborn lambs", "PROBLEM", 84, 117], ["RVFV", "OBSERVATION", 14, 18], ["fetal", "ANATOMY", 54, 59], ["malformation", "OBSERVATION", 60, 72]]], ["The first recognized outbreak of RVF occurred in Kenya in 1930 [6] , and RVFV has spread from endemic region in sub-Saharan Africa into Egypt [7] , Madagascar and the Arabian Peninsula [8, 9, 10, 11, 12] .", [["RVF", "DISEASE", 33, 36], ["RVFV", "DISEASE", 73, 77], ["RVFV", "ORGANISM", 73, 77], ["RVF", "SPECIES", 33, 36], ["RVFV", "SPECIES", 73, 77], ["RVF", "PROBLEM", 33, 36], ["RVFV", "PROBLEM", 73, 77], ["RVF", "OBSERVATION", 33, 36], ["endemic", "OBSERVATION_MODIFIER", 94, 101]]], ["The potential threat of RVFV introduction into non-endemic countries raises concern of agriculture and public health [13, 14, 15] .", [["RVFV", "DISEASE", 24, 28], ["RVFV", "ORGANISM", 24, 28], ["RVFV", "SPECIES", 24, 28], ["RVFV introduction", "TREATMENT", 24, 41], ["RVFV", "OBSERVATION", 24, 28]]], ["RVFV is a risk group 3 pathogen, Category A pathogen and an overlap select agent by the CDC/USDA [16] .", [["RVFV", "DISEASE", 0, 4], ["RVFV", "ORGANISM", 0, 4], ["RVFV", "SPECIES", 0, 4], ["RVFV", "PROBLEM", 0, 4]]], ["The handling of wild-type (wt) RVFV within the U.S. requires BSL3+ or BSL4 facilities.", [["wild-type (wt) RVFV", "ORGANISM", 16, 35], ["BSL3", "GENE_OR_GENE_PRODUCT", 61, 65], ["RVFV", "SPECIES", 31, 35]]], ["Live-attenuated MP-12 vaccine strain is excluded from select agent rule, and handled at BSL2 level.", [["MP", "CHEMICAL", 16, 18], ["BSL2", "GENE_OR_GENE_PRODUCT", 88, 92], ["BSL2", "PROTEIN", 88, 92], ["MP-12 vaccine strain", "TREATMENT", 16, 36]]], ["MP-12 encodes for functional NSs protein, which is useful for the analyses of various NSs functions at BSL2 level [17, 18, 19] .IntroductionRVFV has a tripartite negative-stranded RNA genome, referred to as Small (S)-, Medium (M)-and Large (L)-segment.", [["IntroductionRVFV", "CHEMICAL", 128, 144], ["MP-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["NSs", "GENE_OR_GENE_PRODUCT", 29, 32], ["NSs", "GENE_OR_GENE_PRODUCT", 86, 89], ["BSL2", "GENE_OR_GENE_PRODUCT", 103, 107], ["MP", "PROTEIN", 0, 2], ["NSs protein", "PROTEIN", 29, 40], ["NSs", "DNA", 86, 89], ["BSL2", "PROTEIN", 103, 107], ["tripartite negative-stranded RNA genome", "DNA", 151, 190], ["Large (L)-segment", "DNA", 234, 251], ["MP", "TEST", 0, 2], ["functional NSs protein", "TREATMENT", 18, 40], ["a tripartite", "TEST", 149, 161], ["stranded RNA genome", "PROBLEM", 171, 190], ["Large (L)-segment", "PROBLEM", 234, 251], ["stranded", "OBSERVATION_MODIFIER", 171, 179], ["RNA genome", "OBSERVATION", 180, 190], ["Small", "OBSERVATION_MODIFIER", 207, 212], ["Large", "OBSERVATION_MODIFIER", 234, 239], ["L", "ANATOMY_MODIFIER", 241, 242], ["segment", "ANATOMY_MODIFIER", 244, 251]]], ["The Ssegment encodes for N and NSs genes in an ambi-sense manner, M-segments encodes for NSm, 78-kD protein, NSm-Gn, Gn, and Gc proteins, and L-segment encodes for RNA-dependent RNA polymerase [20, 21, 22, 23] .", [["NSs", "GENE_OR_GENE_PRODUCT", 31, 34], ["NSm", "GENE_OR_GENE_PRODUCT", 89, 92], ["78-kD", "GENE_OR_GENE_PRODUCT", 94, 99], ["NSm-Gn", "GENE_OR_GENE_PRODUCT", 109, 115], ["Gn", "GENE_OR_GENE_PRODUCT", 117, 119], ["Gc proteins", "GENE_OR_GENE_PRODUCT", 125, 136], ["L-segment", "GENE_OR_GENE_PRODUCT", 142, 151], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 164, 192], ["Ssegment", "DNA", 4, 12], ["N and NSs genes", "DNA", 25, 40], ["NSm", "PROTEIN", 89, 92], ["78-kD protein", "PROTEIN", 94, 107], ["NSm", "PROTEIN", 109, 112], ["Gn", "PROTEIN", 113, 115], ["Gn", "PROTEIN", 117, 119], ["Gc proteins", "PROTEIN", 125, 136], ["L-segment", "PROTEIN", 142, 151], ["RNA-dependent RNA polymerase", "PROTEIN", 164, 192], ["The Ssegment encodes", "TREATMENT", 0, 20], ["N and NSs genes", "TREATMENT", 25, 40], ["NSm", "TEST", 89, 92], ["kD protein", "TEST", 97, 107], ["NSm", "TEST", 109, 112], ["Gn", "TEST", 113, 115], ["Gn", "TEST", 117, 119], ["Gc proteins", "TEST", 125, 136], ["RNA", "TEST", 164, 167], ["dependent RNA polymerase", "PROBLEM", 168, 192]]], ["NSs is a major virulence factor of RVFV and inhibits host general transcription through sequestration of TFIIH p44 [24] or promotion of TFIIH p62 subunits degradation [19] .", [["RVFV", "ORGANISM", 35, 39], ["TFIIH p44", "GENE_OR_GENE_PRODUCT", 105, 114], ["TFIIH p62", "GENE_OR_GENE_PRODUCT", 136, 145], ["NSs", "PROTEIN", 0, 3], ["TFIIH p44", "PROTEIN", 105, 114], ["TFIIH p62 subunits", "PROTEIN", 136, 154], ["RVFV", "SPECIES", 35, 39], ["NSs", "TREATMENT", 0, 3], ["host general transcription", "TREATMENT", 53, 79], ["sequestration of TFIIH p44", "TREATMENT", 88, 114]]], ["NSs also inhibits host antiviral response by inhibiting the activation of interferon (IFN)-b promoter through interaction with Sin3A-associated protein (SAP30) at aa.210-230 [25, 26] , and promotion of dsRNA-dependent protein kinase (PKR) degradation [17, 27, 28] .IntroductionDeveloping countermeasures against RVFV is important for the prevention of RVF outbreaks or decreasing impact of RVFV introduction.", [["RVFV", "DISEASE", 312, 316], ["RVF", "DISEASE", 352, 355], ["RVFV", "DISEASE", 390, 394], ["interferon (IFN)-b", "GENE_OR_GENE_PRODUCT", 74, 92], ["Sin3A-associated protein", "GENE_OR_GENE_PRODUCT", 127, 151], ["SAP30", "GENE_OR_GENE_PRODUCT", 153, 158], ["aa.210-230", "GENE_OR_GENE_PRODUCT", 163, 173], ["dsRNA-dependent protein kinase", "GENE_OR_GENE_PRODUCT", 202, 232], ["PKR", "GENE_OR_GENE_PRODUCT", 234, 237], ["RVFV", "ORGANISM", 312, 316], ["RVFV", "ORGANISM", 390, 394], ["interferon (IFN)-b promoter", "DNA", 74, 101], ["Sin3A", "PROTEIN", 127, 132], ["associated protein", "PROTEIN", 133, 151], ["SAP30", "PROTEIN", 153, 158], ["protein kinase", "PROTEIN", 218, 232], ["PKR", "PROTEIN", 234, 237], ["RVFV", "SPECIES", 312, 316], ["RVF", "SPECIES", 352, 355], ["RVFV", "SPECIES", 390, 394], ["NSs", "TREATMENT", 0, 3], ["interferon (IFN)", "TREATMENT", 74, 90], ["dsRNA-dependent protein kinase", "TEST", 202, 232], ["PKR", "TEST", 234, 237], ["RVFV", "PROBLEM", 312, 316], ["RVF outbreaks", "PROBLEM", 352, 365], ["RVFV introduction", "TREATMENT", 390, 407], ["host antiviral response", "OBSERVATION", 18, 41], ["RVF", "OBSERVATION", 352, 355], ["decreasing", "OBSERVATION_MODIFIER", 369, 379], ["RVFV", "OBSERVATION", 390, 394]]], ["A number of candidate vaccines are under development including live-attenuated vaccine [29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40] , formalin-inactivated vaccine [41, 42] , subunit vaccine [43] , virus-like particle [44, 45, 46, 47] , nonspreading RVFV replicon [48, 49] , viral vectors [50, 51, 52, 53, 54, 55, 56] , and DNA vaccines [57, 58, 59] .", [["formalin", "CHEMICAL", 138, 146], ["formalin", "CHEMICAL", 138, 146], ["formalin", "SIMPLE_CHEMICAL", 138, 146], ["virus-like particle", "ORGANISM", 201, 220], ["RVFV", "ORGANISM", 253, 257], ["DNA", "CELLULAR_COMPONENT", 327, 330], ["RVFV", "SPECIES", 253, 257], ["candidate vaccines", "TREATMENT", 12, 30], ["subunit vaccine", "TREATMENT", 178, 193], ["nonspreading RVFV replicon", "TEST", 240, 266], ["viral vectors", "TEST", 278, 291], ["DNA vaccines", "TEST", 327, 339]]], ["For treatment of ongoing outbreaks, several antivirals have been tested for RVFV infection.", [["RVFV infection", "DISEASE", 76, 90], ["RVFV", "ORGANISM", 76, 80], ["RVFV", "SPECIES", 76, 80], ["treatment", "TREATMENT", 4, 13], ["ongoing outbreaks", "PROBLEM", 17, 34], ["several antivirals", "TREATMENT", 36, 54], ["RVFV infection", "PROBLEM", 76, 90], ["ongoing", "OBSERVATION_MODIFIER", 17, 24], ["outbreaks", "OBSERVATION", 25, 34], ["infection", "OBSERVATION", 81, 90]]], ["Liposome-encapsulated ribavirin is effective to treat RVFV infection in mice [60] , while a potent IFN inducer, polyriboinosinic-polyribocytidylic acid stabilized with poly-L-Lysine and carboxymethyl cellulose [Poly(LCIC)] are effective in combination with ribavirin [61] .", [["Liposome", "CHEMICAL", 0, 8], ["ribavirin", "CHEMICAL", 22, 31], ["RVFV infection", "DISEASE", 54, 68], ["polyriboinosinic-polyribocytidylic acid", "CHEMICAL", 112, 151], ["poly-L-Lysine", "CHEMICAL", 168, 181], ["carboxymethyl cellulose", "CHEMICAL", 186, 209], ["Poly", "CHEMICAL", 211, 215], ["LCIC", "CHEMICAL", 216, 220], ["ribavirin", "CHEMICAL", 257, 266], ["ribavirin", "CHEMICAL", 22, 31], ["polyriboinosinic-polyribocytidylic acid", "CHEMICAL", 112, 151], ["poly-L-Lysine", "CHEMICAL", 168, 181], ["carboxymethyl", "CHEMICAL", 186, 199], ["Poly(LCIC)", "CHEMICAL", 211, 221], ["ribavirin", "CHEMICAL", 257, 266], ["Liposome", "SIMPLE_CHEMICAL", 0, 8], ["ribavirin", "SIMPLE_CHEMICAL", 22, 31], ["RVFV", "ORGANISM", 54, 58], ["mice", "ORGANISM", 72, 76], ["IFN", "GENE_OR_GENE_PRODUCT", 99, 102], ["polyriboinosinic-polyribocytidylic acid", "SIMPLE_CHEMICAL", 112, 151], ["poly-L-Lysine", "SIMPLE_CHEMICAL", 168, 181], ["carboxymethyl cellulose", "SIMPLE_CHEMICAL", 186, 209], ["Poly(LCIC)", "SIMPLE_CHEMICAL", 211, 221], ["ribavirin", "SIMPLE_CHEMICAL", 257, 266], ["IFN", "PROTEIN", 99, 102], ["mice", "SPECIES", 72, 76], ["RVFV", "SPECIES", 54, 58], ["mice", "SPECIES", 72, 76], ["Liposome", "TREATMENT", 0, 8], ["encapsulated ribavirin", "TREATMENT", 9, 31], ["RVFV infection", "PROBLEM", 54, 68], ["a potent IFN inducer", "TREATMENT", 90, 110], ["polyriboinosinic", "TEST", 112, 128], ["polyribocytidylic acid", "TEST", 129, 151], ["poly-L-Lysine and carboxymethyl cellulose [Poly(LCIC)", "TREATMENT", 168, 221], ["ribavirin", "TREATMENT", 257, 266], ["ribavirin", "OBSERVATION", 22, 31]]], ["Therapeutic administration of IFN-a into rhesus monkeys infected with RVFV also limits RVFV replication [62] .", [["IFN", "CHEMICAL", 30, 33], ["IFN", "GENE_OR_GENE_PRODUCT", 30, 33], ["rhesus", "ORGANISM", 41, 47], ["monkeys", "ORGANISM", 48, 55], ["RVFV", "ORGANISM", 70, 74], ["RVFV", "ORGANISM", 87, 91], ["IFN", "PROTEIN", 30, 33], ["rhesus monkeys", "SPECIES", 41, 55], ["rhesus monkeys", "SPECIES", 41, 55], ["RVFV", "SPECIES", 70, 74], ["RVFV", "SPECIES", 87, 91], ["Therapeutic administration", "TREATMENT", 0, 26], ["IFN", "TREATMENT", 30, 33], ["RVFV", "PROBLEM", 70, 74]]], ["The 6-fluoro-3-hydroxy-2-pyrazinecarboxamide (T-705) is shown to be more effective to inhibit RVFV replication than ribavirin [63] , while antiviral small molecule, LJ001 was shown to be effective to numerous enveloped viruses including RVFV [64] .", [["6-fluoro-3-hydroxy-2-pyrazinecarboxamide", "CHEMICAL", 4, 44], ["T-705", "CHEMICAL", 46, 51], ["ribavirin", "CHEMICAL", 116, 125], ["LJ001", "CHEMICAL", 165, 170], ["6-fluoro-3-hydroxy-2-pyrazinecarboxamide", "CHEMICAL", 4, 44], ["T-705", "CHEMICAL", 46, 51], ["ribavirin", "CHEMICAL", 116, 125], ["LJ001", "CHEMICAL", 165, 170], ["6-fluoro-3-hydroxy-2-pyrazinecarboxamide", "SIMPLE_CHEMICAL", 4, 44], ["T-705", "SIMPLE_CHEMICAL", 46, 51], ["RVFV", "ORGANISM", 94, 98], ["LJ001", "SIMPLE_CHEMICAL", 165, 170], ["RVFV", "ORGANISM", 237, 241], ["RVFV", "SPECIES", 94, 98], ["RVFV", "SPECIES", 237, 241], ["The 6-fluoro", "TEST", 0, 12], ["ribavirin", "TREATMENT", 116, 125], ["antiviral small molecule", "PROBLEM", 139, 163], ["RVFV", "PROBLEM", 237, 241], ["enveloped", "OBSERVATION_MODIFIER", 209, 218], ["viruses", "OBSERVATION", 219, 226]]], ["These studies suggest that increased innate immune responses could inhibit RVFV replication in addition to antivirals specific to viral proteins.IntroductionSince the major virulence factor, NSs protein, is an antagonist of IFN responses, the direct attenuation of NSs function may increase host innate immune responses in cells infected with RVFV potentially limiting RVFV replication.", [["cells", "ANATOMY", 323, 328], ["RVFV", "ORGANISM", 75, 79], ["NSs", "GENE_OR_GENE_PRODUCT", 191, 194], ["IFN", "GENE_OR_GENE_PRODUCT", 224, 227], ["NSs", "GENE_OR_GENE_PRODUCT", 265, 268], ["cells", "CELL", 323, 328], ["RVFV", "ORGANISM", 343, 347], ["RVFV", "ORGANISM", 369, 373], ["viral proteins", "PROTEIN", 130, 144], ["major virulence factor", "PROTEIN", 167, 189], ["NSs protein", "PROTEIN", 191, 202], ["IFN", "PROTEIN", 224, 227], ["NSs", "PROTEIN", 265, 268], ["RVFV", "SPECIES", 75, 79], ["RVFV", "SPECIES", 343, 347], ["RVFV", "SPECIES", 369, 373], ["These studies", "TEST", 0, 13], ["increased innate immune responses", "PROBLEM", 27, 60], ["RVFV replication", "TREATMENT", 75, 91], ["antivirals", "TREATMENT", 107, 117], ["viral proteins", "PROBLEM", 130, 144], ["an antagonist of IFN responses", "TREATMENT", 207, 237], ["NSs function", "TREATMENT", 265, 277], ["RVFV", "PROBLEM", 343, 347], ["RVFV replication", "TREATMENT", 369, 385], ["increased", "OBSERVATION_MODIFIER", 27, 36]]], ["Thus, we aimed to attenuate RVFV NSs function(s) by co-expressing nonfunctional NSs.", [["RVFV", "ORGANISM", 28, 32], ["NSs", "GENE_OR_GENE_PRODUCT", 80, 83], ["NSs", "PROTEIN", 80, 83], ["RVFV", "SPECIES", 28, 32], ["nonfunctional NSs", "OBSERVATION", 66, 83]]], ["It has been shown that recombinant MP-12 virus encoding truncated NSs at aa.210 to 230 (SAP30-binding domain) does not inhibit IFN-b mRNA synthesis [26] .", [["MP-12 virus", "ORGANISM", 35, 46], ["IFN-b", "GENE_OR_GENE_PRODUCT", 127, 132], ["truncated NSs", "PROTEIN", 56, 69], ["210 to 230 (SAP30-binding domain", "PROTEIN", 76, 108], ["IFN-b mRNA", "RNA", 127, 137], ["recombinant MP", "TEST", 23, 37], ["IFN", "TEST", 127, 130]]], ["Thus, we employed a similar strategy to abolish a part of NSs functions by truncating each 17 to 25 aa.", [["NSs", "GENE_OR_GENE_PRODUCT", 58, 61], ["NSs", "DNA", 58, 61]]], ["Co-expression of such truncated NSs may exhibit dominant-negative phenotype by self-association through the Cterminus at the self-association domain (aa.249 to 265) [65] .", [["NSs", "GENE_OR_GENE_PRODUCT", 32, 35], ["truncated NSs", "PROTEIN", 22, 35], ["Cterminus", "PROTEIN", 108, 117], ["self-association domain", "PROTEIN", 125, 148], ["such truncated NSs", "PROBLEM", 17, 35], ["dominant", "OBSERVATION_MODIFIER", 48, 56], ["negative phenotype", "OBSERVATION", 57, 75]]], ["In this study, we generated NSs encoding deletions of 17 to 25 amino acids, characterized the functions of truncated NSs, and analyzed the dominant-negative effects of co-expressed truncated NSs in cells infected with RVFV.ResultsGeneration of recombinant MP-12 encoding NSs encoding a 17 to 25 aa. truncation Using reverse genetics for the RVFV MP-12 strain, we recovered 11 recombinant MP-12 viruses which encode NSs protein with a 17 to 25 aa. truncation (Fig. 1 ).", [["cells", "ANATOMY", 198, 203], ["amino acids", "CHEMICAL", 63, 74], ["amino acids", "CHEMICAL", 63, 74], ["amino acids", "AMINO_ACID", 63, 74], ["NSs", "GENE_OR_GENE_PRODUCT", 117, 120], ["NSs", "GENE_OR_GENE_PRODUCT", 191, 194], ["cells", "CELL", 198, 203], ["RVFV", "ORGANISM", 218, 222], ["MP-12", "GENE_OR_GENE_PRODUCT", 256, 261], ["NSs", "GENE_OR_GENE_PRODUCT", 271, 274], ["RVFV MP-12 strain", "ORGANISM", 341, 358], ["MP-12 viruses", "ORGANISM", 388, 401], ["NSs", "GENE_OR_GENE_PRODUCT", 415, 418], ["NSs", "DNA", 28, 31], ["truncated NSs", "PROTEIN", 107, 120], ["truncated NSs", "PROTEIN", 181, 194], ["recombinant MP-12", "PROTEIN", 244, 261], ["NSs", "PROTEIN", 271, 274], ["MP", "PROTEIN", 388, 390], ["NSs protein", "PROTEIN", 415, 426], ["RVFV", "SPECIES", 218, 222], ["RVFV MP-12", "SPECIES", 341, 351], ["this study", "TEST", 3, 13], ["NSs encoding deletions", "TREATMENT", 28, 50], ["amino acids", "TEST", 63, 74], ["truncated NSs", "TREATMENT", 107, 120], ["co-expressed truncated NSs in cells", "PROBLEM", 168, 203], ["RVFV", "PROBLEM", 218, 222], ["recombinant MP", "TEST", 244, 258], ["encoding NSs", "TREATMENT", 262, 274], ["the RVFV MP", "TEST", 337, 348], ["NSs protein", "TEST", 415, 426]]], ["These NSs mutants exhibited different plaque phenotypes in plaque assay (Fig. S1 ) suggesting possible variation of attenuation by each NSs mutant.", [["plaque", "ANATOMY", 38, 44], ["plaque", "ANATOMY", 59, 65], ["NSs", "GENE_OR_GENE_PRODUCT", 6, 9], ["plaque", "PATHOLOGICAL_FORMATION", 38, 44], ["S1", "GENE_OR_GENE_PRODUCT", 78, 80], ["NSs", "GENE_OR_GENE_PRODUCT", 136, 139], ["S1", "PROTEIN", 78, 80], ["NSs mutant", "PROTEIN", 136, 146], ["These NSs mutants", "PROBLEM", 0, 17], ["different plaque phenotypes in plaque assay", "PROBLEM", 28, 71], ["variation of attenuation", "PROBLEM", 103, 127], ["different", "OBSERVATION_MODIFIER", 28, 37], ["plaque", "OBSERVATION", 38, 44], ["plaque", "OBSERVATION", 59, 65], ["suggesting possible", "UNCERTAINTY", 83, 102], ["attenuation", "OBSERVATION_MODIFIER", 116, 127], ["NSs mutant", "OBSERVATION", 136, 146]]], ["The plaques of NSD6-30 and NSD56-80 were clear in neutral red stain, while other mutants made turbid plaques.", [["plaques", "ANATOMY", 4, 11], ["plaques", "ANATOMY", 101, 108], ["NSD6-30", "GENE_OR_GENE_PRODUCT", 15, 22], ["NSD56-80", "GENE_OR_GENE_PRODUCT", 27, 35], ["The plaques", "TEST", 0, 11], ["NSD6", "TEST", 15, 19], ["NSD56", "TEST", 27, 32], ["neutral red stain", "TEST", 50, 67], ["turbid plaques", "PROBLEM", 94, 108], ["plaques", "OBSERVATION", 4, 11], ["clear", "OBSERVATION", 41, 46], ["turbid", "OBSERVATION_MODIFIER", 94, 100], ["plaques", "OBSERVATION", 101, 108]]], ["To test the functions of each NSs protein, VeroE6 cells (type-I IFNincompetent) were mock-infected or infected with MP-12, rMP12-C13type (a control lacking NSs functions) [18] , and NSs mutants using an moi of 3.", [["VeroE6 cells", "ANATOMY", 43, 55], ["VeroE6 cells", "CELL", 43, 55], ["type-I IFNincompetent", "GENE_OR_GENE_PRODUCT", 57, 78], ["rMP12", "ORGANISM", 123, 128], ["NSs", "ORGANISM", 182, 185], ["NSs protein", "PROTEIN", 30, 41], ["VeroE6 cells", "CELL_LINE", 43, 55], ["rMP12", "PROTEIN", 123, 128], ["C13type", "PROTEIN", 129, 136], ["NSs", "PROTEIN", 156, 159], ["NSs mutants", "PROTEIN", 182, 193], ["each NSs protein", "TREATMENT", 25, 41], ["VeroE6 cells", "TREATMENT", 43, 55], ["MP", "TEST", 116, 118], ["rMP12", "TREATMENT", 123, 128], ["C13type", "TREATMENT", 129, 136], ["NSs mutants", "TREATMENT", 182, 193]]], ["After 16 hours, cells were collected and the abundance of PKR was measured ( Fig. 2A) as described previously [17] .", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["PKR", "GENE_OR_GENE_PRODUCT", 58, 61], ["PKR", "PROTEIN", 58, 61], ["cells", "TEST", 16, 21], ["PKR", "TEST", 58, 61], ["PKR", "OBSERVATION", 58, 61]]], ["As expected, PKR was not detectable in cells infected with MP-12 by post-translational downregulation [17] , but was detected in cells mock-infected or infected with rMP12-C13type.", [["cells", "ANATOMY", 39, 44], ["cells", "ANATOMY", 129, 134], ["MP-12", "CHEMICAL", 59, 64], ["PKR", "GENE_OR_GENE_PRODUCT", 13, 16], ["cells", "CELL", 39, 44], ["MP-12", "GENE_OR_GENE_PRODUCT", 59, 64], ["cells", "CELL", 129, 134], ["rMP12-C13type", "GENE_OR_GENE_PRODUCT", 166, 179], ["PKR", "PROTEIN", 13, 16], ["rMP12", "PROTEIN", 166, 171], ["C13type", "PROTEIN", 172, 179], ["PKR", "TEST", 13, 16], ["MP", "TEST", 59, 61], ["infected", "OBSERVATION_MODIFIER", 152, 160]]], ["However, cells infected with the MP-12 encoding partially truncated NSs did not decrease PKR abundance.ResultsNext, we tested if partial deletions within the NSs gene would affect the inhibition of IFN-b mRNA synthesis.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["MP-12", "GENE_OR_GENE_PRODUCT", 33, 38], ["PKR", "GENE_OR_GENE_PRODUCT", 89, 92], ["NSs", "GENE_OR_GENE_PRODUCT", 158, 161], ["IFN-b", "GENE_OR_GENE_PRODUCT", 198, 203], ["MP-12", "DNA", 33, 38], ["PKR", "PROTEIN", 89, 92], ["NSs gene", "DNA", 158, 166], ["IFN-b mRNA", "RNA", 198, 208], ["cells infected", "PROBLEM", 9, 23], ["the MP", "TEST", 29, 35], ["partially truncated NSs", "PROBLEM", 48, 71], ["partial deletions", "PROBLEM", 129, 146], ["the NSs gene", "TREATMENT", 154, 166], ["IFN", "PROBLEM", 198, 201], ["b mRNA synthesis", "TREATMENT", 202, 218], ["decrease", "OBSERVATION_MODIFIER", 80, 88], ["PKR", "OBSERVATION", 89, 92]]], ["Type-I IFNcompetent A549 cells were mock-infected or infected with MP-12, rMP12-C13type or NSs mutants at an moi of 3, and then total RNA was extracted at 7 hpi.", [["A549 cells", "ANATOMY", 20, 30], ["A549 cells", "CELL", 20, 30], ["MP-12", "GENE_OR_GENE_PRODUCT", 67, 72], ["rMP12", "GENE_OR_GENE_PRODUCT", 74, 79], ["C13type", "GENE_OR_GENE_PRODUCT", 80, 87], ["NSs", "ORGANISM", 91, 94], ["Type-I IFNcompetent A549 cells", "CELL_LINE", 0, 30], ["rMP12", "PROTEIN", 74, 79], ["C13type", "PROTEIN", 80, 87], ["Type-I IFNcompetent A549 cells", "PROBLEM", 0, 30], ["MP", "TEST", 67, 69], ["rMP12", "TEST", 74, 79], ["NSs mutants", "PROBLEM", 91, 102], ["A549 cells", "OBSERVATION", 20, 30]]], ["Northern blot was performed using RNA probe specific to human IFN-b, ISG56 or RVFV anti-viralsense S RNA/N mRNA as described previously [66, 67] .", [["human", "ORGANISM", 56, 61], ["IFN-b", "GENE_OR_GENE_PRODUCT", 62, 67], ["ISG56", "GENE_OR_GENE_PRODUCT", 69, 74], ["RVFV", "ORGANISM", 78, 82], ["anti-viralsense S", "GENE_OR_GENE_PRODUCT", 83, 100], ["human IFN-b, ISG56 or RVFV anti-viralsense S RNA", "RNA", 56, 104], ["N mRNA", "RNA", 105, 111], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["RVFV", "SPECIES", 78, 82], ["Northern blot", "TEST", 0, 13], ["RNA probe", "TREATMENT", 34, 43], ["ISG56", "TREATMENT", 69, 74]]], ["We tested ISG56 gene, one of the genes controlled under IFN-stimulated response element (ISRE), to confirm the inhibition of host transcription suppression including IFN-b mRNA by NSs.", [["ISG56", "GENE_OR_GENE_PRODUCT", 10, 15], ["IFN-stimulated response element", "GENE_OR_GENE_PRODUCT", 56, 87], ["IFN-b", "GENE_OR_GENE_PRODUCT", 166, 171], ["ISG56 gene", "DNA", 10, 20], ["IFN-stimulated response element", "DNA", 56, 87], ["ISRE", "DNA", 89, 93], ["IFN-b mRNA", "RNA", 166, 176], ["NSs", "PROTEIN", 180, 183], ["IFN-stimulated response element", "TREATMENT", 56, 87], ["host transcription suppression", "TREATMENT", 125, 155], ["IFN-b mRNA", "TREATMENT", 166, 176]]], ["As expected, cells infected with MP-12 inhibited the synthesis of IFNb and ISG56 mRNA, while those infected with rMP12-C13type induced both IFN-b and ISG56 mRNA (Fig. 2B) .", [["cells", "ANATOMY", 13, 18], ["MP-12", "CHEMICAL", 33, 38], ["cells", "CELL", 13, 18], ["MP-12", "GENE_OR_GENE_PRODUCT", 33, 38], ["IFNb", "GENE_OR_GENE_PRODUCT", 66, 70], ["ISG56", "GENE_OR_GENE_PRODUCT", 75, 80], ["rMP12-C13type", "GENE_OR_GENE_PRODUCT", 113, 126], ["IFN-b", "GENE_OR_GENE_PRODUCT", 140, 145], ["ISG56", "GENE_OR_GENE_PRODUCT", 150, 155], ["IFNb and ISG56 mRNA", "RNA", 66, 85], ["rMP12", "PROTEIN", 113, 118], ["C13type", "PROTEIN", 119, 126], ["IFN-b and ISG56 mRNA", "RNA", 140, 160], ["cells infected", "PROBLEM", 13, 27], ["MP", "TEST", 33, 35], ["the synthesis of IFNb", "PROBLEM", 49, 70], ["ISG56 mRNA", "PROBLEM", 75, 85], ["rMP12", "TEST", 113, 118], ["ISG56 mRNA", "PROBLEM", 150, 160]]], ["Interestingly, none of NSs mutants, including NSD210-230 lacking SAP30binding domain, had inhibited IFN-b mRNA synthesis.", [["NSs", "GENE_OR_GENE_PRODUCT", 23, 26], ["NSD210-230", "GENE_OR_GENE_PRODUCT", 46, 56], ["IFN-b", "GENE_OR_GENE_PRODUCT", 100, 105], ["NSs mutants", "PROTEIN", 23, 34], ["NSD210", "PROTEIN", 46, 52], ["SAP30binding domain", "PROTEIN", 65, 84], ["IFN-b mRNA", "RNA", 100, 110], ["NSs mutants", "PROBLEM", 23, 34], ["NSD210", "TEST", 46, 52], ["lacking SAP30binding domain", "PROBLEM", 57, 84], ["NSs mutants", "OBSERVATION", 23, 34]]], ["Viral replication of those mutants was significantly decreased in type-I IFN-competent MRC-5 cells (Fig. S2) .", [["MRC-5 cells", "ANATOMY", 87, 98], ["type-I IFN", "GENE_OR_GENE_PRODUCT", 66, 76], ["MRC-5 cells", "CELL", 87, 98], ["type-I IFN-competent MRC-5 cells", "CELL_LINE", 66, 98], ["S2", "PROTEIN", 105, 107], ["Viral replication of those mutants", "PROBLEM", 0, 34], ["significantly", "OBSERVATION_MODIFIER", 39, 52], ["decreased", "OBSERVATION_MODIFIER", 53, 62]]], ["Therefore, it was concluded that a series of MP-12 encoding partially truncated NSs gene does not degrade PKR and inhibit IFN-b mRNA synthesis.ResultsIn Western blot as shown in Fig. 2A , all NSs mutants, except for NSD249-265, could be detectable by using anti-RVFV mouse polyclonal antibody.", [["NSD249-265", "CHEMICAL", 216, 226], ["MP-12", "GENE_OR_GENE_PRODUCT", 45, 50], ["NSs", "GENE_OR_GENE_PRODUCT", 80, 83], ["PKR", "GENE_OR_GENE_PRODUCT", 106, 109], ["IFN-b", "GENE_OR_GENE_PRODUCT", 122, 127], ["2A", "GENE_OR_GENE_PRODUCT", 183, 185], ["NSs", "GENE_OR_GENE_PRODUCT", 192, 195], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 216, 226], ["mouse", "ORGANISM", 267, 272], ["MP-12 encoding partially truncated NSs gene", "DNA", 45, 88], ["PKR", "PROTEIN", 106, 109], ["IFN-b mRNA", "RNA", 122, 132], ["NSs mutants", "PROTEIN", 192, 203], ["NSD249", "PROTEIN", 216, 222], ["anti-RVFV mouse polyclonal antibody", "PROTEIN", 257, 292], ["mouse", "SPECIES", 267, 272], ["anti-RVFV", "SPECIES", 257, 266], ["mouse", "SPECIES", 267, 272], ["MP", "TEST", 45, 47], ["encoding partially truncated NSs gene", "PROBLEM", 51, 88], ["PKR", "TEST", 106, 109], ["IFN", "TEST", 122, 125], ["all NSs mutants", "TREATMENT", 188, 203], ["NSD249", "TEST", 216, 222], ["anti-RVFV mouse polyclonal antibody", "TREATMENT", 257, 292], ["NSs mutants", "OBSERVATION", 192, 203]]], ["It was possible the anti-RVFV polyclonal antibody does not sufficiently contain antibodies reactive to linear epitopes except for the C-terminus.", [["C-terminus", "GENE_OR_GENE_PRODUCT", 134, 144], ["anti-RVFV polyclonal antibody", "PROTEIN", 20, 49], ["antibodies", "PROTEIN", 80, 90], ["linear epitopes", "PROTEIN", 103, 118], ["C-terminus", "PROTEIN", 134, 144], ["anti-RVFV", "SPECIES", 20, 29], ["the anti-RVFV polyclonal antibody", "TEST", 16, 49], ["the C-terminus", "PROBLEM", 130, 144]]], ["Thus, we next tested the accumulation of NSD249-265 by using indirect immunofluorescent assay to know if the same anti-RVFV polyclonal antibody can recognize conformational epitopes on NSD249-265.", [["NSD249-265", "CHEMICAL", 41, 51], ["NSD249-265", "CHEMICAL", 185, 195], ["NSD249-265", "CHEMICAL", 41, 51], ["NSD249-265", "SIMPLE_CHEMICAL", 41, 51], ["anti-RVFV polyclonal antibody", "PROTEIN", 114, 143], ["conformational epitopes", "PROTEIN", 158, 181], ["anti-RVFV", "SPECIES", 114, 123], ["NSD249", "TEST", 41, 47], ["indirect immunofluorescent assay", "TEST", 61, 93], ["the same anti-RVFV polyclonal antibody", "PROBLEM", 105, 143], ["conformational epitopes", "TEST", 158, 181], ["NSD249", "TEST", 185, 191]]], ["293 cells were transfected with in vitro synthesized RNA encoding NSs of MP-12, NSD249-265 or chloramphenicol acetyltransferase (CAT) (control), and the cells were fixed with methanol at 16 hours post transfection.", [["293 cells", "ANATOMY", 0, 9], ["cells", "ANATOMY", 153, 158], ["MP-12, NSD249-265", "CHEMICAL", 73, 90], ["chloramphenicol", "CHEMICAL", 94, 109], ["methanol", "CHEMICAL", 175, 183], ["chloramphenicol", "CHEMICAL", 94, 109], ["methanol", "CHEMICAL", 175, 183], ["293 cells", "CELL", 0, 9], ["MP-12", "GENE_OR_GENE_PRODUCT", 73, 78], ["NSD249-265", "SIMPLE_CHEMICAL", 80, 90], ["chloramphenicol acetyltransferase", "GENE_OR_GENE_PRODUCT", 94, 127], ["CAT", "SIMPLE_CHEMICAL", 129, 132], ["cells", "CELL", 153, 158], ["methanol", "SIMPLE_CHEMICAL", 175, 183], ["293 cells", "CELL_LINE", 0, 9], ["NSs", "PROTEIN", 66, 69], ["MP", "PROTEIN", 73, 75], ["chloramphenicol acetyltransferase", "PROTEIN", 94, 127], ["CAT", "PROTEIN", 129, 132], ["vitro synthesized RNA", "TREATMENT", 35, 56], ["MP", "TEST", 73, 75], ["NSD249", "TREATMENT", 80, 86], ["chloramphenicol acetyltransferase", "TREATMENT", 94, 127], ["the cells", "TREATMENT", 149, 158], ["methanol", "TREATMENT", 175, 183]]], ["Nuclear filamentous inclusion was observed in cells expressing NSs of MP-12 or NSD249-265, while the specific signals of NSs accumulation were weaker in cells expressing NSD249-265 than those expressing MP-12 NSs (Fig. 3) .", [["cells", "ANATOMY", 46, 51], ["cells", "ANATOMY", 153, 158], ["NSD249-265", "CHEMICAL", 79, 89], ["NSD249-265", "CHEMICAL", 170, 180], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["cells", "CELL", 46, 51], ["MP-12", "GENE_OR_GENE_PRODUCT", 70, 75], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 79, 89], ["NSs", "GENE_OR_GENE_PRODUCT", 121, 124], ["cells", "CELL", 153, 158], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 170, 180], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 203, 212], ["NSs", "PROTEIN", 63, 66], ["MP", "PROTEIN", 70, 72], ["NSs", "PROTEIN", 121, 124], ["NSD249", "PROTEIN", 170, 176], ["MP", "PROTEIN", 203, 205], ["Nuclear filamentous inclusion", "TEST", 0, 29], ["MP", "TEST", 70, 72], ["NSD249", "TEST", 79, 85], ["NSs accumulation", "PROBLEM", 121, 137], ["NSD249", "TEST", 170, 176], ["MP", "TEST", 203, 205], ["filamentous", "OBSERVATION_MODIFIER", 8, 19], ["inclusion", "OBSERVATION", 20, 29], ["NSs accumulation", "OBSERVATION", 121, 137]]], ["NSD249-265 was also accumulated in cytoplasm.ResultsNext, we tested the cellular localization of truncated NSs other than NSD249-265 by Western blot (Fig. 4) .", [["cytoplasm", "ANATOMY", 35, 44], ["cellular", "ANATOMY", 72, 80], ["NSD249-265", "CHEMICAL", 0, 10], ["NSD249-265", "CHEMICAL", 122, 132], ["NSD249-265", "CHEMICAL", 0, 10], ["NSD249-265", "CHEMICAL", 122, 132], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 0, 10], ["cytoplasm", "ORGANISM_SUBSTANCE", 35, 44], ["cellular", "CELL", 72, 80], ["NSs", "GENE_OR_GENE_PRODUCT", 107, 110], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 122, 132], ["truncated NSs", "PROTEIN", 97, 110], ["truncated NSs", "TREATMENT", 97, 110], ["NSD249", "TEST", 122, 128], ["cytoplasm", "OBSERVATION_MODIFIER", 35, 44]]], ["We did not include NSD249-265 for the experiment as no antibodies were available to detect this NSs in Western blot.", [["NSD249-265", "CHEMICAL", 19, 29], ["NSD249-265", "CHEMICAL", 19, 29], ["antibodies", "PROTEIN", 55, 65], ["NSD249", "TEST", 19, 25], ["antibodies", "PROBLEM", 55, 65], ["this NSs", "PROBLEM", 91, 99]]], ["293 cells were mock-infected or infected with MP-12 or NSs truncation mutants at an moi of 3.", [["293 cells", "ANATOMY", 0, 9], ["293 cells", "CELL", 0, 9], ["MP-12", "GENE_OR_GENE_PRODUCT", 46, 51], ["NSs", "ORGANISM", 55, 58], ["293 cells", "CELL_LINE", 0, 9], ["MP", "TEST", 46, 48], ["NSs truncation mutants", "PROBLEM", 55, 77]]], ["Cells were collected at 16 hpi, and nuclear and cellular fractions were analyzed for the presence of NSs proteins.", [["Cells", "ANATOMY", 0, 5], ["nuclear", "ANATOMY", 36, 43], ["cellular fractions", "ANATOMY", 48, 66], ["Cells", "CELL", 0, 5], ["nuclear", "CELLULAR_COMPONENT", 36, 43], ["cellular", "CELL", 48, 56], ["NSs", "GENE_OR_GENE_PRODUCT", 101, 104], ["NSs proteins", "PROTEIN", 101, 113], ["Cells", "TEST", 0, 5], ["NSs proteins", "PROBLEM", 101, 113], ["NSs proteins", "OBSERVATION", 101, 113]]], ["MP-12 NSs were accumulated both at cytoplasm and nucleus, while N proteins were exclusively localized at cytoplasm, which is consistent with previous study [65] .", [["cytoplasm", "ANATOMY", 35, 44], ["nucleus", "ANATOMY", 49, 56], ["cytoplasm", "ANATOMY", 105, 114], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 0, 9], ["cytoplasm", "ORGANISM_SUBSTANCE", 35, 44], ["nucleus", "CELLULAR_COMPONENT", 49, 56], ["cytoplasm", "ORGANISM_SUBSTANCE", 105, 114], ["NSs", "PROTEIN", 6, 9], ["N proteins", "PROTEIN", 64, 74], ["MP", "TEST", 0, 2], ["NSs", "TREATMENT", 6, 9], ["previous study", "TEST", 141, 155], ["nucleus", "ANATOMY", 49, 56], ["consistent with", "UNCERTAINTY", 125, 140]]], ["Abundant accumulation of NSs in nucleus was only observed in cells infected with NSsD6-30, NSsD 31-55 and NSsD56-80, while other mutants, NSsD 81-105, NSsD106-130, NSsD131-155, NSsD156-180, NSsD181-205 and NSsD206-230, NSsD231-248 poorly accumulated NSs in nucleus.Co-expression of nonfunctional truncated NSs in cells infected with MP-12To find if co-expression of nonfunctional NSs is able to attenuate PKR degradation function of MP-12 NSs, VeroE6 cells were infected with MP-12 and then co-infected with rMP12-C13type or one of the NSs truncation mutants using an moi of 3.", [["nucleus", "ANATOMY", 32, 39], ["cells", "ANATOMY", 61, 66], ["nucleus", "ANATOMY", 257, 264], ["cells", "ANATOMY", 313, 318], ["VeroE6 cells", "ANATOMY", 444, 456], ["NSsD106-130, NSsD131-155, NSsD156-180, NSsD181-205", "CHEMICAL", 151, 201], ["NSsD206-230", "CHEMICAL", 206, 217], ["NSsD231-248", "CHEMICAL", 219, 230], ["MP-12", "CHEMICAL", 476, 481], ["NSs", "GENE_OR_GENE_PRODUCT", 25, 28], ["nucleus", "CELLULAR_COMPONENT", 32, 39], ["cells", "CELL", 61, 66], ["NSsD6-30", "ORGANISM", 81, 89], ["NSsD 31-55", "ORGANISM", 91, 101], ["NSsD56-80", "ORGANISM", 106, 115], ["NSsD231-248", "SIMPLE_CHEMICAL", 219, 230], ["NSs", "GENE_OR_GENE_PRODUCT", 250, 253], ["nucleus", "CELLULAR_COMPONENT", 257, 264], ["NSs", "GENE_OR_GENE_PRODUCT", 306, 309], ["cells", "CELL", 313, 318], ["MP-12To", "GENE_OR_GENE_PRODUCT", 333, 340], ["NSs", "GENE_OR_GENE_PRODUCT", 380, 383], ["PKR", "GENE_OR_GENE_PRODUCT", 405, 408], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 433, 442], ["VeroE6 cells", "CELL", 444, 456], ["MP-12", "CELL", 476, 481], ["rMP12-C13type", "GENE_OR_GENE_PRODUCT", 508, 521], ["NSs", "PROTEIN", 25, 28], ["NSsD 81-105", "DNA", 138, 149], ["NSsD106-130", "DNA", 151, 162], ["NSsD131-155", "DNA", 164, 175], ["NSsD156-180", "DNA", 177, 188], ["NSsD181-205", "DNA", 190, 201], ["NSsD206-230", "DNA", 206, 217], ["NSsD231-248", "DNA", 219, 230], ["NSs", "DNA", 250, 253], ["nonfunctional truncated NSs", "PROTEIN", 282, 309], ["MP", "PROTEIN", 333, 335], ["nonfunctional NSs", "PROTEIN", 366, 383], ["PKR", "PROTEIN", 405, 408], ["VeroE6 cells", "CELL_LINE", 444, 456], ["rMP12", "PROTEIN", 508, 513], ["C13type", "PROTEIN", 514, 521], ["NSs truncation mutants", "PROTEIN", 536, 558], ["Abundant accumulation of NSs in nucleus", "PROBLEM", 0, 39], ["NSsD6", "TEST", 81, 86], ["NSsD", "TEST", 91, 95], ["NSsD56", "TREATMENT", 106, 112], ["NSsD", "TEST", 138, 142], ["NSsD106", "TREATMENT", 151, 158], ["NSsD131", "TREATMENT", 164, 171], ["NSsD156", "TREATMENT", 177, 184], ["NSsD181", "TREATMENT", 190, 197], ["NSsD206", "TREATMENT", 206, 213], ["poorly accumulated NSs in nucleus", "PROBLEM", 231, 264], ["nonfunctional truncated NSs in cells", "PROBLEM", 282, 318], ["MP", "TEST", 333, 335], ["nonfunctional NSs", "PROBLEM", 366, 383], ["MP", "TEST", 433, 435], ["NSs", "TREATMENT", 439, 442], ["VeroE6 cells", "PROBLEM", 444, 456], ["MP", "TEST", 476, 478], ["rMP12", "TREATMENT", 508, 513], ["the NSs truncation mutants", "TREATMENT", 532, 558], ["accumulation", "OBSERVATION_MODIFIER", 9, 21], ["NSs", "OBSERVATION", 25, 28], ["nucleus", "ANATOMY", 32, 39], ["accumulated", "OBSERVATION_MODIFIER", 238, 249], ["NSs", "OBSERVATION", 250, 253], ["nucleus", "ANATOMY", 257, 264]]], ["Cells were collected at 16 hpi and Western blot was used to measure abundance of PKR and RVFV NSs.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["PKR", "GENE_OR_GENE_PRODUCT", 81, 84], ["RVFV", "ORGANISM", 89, 93], ["PKR", "PROTEIN", 81, 84], ["RVFV NSs", "PROTEIN", 89, 97], ["RVFV", "SPECIES", 89, 93], ["Cells", "TEST", 0, 5], ["PKR", "TREATMENT", 81, 84], ["RVFV NSs", "TREATMENT", 89, 97], ["PKR", "OBSERVATION", 81, 84], ["RVFV NSs", "OBSERVATION", 89, 97]]], ["However, it was found that levels of MP-12 NSs accumulation were not identical to those expressing truncated NSs (Fig. S3) .", [["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 37, 46], ["NSs", "GENE_OR_GENE_PRODUCT", 109, 112], ["MP", "PROTEIN", 37, 39], ["truncated NSs", "PROTEIN", 99, 112], ["S3", "PROTEIN", 119, 121], ["MP", "TEST", 37, 39], ["NSs accumulation", "PROBLEM", 43, 59], ["S3", "ANATOMY", 119, 121]]], ["Only cells co-infected with NSD6-30 and NSD56-80 allowed an efficient accumulation of MP-12 NSs.", [["cells", "ANATOMY", 5, 10], ["NSD56-80", "CHEMICAL", 40, 48], ["NSD56-80", "CHEMICAL", 40, 48], ["cells", "CELL", 5, 10], ["NSD6-30", "ORGANISM", 28, 35], ["NSD56-80", "CELL", 40, 48], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 86, 95], ["NSD6", "PROTEIN", 28, 32], ["MP", "PROTEIN", 86, 88], ["cells co-infected", "PROBLEM", 5, 22], ["NSD6", "TEST", 28, 32], ["NSD56", "TEST", 40, 45], ["MP-12 NSs", "TREATMENT", 86, 95], ["co-infected", "OBSERVATION", 11, 22]]], ["As a result, PKR was abundantly detected in cells infected with MP-12 and NSs mutants.Co-expression of nonfunctional truncated NSs in cells infected with MP-12We attempted to allow accumulation of MP-12 NSs by using 293 cells.", [["cells", "ANATOMY", 44, 49], ["cells", "ANATOMY", 134, 139], ["293 cells", "ANATOMY", 216, 225], ["MP-12We", "CHEMICAL", 154, 161], ["PKR", "GENE_OR_GENE_PRODUCT", 13, 16], ["cells", "CELL", 44, 49], ["MP-12", "GENE_OR_GENE_PRODUCT", 64, 69], ["NSs", "GENE_OR_GENE_PRODUCT", 74, 77], ["NSs", "GENE_OR_GENE_PRODUCT", 127, 130], ["cells", "CELL", 134, 139], ["MP-12We", "GENE_OR_GENE_PRODUCT", 154, 161], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 197, 206], ["293 cells", "CELL", 216, 225], ["PKR", "PROTEIN", 13, 16], ["NSs mutants", "PROTEIN", 74, 85], ["nonfunctional truncated NSs", "PROTEIN", 103, 130], ["MP", "PROTEIN", 197, 199], ["293 cells", "CELL_LINE", 216, 225], ["PKR", "TEST", 13, 16], ["MP", "TEST", 64, 66], ["NSs mutants", "TREATMENT", 74, 85], ["nonfunctional truncated NSs in cells", "PROBLEM", 103, 139], ["MP", "TEST", 154, 156], ["MP-12 NSs", "TREATMENT", 197, 206], ["nonfunctional", "OBSERVATION_MODIFIER", 103, 116], ["truncated NSs", "OBSERVATION", 117, 130]]], ["Cells were mock-infected or infected with rMP12-NSs-Flag, which encode Flag-tagged NSs in place of intact NSs, at an moi of 3, and subsequently mock-transfected (a control) or immediately transfected with in vitro synthesized RNA encoding CAT (a control), or NSs mutants, as described previously [17] .", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["rMP12", "GENE_OR_GENE_PRODUCT", 42, 47], ["Flag", "GENE_OR_GENE_PRODUCT", 52, 56], ["Flag", "GENE_OR_GENE_PRODUCT", 71, 75], ["NSs", "GENE_OR_GENE_PRODUCT", 83, 86], ["NSs", "GENE_OR_GENE_PRODUCT", 106, 109], ["CAT", "GENE_OR_GENE_PRODUCT", 239, 242], ["NSs", "GENE_OR_GENE_PRODUCT", 259, 262], ["rMP12", "PROTEIN", 42, 47], ["NSs", "DNA", 48, 51], ["Flag", "PROTEIN", 52, 56], ["Flag", "PROTEIN", 71, 75], ["NSs", "PROTEIN", 83, 86], ["NSs", "PROTEIN", 106, 109], ["CAT", "PROTEIN", 239, 242], ["NSs mutants", "PROTEIN", 259, 270], ["Cells", "TEST", 0, 5], ["rMP12", "TREATMENT", 42, 47], ["NSs", "TREATMENT", 48, 51], ["Flag", "TREATMENT", 52, 56], ["tagged NSs", "TREATMENT", 76, 86], ["intact NSs", "TREATMENT", 99, 109], ["vitro synthesized RNA", "TREATMENT", 208, 229], ["NSs mutants", "TREATMENT", 259, 270], ["intact NSs", "OBSERVATION", 99, 109]]], ["Cells were collected at 16 hpi, and the abundance of PKR and RVFV proteins were analyzed by Western blot.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["PKR", "GENE_OR_GENE_PRODUCT", 53, 56], ["RVFV", "ORGANISM", 61, 65], ["PKR", "PROTEIN", 53, 56], ["RVFV proteins", "PROTEIN", 61, 74], ["RVFV", "SPECIES", 61, 65], ["Cells", "TEST", 0, 5], ["PKR", "TEST", 53, 56], ["RVFV proteins", "TEST", 61, 74], ["PKR", "OBSERVATION", 53, 56]]], ["All cells infected with rMP12-NSs-Flag accumulated abundant levels of NSs (Fig. 5A) .", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["rMP12", "GENE_OR_GENE_PRODUCT", 24, 29], ["Flag", "GENE_OR_GENE_PRODUCT", 34, 38], ["rMP12", "PROTEIN", 24, 29], ["NSs", "PROTEIN", 30, 33], ["Flag", "PROTEIN", 34, 38], ["NSs", "PROTEIN", 70, 73], ["rMP12", "TREATMENT", 24, 29], ["NSs", "TREATMENT", 30, 33], ["cells", "ANATOMY", 4, 9], ["infected", "OBSERVATION", 10, 18], ["abundant", "OBSERVATION_MODIFIER", 51, 59], ["levels", "OBSERVATION_MODIFIER", 60, 66]]], ["PKR was degraded in infected cells mock-transfected or transfected with CAT RNA, while PKR was also degraded in infected cells transfected with RNA encoding NSD6-30, NSD31-55, NSD56-80, NSD81-105, NSD106-130, NSD131-155, NSD156-180, NSD181-205, NSD206-230 or NSD231-248.", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 121, 126], ["NSD131-155, NSD156-180, NSD181-205, NSD206-230", "CHEMICAL", 209, 255], ["NSD231-248", "CHEMICAL", 259, 269], ["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 29, 34], ["CAT", "GENE_OR_GENE_PRODUCT", 72, 75], ["PKR", "GENE_OR_GENE_PRODUCT", 87, 90], ["cells", "CELL", 121, 126], ["NSD6-30", "GENE_OR_GENE_PRODUCT", 157, 164], ["NSD31-55", "GENE_OR_GENE_PRODUCT", 166, 174], ["NSD56", "GENE_OR_GENE_PRODUCT", 176, 181], ["NSD81", "GENE_OR_GENE_PRODUCT", 186, 191], ["NSD106-130", "GENE_OR_GENE_PRODUCT", 197, 207], ["NSD231-248", "SIMPLE_CHEMICAL", 259, 269], ["PKR", "PROTEIN", 0, 3], ["CAT RNA", "RNA", 72, 79], ["PKR", "PROTEIN", 87, 90], ["infected cells", "CELL_TYPE", 112, 126], ["NSD6", "PROTEIN", 157, 161], ["NSD31", "PROTEIN", 166, 171], ["NSD56", "PROTEIN", 176, 181], ["NSD156", "DNA", 221, 227], ["NSD181", "DNA", 233, 239], ["NSD206", "DNA", 245, 251], ["NSD231-248", "DNA", 259, 269], ["PKR", "TEST", 0, 3], ["infected cells mock", "PROBLEM", 20, 39], ["CAT RNA", "TEST", 72, 79], ["PKR", "TEST", 87, 90], ["infected cells", "PROBLEM", 112, 126], ["RNA", "TEST", 144, 147], ["NSD6", "TEST", 157, 161], ["NSD31", "TEST", 166, 171], ["NSD56", "TEST", 176, 181], ["NSD81", "TEST", 186, 191], ["NSD106", "TEST", 197, 203], ["NSD131", "TEST", 209, 215], ["NSD156", "TEST", 221, 227], ["NSD181", "TEST", 233, 239], ["NSD206", "TEST", 245, 251], ["NSD231", "TEST", 259, 265], ["infected cells mock", "OBSERVATION", 20, 39]]], ["On the other hand, the expression of NSD249-265 lacking the Cterminus self-association domain slightly increased the abundance of PKR in cells infected with rMP12-NSs-Flag.Co-expression of nonfunctional truncated NSs in cells infected with MP-12We next tested the effect of co-expression of NSs mutants in the inhibition of IFN-b mRNA synthesis by MP-12 NSs.", [["cells", "ANATOMY", 137, 142], ["cells", "ANATOMY", 220, 225], ["NSD249-265", "CHEMICAL", 37, 47], ["MP-12 NSs", "CHEMICAL", 348, 357], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 37, 47], ["Cterminus", "GENE_OR_GENE_PRODUCT", 60, 69], ["PKR", "GENE_OR_GENE_PRODUCT", 130, 133], ["cells", "CELL", 137, 142], ["rMP12", "GENE_OR_GENE_PRODUCT", 157, 162], ["Flag", "GENE_OR_GENE_PRODUCT", 167, 171], ["NSs", "GENE_OR_GENE_PRODUCT", 213, 216], ["cells", "CELL", 220, 225], ["MP-12We", "GENE_OR_GENE_PRODUCT", 240, 247], ["NSs", "GENE_OR_GENE_PRODUCT", 291, 294], ["IFN-b", "GENE_OR_GENE_PRODUCT", 324, 329], ["MP-12 NSs", "SIMPLE_CHEMICAL", 348, 357], ["NSD249", "PROTEIN", 37, 43], ["Cterminus self-association domain", "PROTEIN", 60, 93], ["PKR", "PROTEIN", 130, 133], ["rMP12", "PROTEIN", 157, 162], ["NSs", "PROTEIN", 163, 166], ["Flag", "PROTEIN", 167, 171], ["nonfunctional truncated NSs", "PROTEIN", 189, 216], ["MP", "PROTEIN", 240, 242], ["NSs mutants", "PROTEIN", 291, 302], ["IFN-b mRNA", "RNA", 324, 334], ["NSD249", "TEST", 37, 43], ["PKR in cells", "PROBLEM", 130, 142], ["rMP12", "TREATMENT", 157, 162], ["nonfunctional truncated NSs in cells", "PROBLEM", 189, 225], ["MP", "TEST", 240, 242], ["NSs mutants", "TREATMENT", 291, 302], ["IFN", "TREATMENT", 324, 327], ["b mRNA synthesis", "TREATMENT", 328, 344], ["MP", "TEST", 348, 350], ["NSs", "TREATMENT", 354, 357], ["slightly", "OBSERVATION_MODIFIER", 94, 102], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["PKR", "OBSERVATION", 130, 133], ["nonfunctional", "OBSERVATION_MODIFIER", 189, 202], ["truncated NSs", "OBSERVATION", 203, 216]]], ["A549 cells were mock-infected or infected with rMP12-NSs-Flag using moi of 3 and then either mock-transfected or immediately transfected with in vitro synthesized RNA encoding CAT or NSs mutants.", [["A549 cells", "ANATOMY", 0, 10], ["A549 cells", "CELL", 0, 10], ["rMP12", "GENE_OR_GENE_PRODUCT", 47, 52], ["Flag", "GENE_OR_GENE_PRODUCT", 57, 61], ["CAT", "GENE_OR_GENE_PRODUCT", 176, 179], ["NSs", "GENE_OR_GENE_PRODUCT", 183, 186], ["A549 cells", "CELL_LINE", 0, 10], ["rMP12", "PROTEIN", 47, 52], ["NSs", "PROTEIN", 53, 56], ["Flag", "PROTEIN", 57, 61], ["CAT", "PROTEIN", 176, 179], ["NSs mutants", "PROTEIN", 183, 194], ["A549 cells", "PROBLEM", 0, 10], ["infected", "PROBLEM", 33, 41], ["rMP12", "TREATMENT", 47, 52], ["NSs", "TREATMENT", 53, 56], ["vitro synthesized RNA", "TREATMENT", 145, 166], ["NSs mutants", "TREATMENT", 183, 194]]], ["Total RNA was extracted at 7 hpi, and Northern blot was performed as described above.", [["Total RNA", "TREATMENT", 0, 9], ["Northern blot", "TEST", 38, 51]]], ["None of cells transfected with RNA encoding NSs mutants increased the synthesis of IFN-b mRNA (Fig. 5B) .", [["cells", "ANATOMY", 8, 13], ["cells", "CELL", 8, 13], ["NSs", "GENE_OR_GENE_PRODUCT", 44, 47], ["IFN-b", "GENE_OR_GENE_PRODUCT", 83, 88], ["NSs mutants", "PROTEIN", 44, 55], ["IFN-b mRNA", "RNA", 83, 93], ["RNA encoding NSs mutants", "TREATMENT", 31, 55], ["the synthesis of IFN", "TREATMENT", 66, 86]]], ["On the other hand, cells transfected with RNA encoding NSD249-265 slightly increased ISG56 mRNA abundance (Fig. 5B) .", [["cells", "ANATOMY", 19, 24], ["NSD249-265", "CHEMICAL", 55, 65], ["cells", "CELL", 19, 24], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 55, 65], ["ISG56", "GENE_OR_GENE_PRODUCT", 85, 90], ["NSD249", "PROTEIN", 55, 61], ["ISG56 mRNA", "RNA", 85, 95], ["RNA encoding NSD249", "TEST", 42, 61], ["slightly increased ISG56 mRNA abundance", "PROBLEM", 66, 105]]], ["These results suggest that nonfunctional NSs encoding the C-terminus self-association domain do not have dominant-negative function, while those lacking the C-terminus domain slightly inhibit PKR degradation as well as ISG56 mRNA synthesis.Co-expression of nonfunctional truncated NSs in cells infected with MP-12Co-affinity precipitation studies were conducted with use of Strep-tagged protein purification to know if over-expressed truncated NSs can interact with MP-12 NSs in infected cells.", [["cells", "ANATOMY", 288, 293], ["cells", "ANATOMY", 488, 493], ["MP-12Co", "CHEMICAL", 308, 315], ["C", "CHEMICAL", 58, 59], ["C", "CHEMICAL", 157, 158], ["NSs", "GENE_OR_GENE_PRODUCT", 41, 44], ["PKR", "GENE_OR_GENE_PRODUCT", 192, 195], ["ISG56", "GENE_OR_GENE_PRODUCT", 219, 224], ["NSs", "GENE_OR_GENE_PRODUCT", 281, 284], ["cells", "CELL", 288, 293], ["NSs", "GENE_OR_GENE_PRODUCT", 444, 447], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 466, 475], ["cells", "CELL", 488, 493], ["NSs", "DNA", 41, 44], ["C-terminus self-association domain", "PROTEIN", 58, 92], ["C-terminus domain", "PROTEIN", 157, 174], ["PKR", "PROTEIN", 192, 195], ["ISG56 mRNA", "RNA", 219, 229], ["nonfunctional truncated NSs", "PROTEIN", 257, 284], ["truncated NSs", "PROTEIN", 434, 447], ["MP", "PROTEIN", 466, 468], ["infected cells", "CELL_TYPE", 479, 493], ["nonfunctional NSs", "PROBLEM", 27, 44], ["the C-terminus domain", "PROBLEM", 153, 174], ["PKR degradation", "PROBLEM", 192, 207], ["ISG56 mRNA synthesis", "PROBLEM", 219, 239], ["nonfunctional truncated NSs in cells", "PROBLEM", 257, 293], ["MP", "TEST", 308, 310], ["affinity precipitation studies", "TEST", 316, 346], ["Strep", "PROBLEM", 374, 379], ["tagged protein purification", "TREATMENT", 380, 407], ["MP", "TEST", 466, 468], ["NSs in infected cells", "TREATMENT", 472, 493], ["negative function", "OBSERVATION", 114, 131], ["nonfunctional", "OBSERVATION_MODIFIER", 257, 270], ["truncated NSs", "OBSERVATION", 271, 284], ["infected cells", "OBSERVATION", 479, 493]]], ["293 cells were infected with moi 3 of rMP-12-NSs-SF (recombinant virus tagged with tandem Strep-Tag and Flag) [19] and were then transfected using the in vitro synthesized capped RNA encoding each of the truncated NSs mutants.", [["293 cells", "ANATOMY", 0, 9], ["293 cells", "CELL", 0, 9], ["rMP-12-NSs-SF", "ORGANISM", 38, 51], ["recombinant virus", "ORGANISM", 53, 70], ["Strep-Tag", "GENE_OR_GENE_PRODUCT", 90, 99], ["Flag", "GENE_OR_GENE_PRODUCT", 104, 108], ["NSs", "GENE_OR_GENE_PRODUCT", 214, 217], ["293 cells", "CELL_LINE", 0, 9], ["NSs", "DNA", 45, 48], ["SF", "PROTEIN", 49, 51], ["Strep", "PROTEIN", 90, 95], ["Tag", "PROTEIN", 96, 99], ["Flag", "PROTEIN", 104, 108], ["capped RNA", "RNA", 172, 182], ["truncated NSs mutants", "PROTEIN", 204, 225], ["moi", "TEST", 29, 32], ["rMP", "TEST", 38, 41], ["NSs", "TEST", 45, 48], ["recombinant virus", "PROBLEM", 53, 70], ["tandem Strep", "TEST", 83, 95], ["the in vitro synthesized capped RNA", "TREATMENT", 147, 182], ["capped RNA", "OBSERVATION", 172, 182]]], ["After 6 hours, newly synthesized host and viral proteins were labeled with [ 35 S] methionine/cysteine for 4 hours.", [["[ 35 S] methionine/cysteine", "CHEMICAL", 75, 102], ["[ 35 S] methionine", "CHEMICAL", 75, 93], ["cysteine", "CHEMICAL", 94, 102], ["[ 35 S] methionine/cysteine", "SIMPLE_CHEMICAL", 75, 102], ["viral proteins", "PROTEIN", 42, 56], ["newly synthesized host", "PROBLEM", 15, 37], ["viral proteins", "PROBLEM", 42, 56], ["methionine/cysteine", "TREATMENT", 83, 102]]], ["Whole cell lysates were mixed with Strep-Tactin beads, and SF-tagged MP-12 NSs and bound host and viral proteins were precipitated.", [["cell lysates", "ANATOMY", 6, 18], ["cell lysates", "ORGANISM_SUBSTANCE", 6, 18], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 69, 78], ["SF", "PROTEIN", 59, 61], ["MP", "PROTEIN", 69, 71], ["NSs", "PROTEIN", 75, 78], ["viral proteins", "PROTEIN", 98, 112], ["Whole cell lysates", "TEST", 0, 18], ["Strep", "TEST", 35, 40], ["Tactin beads", "TEST", 41, 53], ["SF", "TEST", 59, 61], ["tagged MP", "TEST", 62, 71], ["viral proteins", "PROBLEM", 98, 112], ["viral proteins", "OBSERVATION", 98, 112]]], ["Presence of NSs bands were visualized with autoradiography ( Fig. 6 ).", [["NSs bands", "DNA", 12, 21], ["NSs bands", "TREATMENT", 12, 21], ["autoradiography", "TEST", 43, 58], ["NSs bands", "OBSERVATION", 12, 21]]], ["As expected, MP-12 NSs was co-precipitated with NSs-SF, and MP-12 NSs was migrating slightly faster than that of NSs-SF.", [["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 13, 22], ["NSs-SF", "GENE_OR_GENE_PRODUCT", 48, 54], ["MP-12", "GENE_OR_GENE_PRODUCT", 60, 65], ["MP", "PROTEIN", 13, 15], ["NSs", "PROTEIN", 48, 51], ["SF", "PROTEIN", 52, 54], ["MP", "PROTEIN", 60, 62], ["MP", "TEST", 13, 15], ["NSs", "TREATMENT", 48, 51], ["MP", "TEST", 60, 62], ["NSs", "TREATMENT", 66, 69]]], ["The expression of truncated NSs was lower than that of MP-12 NSs (see input), while the expression of NSsD206-230 was not detectable.", [["NSsD206-230", "CHEMICAL", 102, 113], ["NSsD206-230", "CHEMICAL", 102, 113], ["NSs", "GENE_OR_GENE_PRODUCT", 28, 31], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 55, 64], ["NSsD206-230", "GENE_OR_GENE_PRODUCT", 102, 113], ["truncated NSs", "PROTEIN", 18, 31], ["MP", "PROTEIN", 55, 57], ["NSs", "PROTEIN", 61, 64], ["NSsD206", "PROTEIN", 102, 109], ["truncated NSs", "PROBLEM", 18, 31], ["MP", "TEST", 55, 57], ["NSsD206", "TEST", 102, 109]]], ["The same phenomenon was observed in a repeated experiment, suggesting the instability of NSsD206-230 expression in this experiment.", [["NSsD206-230", "CHEMICAL", 89, 100], ["NSsD206-230", "GENE_OR_GENE_PRODUCT", 89, 100], ["NSsD206", "DNA", 89, 96], ["the instability of NSsD206", "PROBLEM", 70, 96]]], ["On the other hand, we could not detect co-precipitation of any truncated NSs with NSs-SF.", [["NSs", "GENE_OR_GENE_PRODUCT", 73, 76], ["truncated NSs", "PROTEIN", 63, 76], ["NSs", "PROTEIN", 82, 85], ["any truncated NSs", "PROBLEM", 59, 76], ["NSs", "TEST", 82, 85]]], ["Collectively, our results suggest that those truncated NSs accumulates in cells at low level, mislocalizes, and do not interrupt the MP-12 NSs functions by co-expression.Generation of nonfunctional NSs with point mutations at C-terminusAs NSs lacking C-terminus exhibited slight dominant-negative effect on PKR degradation, we hypothesized that an intact sequence at aa.1 to 248 is required for the dominant-negative effect.", [["cells", "ANATOMY", 74, 79], ["C", "CHEMICAL", 226, 227], ["C", "CHEMICAL", 251, 252], ["NSs", "GENE_OR_GENE_PRODUCT", 55, 58], ["cells", "CELL", 74, 79], ["MP-12", "GENE_OR_GENE_PRODUCT", 133, 138], ["NSs", "GENE_OR_GENE_PRODUCT", 198, 201], ["PKR", "GENE_OR_GENE_PRODUCT", 307, 310], ["truncated NSs", "PROTEIN", 45, 58], ["MP", "PROTEIN", 133, 135], ["NSs", "PROTEIN", 239, 242], ["C-terminus", "PROTEIN", 251, 261], ["PKR", "PROTEIN", 307, 310], ["those truncated NSs", "PROBLEM", 39, 58], ["the MP", "TEST", 129, 135], ["nonfunctional NSs", "PROBLEM", 184, 201], ["point mutations", "PROBLEM", 207, 222], ["C-terminus", "TEST", 226, 236], ["PKR degradation", "PROBLEM", 307, 322], ["an intact sequence", "TEST", 345, 363], ["nonfunctional NSs", "OBSERVATION", 184, 201], ["slight", "OBSERVATION_MODIFIER", 272, 278], ["dominant", "OBSERVATION_MODIFIER", 279, 287], ["negative effect", "OBSERVATION_MODIFIER", 288, 303], ["negative effect", "OBSERVATION", 408, 423]]], ["We next tested the effect of the C-terminus on the dominant-negative effect.", [["C", "CHEMICAL", 33, 34], ["C-terminus", "GENE_OR_GENE_PRODUCT", 33, 43], ["C-terminus", "PROTEIN", 33, 43], ["the C-terminus", "PROBLEM", 29, 43], ["negative effect", "OBSERVATION", 60, 75]]], ["We substituted two sequential acidic amino acids triplets located at the C-terminus with alanines as shown in Fig. 7A; i.e., NSs-E253-255A/D257-259A, NSsD257-259A or NSs-E253-255A.", [["amino acids", "CHEMICAL", 37, 48], ["amino acids", "CHEMICAL", 37, 48], ["C", "CHEMICAL", 73, 74], ["alanines", "CHEMICAL", 89, 97], ["amino acids", "AMINO_ACID", 37, 48], ["alanines", "AMINO_ACID", 89, 97], ["acidic amino acids triplets", "PROTEIN", 30, 57], ["C-terminus", "PROTEIN", 73, 83], ["NSs-E253-255A", "PROTEIN", 166, 179], ["two sequential acidic amino acids triplets", "TREATMENT", 15, 57], ["alanines", "TREATMENT", 89, 97]]], ["We found that NSs-E253-255A could form filamentous inclusion bodies (data not shown), and accumulation was equivalent to that of MP-12 NSs (Fig. 7B) .", [["filamentous inclusion bodies", "ANATOMY", 39, 67], ["NSs-E253-255A", "CHEMICAL", 14, 27], ["NSs", "DNA", 14, 17], ["E253", "DNA", 18, 22], ["MP", "PROTEIN", 129, 131], ["NSs", "TEST", 14, 17], ["filamentous inclusion bodies", "PROBLEM", 39, 67], ["MP", "TEST", 129, 131]]], ["On the other hand, NSs-E253-255A/D257-259A or NSsD257-259A did not accumulate in cells efficiently, and the NSs could not be detected with IFA (data not shown).", [["cells", "ANATOMY", 81, 86], ["NSsD257-259A", "CHEMICAL", 46, 58], ["NSsD257-259A", "GENE_OR_GENE_PRODUCT", 46, 58], ["cells", "CELL", 81, 86], ["NSs-E253-255A/D257-259A or NSsD257-259A", "DNA", 19, 58], ["NSs", "PROTEIN", 108, 111], ["NSsD257", "TREATMENT", 46, 53], ["the NSs", "TREATMENT", 104, 111], ["IFA", "TEST", 139, 142]]], ["We then tested PKR degradation function and IFN-b mRNA suppression function of those mutants using VeroE6 cells and A549 cells using the same method as described above.", [["VeroE6 cells", "ANATOMY", 99, 111], ["A549 cells", "ANATOMY", 116, 126], ["PKR", "GENE_OR_GENE_PRODUCT", 15, 18], ["IFN-b", "GENE_OR_GENE_PRODUCT", 44, 49], ["VeroE6 cells", "CELL", 99, 111], ["A549 cells", "CELL", 116, 126], ["PKR", "PROTEIN", 15, 18], ["IFN", "PROTEIN", 44, 47], ["VeroE6 cells", "CELL_LINE", 99, 111], ["A549 cells", "CELL_LINE", 116, 126], ["PKR degradation function", "TEST", 15, 39], ["IFN", "TEST", 44, 47], ["VeroE6 cells", "TREATMENT", 99, 111], ["A549 cells", "TREATMENT", 116, 126], ["A549 cells", "OBSERVATION", 116, 126]]], ["Cells infected with NSs-E253-255A degraded PKR (Fig. 7B) , and inhibited the synthesis of IFN-b mRNA (Fig. 7C) , while those infected with NSs-E253-255A/ D257-259A or NSsD257-259A did not degrade PKR and did not inhibit IFN-b mRNA synthesis.", [["Cells", "ANATOMY", 0, 5], ["NSsD257-259A", "CHEMICAL", 167, 179], ["NSsD257-259A", "CHEMICAL", 167, 179], ["Cells", "CELL", 0, 5], ["NSs-E253-255A", "GENE_OR_GENE_PRODUCT", 20, 33], ["PKR", "GENE_OR_GENE_PRODUCT", 43, 46], ["Fig. 7B", "GENE_OR_GENE_PRODUCT", 48, 55], ["IFN-b", "GENE_OR_GENE_PRODUCT", 90, 95], ["NSs", "GENE_OR_GENE_PRODUCT", 139, 142], ["PKR", "GENE_OR_GENE_PRODUCT", 196, 199], ["IFN-b", "GENE_OR_GENE_PRODUCT", 220, 225], ["NSs", "PROTEIN", 20, 23], ["E253-255A", "PROTEIN", 24, 33], ["PKR", "PROTEIN", 43, 46], ["Fig. 7B", "PROTEIN", 48, 55], ["IFN-b mRNA", "RNA", 90, 100], ["NSs", "PROTEIN", 139, 142], ["E253-255A", "PROTEIN", 143, 152], ["PKR", "PROTEIN", 196, 199], ["IFN-b mRNA", "RNA", 220, 230], ["NSs", "TEST", 20, 23], ["IFN", "TEST", 90, 93], ["NSs", "TREATMENT", 139, 142], ["PKR", "TEST", 196, 199], ["IFN", "PROBLEM", 220, 223], ["b mRNA synthesis", "PROBLEM", 224, 240]]], ["The results suggest that the glutamic acid at aa.253 to 255 can be replaced without affecting [26] and C-terminus selfassociation domain (aa.249-265) [65] .", [["glutamic acid", "CHEMICAL", 29, 42], ["glutamic acid", "CHEMICAL", 29, 42], ["C", "CHEMICAL", 103, 104], ["glutamic acid", "AMINO_ACID", 29, 42], ["C-terminus selfassociation domain", "PROTEIN", 103, 136], ["the glutamic acid at aa", "PROBLEM", 25, 48], ["C-terminus selfassociation domain", "PROBLEM", 103, 136]]], ["The rMP12-C13type (C13type) encodes an in-frame truncation of aa.", [["rMP12-C13type", "GENE_OR_GENE_PRODUCT", 4, 17], ["C13type", "GENE_OR_GENE_PRODUCT", 19, 26], ["rMP12", "PROTEIN", 4, 9], ["C13type", "PROTEIN", 10, 17], ["C13type", "PROTEIN", 19, 26]]], ["16-198, NSs functions, while aspartic acid at aa.257 to 259 is important for NSs stability.Co-expression of nonfunctional NSs with point mutations at the C-terminus in cells infected with MP-12We next tested the effect of co-expression of NSs-E253-255A/ D257-259A, NSsD257-259A or NSs-E253-255A in infected cells, as described above.", [["cells", "ANATOMY", 168, 173], ["cells", "ANATOMY", 307, 312], ["aspartic acid", "CHEMICAL", 29, 42], ["aspartic acid", "CHEMICAL", 29, 42], ["C", "CHEMICAL", 154, 155], ["aspartic acid", "AMINO_ACID", 29, 42], ["NSs", "GENE_OR_GENE_PRODUCT", 122, 125], ["cells", "CELL", 168, 173], ["MP-12We", "GENE_OR_GENE_PRODUCT", 188, 195], ["NSs", "GENE_OR_GENE_PRODUCT", 239, 242], ["cells", "CELL", 307, 312], ["nonfunctional NSs", "PROTEIN", 108, 125], ["C-terminus", "PROTEIN", 154, 164], ["MP", "PROTEIN", 188, 190], ["NSs", "PROTEIN", 239, 242], ["E253-255A", "PROTEIN", 243, 252], ["infected cells", "CELL_TYPE", 298, 312], ["aspartic acid at aa", "PROBLEM", 29, 48], ["nonfunctional NSs", "PROBLEM", 108, 125], ["point mutations", "PROBLEM", 131, 146], ["MP", "TEST", 188, 190], ["NSs", "TEST", 239, 242], ["A in infected cells", "PROBLEM", 293, 312], ["stability", "OBSERVATION", 81, 90], ["nonfunctional NSs", "OBSERVATION", 108, 125], ["infected cells", "OBSERVATION", 298, 312]]], ["293 cells were mock-infected or infected with rMP12-NSs-Flag using a moi of 3, then cells were mocktransfected or transfected with in vitro synthesized RNA encoding CAT, NSD249-265, NSs-E253-255A/D257-259A, NSsD257-259A or NSs-E253-255A.", [["293 cells", "ANATOMY", 0, 9], ["cells", "ANATOMY", 84, 89], ["293 cells", "CELL", 0, 9], ["rMP12", "GENE_OR_GENE_PRODUCT", 46, 51], ["Flag", "GENE_OR_GENE_PRODUCT", 56, 60], ["cells", "CELL", 84, 89], ["CAT", "GENE_OR_GENE_PRODUCT", 165, 168], ["NSsD257-259A", "GENE_OR_GENE_PRODUCT", 207, 219], ["293 cells", "CELL_LINE", 0, 9], ["rMP12", "PROTEIN", 46, 51], ["NSs", "DNA", 52, 55], ["Flag", "PROTEIN", 56, 60], ["CAT", "PROTEIN", 165, 168], ["NSD249", "PROTEIN", 170, 176], ["E253-255A", "PROTEIN", 186, 195], ["E253-255A", "PROTEIN", 227, 236], ["rMP12", "TREATMENT", 46, 51], ["NSs", "TREATMENT", 52, 55]]], ["Cells were collected at 16 hpi for Western blot analysis.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["Western blot analysis", "TEST", 35, 56]]], ["As shown in Fig. 8A , co-expression of NSs-E253-255A/D257-259A or NSs-D257-259A or NSs-E253-255A did not inhibit PKR degradation by rMP12-NSs-Flag, while that of NSD249-265 very slightly increased the PKR abundance, which is consistent with the result in Fig. 5A .Co-expression of nonfunctional NSs with point mutations at the C-terminus in cells infected with MP-12To test the co-expression effect of those NSs mutants in IFN-b mRNA synthesis, A549 cells were mock-infected or infected with rMP12-NSs-Flag at a moi of 3, and immediately transfected with in vitro synthesized RNA encoding NSs-E253-255A/D257-259A, NSsD257-259A or NSs-E253-255A.", [["cells", "ANATOMY", 341, 346], ["A549 cells", "ANATOMY", 445, 455], ["NSD249-265", "CHEMICAL", 162, 172], ["D257-259A", "CHEMICAL", 53, 62], ["NSs-D257-259A", "CHEMICAL", 66, 79], ["NSs-E253-255A", "CHEMICAL", 83, 96], ["NSD249-265", "CHEMICAL", 162, 172], ["C", "CHEMICAL", 327, 328], ["NSs-D257-259A", "GENE_OR_GENE_PRODUCT", 66, 79], ["PKR", "GENE_OR_GENE_PRODUCT", 113, 116], ["rMP12", "GENE_OR_GENE_PRODUCT", 132, 137], ["Flag", "GENE_OR_GENE_PRODUCT", 142, 146], ["NSD249-265", "SIMPLE_CHEMICAL", 162, 172], ["PKR", "GENE_OR_GENE_PRODUCT", 201, 204], ["NSs", "GENE_OR_GENE_PRODUCT", 295, 298], ["cells", "CELL", 341, 346], ["MP-12To", "GENE_OR_GENE_PRODUCT", 361, 368], ["NSs", "GENE_OR_GENE_PRODUCT", 408, 411], ["IFN-b", "GENE_OR_GENE_PRODUCT", 423, 428], ["A549 cells", "CELL", 445, 455], ["rMP12", "GENE_OR_GENE_PRODUCT", 492, 497], ["Flag", "GENE_OR_GENE_PRODUCT", 502, 506], ["NSs-", "GENE_OR_GENE_PRODUCT", 589, 593], ["NSsD257-259A", "GENE_OR_GENE_PRODUCT", 614, 626], ["NSs-E253-255A", "GENE_OR_GENE_PRODUCT", 630, 643], ["PKR", "PROTEIN", 113, 116], ["rMP12", "PROTEIN", 132, 137], ["NSs", "DNA", 138, 141], ["Flag", "PROTEIN", 142, 146], ["PKR", "PROTEIN", 201, 204], ["nonfunctional NSs", "PROTEIN", 281, 298], ["C-terminus", "PROTEIN", 327, 337], ["MP", "PROTEIN", 361, 363], ["NSs mutants", "PROTEIN", 408, 419], ["IFN-b mRNA", "RNA", 423, 433], ["A549 cells", "CELL_LINE", 445, 455], ["rMP12", "PROTEIN", 492, 497], ["NSs", "PROTEIN", 498, 501], ["Flag", "PROTEIN", 502, 506], ["E253-255A", "PROTEIN", 593, 602], ["D257-259A", "PROTEIN", 603, 612], ["E253-255A", "PROTEIN", 634, 643], ["NSD249", "TEST", 162, 168], ["the PKR abundance", "TEST", 197, 214], ["nonfunctional NSs", "PROBLEM", 281, 298], ["point mutations", "PROBLEM", 304, 319], ["MP", "TEST", 361, 363], ["those NSs mutants", "PROBLEM", 402, 419], ["IFN", "TEST", 423, 426], ["b mRNA synthesis", "TREATMENT", 427, 443], ["A549 cells", "PROBLEM", 445, 455], ["rMP12", "TREATMENT", 492, 497], ["NSs", "TREATMENT", 498, 501], ["PKR abundance", "OBSERVATION", 201, 214], ["consistent with", "UNCERTAINTY", 225, 240], ["nonfunctional NSs", "OBSERVATION", 281, 298]]], ["Total RNA was extracted at 7 hpi, and Northern blot was performed to detect IFN-b, ISG56 or RVFV S-RNA/N mRNA.", [["IFN-b", "GENE_OR_GENE_PRODUCT", 76, 81], ["ISG56", "GENE_OR_GENE_PRODUCT", 83, 88], ["RVFV", "ORGANISM", 92, 96], ["IFN-b, ISG56 or RVFV S-RNA/N mRNA", "RNA", 76, 109], ["RVFV", "SPECIES", 92, 96], ["Total RNA", "PROBLEM", 0, 9], ["Northern blot", "TEST", 38, 51], ["IFN", "TEST", 76, 79], ["ISG56", "TEST", 83, 88], ["RVFV S", "TEST", 92, 98], ["mRNA", "PROBLEM", 105, 109]]], ["None of those mutants attenuated NSsmediated IFN-b mRNA synthesis suppression (Fig. 8B) .", [["IFN-b", "GENE_OR_GENE_PRODUCT", 45, 50], ["NSsmediated IFN-b mRNA", "RNA", 33, 55], ["IFN-b mRNA synthesis suppression", "TREATMENT", 45, 77]]], ["These results suggest that attenuation of PKR degradation function might occur due to the accumulation of nonfunctional truncated NSs with some stability (Fig. 3) by the lack of C-terminus 17 amino acids residues.Co-expression of nonfunctional NSs with point mutations at the C-terminus in cells infected with MP-12Next, we tested whether the co-expression of NSD249-265 can inhibit MP-12 replication.", [["cells", "ANATOMY", 290, 295], ["amino acids", "CHEMICAL", 192, 203], ["NSD249-265", "CHEMICAL", 360, 370], ["amino acids", "CHEMICAL", 192, 203], ["C", "CHEMICAL", 276, 277], ["NSD249-265", "CHEMICAL", 360, 370], ["PKR", "GENE_OR_GENE_PRODUCT", 42, 45], ["amino acids", "AMINO_ACID", 192, 203], ["NSs", "GENE_OR_GENE_PRODUCT", 244, 247], ["cells", "CELL", 290, 295], ["MP-12Next", "GENE_OR_GENE_PRODUCT", 310, 319], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 360, 370], ["MP-12", "GENE_OR_GENE_PRODUCT", 383, 388], ["PKR", "PROTEIN", 42, 45], ["nonfunctional truncated NSs", "PROTEIN", 106, 133], ["C-terminus 17 amino acids residues", "PROTEIN", 178, 212], ["nonfunctional NSs", "PROTEIN", 230, 247], ["C-terminus", "PROTEIN", 276, 286], ["MP", "PROTEIN", 310, 312], ["PKR degradation function", "PROBLEM", 42, 66], ["nonfunctional truncated NSs", "PROBLEM", 106, 133], ["C-terminus 17 amino acids residues", "TREATMENT", 178, 212], ["nonfunctional NSs", "PROBLEM", 230, 247], ["point mutations", "PROBLEM", 253, 268], ["NSD249", "TEST", 360, 366], ["MP", "TEST", 383, 385], ["attenuation", "OBSERVATION_MODIFIER", 27, 38], ["PKR", "OBSERVATION", 42, 45], ["nonfunctional", "OBSERVATION_MODIFIER", 106, 119], ["truncated NSs", "OBSERVATION", 120, 133], ["stability", "OBSERVATION_MODIFIER", 144, 153], ["nonfunctional NSs", "OBSERVATION", 230, 247]]], ["A549 cells were infected with MP-12 using an moi of 0.01, and then were either mock-transfected or immediately transfected with in vitro synthesized RNA encoding CAT (RNA transfection control), NSD249-265 or NSs-E253-255A (a control with functional NSs).", [["A549 cells", "ANATOMY", 0, 10], ["MP-12", "CHEMICAL", 30, 35], ["NSD249-265", "CHEMICAL", 194, 204], ["NSs-E253-255A", "CHEMICAL", 208, 221], ["A549 cells", "CELL", 0, 10], ["CAT", "GENE_OR_GENE_PRODUCT", 162, 165], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 194, 204], ["NSs", "ORGANISM", 208, 211], ["A549 cells", "CELL_LINE", 0, 10], ["CAT", "PROTEIN", 162, 165], ["A549 cells", "PROBLEM", 0, 10], ["MP", "TEST", 30, 32], ["an moi", "TEST", 42, 48], ["vitro synthesized RNA", "TREATMENT", 131, 152], ["CAT (RNA transfection control", "TREATMENT", 162, 191], ["NSD249", "TEST", 194, 200], ["NSs", "TREATMENT", 208, 211], ["functional NSs", "TREATMENT", 238, 252]]], ["Culture supernatants were harvested at 72 hpi for viral titration using plaque assay.", [["supernatants", "ANATOMY", 8, 20], ["plaque", "ANATOMY", 72, 78], ["Culture supernatants", "TEST", 0, 20], ["viral titration", "TREATMENT", 50, 65], ["plaque assay", "TEST", 72, 84]]], ["RVFV titer was significantly decreased by the CAT RNA transfection when compared to mock-transfection control.", [["RVFV", "ORGANISM", 0, 4], ["CAT", "GENE_OR_GENE_PRODUCT", 46, 49], ["CAT RNA", "RNA", 46, 53], ["RVFV", "SPECIES", 0, 4], ["RVFV titer", "TEST", 0, 10], ["the CAT RNA transfection", "TREATMENT", 42, 66], ["mock-transfection control", "TREATMENT", 84, 109], ["significantly", "OBSERVATION_MODIFIER", 15, 28], ["decreased", "OBSERVATION_MODIFIER", 29, 38]]], ["Transfection with RNA encoding NSD249-265 did not further decrease RVFV titer compared to CAT RNA transfected control, while RNA encoding NSs-E253-255A increased RVFV titer significantly.", [["NSD249-265", "CHEMICAL", 31, 41], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 31, 41], ["RVFV", "ORGANISM", 67, 71], ["CAT", "GENE_OR_GENE_PRODUCT", 90, 93], ["NSs-E253-255A", "GENE_OR_GENE_PRODUCT", 138, 151], ["RVFV", "ORGANISM", 162, 166], ["NSD249", "PROTEIN", 31, 37], ["CAT RNA", "RNA", 90, 97], ["RVFV", "SPECIES", 67, 71], ["RVFV", "SPECIES", 162, 166], ["further decrease RVFV titer", "PROBLEM", 50, 77], ["CAT RNA transfected control", "TREATMENT", 90, 117], ["increased RVFV titer", "PROBLEM", 152, 172]]], ["These results suggest that co-expression of NSD249-265 NSs does not significantly decrease viral replication, while that of NSs-E253-255A facilitates RVFV replication by inhibiting IFN-b and PKR in transfected cells.", [["cells", "ANATOMY", 210, 215], ["NSD249-265", "CHEMICAL", 44, 54], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 44, 54], ["NSs-E253-255A", "GENE_OR_GENE_PRODUCT", 124, 137], ["RVFV", "ORGANISM", 150, 154], ["IFN-b", "GENE_OR_GENE_PRODUCT", 181, 186], ["PKR", "GENE_OR_GENE_PRODUCT", 191, 194], ["cells", "CELL", 210, 215], ["NSD249", "PROTEIN", 44, 50], ["IFN", "PROTEIN", 181, 184], ["PKR", "PROTEIN", 191, 194], ["transfected cells", "CELL_LINE", 198, 215], ["RVFV", "SPECIES", 150, 154], ["NSD249", "TEST", 44, 50], ["NSs", "TREATMENT", 55, 58], ["viral replication", "TREATMENT", 91, 108], ["NSs-", "TEST", 124, 128], ["RVFV replication", "TREATMENT", 150, 166], ["IFN", "TEST", 181, 184], ["PKR in transfected cells", "TREATMENT", 191, 215], ["transfected cells", "OBSERVATION", 198, 215]]], ["Overall, co-expression of truncated NSs inhibited neither NSs functions nor RVFV replication efficiently.", [["NSs", "GENE_OR_GENE_PRODUCT", 36, 39], ["NSs", "GENE_OR_GENE_PRODUCT", 58, 61], ["RVFV", "ORGANISM", 76, 80], ["truncated NSs", "PROTEIN", 26, 39], ["RVFV", "SPECIES", 76, 80], ["truncated NSs", "PROBLEM", 26, 39]]], ["Even though NSs encode self-association domain at the Cterminus domain, the expressed protein mislocalizes in cells, and does not maintain the stability of intact NSs, which minimizes the dominant-negative effect on MP-12 NSs.", [["cells", "ANATOMY", 110, 115], ["NSs", "GENE_OR_GENE_PRODUCT", 12, 15], ["cells", "CELL", 110, 115], ["NSs", "GENE_OR_GENE_PRODUCT", 163, 166], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 216, 225], ["NSs", "PROTEIN", 12, 15], ["self-association domain", "PROTEIN", 23, 46], ["Cterminus domain", "PROTEIN", 54, 70], ["NSs", "PROTEIN", 163, 166], ["MP-12 NSs", "PROTEIN", 216, 225], ["the expressed protein mislocalizes in cells", "PROBLEM", 72, 115], ["intact NSs", "TREATMENT", 156, 166], ["MP", "TEST", 216, 218], ["intact NSs", "OBSERVATION", 156, 166], ["dominant", "OBSERVATION_MODIFIER", 188, 196], ["negative effect", "OBSERVATION_MODIFIER", 197, 212]]], ["Discussion Dominant-negative suppression of viral replication has been characterized in a number of different viral proteins [68, 69, 70, 71, 72, 73] .", [["viral proteins", "PROTEIN", 110, 124], ["viral replication", "PROBLEM", 44, 61], ["different viral proteins", "TEST", 100, 124], ["viral replication", "OBSERVATION", 44, 61]]], ["For RVFV, L proteins form oligomer, and exhibit dominant-negative function [74] .", [["RVFV", "ORGANISM", 4, 8], ["L proteins", "GENE_OR_GENE_PRODUCT", 10, 20], ["RVFV, L proteins", "PROTEIN", 4, 20], ["RVFV", "SPECIES", 4, 8], ["RVFV", "PROBLEM", 4, 8], ["L proteins form oligomer", "PROBLEM", 10, 34], ["oligomer", "OBSERVATION", 26, 34], ["dominant", "OBSERVATION_MODIFIER", 48, 56], ["negative function", "OBSERVATION", 57, 74]]], ["In this study, we used NSs protein as a target protein of dominant-negative suppression, because a lack of NSs dramatically attenuates RVFV [75, 76] .Co-expression of nonfunctional NSs with point mutations at the C-terminus in cells infected with MP-12Since NSs can self-associate and form filamentous inclusion bodies in infected cells [65, 77] , we hypothesized that co-expression of nonfunctional NSs with the C-terminal self-association domain in cells infected with RVFV allows incorporation of such nonfunctional NSs into the NSs filament, and attenuates a part of NSs functions.", [["cells", "ANATOMY", 227, 232], ["filamentous inclusion bodies", "ANATOMY", 290, 318], ["cells", "ANATOMY", 331, 336], ["cells", "ANATOMY", 451, 456], ["C", "CHEMICAL", 213, 214], ["C", "CHEMICAL", 413, 414], ["NSs", "GENE_OR_GENE_PRODUCT", 107, 110], ["RVFV", "ORGANISM", 135, 139], ["NSs", "GENE_OR_GENE_PRODUCT", 181, 184], ["cells", "CELL", 227, 232], ["MP-12Since NSs", "ORGANISM", 247, 261], ["cells", "CELL", 331, 336], ["NSs", "GENE_OR_GENE_PRODUCT", 400, 403], ["cells", "CELL", 451, 456], ["RVFV", "ORGANISM", 471, 475], ["NSs", "GENE_OR_GENE_PRODUCT", 519, 522], ["NSs", "GENE_OR_GENE_PRODUCT", 532, 535], ["NSs", "GENE_OR_GENE_PRODUCT", 571, 574], ["NSs protein", "PROTEIN", 23, 34], ["NSs", "PROTEIN", 107, 110], ["nonfunctional NSs", "PROTEIN", 167, 184], ["C-terminus", "PROTEIN", 213, 223], ["infected cells", "CELL_TYPE", 322, 336], ["nonfunctional NSs", "PROTEIN", 386, 403], ["C-terminal self-association domain", "PROTEIN", 413, 447], ["NSs", "PROTEIN", 519, 522], ["NSs", "PROTEIN", 571, 574], ["RVFV", "SPECIES", 135, 139], ["RVFV", "SPECIES", 471, 475], ["this study", "TEST", 3, 13], ["NSs protein", "TREATMENT", 23, 34], ["nonfunctional NSs", "PROBLEM", 167, 184], ["point mutations", "PROBLEM", 190, 205], ["MP", "TEST", 247, 249], ["NSs", "TREATMENT", 258, 261], ["filamentous inclusion bodies in infected cells", "PROBLEM", 290, 336], ["nonfunctional NSs", "PROBLEM", 386, 403], ["the C-terminal self-association domain in cells", "PROBLEM", 409, 456], ["RVFV", "TREATMENT", 471, 475], ["such nonfunctional NSs", "TREATMENT", 500, 522], ["negative suppression", "OBSERVATION", 67, 87], ["nonfunctional NSs", "OBSERVATION", 167, 184], ["infected cells", "OBSERVATION", 322, 336]]], ["However, our results were not as expected; 1) most of truncated NSs localized at cytoplasm, 2) all of truncated NSs did Our results suggest truncation of NSs causes mis-folding and/or mis-localization of protein, which might abolish the ability to interact with authentic MP-12 NSs through the C-terminus selfassociation domain.", [["cytoplasm", "ANATOMY", 81, 90], ["C", "CHEMICAL", 294, 295], ["NSs", "GENE_OR_GENE_PRODUCT", 64, 67], ["cytoplasm", "ORGANISM_SUBSTANCE", 81, 90], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 272, 281], ["truncated NSs", "PROTEIN", 54, 67], ["truncated NSs", "PROTEIN", 102, 115], ["NSs", "PROTEIN", 154, 157], ["MP-12 NSs", "PROTEIN", 272, 281], ["C-terminus selfassociation domain", "PROTEIN", 294, 327], ["truncated NSs", "PROBLEM", 54, 67], ["truncated NSs", "PROBLEM", 102, 115], ["truncation of NSs", "PROBLEM", 140, 157], ["mis-folding", "PROBLEM", 165, 176], ["mis-localization of protein", "PROBLEM", 184, 211], ["authentic MP", "TEST", 262, 274]]], ["Unexpectedly, only the co-expression of NSs lacking C-terminus self-association domain (NSD249-265) slightly inhibited PKR degradation by MP-12 NSs.", [["NSD249-265", "CHEMICAL", 88, 98], ["MP-12 NSs", "CHEMICAL", 138, 147], ["C", "CHEMICAL", 52, 53], ["NSs", "GENE_OR_GENE_PRODUCT", 40, 43], ["PKR", "GENE_OR_GENE_PRODUCT", 119, 122], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 138, 147], ["NSs", "PROTEIN", 40, 43], ["C-terminus self-association domain", "PROTEIN", 52, 86], ["NSD249", "PROTEIN", 88, 94], ["PKR", "PROTEIN", 119, 122], ["NSs", "PROBLEM", 40, 43], ["NSD249", "TEST", 88, 94], ["slightly inhibited PKR degradation", "PROBLEM", 100, 134], ["MP", "TEST", 138, 140]]], ["The NSD249-265 could accumulate both in cytoplasm and nucleus, which is consistent with previous study [65] .", [["cytoplasm", "ANATOMY", 40, 49], ["nucleus", "ANATOMY", 54, 61], ["NSD249-265", "CHEMICAL", 4, 14], ["NSD249-265", "CHEMICAL", 4, 14], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 4, 14], ["cytoplasm", "ORGANISM_SUBSTANCE", 40, 49], ["nucleus", "CELLULAR_COMPONENT", 54, 61], ["NSD249-265", "DNA", 4, 14], ["The NSD249", "TEST", 0, 10], ["previous study", "TEST", 88, 102], ["both", "OBSERVATION_MODIFIER", 32, 36], ["cytoplasm", "OBSERVATION_MODIFIER", 40, 49], ["nucleus", "ANATOMY_MODIFIER", 54, 61], ["consistent with", "UNCERTAINTY", 72, 87]]], ["We speculate that NSD249-265 could compete with host factors required for PKR degradation with intact NSs.", [["NSD249-265", "CHEMICAL", 18, 28], ["NSD249-265", "CHEMICAL", 18, 28], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 18, 28], ["PKR", "GENE_OR_GENE_PRODUCT", 74, 77], ["NSs", "GENE_OR_GENE_PRODUCT", 102, 105], ["PKR", "PROTEIN", 74, 77], ["NSs", "PROTEIN", 102, 105], ["host factors", "TREATMENT", 48, 60], ["PKR degradation", "PROBLEM", 74, 89], ["intact NSs", "TREATMENT", 95, 105], ["intact NSs", "OBSERVATION", 95, 105]]], ["In the meantime, co-expression of NSD249-265 NSs did not result in a significant decrease of RVFV replication when compared to CAT RNA transfection control.", [["NSD249-265", "CHEMICAL", 34, 44], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 34, 44], ["RVFV", "ORGANISM", 93, 97], ["CAT", "GENE_OR_GENE_PRODUCT", 127, 130], ["NSD249", "PROTEIN", 34, 40], ["CAT RNA", "RNA", 127, 134], ["RVFV", "SPECIES", 93, 97], ["NSD249", "TEST", 34, 40], ["NSs", "TREATMENT", 45, 48], ["RVFV replication", "TREATMENT", 93, 109], ["CAT RNA transfection control", "TREATMENT", 127, 155], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["decrease", "OBSERVATION_MODIFIER", 81, 89], ["RVFV replication", "OBSERVATION", 93, 109]]], ["Therefore, the co-expression of NSs fragments in infected cells might not be an effective strategy to inhibit RVFV replication in vivo.Co-expression of nonfunctional NSs with point mutations at the C-terminus in cells infected with MP-12Another novel finding is that all of truncation mutants; i.e., NSD6-30, NSD31-55, NSD56-80, NSD81-105, NSD106-130, NSD131-155, NSD156-180, NSD181-205, NSD206-230, NSD231-248 and NSD249-265, had lacked both PKR degradation and IFN-b suppression functions.", [["fragments", "ANATOMY", 36, 45], ["cells", "ANATOMY", 58, 63], ["cells", "ANATOMY", 212, 217], ["NSD131-155, NSD156-180, NSD181-205, NSD206-230, NSD231-248", "CHEMICAL", 352, 410], ["NSD249-265", "CHEMICAL", 415, 425], ["C", "CHEMICAL", 198, 199], ["NSs", "GENE_OR_GENE_PRODUCT", 32, 35], ["cells", "CELL", 58, 63], ["RVFV", "ORGANISM", 110, 114], ["NSs", "GENE_OR_GENE_PRODUCT", 166, 169], ["cells", "CELL", 212, 217], ["MP-12Another", "GENE_OR_GENE_PRODUCT", 232, 244], ["NSD6-30", "ORGANISM", 300, 307], ["NSD31-55", "GENE_OR_GENE_PRODUCT", 309, 317], ["PKR", "GENE_OR_GENE_PRODUCT", 443, 446], ["IFN-b", "GENE_OR_GENE_PRODUCT", 463, 468], ["NSs fragments", "DNA", 32, 45], ["infected cells", "CELL_TYPE", 49, 63], ["nonfunctional NSs", "PROTEIN", 152, 169], ["C-terminus", "PROTEIN", 198, 208], ["truncation mutants", "PROTEIN", 274, 292], ["NSD6", "PROTEIN", 300, 304], ["PKR", "PROTEIN", 443, 446], ["IFN", "PROTEIN", 463, 466], ["RVFV", "SPECIES", 110, 114], ["NSs fragments", "PROBLEM", 32, 45], ["infected cells", "PROBLEM", 49, 63], ["RVFV replication", "TREATMENT", 110, 126], ["nonfunctional NSs", "PROBLEM", 152, 169], ["point mutations", "PROBLEM", 175, 190], ["MP", "TEST", 232, 234], ["truncation mutants", "PROBLEM", 274, 292], ["NSD6", "TEST", 300, 304], ["NSD31", "TEST", 309, 314], ["NSD56", "TEST", 319, 324], ["NSD81", "TEST", 329, 334], ["NSD106", "TEST", 340, 346], ["NSD131", "TEST", 352, 358], ["NSD156", "TEST", 364, 370], ["NSD181", "TEST", 376, 382], ["NSD206", "TEST", 388, 394], ["NSD231", "TEST", 400, 406], ["NSD249", "TEST", 415, 421], ["both PKR degradation", "PROBLEM", 438, 458], ["IFN", "TEST", 463, 466], ["NSs fragments", "OBSERVATION", 32, 45], ["infected cells", "OBSERVATION", 49, 63], ["nonfunctional NSs", "OBSERVATION", 152, 169], ["PKR degradation", "OBSERVATION", 443, 458]]], ["This suggests that conformation structure might be important for those NSs functions rather than the presence of linear domain.", [["NSs", "PROTEIN", 71, 74], ["linear domain", "PROTEIN", 113, 126], ["those NSs functions", "PROBLEM", 65, 84]]], ["Our results suggest that those truncated NSs decrease accumulation level, and change the localization pattern in cells.", [["cells", "ANATOMY", 113, 118], ["NSs", "GENE_OR_GENE_PRODUCT", 41, 44], ["cells", "CELL", 113, 118], ["NSs", "PROTEIN", 41, 44], ["those truncated NSs decrease accumulation level", "PROBLEM", 25, 72], ["the localization pattern in cells", "PROBLEM", 85, 118]]], ["The stability and cellular localization of NSs, which are probably controlled by conformational domain, might be important for biological functions of NSs.", [["cellular", "ANATOMY", 18, 26], ["cellular", "CELL", 18, 26], ["NSs", "GENE_OR_GENE_PRODUCT", 43, 46], ["NSs", "GENE_OR_GENE_PRODUCT", 151, 154], ["NSs", "PROTEIN", 43, 46], ["conformational domain", "PROTEIN", 81, 102], ["NSs", "PROTEIN", 151, 154], ["NSs", "TREATMENT", 43, 46], ["NSs", "TREATMENT", 151, 154], ["stability", "OBSERVATION_MODIFIER", 4, 13], ["cellular", "OBSERVATION_MODIFIER", 18, 26], ["localization", "OBSERVATION_MODIFIER", 27, 39], ["NSs", "OBSERVATION", 43, 46]]], ["Although the C-terminus 17 amino acids were determined as a self-association domain important for filament formation [65] , our result suggests that filament formation does not occur by NSs encoding an in-frame truncation with 25 amino acids.", [["filament", "ANATOMY", 98, 106], ["filament", "ANATOMY", 149, 157], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "CHEMICAL", 230, 241], ["C", "CHEMICAL", 13, 14], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "CHEMICAL", 230, 241], ["amino acids", "AMINO_ACID", 27, 38], ["filament", "CELLULAR_COMPONENT", 98, 106], ["filament", "CELLULAR_COMPONENT", 149, 157], ["amino acids", "AMINO_ACID", 230, 241], ["C-terminus 17 amino acids", "PROTEIN", 13, 38], ["self-association domain", "PROTEIN", 60, 83], ["NSs", "PROTEIN", 186, 189], ["the C-terminus", "TEST", 9, 23], ["amino acids", "TEST", 27, 38], ["filament formation", "PROBLEM", 149, 167], ["an in-frame truncation", "TREATMENT", 199, 221], ["25 amino acids", "TREATMENT", 227, 241]]], ["It is possible that the C-terminus 17 amino acids are the prerequisite of NSs self-association, and other structural domains play a role in the filament formation through the C-terminus domain.Co-expression of nonfunctional NSs with point mutations at the C-terminus in cells infected with MP-12Our result showed that NSD206-230 dominantly localized at cytoplasm.", [["filament", "ANATOMY", 144, 152], ["cells", "ANATOMY", 270, 275], ["cytoplasm", "ANATOMY", 353, 362], ["amino acids", "CHEMICAL", 38, 49], ["NSD206-230", "CHEMICAL", 318, 328], ["C", "CHEMICAL", 24, 25], ["amino acids", "CHEMICAL", 38, 49], ["C", "CHEMICAL", 175, 176], ["C", "CHEMICAL", 256, 257], ["amino acids", "AMINO_ACID", 38, 49], ["NSs", "GENE_OR_GENE_PRODUCT", 74, 77], ["filament", "CELLULAR_COMPONENT", 144, 152], ["NSs", "GENE_OR_GENE_PRODUCT", 224, 227], ["cells", "CELL", 270, 275], ["MP-12Our", "GENE_OR_GENE_PRODUCT", 290, 298], ["NSD206-230", "GENE_OR_GENE_PRODUCT", 318, 328], ["cytoplasm", "ORGANISM_SUBSTANCE", 353, 362], ["NSs", "PROTEIN", 74, 77], ["structural domains", "PROTEIN", 106, 124], ["C-terminus domain", "PROTEIN", 175, 192], ["nonfunctional NSs", "PROTEIN", 210, 227], ["C-terminus", "PROTEIN", 256, 266], ["MP", "PROTEIN", 290, 292], ["the C-terminus 17 amino acids", "PROBLEM", 20, 49], ["nonfunctional NSs", "PROBLEM", 210, 227], ["point mutations", "PROBLEM", 233, 248], ["MP", "TEST", 290, 292], ["NSD206", "TEST", 318, 324], ["nonfunctional NSs", "OBSERVATION", 210, 227]]], ["Previous study showed that rec-ZHD210-230 (recombinant ZH548 encoding an in-frame truncation in NSs at 210-230) could induce IFN-b mRNA due to a lack of SAP30-binding domain in infected cells [26] .", [["cells", "ANATOMY", 186, 191], ["rec-ZHD210-230", "CHEMICAL", 27, 41], ["rec-ZHD210-230", "CHEMICAL", 27, 41], ["rec-ZHD210-230", "GENE_OR_GENE_PRODUCT", 27, 41], ["ZH548", "GENE_OR_GENE_PRODUCT", 55, 60], ["IFN-b", "GENE_OR_GENE_PRODUCT", 125, 130], ["SAP30", "GENE_OR_GENE_PRODUCT", 153, 158], ["cells", "CELL", 186, 191], ["rec-ZHD210-230", "DNA", 27, 41], ["recombinant ZH548", "PROTEIN", 43, 60], ["NSs", "PROTEIN", 96, 99], ["IFN-b mRNA", "RNA", 125, 135], ["SAP30-binding domain", "PROTEIN", 153, 173], ["infected cells", "CELL_TYPE", 177, 191], ["Previous study", "TEST", 0, 14], ["rec-ZHD210", "TEST", 27, 37], ["an in-frame truncation in NSs", "TREATMENT", 70, 99], ["SAP30-binding domain in infected cells", "PROBLEM", 153, 191], ["infected cells", "OBSERVATION", 177, 191]]], ["It was also shown that NSs binding to SAP30 is required for NSs filaments to target pericentromeric DNA and induce nuclear anomalies [78] .", [["filaments", "ANATOMY", 64, 73], ["pericentromeric", "ANATOMY", 84, 99], ["nuclear", "ANATOMY", 115, 122], ["nuclear anomalies", "DISEASE", 115, 132], ["NSs", "GENE_OR_GENE_PRODUCT", 23, 26], ["SAP30", "GENE_OR_GENE_PRODUCT", 38, 43], ["NSs", "GENE_OR_GENE_PRODUCT", 60, 63], ["pericentromeric", "CELLULAR_COMPONENT", 84, 99], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["nuclear", "CELLULAR_COMPONENT", 115, 122], ["NSs", "PROTEIN", 23, 26], ["SAP30", "PROTEIN", 38, 43], ["pericentromeric DNA", "DNA", 84, 103], ["NSs binding", "PROBLEM", 23, 34], ["NSs filaments", "TREATMENT", 60, 73], ["pericentromeric DNA", "PROBLEM", 84, 103], ["nuclear anomalies", "PROBLEM", 115, 132]]], ["They described that rec-ZHD210-230 expresses a stable NSs protein located in the nucleus in the discussion [78] .", [["nucleus", "ANATOMY", 81, 88], ["rec-ZHD210-230", "CHEMICAL", 20, 34], ["rec-ZHD210-230", "GENE_OR_GENE_PRODUCT", 20, 34], ["nucleus", "CELLULAR_COMPONENT", 81, 88], ["rec-ZHD210", "PROTEIN", 20, 30], ["NSs protein", "PROTEIN", 54, 65], ["stable", "OBSERVATION_MODIFIER", 47, 53], ["nucleus", "ANATOMY", 81, 88]]], ["Thus, it might be possible that NSs encoding 20 aa. does not change the nuclear localization.", [["nuclear", "ANATOMY", 72, 79], ["nuclear", "CELLULAR_COMPONENT", 72, 79], ["NSs", "DNA", 32, 35]]], ["On the other hand, NSD6-30, NSD31-55, NSD56-80 and NSD249-265, all of which encode SAP30-binding domain at aa.210-130, could be accumulated in nucleus, whereas they did not inhibit IFN-b gene, suggesting that NSs has another structural requirement to inhibit IFN-b gene activation in addition to SAP30 binding.", [["nucleus", "ANATOMY", 143, 150], ["NSD249-265", "CHEMICAL", 51, 61], ["NSD6-30", "GENE_OR_GENE_PRODUCT", 19, 26], ["NSD31-55", "GENE_OR_GENE_PRODUCT", 28, 36], ["NSD56-80", "GENE_OR_GENE_PRODUCT", 38, 46], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 51, 61], ["SAP30", "GENE_OR_GENE_PRODUCT", 83, 88], ["nucleus", "CELLULAR_COMPONENT", 143, 150], ["IFN-b", "GENE_OR_GENE_PRODUCT", 181, 186], ["NSs", "GENE_OR_GENE_PRODUCT", 209, 212], ["IFN-b", "GENE_OR_GENE_PRODUCT", 259, 264], ["SAP30", "GENE_OR_GENE_PRODUCT", 296, 301], ["NSD6", "PROTEIN", 19, 23], ["SAP30", "PROTEIN", 83, 88], ["binding domain", "PROTEIN", 89, 103], ["IFN-b gene", "DNA", 181, 191], ["NSs", "PROTEIN", 209, 212], ["IFN", "PROTEIN", 259, 262], ["SAP30", "PROTEIN", 296, 301], ["NSD6", "TEST", 19, 23], ["NSD31", "TEST", 28, 33], ["NSD56", "TEST", 38, 43], ["NSD249", "TEST", 51, 57], ["NSs", "TREATMENT", 209, 212], ["another structural requirement", "PROBLEM", 217, 247], ["IFN-b gene activation", "TREATMENT", 259, 280], ["SAP30 binding", "PROBLEM", 296, 309], ["accumulated", "OBSERVATION", 128, 139], ["nucleus", "ANATOMY", 143, 150]]], ["The requirement of NSs localization and IFN-b gene suppression should be further studied to understand the detailed mechanism of IFN-b gene regulation by RVFV NSs.Co-expression of nonfunctional NSs with point mutations at the C-terminus in cells infected with MP-12We also characterized the role of C-terminus acidic residues in NSs functions.", [["cells", "ANATOMY", 240, 245], ["C", "CHEMICAL", 226, 227], ["C", "CHEMICAL", 299, 300], ["NSs", "GENE_OR_GENE_PRODUCT", 19, 22], ["IFN-b", "GENE_OR_GENE_PRODUCT", 40, 45], ["IFN-b", "GENE_OR_GENE_PRODUCT", 129, 134], ["RVFV", "ORGANISM", 154, 158], ["NSs", "GENE_OR_GENE_PRODUCT", 194, 197], ["cells", "CELL", 240, 245], ["MP-12We", "GENE_OR_GENE_PRODUCT", 260, 267], ["NSs", "GENE_OR_GENE_PRODUCT", 329, 332], ["IFN", "PROTEIN", 40, 43], ["IFN", "PROTEIN", 129, 132], ["RVFV NSs", "PROTEIN", 154, 162], ["nonfunctional NSs", "PROTEIN", 180, 197], ["C-terminus", "PROTEIN", 226, 236], ["MP", "PROTEIN", 260, 262], ["C-terminus acidic residues", "PROTEIN", 299, 325], ["NSs", "PROTEIN", 329, 332], ["RVFV", "SPECIES", 154, 158], ["NSs localization", "TREATMENT", 19, 35], ["IFN-b gene suppression", "TREATMENT", 40, 62], ["IFN-b gene regulation", "TREATMENT", 129, 150], ["RVFV NSs", "TREATMENT", 154, 162], ["nonfunctional NSs", "PROBLEM", 180, 197], ["point mutations", "PROBLEM", 203, 218], ["C-terminus acidic residues in NSs functions", "PROBLEM", 299, 342], ["nonfunctional NSs", "OBSERVATION", 180, 197], ["acidic residues", "OBSERVATION", 310, 325], ["NSs functions", "OBSERVATION", 329, 342]]], ["We found that both NSs-E253-255A/D257-259A and NSsD257-259A were not abundantly accumulated in infected cells.", [["cells", "ANATOMY", 104, 109], ["NSsD257-259A", "CHEMICAL", 47, 59], ["D257-259A", "GENE_OR_GENE_PRODUCT", 33, 42], ["NSsD257-259A", "GENE_OR_GENE_PRODUCT", 47, 59], ["cells", "CELL", 104, 109], ["NSs-E253-255A/D257-259A and NSsD257-259A", "DNA", 19, 59], ["infected cells", "CELL_TYPE", 95, 109], ["NSsD257", "TEST", 47, 54], ["infected cells", "OBSERVATION", 95, 109]]], ["On the other hand, the NSs-E253-255A accumulated efficiently in cells, and showed a similar phenotype with authentic NSs.", [["cells", "ANATOMY", 64, 69], ["cells", "CELL", 64, 69], ["authentic NSs", "TREATMENT", 107, 120], ["authentic NSs", "OBSERVATION", 107, 120]]], ["Thus, the aspartic acids at 257-259 but not glutamic acid at 253-255 must be important for the stability of NSs.", [["aspartic acids", "CHEMICAL", 10, 24], ["257-259", "CHEMICAL", 28, 35], ["glutamic acid", "CHEMICAL", 44, 57], ["aspartic acids", "CHEMICAL", 10, 24], ["glutamic acid", "CHEMICAL", 44, 57], ["aspartic acids", "AMINO_ACID", 10, 24], ["glutamic acid", "AMINO_ACID", 44, 57], ["NSs", "GENE_OR_GENE_PRODUCT", 108, 111], ["NSs", "PROTEIN", 108, 111], ["the aspartic acids", "TEST", 6, 24], ["glutamic acid", "TEST", 44, 57], ["NSs", "TREATMENT", 108, 111]]], ["Since the accumulation of NSs-E253-255A/D257-259A and NSsD257-259A were very low, we could not determine whether those mutants are lacking the functions to degrade PKR or inhibit IFNb mRNA synthesis.Co-expression of nonfunctional NSs with point mutations at the C-terminus in cells infected with MP-12We noted that the co-infection of recombinant MP-12 encoding truncated NSs with MP-12, except for NSD6-30 and NSD56-80, had resulted in dominant accumulation of truncated NSs.", [["cells", "ANATOMY", 276, 281], ["MP-12", "CHEMICAL", 381, 386], ["NSD56-80", "CHEMICAL", 411, 419], ["NSsD257-259A", "CHEMICAL", 54, 66], ["C", "CHEMICAL", 262, 263], ["NSs-E253-255A/D257-259A", "GENE_OR_GENE_PRODUCT", 26, 49], ["NSsD257-259A", "GENE_OR_GENE_PRODUCT", 54, 66], ["PKR", "GENE_OR_GENE_PRODUCT", 164, 167], ["IFNb", "GENE_OR_GENE_PRODUCT", 179, 183], ["NSs", "GENE_OR_GENE_PRODUCT", 230, 233], ["cells", "CELL", 276, 281], ["MP-12We", "GENE_OR_GENE_PRODUCT", 296, 303], ["MP-12", "GENE_OR_GENE_PRODUCT", 347, 352], ["NSs", "GENE_OR_GENE_PRODUCT", 372, 375], ["MP-12", "GENE_OR_GENE_PRODUCT", 381, 386], ["NSD6-30", "GENE_OR_GENE_PRODUCT", 399, 406], ["NSD56-80", "GENE_OR_GENE_PRODUCT", 411, 419], ["NSs", "GENE_OR_GENE_PRODUCT", 472, 475], ["NSs-E253-255A/D257-259A and NSsD257-259A", "DNA", 26, 66], ["PKR", "PROTEIN", 164, 167], ["IFNb mRNA", "RNA", 179, 188], ["nonfunctional NSs", "PROTEIN", 216, 233], ["C-terminus", "PROTEIN", 262, 272], ["MP", "PROTEIN", 296, 298], ["recombinant MP-12", "PROTEIN", 335, 352], ["truncated NSs", "PROTEIN", 362, 375], ["MP", "PROTEIN", 381, 383], ["NSD6", "PROTEIN", 399, 403], ["NSD56", "PROTEIN", 411, 416], ["truncated NSs", "PROTEIN", 462, 475], ["NSsD257", "TREATMENT", 54, 61], ["mRNA synthesis", "PROBLEM", 184, 198], ["nonfunctional NSs", "PROBLEM", 216, 233], ["point mutations", "PROBLEM", 239, 254], ["MP", "TEST", 296, 298], ["recombinant MP", "TEST", 335, 349], ["MP", "TEST", 381, 383], ["NSD6", "TEST", 399, 403], ["NSD56", "TEST", 411, 416], ["dominant accumulation of truncated NSs", "PROBLEM", 437, 475], ["nonfunctional NSs", "OBSERVATION", 216, 233], ["co-infection", "OBSERVATION", 319, 331], ["dominant", "OBSERVATION_MODIFIER", 437, 445], ["accumulation of", "OBSERVATION", 446, 461], ["truncated NSs", "OBSERVATION", 462, 475]]], ["This effect may possibly occur at the transcription or translation level rather than post-translation level, since MP-12 NSs can also accumulate with truncated NSs when RNA transfection was used for truncated NSs expression.", [["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 115, 124], ["NSs", "GENE_OR_GENE_PRODUCT", 160, 163], ["NSs", "GENE_OR_GENE_PRODUCT", 209, 212], ["MP", "PROTEIN", 115, 117], ["NSs", "PROTEIN", 209, 212], ["translation level", "TEST", 55, 72], ["post-translation level", "TEST", 85, 107], ["MP", "TEST", 115, 117], ["NSs", "TREATMENT", 121, 124], ["truncated NSs", "TREATMENT", 150, 163], ["RNA transfection", "TREATMENT", 169, 185], ["truncated NSs expression", "PROBLEM", 199, 223], ["may possibly", "UNCERTAINTY", 12, 24]]], ["If a selective viral transcription of truncated NSs mRNA, or a selective translation of truncated NSs proteins could occur in co-infected cells, then a virus exhibiting these traits may be useful for post-exposure vaccination.", [["cells", "ANATOMY", 138, 143], ["NSs", "GENE_OR_GENE_PRODUCT", 48, 51], ["NSs", "GENE_OR_GENE_PRODUCT", 98, 101], ["cells", "CELL", 138, 143], ["truncated NSs mRNA", "RNA", 38, 56], ["truncated NSs proteins", "PROTEIN", 88, 110], ["co-infected cells", "CELL_TYPE", 126, 143], ["a selective viral transcription", "TREATMENT", 3, 34], ["truncated NSs mRNA", "TREATMENT", 38, 56], ["truncated NSs proteins", "PROBLEM", 88, 110], ["co-infected cells", "PROBLEM", 126, 143], ["a virus", "PROBLEM", 150, 157], ["post-exposure vaccination", "TREATMENT", 200, 225], ["co-infected cells", "OBSERVATION", 126, 143]]], ["However, new studies will be required to detail this mechanism.Co-expression of nonfunctional NSs with point mutations at the C-terminus in cells infected with MP-12In summary, short in-frame truncations of RVFV NSs affect the expression level and cellular localization, which lessen or abolish biological functions of NSs most probably due to the lack of functional conformation domains.", [["cells", "ANATOMY", 140, 145], ["cellular", "ANATOMY", 248, 256], ["C", "CHEMICAL", 126, 127], ["NSs", "GENE_OR_GENE_PRODUCT", 94, 97], ["cells", "CELL", 140, 145], ["MP-12In", "GENE_OR_GENE_PRODUCT", 160, 167], ["RVFV NSs", "ORGANISM", 207, 215], ["cellular", "CELL", 248, 256], ["nonfunctional NSs", "PROTEIN", 80, 97], ["C-terminus", "PROTEIN", 126, 136], ["RVFV NSs", "PROTEIN", 207, 215], ["NSs", "PROTEIN", 319, 322], ["functional conformation domains", "PROTEIN", 356, 387], ["RVFV", "SPECIES", 207, 211], ["new studies", "TEST", 9, 20], ["nonfunctional NSs", "PROBLEM", 80, 97], ["point mutations", "PROBLEM", 103, 118], ["RVFV NSs", "TREATMENT", 207, 215], ["cellular localization", "TEST", 248, 269], ["NSs", "PROBLEM", 319, 322], ["nonfunctional NSs", "OBSERVATION", 80, 97], ["RVFV", "OBSERVATION", 207, 211]]], ["Thus, co-expression of truncated nonfunctional NSs in RVFV-infected cells does not attenuate NSs functions of RVFV.Media, Cells and VirusesVeroE6 cells (ATCC CRL-1586), 293 cells (ATCC CRL-1573) and A549 cells (ATCC CCL-185) were maintained in Dulbecco's modified minimum essential medium (DMEM) containing 10% fetal calf serum (FCS).", [["cells", "ANATOMY", 68, 73], ["Cells", "ANATOMY", 122, 127], ["VirusesVeroE6 cells", "ANATOMY", 132, 151], ["ATCC CRL-1586), 293 cells", "ANATOMY", 153, 178], ["ATCC CRL-1573", "ANATOMY", 180, 193], ["A549 cells", "ANATOMY", 199, 209], ["ATCC CCL-185", "ANATOMY", 211, 223], ["fetal calf serum", "ANATOMY", 311, 327], ["CCL-185", "CHEMICAL", 216, 223], ["NSs", "GENE_OR_GENE_PRODUCT", 47, 50], ["RVFV", "ORGANISM", 54, 58], ["cells", "CELL", 68, 73], ["NSs", "GENE_OR_GENE_PRODUCT", 93, 96], ["RVFV", "ORGANISM", 110, 114], ["Cells", "CELL", 122, 127], ["VirusesVeroE6 cells", "CELL", 132, 151], ["ATCC CRL-1586", "CELL", 153, 166], ["293 cells", "CELL", 169, 178], ["ATCC CRL-1573", "CELL", 180, 193], ["A549 cells", "CELL", 199, 209], ["ATCC CCL-185", "CELL", 211, 223], ["fetal calf", "ORGANISM_SUBSTANCE", 311, 321], ["serum", "ORGANISM_SUBSTANCE", 322, 327], ["FCS", "ORGANISM_SUBSTANCE", 329, 332], ["truncated nonfunctional NSs", "PROTEIN", 23, 50], ["RVFV-infected cells", "CELL_TYPE", 54, 73], ["NSs", "PROTEIN", 93, 96], ["VirusesVeroE6 cells", "CELL_LINE", 132, 151], ["ATCC CRL-1586", "CELL_LINE", 153, 166], ["293 cells", "CELL_LINE", 169, 178], ["ATCC CRL-1573", "CELL_LINE", 180, 193], ["A549 cells", "CELL_LINE", 199, 209], ["ATCC CCL-185", "CELL_LINE", 211, 223], ["calf", "SPECIES", 317, 321], ["RVFV", "SPECIES", 54, 58], ["RVFV", "SPECIES", 110, 114], ["ATCC CRL-1586)", "SPECIES", 153, 167], ["ATCC CRL-1573)", "SPECIES", 180, 194], ["ATCC CCL-185", "SPECIES", 211, 223], ["truncated nonfunctional NSs in RVFV", "PROBLEM", 23, 58], ["infected cells", "PROBLEM", 59, 73], ["RVFV", "PROBLEM", 110, 114], ["VirusesVeroE6 cells", "TEST", 132, 151], ["ATCC CRL", "TEST", 153, 161], ["ATCC CRL", "TEST", 180, 188], ["A549 cells", "TEST", 199, 209], ["ATCC CCL", "TEST", 211, 219], ["10% fetal calf serum", "TEST", 307, 327], ["nonfunctional NSs", "OBSERVATION", 33, 50], ["infected cells", "OBSERVATION", 59, 73], ["RVFV", "OBSERVATION", 110, 114], ["Cells", "ANATOMY", 122, 127], ["A549 cells", "OBSERVATION", 199, 209], ["medium", "OBSERVATION_MODIFIER", 282, 288], ["calf", "ANATOMY", 317, 321]]], ["BHK/T7-9 cells that stably express T7 RNA polymerase [79] were maintained in MEM-alpha containing 10% FCS.", [["BHK/T7-9 cells", "ANATOMY", 0, 14], ["BHK", "CELL", 0, 3], ["T7-9 cells", "CELL", 4, 14], ["T7", "GENE_OR_GENE_PRODUCT", 35, 37], ["MEM-alpha", "GENE_OR_GENE_PRODUCT", 77, 86], ["BHK/T7-9 cells", "CELL_LINE", 0, 14], ["T7 RNA polymerase", "PROTEIN", 35, 52], ["BHK/T7-9 cells", "TEST", 0, 14], ["RNA polymerase", "TEST", 38, 52], ["T7", "ANATOMY", 4, 6], ["9 cells", "OBSERVATION_MODIFIER", 7, 14], ["T7", "ANATOMY", 35, 37]]], ["Penicilin (100 U/ml) and streptomycin (100 g/ml) were added to the culture media.PlasmidsThe plasmid encoding anti-viral-sense of MP-12 S-segment at the downstream of the T7 promoter, pProT7-S(+), was described previously [18] .", [["plasmid", "ANATOMY", 93, 100], ["Penicilin", "CHEMICAL", 0, 9], ["streptomycin", "CHEMICAL", 25, 37], ["Penicilin", "CHEMICAL", 0, 9], ["streptomycin", "CHEMICAL", 25, 37], ["Penicilin", "SIMPLE_CHEMICAL", 0, 9], ["streptomycin", "SIMPLE_CHEMICAL", 25, 37], ["MP-12", "GENE_OR_GENE_PRODUCT", 130, 135], ["plasmid", "DNA", 93, 100], ["MP-12 S-segment", "DNA", 130, 145], ["T7 promoter", "DNA", 171, 182], ["ProT7", "DNA", 185, 190], ["S", "DNA", 191, 192], ["Penicilin", "TREATMENT", 0, 9], ["streptomycin", "TREATMENT", 25, 37], ["the culture media", "TREATMENT", 63, 80], ["Plasmids", "TREATMENT", 81, 89], ["MP", "TEST", 130, 132], ["the T7 promoter", "TREATMENT", 167, 182], ["T7", "ANATOMY", 171, 173]]], ["Serial deletion of 75 bp (25 aa.) was introduced into the NSs open reading frame (ORF) of pProT7-S(+) by sitedirected mutagenesis with Pfu Turbo DNA polymerase (Stratagene), designated as pProT7-S(+)-NSD6-30, NSD31-55, NSD56-80, NSD81-105, NSD106-130, NSD131-155, NSD156-180, NSD181-205, NSD206-230 or NSD231-248, respectively.", [["NSD231-248", "CHEMICAL", 302, 312], ["pProT7-S(+)", "GENE_OR_GENE_PRODUCT", 90, 101], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["pProT7-S", "GENE_OR_GENE_PRODUCT", 188, 196], ["NSD31-55", "GENE_OR_GENE_PRODUCT", 209, 217], ["NSD231-248", "CELL", 302, 312], ["75 bp", "DNA", 19, 24], ["NSs open reading frame", "DNA", 58, 80], ["ORF", "DNA", 82, 85], ["pProT7", "DNA", 90, 96], ["S", "DNA", 97, 98], ["Pfu Turbo DNA polymerase", "DNA", 135, 159], ["NSD231-248", "DNA", 302, 312], ["Serial deletion", "TEST", 0, 15], ["bp", "TEST", 22, 24], ["pProT7", "TEST", 90, 96], ["NSD6", "TEST", 200, 204], ["NSD31", "TEST", 209, 214], ["NSD81", "TEST", 229, 234], ["NSD106", "TEST", 240, 246], ["NSD131", "TEST", 252, 258], ["NSD156", "TEST", 264, 270], ["NSD181", "TEST", 276, 282], ["NSD206", "TEST", 288, 294]]], ["For C-terminus mutant, the PCR fragment encoding NSs ORF with C-terminus 51 bp (17 aa.) deletion was amplified, and cloned between HpaI and SpeI of pProT7-S(+) [18] , designated as NSD249-265.", [["NSD249-265", "CHEMICAL", 181, 191], ["NSs", "GENE_OR_GENE_PRODUCT", 49, 52], ["HpaI", "GENE_OR_GENE_PRODUCT", 131, 135], ["SpeI", "GENE_OR_GENE_PRODUCT", 140, 144], ["pProT7", "GENE_OR_GENE_PRODUCT", 148, 154], ["NSD249-265", "SIMPLE_CHEMICAL", 181, 191], ["C-terminus mutant", "PROTEIN", 4, 21], ["PCR fragment", "DNA", 27, 39], ["NSs ORF", "DNA", 49, 56], ["C-terminus 51 bp (17 aa.) deletion", "DNA", 62, 96], ["HpaI", "DNA", 131, 135], ["pProT7", "DNA", 148, 154], ["NSD249-265", "DNA", 181, 191], ["C-terminus mutant", "PROBLEM", 4, 21], ["the PCR fragment", "PROBLEM", 23, 39], ["NSs ORF", "TEST", 49, 56], ["C", "TEST", 62, 63], ["bp", "TEST", 76, 78], ["deletion", "PROBLEM", 88, 96], ["HpaI", "TEST", 131, 135], ["pProT7", "TEST", 148, 154]]], ["The alanine substitutions of NSs-E253-255A/ D257-259A, NSs-E253-255A or NSsD257-259A were made onto pProT7-S(+) plasmid by site-directed mutagenesis with Pfu Ultra (Agilent Technologies), and designated as pProT7-NSs-E253-255A/D257-259A, NSs-E253-255A or NSsD257-259A, respectively.", [["alanine", "CHEMICAL", 4, 11], ["alanine", "CHEMICAL", 4, 11], ["alanine", "AMINO_ACID", 4, 11], ["NSs-E253-255A", "GENE_OR_GENE_PRODUCT", 55, 68], ["pProT7", "GENE_OR_GENE_PRODUCT", 206, 212], ["NSs-E253-255A", "GENE_OR_GENE_PRODUCT", 238, 251], ["NSsD257-259A", "GENE_OR_GENE_PRODUCT", 255, 267], ["NSs", "PROTEIN", 29, 32], ["E253-255A", "PROTEIN", 33, 42], ["D257", "PROTEIN", 44, 48], ["259A", "PROTEIN", 49, 53], ["NSs", "PROTEIN", 55, 58], ["E253-255A", "PROTEIN", 59, 68], ["NSsD257-259A", "DNA", 72, 84], ["pProT7-S(+) plasmid", "DNA", 100, 119], ["pProT7", "DNA", 206, 212], ["NSs", "DNA", 238, 241], ["E253-255A", "DNA", 242, 251], ["NSsD257", "DNA", 255, 262], ["The alanine substitutions of NSs", "TREATMENT", 0, 32], ["NSs", "TREATMENT", 55, 58], ["NSsD257", "TREATMENT", 72, 79], ["Pfu Ultra (Agilent Technologies", "TREATMENT", 154, 185], ["NSs", "TEST", 238, 241]]], ["NSs ORF of those NSs mutants were amplified by PCR with Phusion High Fidelity DNA polymerase (New England Biolab), and cloned into pcDNA3.1mycHisA (Invitrogen) between KpnI and XhoI, and designated as pcDNA3.1mycHisA-NSD6- were transfected with those plasmids as described previously [18] .Northern blot analysisTotal RNA was extracted from infected or mock-infected cells using TRIzol reagent.", [["plasmids", "ANATOMY", 251, 259], ["cells", "ANATOMY", 367, 372], ["NSs", "GENE_OR_GENE_PRODUCT", 17, 20], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 131, 137], ["mycHisA", "GENE_OR_GENE_PRODUCT", 139, 146], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 148, 158], ["KpnI", "GENE_OR_GENE_PRODUCT", 168, 172], ["XhoI", "GENE_OR_GENE_PRODUCT", 177, 181], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 201, 207], ["1mycHisA", "GENE_OR_GENE_PRODUCT", 208, 216], ["NSD6", "GENE_OR_GENE_PRODUCT", 217, 221], ["cells", "CELL", 367, 372], ["TRIzol", "ORGANISM", 379, 385], ["NSs ORF", "DNA", 0, 7], ["NSs mutants", "DNA", 17, 28], ["Phusion High Fidelity DNA polymerase", "PROTEIN", 56, 92], ["pcDNA3", "DNA", 131, 137], ["mycHisA", "DNA", 139, 146], ["KpnI", "DNA", 168, 172], ["XhoI", "DNA", 177, 181], ["pcDNA3", "DNA", 201, 207], ["1mycHisA", "PROTEIN", 208, 216], ["NSD6", "DNA", 217, 221], ["plasmids", "DNA", 251, 259], ["those NSs mutants", "TREATMENT", 11, 28], ["PCR", "TEST", 47, 50], ["Phusion", "TEST", 56, 63], ["High Fidelity DNA polymerase", "PROBLEM", 64, 92], ["KpnI and XhoI", "TREATMENT", 168, 181], ["those plasmids", "TREATMENT", 245, 259], ["Northern blot analysisTotal RNA", "PROBLEM", 290, 321], ["infected cells", "PROBLEM", 358, 372], ["TRIzol reagent", "TREATMENT", 379, 393], ["analysisTotal RNA", "OBSERVATION", 304, 321], ["infected", "OBSERVATION_MODIFIER", 341, 349], ["infected cells", "OBSERVATION", 358, 372]]], ["Denatured RNA was separated on 1% denaturing agarose-formaldehyde gels and transferred onto a nylon membrane (Roche Applied Science).", [["nylon membrane", "ANATOMY", 94, 108], ["agarose-formaldehyde", "CHEMICAL", 45, 65], ["formaldehyde", "CHEMICAL", 53, 65], ["agarose", "SIMPLE_CHEMICAL", 45, 52], ["Denatured RNA", "RNA", 0, 13], ["1% denaturing agarose-formaldehyde gels", "TREATMENT", 31, 70], ["a nylon membrane", "TREATMENT", 92, 108]]], ["Northern blot analysis was performed as described previously with strand-specific RNA probes to detect RVFV anti-sense S-segment/N mRNA, human IFN-b mRNA, or human ISG56 mRNA [66, 67] .Western blot analysisWestern blot analysis was performed as described previously [17] .", [["S-segment/N", "GENE_OR_GENE_PRODUCT", 119, 130], ["human", "ORGANISM", 137, 142], ["IFN-b", "GENE_OR_GENE_PRODUCT", 143, 148], ["human", "ORGANISM", 158, 163], ["ISG56", "GENE_OR_GENE_PRODUCT", 164, 169], ["RNA probes", "RNA", 82, 92], ["RVFV anti-sense S-segment/N mRNA", "RNA", 103, 135], ["human IFN-b mRNA", "RNA", 137, 153], ["human ISG56 mRNA", "RNA", 158, 174], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 158, 163], ["RVFV", "SPECIES", 103, 107], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 158, 163], ["Northern blot analysis", "TEST", 0, 22], ["blot analysis", "TEST", 214, 227]]], ["The membranes were incubated with anti-PKR monoclonalAnalysis of virus replicationA549 cells were infected with rMP12-NSs-Flag at an moi of 0.01, and mock-transfected or immediately transfected with in vitro synthesized RNA encoding CAT, NSD249-265 or NSs-E253-255A.", [["membranes", "ANATOMY", 4, 13], ["A549 cells", "ANATOMY", 82, 92], ["NSD249-265", "CHEMICAL", 238, 248], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["A549 cells", "CELL", 82, 92], ["rMP12", "GENE_OR_GENE_PRODUCT", 112, 117], ["Flag", "GENE_OR_GENE_PRODUCT", 122, 126], ["CAT", "GENE_OR_GENE_PRODUCT", 233, 236], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 238, 248], ["NSs-E253-255A", "GENE_OR_GENE_PRODUCT", 252, 265], ["anti-PKR monoclonal", "PROTEIN", 34, 53], ["A549 cells", "CELL_LINE", 82, 92], ["rMP12", "PROTEIN", 112, 117], ["NSs", "DNA", 118, 121], ["Flag", "PROTEIN", 122, 126], ["CAT", "PROTEIN", 233, 236], ["NSD249", "PROTEIN", 238, 244], ["NSs-E253-255A", "PROTEIN", 252, 265], ["anti-PKR", "TREATMENT", 34, 42], ["virus replicationA549 cells", "TREATMENT", 65, 92], ["rMP12", "TREATMENT", 112, 117], ["NSs", "TREATMENT", 118, 121]]], ["At 72 hpi, culture supernatants were collected, and plaque assay was performed as described previously [18, 80] .In vitro RNA synthesisThe pcDNA3.1mycHisA plasmids encoding CAT [17] , NSD6-30, NSD31-55, NSD56-80, NSD81-105, NSD106-130, NSD131-155, NSD156-180, NSD181-205, NSD206-230, NSD231-248, NSD249-265, NSs-E253-255A/D257-259A, NSs-E253-255A or NSsD257-259A were linearized, and in vitro transcribed by using mMESSAGE mMACHINE T7 Ultra kit (Ambion) according to manufacturer's instruction.", [["supernatants", "ANATOMY", 19, 31], ["plaque", "ANATOMY", 52, 58], ["pcDNA3.1mycHisA", "GENE_OR_GENE_PRODUCT", 139, 154], ["CAT [17]", "GENE_OR_GENE_PRODUCT", 173, 181], ["NSD6-30", "GENE_OR_GENE_PRODUCT", 184, 191], ["NSD31-55", "GENE_OR_GENE_PRODUCT", 193, 201], ["NSD56", "GENE_OR_GENE_PRODUCT", 203, 208], ["NSD106", "GENE_OR_GENE_PRODUCT", 224, 230], ["pcDNA3.1mycHisA plasmids", "DNA", 139, 163], ["CAT", "PROTEIN", 173, 176], ["NSD231-248, NSD249-265", "DNA", 284, 306], ["NSs-E253-255A/D257-259A", "DNA", 308, 331], ["NSs-E253-255A", "DNA", 333, 346], ["NSsD257-259A", "DNA", 350, 362], ["culture supernatants", "TEST", 11, 31], ["plaque assay", "TEST", 52, 64], ["vitro RNA synthesis", "TREATMENT", 116, 135], ["The pcDNA3.1mycHisA plasmids", "TREATMENT", 135, 163], ["NSD6", "TEST", 184, 188], ["NSD31", "TEST", 193, 198], ["NSD56", "TEST", 203, 208], ["NSD81", "TEST", 213, 218], ["NSD106", "TEST", 224, 230], ["NSD131", "TEST", 236, 242], ["NSD156", "TEST", 248, 254], ["NSD181", "TEST", 260, 266], ["NSD206", "TEST", 272, 278], ["NSD231", "TEST", 284, 290], ["NSD249", "TEST", 296, 302], ["NSs-", "TEST", 308, 312], ["NSs-E253-255A", "TEST", 333, 346], ["NSsD257", "TEST", 350, 357]]], ["The linearized CAT DNA contained myc-His tag at the 39end.TransfectionTransfection of in vitro synthesized RNA was performed by using TransIT-mRNA Transfection Kit (Mirus) according to manufacturer's instruction.", [["myc-His", "CHEMICAL", 33, 40], ["CAT", "GENE_OR_GENE_PRODUCT", 15, 18], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["myc", "GENE_OR_GENE_PRODUCT", 33, 36], ["Kit", "GENE_OR_GENE_PRODUCT", 160, 163], ["linearized CAT DNA", "DNA", 4, 22], ["myc-His tag", "DNA", 33, 44], ["39end", "DNA", 52, 57], ["TransIT", "PROTEIN", 134, 141], ["His tag", "TEST", 37, 44], ["TransfectionTransfection", "TREATMENT", 58, 82], ["vitro synthesized RNA", "TREATMENT", 89, 110]]], ["Co-expression of truncated NSs in RVFV-infected cells.", [["cells", "ANATOMY", 48, 53], ["RVFV-infected", "DISEASE", 34, 47], ["NSs", "GENE_OR_GENE_PRODUCT", 27, 30], ["RVFV", "ORGANISM", 34, 38], ["cells", "CELL", 48, 53], ["truncated NSs", "PROTEIN", 17, 30], ["RVFV-infected cells", "CELL_TYPE", 34, 53], ["RVFV", "SPECIES", 34, 38], ["truncated NSs", "PROBLEM", 17, 30], ["RVFV", "PROBLEM", 34, 38], ["infected cells", "PROBLEM", 39, 53], ["truncated NSs", "OBSERVATION", 17, 30], ["RVFV", "OBSERVATION", 34, 38], ["infected cells", "OBSERVATION", 39, 53]]], ["293 cells were mock-infected or infected with rMP12-NSs-Flag at an moi of 3, and mock-transfected or immediately transfected with in vitro transcribed RNA encoding CAT (control) or NSs with indicated NSs mutants.", [["293 cells", "ANATOMY", 0, 9], ["293 cells", "CELL", 0, 9], ["rMP12", "GENE_OR_GENE_PRODUCT", 46, 51], ["Flag", "GENE_OR_GENE_PRODUCT", 56, 60], ["CAT", "GENE_OR_GENE_PRODUCT", 164, 167], ["NSs", "GENE_OR_GENE_PRODUCT", 181, 184], ["NSs", "GENE_OR_GENE_PRODUCT", 200, 203], ["293 cells", "CELL_LINE", 0, 9], ["rMP12", "PROTEIN", 46, 51], ["NSs", "DNA", 52, 55], ["Flag", "PROTEIN", 56, 60], ["CAT", "PROTEIN", 164, 167], ["NSs", "PROTEIN", 181, 184], ["NSs mutants", "PROTEIN", 200, 211], ["rMP12", "TREATMENT", 46, 51], ["NSs", "TREATMENT", 52, 55], ["Flag", "TREATMENT", 56, 60], ["NSs", "TREATMENT", 181, 184], ["NSs mutants", "TREATMENT", 200, 211]]], ["Cells were collected at 16 hpi, and NSs-Flag/NSs (a-RVFV antibody), NSs-Flag (a-Flag antibody), PKR (anti-PKR antibody), CAT-myc (anti-myc antibody) and b-actin (anti-actin antibody) were detected by Western blot.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Flag", "GENE_OR_GENE_PRODUCT", 40, 44], ["NSs", "GENE_OR_GENE_PRODUCT", 45, 48], ["a-RVFV antibody", "GENE_OR_GENE_PRODUCT", 50, 65], ["NSs-Flag", "GENE_OR_GENE_PRODUCT", 68, 76], ["a-Flag antibody", "GENE_OR_GENE_PRODUCT", 78, 93], ["PKR", "GENE_OR_GENE_PRODUCT", 96, 99], ["anti-PKR antibody", "GENE_OR_GENE_PRODUCT", 101, 118], ["CAT-myc", "GENE_OR_GENE_PRODUCT", 121, 128], ["anti-myc antibody", "GENE_OR_GENE_PRODUCT", 130, 147], ["b-actin", "GENE_OR_GENE_PRODUCT", 153, 160], ["anti-actin", "GENE_OR_GENE_PRODUCT", 162, 172], ["NSs", "PROTEIN", 36, 39], ["Flag", "PROTEIN", 40, 44], ["NSs", "PROTEIN", 45, 48], ["a-RVFV antibody", "PROTEIN", 50, 65], ["NSs", "PROTEIN", 68, 71], ["Flag", "PROTEIN", 72, 76], ["a-Flag antibody", "PROTEIN", 78, 93], ["PKR", "PROTEIN", 96, 99], ["PKR antibody", "PROTEIN", 106, 118], ["CAT", "PROTEIN", 121, 124], ["myc", "PROTEIN", 125, 128], ["anti", "PROTEIN", 130, 134], ["myc antibody", "PROTEIN", 135, 147], ["b-actin", "PROTEIN", 153, 160], ["anti-actin antibody", "PROTEIN", 162, 181], ["Cells", "TEST", 0, 5], ["NSs", "TEST", 36, 39], ["Flag", "TEST", 40, 44], ["NSs", "TEST", 45, 48], ["a-RVFV antibody", "TEST", 50, 65], ["NSs", "TEST", 68, 71], ["Flag (a-Flag antibody", "TEST", 72, 93], ["PKR", "TEST", 96, 99], ["anti-PKR antibody", "TEST", 101, 118], ["CAT", "TEST", 121, 124], ["myc", "TEST", 125, 128], ["anti", "TEST", 130, 134], ["myc antibody", "TEST", 135, 147], ["b-actin", "TEST", 153, 160], ["anti-actin antibody", "TEST", 162, 181]]], ["(B) A549 cells were mock-infected or infected with rMP12-NSs-Flag at an moi of 3, and mock-transfected or immediately transfected with in vitro transcribed RNA encoding CAT or NSs with indicated NSs mutants.", [["A549 cells", "ANATOMY", 4, 14], ["B) A549 cells", "CELL", 1, 14], ["rMP12", "GENE_OR_GENE_PRODUCT", 51, 56], ["Flag", "GENE_OR_GENE_PRODUCT", 61, 65], ["CAT", "GENE_OR_GENE_PRODUCT", 169, 172], ["NSs", "GENE_OR_GENE_PRODUCT", 176, 179], ["NSs", "GENE_OR_GENE_PRODUCT", 195, 198], ["A549 cells", "CELL_LINE", 4, 14], ["rMP12", "PROTEIN", 51, 56], ["NSs", "PROTEIN", 57, 60], ["Flag", "PROTEIN", 61, 65], ["CAT", "PROTEIN", 169, 172], ["NSs", "PROTEIN", 176, 179], ["NSs mutants", "PROTEIN", 195, 206], ["infected", "PROBLEM", 37, 45], ["rMP12", "TREATMENT", 51, 56], ["NSs", "TREATMENT", 57, 60], ["NSs", "TREATMENT", 176, 179], ["NSs mutants", "TREATMENT", 195, 206]]], ["As a control to induce IFN-b and ISG56 mRNA synthesis, A549 cells were infected with rMP12-C13type (C13type) at an moi of 3.", [["A549 cells", "ANATOMY", 55, 65], ["IFN-b", "GENE_OR_GENE_PRODUCT", 23, 28], ["ISG56", "GENE_OR_GENE_PRODUCT", 33, 38], ["A549 cells", "CELL", 55, 65], ["rMP12-C13type", "GENE_OR_GENE_PRODUCT", 85, 98], ["IFN", "PROTEIN", 23, 26], ["ISG56 mRNA", "RNA", 33, 43], ["A549 cells", "CELL_LINE", 55, 65], ["rMP12", "PROTEIN", 85, 90], ["C13type", "PROTEIN", 91, 98], ["C13type", "DNA", 100, 107], ["IFN", "TEST", 23, 26], ["ISG56 mRNA synthesis", "TREATMENT", 33, 53], ["A549 cells", "PROBLEM", 55, 65], ["A549 cells", "OBSERVATION", 55, 65]]], ["Total RNA was extracted at 7 hpi, and IFN-b mRNA, ISG56 mRNA and RVFV anti-viral-sense S-RNA/N mRNA were detected by Northern blot with specific RNA probe.", [["IFN-b", "GENE_OR_GENE_PRODUCT", 38, 43], ["ISG56", "GENE_OR_GENE_PRODUCT", 50, 55], ["RVFV", "ORGANISM", 65, 69], ["IFN-b mRNA", "RNA", 38, 48], ["ISG56 mRNA", "RNA", 50, 60], ["RVFV anti-viral-sense S-RNA", "RNA", 65, 92], ["N mRNA", "RNA", 93, 99], ["RVFV", "SPECIES", 65, 69], ["Total RNA", "PROBLEM", 0, 9], ["IFN", "TEST", 38, 41], ["mRNA", "TEST", 56, 60], ["RVFV anti-viral", "TREATMENT", 65, 80], ["RNA/N mRNA", "TREATMENT", 89, 99]]], ["Representative data from at least 3 independent experiments are shown.", [["Representative data", "TEST", 0, 19]]], ["(C) A549 cells were infected with MP-12 at moi of 0.01, and mock-transfected or immediately transfected with in vitro transcribed RNA encoding CAT or NSs of NSD249-265 or NSs-E253-255A.", [["A549 cells", "ANATOMY", 4, 14], ["MP-12", "CHEMICAL", 34, 39], ["NSD249-265", "CHEMICAL", 157, 167], ["A549 cells", "CELL", 4, 14], ["CAT", "GENE_OR_GENE_PRODUCT", 143, 146], ["NSD249-265", "GENE_OR_GENE_PRODUCT", 157, 167], ["NSs-E253-255A", "GENE_OR_GENE_PRODUCT", 171, 184], ["(C) A549 cells", "CELL_LINE", 0, 14], ["CAT", "PROTEIN", 143, 146], ["NSs", "PROTEIN", 150, 153], ["NSD249", "PROTEIN", 157, 163], ["NSs-E253-255A", "PROTEIN", 171, 184], ["A549 cells", "PROBLEM", 4, 14], ["MP", "TEST", 34, 36], ["NSs of NSD249", "TREATMENT", 150, 163]]], ["Culture supernatants were harvested at 72 hpi, and virus titers were measured by plaque assay.", [["supernatants", "ANATOMY", 8, 20], ["plaque", "ANATOMY", 81, 87], ["Culture supernatants", "TEST", 0, 20], ["virus titers", "TEST", 51, 63], ["plaque", "OBSERVATION", 81, 87]]], ["P-values of unpaired Student's t-test are shown (*; p,0.05, ns; not significant). doi:10.1371/journal.pone.0045730.g008Separation of nuclear and cytoplasmic fractionsVeroE6 cells were mock-infected or infected with MP-12 or recombinant MP-12 encoding partially truncated NSs at an moi of 4 in 6-well plate.", [["nuclear", "ANATOMY", 133, 140], ["cytoplasmic fractionsVeroE6 cells", "ANATOMY", 145, 178], ["nuclear", "CELLULAR_COMPONENT", 133, 140], ["cytoplasmic", "ORGANISM_SUBSTANCE", 145, 156], ["VeroE6 cells", "CELL", 166, 178], ["MP-12", "GENE_OR_GENE_PRODUCT", 215, 220], ["MP-12", "GENE_OR_GENE_PRODUCT", 236, 241], ["VeroE6 cells", "CELL_LINE", 166, 178], ["recombinant MP-12 encoding partially truncated NSs", "PROTEIN", 224, 274], ["unpaired Student's t-test", "TEST", 12, 37], ["p,", "TEST", 52, 54], ["ns", "TREATMENT", 60, 62], ["MP", "TEST", 215, 217], ["recombinant MP", "TEST", 224, 238], ["encoding partially truncated NSs", "PROBLEM", 242, 274], ["cytoplasmic fractions", "OBSERVATION", 145, 166]]], ["At 16 hpi, cells were collected, and washed once in PBS.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16]]], ["Then, cytoplasmic fraction was lyzed with PBS containing 1% TritonX-100 on ice for 5 min.", [["cytoplasmic", "ANATOMY", 6, 17], ["TritonX-100", "CHEMICAL", 60, 71], ["cytoplasmic", "ORGANISM_SUBSTANCE", 6, 17], ["TritonX-100", "SIMPLE_CHEMICAL", 60, 71], ["cytoplasmic fraction", "TEST", 6, 26], ["PBS", "TREATMENT", 42, 45], ["cytoplasmic fraction", "OBSERVATION", 6, 26]]], ["After centrifugation at 10,000 xg at 4 u C for 5 min, nuclear fraction was washed once with cold PBS, and resuspended in PBS containing 1% TritonX-100.", [["nuclear", "ANATOMY", 54, 61], ["TritonX-100", "CHEMICAL", 139, 150], ["TritonX-100", "SIMPLE_CHEMICAL", 139, 150], ["centrifugation", "TREATMENT", 6, 20], ["nuclear fraction", "TEST", 54, 70], ["cold PBS", "TREATMENT", 92, 100], ["PBS", "TREATMENT", 121, 124]]], ["Both cytoplasmic and nuclear fractions were mixed with 26 SDS sample buffer, and subjected to SDS-PAGE and Western blot analysis.Separation of nuclear and cytoplasmic fractionsCo-affinity precipitation SF (Strep-Flag)-tagged protein was precipitated with Strep-Tactin magnetic beads (Qiagen).", [["cytoplasmic", "ANATOMY", 5, 16], ["nuclear fractions", "ANATOMY", 21, 38], ["nuclear", "ANATOMY", 143, 150], ["cytoplasmic fractions", "ANATOMY", 155, 176], ["cytoplasmic", "ORGANISM_SUBSTANCE", 5, 16], ["nuclear", "CELLULAR_COMPONENT", 21, 28], ["nuclear", "CELLULAR_COMPONENT", 143, 150], ["cytoplasmic", "ORGANISM_SUBSTANCE", 155, 166], ["Co-affinity precipitation SF (Strep-Flag)-tagged protein", "PROTEIN", 176, 232], ["blot analysis", "TEST", 115, 128], ["nuclear and cytoplasmic fractions", "PROBLEM", 143, 176], ["Co-affinity precipitation SF", "PROBLEM", 176, 204], ["tagged protein", "PROBLEM", 218, 232], ["Strep-Tactin magnetic beads", "TREATMENT", 255, 282], ["cytoplasmic", "OBSERVATION_MODIFIER", 5, 16], ["nuclear fractions", "OBSERVATION", 21, 38], ["cytoplasmic fractions", "OBSERVATION", 155, 176]]], ["293 cells were first infected with rMP-12 tagged with SF-tag (moi 3) and were then transfected with in vitro synthesized capped RNA (encoding NSD6-30, NSD31-55, NSD56-80, NSD81-105, NSD106-130, NSD131-155, NSD156-180, NSD181-205, NSD206-230, NSD231-248, or NSD249-265).", [["293 cells", "ANATOMY", 0, 9], ["NSD156-180, NSD181-205, NSD206-230, NSD231-248", "CHEMICAL", 206, 252], ["NSD249-265", "CHEMICAL", 257, 267], ["293 cells", "CELL", 0, 9], ["SF-tag", "GENE_OR_GENE_PRODUCT", 54, 60], ["NSD6-30", "GENE_OR_GENE_PRODUCT", 142, 149], ["NSD31-55", "GENE_OR_GENE_PRODUCT", 151, 159], ["NSD56-80", "GENE_OR_GENE_PRODUCT", 161, 169], ["293 cells", "CELL_LINE", 0, 9], ["rMP-12", "DNA", 35, 41], ["SF-tag", "DNA", 54, 60], ["NSD6", "PROTEIN", 142, 146], ["NSD31", "PROTEIN", 151, 156], ["NSD56", "PROTEIN", 161, 166], ["NSD249-265", "DNA", 257, 267], ["rMP", "TEST", 35, 38], ["NSD6", "TEST", 142, 146], ["NSD31", "TEST", 151, 156], ["NSD56", "TEST", 161, 166], ["NSD81", "TEST", 171, 176], ["NSD106", "TEST", 182, 188], ["NSD131", "TEST", 194, 200], ["NSD156", "TEST", 206, 212], ["NSD181", "TEST", 218, 224], ["NSD206", "TEST", 230, 236], ["NSD231", "TEST", 242, 248], ["NSD249", "TEST", 257, 263]]], ["After incubation for 6 hours, newly synthesized proteins were then labeled with [ 35 S] methionine/cysteine (MP Biomedicals).", [["[ 35 S] methionine/cysteine", "CHEMICAL", 80, 107], ["[ 35 S] methionine", "CHEMICAL", 80, 98], ["cysteine", "CHEMICAL", 99, 107], ["[ 35 S] methionine/cysteine", "SIMPLE_CHEMICAL", 80, 107], ["newly synthesized proteins", "PROBLEM", 30, 56], ["methionine/cysteine (MP Biomedicals", "TREATMENT", 88, 123]]], ["Using cell lysates, SF-tagged proteins were precipitated with Strep-Tactin beads according to manufacturer's instructions.", [["cell lysates", "ANATOMY", 6, 18], ["cell lysates", "ORGANISM_SUBSTANCE", 6, 18], ["SF-tagged proteins", "PROTEIN", 20, 38], ["cell lysates", "TEST", 6, 18], ["SF-tagged proteins", "TEST", 20, 38], ["Strep-Tactin beads", "TREATMENT", 62, 80]]], ["Then, co-precipitated proteins were analyzed by separating on 10% SDS-PAGE gel and followed by autoradiography.Statistical analysisUnpaired Student's t-test was performed by using the Graphpad Prism 5.03 program (Graphpad Software Inc.) for the comparison of two groups,Ethics statementAll the recombinant DNA and RVFV were created upon the approval of the Notification of Use by the Institutional Biosafety Committee at UTMB.", [["DNA", "CELLULAR_COMPONENT", 306, 309], ["RVFV", "ORGANISM", 314, 318], ["co-precipitated proteins", "PROTEIN", 6, 30], ["recombinant DNA", "DNA", 294, 309], ["RVFV", "SPECIES", 314, 318], ["co-precipitated proteins", "PROBLEM", 6, 30], ["Student's t-test", "TEST", 140, 156], ["RVFV", "PROBLEM", 314, 318]]], ["Figure S1 Plaque phenotypes of MP-12 encoding NSs mutants.", [["MP-12", "GENE_OR_GENE_PRODUCT", 31, 36], ["NSs", "GENE_OR_GENE_PRODUCT", 46, 49], ["MP", "PROTEIN", 31, 33], ["NSs mutants", "PROTEIN", 46, 57], ["Figure S1 Plaque phenotypes", "PROBLEM", 0, 27], ["MP", "TEST", 31, 33], ["Plaque", "OBSERVATION", 10, 16]]], ["VeroE6 cells were infected with indicated virus as 10-fold dilution, and overlaid with 0.6% noble agar containing 5% FBS and 5% Tryptose phosphate broth in MEM as described previously [80] .", [["VeroE6 cells", "ANATOMY", 0, 12], ["FBS", "ANATOMY", 117, 120], ["Tryptose phosphate", "CHEMICAL", 128, 146], ["MEM", "CHEMICAL", 156, 159], ["Tryptose phosphate", "CHEMICAL", 128, 146], ["VeroE6 cells", "CELL", 0, 12], ["FBS", "ORGANISM_SUBSTANCE", 117, 120], ["Tryptose", "SIMPLE_CHEMICAL", 128, 136], ["VeroE6 cells", "CELL_LINE", 0, 12], ["VeroE6 cells", "PROBLEM", 0, 12], ["virus", "PROBLEM", 42, 47], ["0.6% noble agar", "TREATMENT", 87, 102], ["5% FBS", "TREATMENT", 114, 120], ["5% Tryptose phosphate broth", "TREATMENT", 125, 152]]], ["Second overlay of agar containing 0.011% of neutral red was performed at 3 dpi.", [["agar", "TEST", 18, 22]]], ["Plaques at 4 dpi are shown.", [["Plaques", "ANATOMY", 0, 7], ["Plaques", "DISEASE", 0, 7], ["Plaques", "PROBLEM", 0, 7], ["4 dpi", "OBSERVATION_MODIFIER", 11, 16]]], ["(TIF) Figure S2 Titer of MP-12 NSs mutants in MRC-5 cells.", [["MRC-5 cells", "ANATOMY", 46, 57], ["MP-12 NSs", "GENE_OR_GENE_PRODUCT", 25, 34], ["MRC-5 cells", "CELL", 46, 57], ["MP", "PROTEIN", 25, 27], ["MRC-5 cells", "CELL_LINE", 46, 57], ["Figure S2 Titer", "TEST", 6, 21], ["MP", "TEST", 25, 27], ["NSs mutants in MRC", "TEST", 31, 49]]], ["Human lung diploid MRC-5 cells were infected with MP-12, rMP12-C13type (C13type) or NSs mutants encoding indicated truncations at an moi of 0.01.", [["lung", "ANATOMY", 6, 10], ["MRC-5 cells", "ANATOMY", 19, 30], ["Human", "ORGANISM", 0, 5], ["lung diploid MRC-5 cells", "CELL", 6, 30], ["MP-12", "GENE_OR_GENE_PRODUCT", 50, 55], ["rMP12-C13type", "GENE_OR_GENE_PRODUCT", 57, 70], ["C13type", "GENE_OR_GENE_PRODUCT", 72, 79], ["NSs", "GENE_OR_GENE_PRODUCT", 84, 87], ["Human lung diploid MRC-5 cells", "CELL_LINE", 0, 30], ["rMP12", "PROTEIN", 57, 62], ["C13type", "DNA", 63, 70], ["C13type", "DNA", 72, 79], ["NSs mutants", "DNA", 84, 95], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human lung diploid MRC", "TEST", 0, 22], ["MP", "TEST", 50, 52], ["rMP12", "TEST", 57, 62], ["NSs mutants", "PROBLEM", 84, 95], ["an moi", "TEST", 130, 136], ["lung", "ANATOMY", 6, 10]]], ["At 72 hpi, culture supernatants were collected, and virus titers were measured by plaque assay using VeroE6 cells.", [["supernatants", "ANATOMY", 19, 31], ["plaque", "ANATOMY", 82, 88], ["VeroE6 cells", "ANATOMY", 101, 113], ["VeroE6 cells", "CELL", 101, 113], ["VeroE6 cells", "CELL_LINE", 101, 113], ["culture supernatants", "TEST", 11, 31], ["virus titers", "TEST", 52, 64], ["VeroE6 cells", "TREATMENT", 101, 113]]], ["Means and standard deviations of 3 independent experiments are shown. **p,0.01, Student's unpaired t-test compared to MP-12.", [["Student's unpaired t-test", "TEST", 80, 105], ["MP", "TEST", 118, 120]]], ["(TIF) Figure S3 Co-infection of MP-12 and MP-12 encoding truncated NSs.", [["MP-12", "GENE_OR_GENE_PRODUCT", 32, 37], ["MP-12", "GENE_OR_GENE_PRODUCT", 42, 47], ["NSs", "GENE_OR_GENE_PRODUCT", 67, 70], ["MP", "PROTEIN", 32, 34], ["MP", "PROTEIN", 42, 44], ["truncated NSs", "PROTEIN", 57, 70], ["MP", "TEST", 32, 34], ["MP", "TEST", 42, 44]]], ["VeroE6 cells were mock-infected or infected with a mixture of MP-12 (an moi of 3) and either of rMP12-C13type (C13type) or indicated NSs truncation mutants (an moi of 3).", [["VeroE6 cells", "ANATOMY", 0, 12], ["VeroE6 cells", "CELL", 0, 12], ["MP-12", "GENE_OR_GENE_PRODUCT", 62, 67], ["rMP12-C13type", "GENE_OR_GENE_PRODUCT", 96, 109], ["C13type", "GENE_OR_GENE_PRODUCT", 111, 118], ["VeroE6 cells", "CELL_LINE", 0, 12], ["rMP12", "PROTEIN", 96, 101], ["C13type", "PROTEIN", 102, 109], ["C13type", "PROTEIN", 111, 118], ["NSs truncation mutants", "PROTEIN", 133, 155], ["VeroE6 cells", "PROBLEM", 0, 12], ["MP", "TEST", 62, 64], ["rMP12", "TEST", 96, 101], ["NSs truncation mutants", "PROBLEM", 133, 155]]], ["Cells were collected at 16 hpi, and PKR (anti-PKR antibody), NSs and N (anti-RVFV antibody) and b-actin (anti-actin antibody) were detected by Western blot.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["PKR", "GENE_OR_GENE_PRODUCT", 36, 39], ["anti-PKR antibody", "GENE_OR_GENE_PRODUCT", 41, 58], ["NSs", "GENE_OR_GENE_PRODUCT", 61, 64], ["anti-RVFV antibody", "GENE_OR_GENE_PRODUCT", 72, 90], ["b-actin", "GENE_OR_GENE_PRODUCT", 96, 103], ["anti-actin", "GENE_OR_GENE_PRODUCT", 105, 115], ["PKR", "PROTEIN", 36, 39], ["PKR antibody", "PROTEIN", 46, 58], ["NSs", "PROTEIN", 61, 64], ["N", "PROTEIN", 69, 70], ["RVFV antibody", "PROTEIN", 77, 90], ["b-actin", "PROTEIN", 96, 103], ["anti-actin antibody", "PROTEIN", 105, 124], ["RVFV", "SPECIES", 77, 81], ["Cells", "TEST", 0, 5], ["PKR", "TEST", 36, 39], ["anti-PKR antibody", "TEST", 41, 58], ["NSs", "TEST", 61, 64], ["N (anti-RVFV antibody", "TEST", 69, 90], ["b-actin (anti-actin antibody", "TEST", 96, 124]]]], "PMC7387922": [["IntroductionThe recent outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Wuhan, China, in December 2019, has infected over 69,16,233 and death of over 4,00,135 (Dated June, 7, 2020) worldwide since its outbreak.", [["acute respiratory syndrome coronavirus", "DISEASE", 42, 80], ["death", "DISEASE", 163, 168], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 35, 80], ["SARS-CoV-2", "ORGANISM", 84, 94], ["severe acute respiratory syndrome coronavirus", "SPECIES", 35, 80], ["SARS-CoV-2", "SPECIES", 84, 94], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 35, 80], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory syndrome coronavirus", "OBSERVATION", 48, 80]]], ["The number of cases is increasing every hour, and due to this reason, the World Health Organization (WHO) has declared it as a global public health emergency.IntroductionThe SARS-CoV-2 is a positive-stranded RNA virus with a genome size of 29.9 kb encoding 12 open reading frames (ORFs) and two untranslated regions of 254 and 229 bp at 5\u2032 and 3\u2032 ends, respectively [1].", [["SARS-CoV-2", "ORGANISM", 174, 184], ["SARS-CoV-2", "DNA", 174, 184], ["open reading frames", "DNA", 260, 279], ["ORFs", "DNA", 281, 285], ["untranslated regions", "DNA", 295, 315], ["5\u2032 and 3\u2032 ends", "DNA", 337, 351], ["SARS-CoV", "SPECIES", 174, 182], ["The SARS-CoV", "TEST", 170, 182], ["a positive-stranded RNA virus", "PROBLEM", 188, 217], ["a genome size", "TEST", 223, 236], ["ORFs", "TEST", 281, 285], ["bp", "TEST", 331, 333], ["increasing", "OBSERVATION_MODIFIER", 23, 33], ["stranded RNA virus", "OBSERVATION", 199, 217], ["size", "OBSERVATION_MODIFIER", 232, 236], ["29.9 kb", "OBSERVATION_MODIFIER", 240, 247]]], ["The molecular organization of the coronavirus genome in 5\u2032 \u2192 3\u2032 direction encodes several proteins.", [["coronavirus", "ORGANISM", 34, 45], ["coronavirus genome", "DNA", 34, 52], ["the coronavirus genome", "PROBLEM", 30, 52], ["coronavirus genome", "OBSERVATION", 34, 52]]], ["The genome includes non-structural and structural proteins.", [["non-structural and structural proteins", "PROTEIN", 20, 58], ["non-structural and structural proteins", "PROBLEM", 20, 58], ["genome", "OBSERVATION", 4, 10], ["structural proteins", "OBSERVATION", 39, 58]]], ["The structural proteins include spike (S), envelope (E), matrix (M), and nucleocapsid (N) proteins [1].", [["spike (S)", "GENE_OR_GENE_PRODUCT", 32, 41], ["matrix", "CELLULAR_COMPONENT", 57, 63], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 73, 98], ["structural proteins", "PROTEIN", 4, 23], ["spike (S), envelope (E), matrix (M)", "PROTEIN", 32, 67], ["nucleocapsid (N) proteins", "PROTEIN", 73, 98], ["The structural proteins", "TEST", 0, 23], ["spike", "PROBLEM", 32, 37], ["envelope (E), matrix (M), and nucleocapsid (N) proteins", "TEST", 43, 98]]], ["The ~66% of the genome at the 5\u2032end contains two overlapping ORFs (ORF1a and ORF1b) encoding polyproteins 1a (PP1a) and 1ab (PP1ab).", [["genome", "CELLULAR_COMPONENT", 16, 22], ["ORF1a", "GENE_OR_GENE_PRODUCT", 67, 72], ["ORF1b", "GENE_OR_GENE_PRODUCT", 77, 82], ["polyproteins 1a", "GENE_OR_GENE_PRODUCT", 93, 108], ["PP1a", "GENE_OR_GENE_PRODUCT", 110, 114], ["1ab", "GENE_OR_GENE_PRODUCT", 120, 123], ["PP1ab", "GENE_OR_GENE_PRODUCT", 125, 130], ["5\u2032end", "DNA", 30, 35], ["ORFs", "DNA", 61, 65], ["ORF1a", "DNA", 67, 72], ["ORF1b", "DNA", 77, 82], ["polyproteins 1a", "PROTEIN", 93, 108], ["PP1a", "PROTEIN", 110, 114], ["1ab", "DNA", 120, 123], ["PP1ab", "DNA", 125, 130], ["two overlapping ORFs", "PROBLEM", 45, 65], ["ORF1a", "TEST", 67, 72], ["encoding polyproteins", "TREATMENT", 84, 105], ["PP1a", "TEST", 110, 114], ["overlapping ORFs", "OBSERVATION", 49, 65]]], ["These polyproteins are processed into 16 functional non-structural proteins by papain-like protease and 3C-like protease, which form the replication transcription complex (RTC).", [["papain-like protease", "GENE_OR_GENE_PRODUCT", 79, 99], ["3C", "GENE_OR_GENE_PRODUCT", 104, 106], ["16 functional non-structural proteins", "PROTEIN", 38, 75], ["papain-like protease and 3C-like protease", "PROTEIN", 79, 120], ["replication transcription complex", "PROTEIN", 137, 170], ["RTC", "PROTEIN", 172, 175], ["These polyproteins", "PROBLEM", 0, 18], ["papain", "TREATMENT", 79, 85], ["protease", "TREATMENT", 91, 99], ["3C-like protease", "TREATMENT", 104, 120], ["the replication transcription complex", "TREATMENT", 133, 170], ["polyproteins", "OBSERVATION", 6, 18], ["16 functional", "OBSERVATION_MODIFIER", 38, 51], ["non-structural proteins", "OBSERVATION", 52, 75]]], ["These non-structural proteins include proteases and RNA processing enzymes [[2], [3], [4]].", [["[3], [4]", "SIMPLE_CHEMICAL", 81, 89], ["non-structural proteins", "PROTEIN", 6, 29], ["proteases", "PROTEIN", 38, 47], ["RNA processing enzymes", "PROTEIN", 52, 74], ["proteases", "TEST", 38, 47], ["RNA processing enzymes", "TEST", 52, 74]]], ["These RNA processing enzymes are uncommon and include exoribonuclease, guanine N7-methyltransferase (N7-MTase), and 2\u2032O-methyltransferase.", [["guanine", "CHEMICAL", 71, 78], ["guanine", "CHEMICAL", 71, 78], ["guanine N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 71, 99], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 101, 109], ["2\u2032O-methyltransferase", "GENE_OR_GENE_PRODUCT", 116, 137], ["RNA processing enzymes", "PROTEIN", 6, 28], ["exoribonuclease", "PROTEIN", 54, 69], ["guanine N7-methyltransferase", "PROTEIN", 71, 99], ["N7", "PROTEIN", 101, 103], ["MTase", "PROTEIN", 104, 109], ["2\u2032O", "PROTEIN", 116, 119], ["methyltransferase", "PROTEIN", 120, 137], ["These RNA processing enzymes", "TEST", 0, 28], ["exoribonuclease", "TEST", 54, 69], ["guanine N7-methyltransferase (N7-MTase)", "TREATMENT", 71, 110]]], ["Approximately, 33% of the genome at 3\u2032 end encodes four major structural proteins S, E, M, and N. These structural proteins play a crucial role in the formation of the new virus particle and its release [5].IntroductionMost viral and eukaryotic cellular mRNA containing polyadenine region at 3\u2032 terminal and a 5\u2032terminal cap structure of N7-methyl-guanine moiety connected through 5\u2032-5\u2032 triphosphate bridge to the first transcribed nucleotide [6,7].", [["cellular", "ANATOMY", 245, 253], ["N7-methyl-guanine", "CHEMICAL", 338, 355], ["5\u2032-5\u2032 triphosphate", "CHEMICAL", 381, 399], ["nucleotide", "CHEMICAL", 432, 442], ["polyadenine", "CHEMICAL", 270, 281], ["N7-methyl-guanine", "CHEMICAL", 338, 355], ["5\u2032-5\u2032 triphosphate", "CHEMICAL", 381, 399], ["nucleotide", "CHEMICAL", 432, 442], ["genome", "CELLULAR_COMPONENT", 26, 32], ["cellular", "CELL", 245, 253], ["3\u2032 terminal", "CELLULAR_COMPONENT", 292, 303], ["N7-methyl-guanine moiety", "SIMPLE_CHEMICAL", 338, 362], ["5\u2032-5\u2032 triphosphate", "SIMPLE_CHEMICAL", 381, 399], ["3\u2032 end", "DNA", 36, 42], ["major structural proteins S, E, M, and N.", "PROTEIN", 56, 97], ["structural proteins", "PROTEIN", 104, 123], ["viral and eukaryotic cellular mRNA", "RNA", 224, 258], ["polyadenine region", "PROTEIN", 270, 288], ["5\u2032-5\u2032 triphosphate bridge", "PROTEIN", 381, 406], ["the new virus particle", "TREATMENT", 164, 186], ["Most viral and eukaryotic cellular mRNA containing polyadenine region", "PROBLEM", 219, 288], ["a 5\u2032terminal cap structure", "TREATMENT", 308, 334], ["N7-methyl-guanine moiety", "TREATMENT", 338, 362], ["triphosphate bridge", "TREATMENT", 387, 406], ["eukaryotic cellular mRNA", "OBSERVATION", 234, 258]]], ["The 5\u2032 terminal cap structure of mRNA plays a key role in protecting its degradation by 5\u2032-exonuclease and efficient translation.", [["5\u2032-exonuclease", "GENE_OR_GENE_PRODUCT", 88, 102], ["5\u2032 terminal cap structure", "RNA", 4, 29], ["mRNA", "RNA", 33, 37], ["5\u2032", "PROTEIN", 88, 90], ["exonuclease", "PROTEIN", 91, 102], ["The 5\u2032 terminal cap structure", "TREATMENT", 0, 29], ["terminal", "OBSERVATION_MODIFIER", 7, 15], ["cap", "OBSERVATION_MODIFIER", 16, 19]]], ["The capping of mRNA (Cap0) is catalyzed by RNA triphosphatase, a guanylyltransferase and guanine-N7-methyltransferase (N7-MTase) in a sequential reaction.", [["guanine", "CHEMICAL", 89, 96], ["guanine", "CHEMICAL", 89, 96], ["N7", "CHEMICAL", 97, 99], ["Cap0", "GENE_OR_GENE_PRODUCT", 21, 25], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 65, 84], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 119, 127], ["mRNA", "RNA", 15, 19], ["Cap0", "PROTEIN", 21, 25], ["RNA triphosphatase", "PROTEIN", 43, 61], ["guanylyltransferase and guanine-N7-methyltransferase", "PROTEIN", 65, 117], ["N7", "PROTEIN", 119, 121], ["MTase", "PROTEIN", 122, 127], ["The capping of mRNA (Cap0)", "TREATMENT", 0, 26], ["a guanylyltransferase", "TREATMENT", 63, 84], ["guanine-N7-methyltransferase (N7-MTase)", "TREATMENT", 89, 128], ["a sequential reaction", "PROBLEM", 132, 153]]], ["The capping of most viruses and eukaryotic mRNA is further methylated at the 2-OH position of the first nucleotide by ribose 2\u2032-O-methyltransferase (2\u2032-O-MTase) enzyme to form the cap1 structure.", [["nucleotide", "CHEMICAL", 104, 114], ["ribose", "CHEMICAL", 118, 124], ["2-OH", "CHEMICAL", 77, 81], ["nucleotide", "CHEMICAL", 104, 114], ["ribose", "CHEMICAL", 118, 124], ["O", "CHEMICAL", 128, 129], ["ribose 2\u2032-O-methyltransferase", "GENE_OR_GENE_PRODUCT", 118, 147], ["2\u2032-O-MTase", "GENE_OR_GENE_PRODUCT", 149, 159], ["cap1", "GENE_OR_GENE_PRODUCT", 180, 184], ["eukaryotic mRNA", "RNA", 32, 47], ["ribose 2\u2032-O-methyltransferase (2\u2032-O-MTase) enzyme", "PROTEIN", 118, 167], ["cap1 structure", "PROTEIN", 180, 194], ["The capping", "TREATMENT", 0, 11], ["most viruses", "PROBLEM", 15, 27], ["ribose", "TEST", 118, 124], ["methyltransferase (2\u2032-O-MTase) enzyme", "TREATMENT", 130, 167], ["capping", "OBSERVATION_MODIFIER", 4, 11], ["most viruses", "OBSERVATION_MODIFIER", 15, 27], ["eukaryotic mRNA", "OBSERVATION", 32, 47], ["cap1 structure", "OBSERVATION", 180, 194]]], ["The 2\u2032O-methylation of viral mRNA cap also helps in protecting RNA recognition as \u201cnonself\u201d by host innate immune system, which makes it a potential target for antiviral drug development [7].IntroductionThe design of antiviral drugs with proven efficacy or vaccines against SARS-CoV-2 is limited due to the poor understanding of its molecular mechanisms of infection.", [["SARS", "DISEASE", 274, 278], ["infection", "DISEASE", 357, 366], ["nonself", "GENE_OR_GENE_PRODUCT", 83, 90], ["SARS-CoV-2", "ORGANISM", 274, 284], ["viral mRNA cap", "RNA", 23, 37], ["SARS-CoV", "SPECIES", 274, 282], ["viral mRNA cap", "TREATMENT", 23, 37], ["antiviral drug development", "TREATMENT", 160, 186], ["antiviral drugs", "TREATMENT", 217, 232], ["vaccines", "TREATMENT", 257, 265], ["SARS", "PROBLEM", 274, 278], ["infection", "PROBLEM", 357, 366], ["infection", "OBSERVATION", 357, 366]]], ["There is a need to design an inhibitor for blocking the SARS-CoV-2 replication within the cell.", [["cell", "ANATOMY", 90, 94], ["SARS", "DISEASE", 56, 60], ["CoV-2", "GENE_OR_GENE_PRODUCT", 61, 66], ["cell", "CELL", 90, 94], ["an inhibitor", "TREATMENT", 26, 38], ["blocking the SARS", "PROBLEM", 43, 60], ["CoV-2 replication", "TREATMENT", 61, 78]]], ["The repurposing of the approved drugs is an alternate way to find out a solution.", [["the approved drugs", "TREATMENT", 19, 37], ["a solution", "TREATMENT", 70, 80]]], ["Recently, clinicians have used the antimalarial and anti-HIV drugs for the treatment of SARS-CoV-2; however, the possible mechanism involved in its inhibition is not known [[8], [9], [10]].IntroductionIn the present study, the 2\u2032-O-methyltransferase (2\u2032OMTase) structure was modeled using a comparative modeling approach and further validated.", [["SARS", "DISEASE", 88, 92], ["2\u2032-O", "CHEMICAL", 227, 231], ["SARS-CoV-2", "ORGANISM", 88, 98], ["[9], [10]]", "SIMPLE_CHEMICAL", 178, 188], ["2\u2032-O-methyltransferase", "GENE_OR_GENE_PRODUCT", 227, 249], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 251, 259], ["2\u2032-O-methyltransferase (2\u2032OMTase", "DNA", 227, 259], ["SARS-CoV", "SPECIES", 88, 96], ["the antimalarial and anti-HIV drugs", "TREATMENT", 31, 66], ["SARS", "PROBLEM", 88, 92], ["the present study", "TEST", 204, 221], ["the 2\u2032-O-methyltransferase (2\u2032OMTase)", "TREATMENT", 223, 260], ["a comparative modeling approach", "TREATMENT", 289, 320]]], ["Besides, the FDA approved drugs were screened against 2\u2032OMTase for selecting the potential candidate for drug repurposing using virtual drug screening followed by redocking analysis using Autodock tool.", [["2\u2032OMTase", "SIMPLE_CHEMICAL", 54, 62], ["drug repurposing", "TREATMENT", 105, 121], ["virtual drug screening", "TEST", 128, 150], ["Autodock tool", "TEST", 188, 201]]], ["The selected best FDA approved drugs were further validated by performing the molecular dynamics simulation.Amino acid sequence retrieval and analysis ::: Material and methodsThe protein sequence encoding ORF1ab polyprotein of Indian isolates of SARS-CoV-2 (GenBank Accession ID: QIA98582.1) constituting 7096 amino acid residues was retrieved from the NCBI Database (https://www.ncbi.nlm.nih.gov/protein/1809484466).", [["Amino acid", "CHEMICAL", 108, 118], ["SARS", "DISEASE", 246, 250], ["amino acid", "CHEMICAL", 310, 320], ["Amino acid", "CHEMICAL", 108, 118], ["amino acid", "CHEMICAL", 310, 320], ["Amino acid", "AMINO_ACID", 108, 118], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 205, 211], ["SARS-CoV-2", "ORGANISM", 246, 256], ["amino acid", "AMINO_ACID", 310, 320], ["ORF1ab polyprotein", "PROTEIN", 205, 223], ["SARS-CoV", "SPECIES", 246, 254], ["drugs", "TREATMENT", 31, 36], ["the molecular dynamics simulation", "TEST", 74, 107], ["Amino acid sequence retrieval", "TREATMENT", 108, 137], ["The protein sequence", "TEST", 175, 195], ["Indian isolates", "TEST", 227, 242], ["SARS", "TEST", 246, 250], ["CoV", "TEST", 251, 254], ["amino acid residues", "PROBLEM", 310, 329]]], ["The retrieved sequence was pairwise aligned with the 2\u2032-O-ribose methyltransferase (NCBI RefSeq ID: YP_009725311.1) encoding region of SARS-CoV-2 isolate from Wuhan to identify the 2\u2032-O-2\u2032OMTase.", [["2\u2032-O-ribose", "CHEMICAL", 53, 64], ["2\u2032-O-ribose", "CHEMICAL", 53, 64], ["2\u2032-O-ribose methyltransferase", "GENE_OR_GENE_PRODUCT", 53, 82], ["2\u2032-O-2\u2032OMTase", "SIMPLE_CHEMICAL", 181, 194], ["2\u2032-O-ribose methyltransferase", "DNA", 53, 82], ["2\u2032-O-2\u2032OMTase", "DNA", 181, 194], ["SARS", "PROBLEM", 135, 139], ["CoV", "TEST", 140, 143]]], ["PSI-BLAST webserver was used to search for 2\u2032OMTase domains from the different strains across the SwissProt database.", [["\u2032OMTase domains", "DNA", 44, 59], ["2\u2032OMTase domains", "TREATMENT", 43, 59]]], ["2\u2032OMTase sequence was aligned with its homologous characterized domains with a query coverage of 100% displaying the sequence identity in the range of 53%\u201393% by T-Coffee Multiple sequence alignment web server.", [["2\u2032OMTase sequence", "DNA", 0, 17], ["the sequence identity", "TEST", 113, 134]]], ["Furthermore, the results were visualized and analyzed for the identification of conserved and semi-conserved amino acid residues by Esprit 3.0 webserver.Comparative modeling, refinement and structure assessment of 2\u2032OMTase ::: Material and methodsThe structure modeling of 2\u2032OMTase was performed by using the comparative modeling approach through Modeller v9.23 Program [11].", [["amino acid", "CHEMICAL", 109, 119], ["amino acid", "CHEMICAL", 109, 119], ["amino acid", "AMINO_ACID", 109, 119], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 273, 281], ["the identification", "TEST", 58, 76], ["semi-conserved amino acid residues", "PROBLEM", 94, 128], ["Esprit", "TEST", 132, 138], ["Comparative modeling", "TEST", 153, 173], ["structure assessment", "TEST", 190, 210]]], ["The homologous protein structures of 2\u2032OMTase with PDB ID: 3R24 [12,13], 2XYR [12,13] from human SARS-CoV and 2\u2032OMTase with PDB ID 5YN5 from Human betacoronavirus 2c EMC/2012 [Unpublished] were retrieved from Protein Data Bank (PDB).", [["OMTase", "SIMPLE_CHEMICAL", 39, 45], ["human", "ORGANISM", 91, 96], ["SARS-CoV", "ORGANISM", 97, 105], ["Human", "ORGANISM", 141, 146], ["OMTase", "PROTEIN", 112, 118], ["PDB ID 5YN5", "PROTEIN", 124, 135], ["human", "SPECIES", 91, 96], ["Human", "SPECIES", 141, 146], ["human SARS-CoV", "SPECIES", 91, 105], ["Human betacoronavirus", "SPECIES", 141, 162], ["The homologous protein structures", "TEST", 0, 33], ["human SARS", "TEST", 91, 101], ["CoV", "TEST", 102, 105], ["PDB", "ANATOMY", 228, 231]]], ["After that, the generated Multiple Sequence Alignment (MSA) was further aligned with the 2\u2032OMTase query sequence to cover the whole sequence for model building.", [["2\u2032OMTase query sequence", "DNA", 89, 112], ["model building", "TREATMENT", 145, 159]]], ["The energy minimized models of 2\u2032OMTase were evaluated by using several programs viz, ProCheck [14], ERRAT [15] and VERIFY3D [16] tools available at SAVES server (https://services.mbi.ucla.edu/SAVES/) and RAMPAGE (http://mordred.bioc.cam.ac.uk/~rapper/rampage.php) server.", [["OMTase", "SIMPLE_CHEMICAL", 33, 39], ["OMTase", "PROTEIN", 33, 39]]], ["The ProSA web server (https://prosa.services.came.sbg.ac.at/prosa.php) was used to estimate the statistical Z-score deviation of the modeled structure from the high-resolution structures deposited in PDB.", [["ProSA", "PROTEIN", 4, 9], ["the statistical Z-score deviation of the modeled structure", "PROBLEM", 92, 150], ["high", "OBSERVATION_MODIFIER", 160, 164], ["PDB", "ANATOMY", 200, 203]]], ["The best-selected energy minimized 2\u2032OMTase modeled structure was used for further analysis.", [["2\u2032OMTase modeled structure", "TREATMENT", 35, 61], ["further analysis", "TEST", 75, 91]]], ["The topology diagram showing the secondary structures present in 2\u2032OMTase was generated by using PDBSum (http://www.ebi.ac.uk/thornton-srv/databases/pdbsum/Generate.html).Screening of FDA drugs approved against 2\u2032OMTase ::: Material and methodsTo identify the potential antivirals drugs candidate for repurposing against 2\u2032OMTase, the PyRx 0.8 virtual screening tool was used.", [["2\u2032OMTase", "SIMPLE_CHEMICAL", 211, 219], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 321, 329], ["OMTase", "PROTEIN", 67, 73], ["PDBSum", "PROTEIN", 97, 103], ["The topology diagram", "TEST", 0, 20], ["FDA drugs", "TREATMENT", 184, 193], ["antivirals drugs", "TREATMENT", 270, 286], ["the PyRx", "TEST", 331, 339], ["virtual screening tool", "TEST", 344, 366], ["secondary structures", "OBSERVATION", 33, 53]]], ["The library includes 3000 FDA approved drugs containing antivirals, antibiotics, protease inhibitors, anticancer, membrane transport and ion channel inhibitors, DNA damage and repair inhibitors etc. All the FDA approved drugs were downloaded from the zinc database and DrugBank and converted into 3D format for high-throughput virtual screening.", [["anticancer", "ANATOMY", 102, 112], ["membrane", "ANATOMY", 114, 122], ["zinc", "CHEMICAL", 251, 255], ["anticancer", "CANCER", 102, 112], ["membrane", "CELLULAR_COMPONENT", 114, 122], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["drugs", "TREATMENT", 39, 44], ["antivirals", "TREATMENT", 56, 66], ["antibiotics", "TREATMENT", 68, 79], ["protease inhibitors", "TREATMENT", 81, 100], ["anticancer", "TREATMENT", 102, 112], ["membrane transport", "TREATMENT", 114, 132], ["ion channel inhibitors", "TREATMENT", 137, 159], ["DNA damage", "PROBLEM", 161, 171], ["repair inhibitors", "TREATMENT", 176, 193], ["drugs", "TREATMENT", 220, 225], ["the zinc database", "TEST", 247, 264], ["virtual screening", "TEST", 327, 344], ["repair inhibitors", "OBSERVATION", 176, 193]]], ["All the FDA approved drugs were energy minimized and converted to autodock vina supporting format by adding quaternion and torsions by following the PyRx 0.8 protocol.", [["torsions", "TREATMENT", 123, 131], ["the PyRx 0.8 protocol", "TREATMENT", 145, 166]]], ["The prepared FDA approved drugs were screened against the catalytic site of SARS-CoV-2\u2032OMTase protein using AutoDock Vina program compiled in PyRx 0.8 by setting the grid center points at X = \u221212.32, Y = 0.34, Z = 9.52 and box dimensions were set as 32.15 \u00c5 \u00d7 32.34 \u00c5 \u00d7 35.51 \u00c5 with the exhaustiveness of 8.", [["catalytic site", "PROTEIN", 58, 72], ["SARS-CoV-2\u2032OMTase protein", "PROTEIN", 76, 101], ["The prepared FDA approved drugs", "TREATMENT", 0, 31], ["SARS", "PROBLEM", 76, 80], ["CoV", "TEST", 81, 84], ["AutoDock Vina program", "TREATMENT", 108, 129], ["Y", "TEST", 200, 201], ["Z", "TEST", 210, 211], ["box dimensions", "TEST", 223, 237]]], ["The drug molecules showing the free energy of binding (\u0394G) between \u221210 kcal/mol \u22128.7 kcal/mol were selected for further analysis.", [["The drug molecules", "TEST", 0, 18], ["further analysis", "TEST", 112, 128]]], ["The free energy of binding of \u22128.3 kcal/mol for sinefungin was taken as reference.Molecular docking analysis of 2\u2032OMTase with selected FDA approved drugs ::: Material and methodsThe selected best FDA approved drugs obtained from virtual screening were redocked using AutoDock v4.2.6 software integrated with MGL Tools 1.5.6 (http://mgltools.scripps.edu/).", [["sinefungin", "CHEMICAL", 48, 58], ["sinefungin", "CHEMICAL", 48, 58], ["sinefungin", "SIMPLE_CHEMICAL", 48, 58], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 112, 120], ["sinefungin", "TREATMENT", 48, 58], ["Molecular docking analysis", "TEST", 82, 108], ["virtual screening", "TEST", 229, 246], ["AutoDock v", "TEST", 267, 277], ["MGL Tools", "TEST", 308, 317]]], ["The ligands and 2\u2032OMTase were prepared and converted into the PDBQT format.", [["2\u2032OMTase", "SIMPLE_CHEMICAL", 16, 24], ["ligands", "ANATOMY_MODIFIER", 4, 11]]], ["The Grid box of 70x70x70 \u00c5 size in x, y and z-direction with default grid point spacing was arranged around the active site by using the grid centering option.", [["70x70x70", "CHEMICAL", 16, 24], ["70x70x70", "CHEMICAL", 16, 24], ["Grid box", "DNA", 4, 12], ["The Grid box", "TEST", 0, 12], ["default grid point spacing", "PROBLEM", 61, 87], ["the grid centering option", "TREATMENT", 133, 158], ["size", "OBSERVATION_MODIFIER", 27, 31], ["grid point spacing", "OBSERVATION", 69, 87]]], ["The conformational search and docking simulation for different ligands were executed using 2000 cycles of the Lamarckian Genetic Algorithm (LGA).", [["different ligands", "PROBLEM", 53, 70]]], ["The best conformation was selected based on the free energy of binding for protein-ligand interaction analysis and estimation of inhibitory constant.", [["protein-ligand interaction analysis", "TEST", 75, 110]]], ["Top ten FDA approved drugs were further used for analysis.", [["drugs", "TREATMENT", 21, 26], ["analysis", "TEST", 49, 57]]], ["The protein-ligand complexes were further analyzed by PyMOL for the identification of hydrophobic contacts and polar interactions.", [["PyMOL", "SIMPLE_CHEMICAL", 54, 59], ["protein-ligand complexes", "PROTEIN", 4, 28], ["hydrophobic contacts", "OBSERVATION", 86, 106]]], ["The 2D interaction of protein and ligand was generated by using the LigPlot+ program.Molecular dynamic simulation of the apo and ligand-bound form of 2\u2032OMTase ::: Material and methodsThe conformational stability and behavioral dynamics of apo and ligand-bound 2\u2032OMTase structures were determined by molecular dynamic (MD) simulation.", [["apo", "SIMPLE_CHEMICAL", 121, 124], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 150, 158], ["apo", "SIMPLE_CHEMICAL", 239, 242], ["LigPlot", "PROTEIN", 68, 75], ["apo", "PROTEIN", 239, 242], ["the LigPlot+ program", "TREATMENT", 64, 84], ["The conformational stability", "PROBLEM", 183, 211], ["stability", "OBSERVATION_MODIFIER", 202, 211]]], ["Sinefungin, dihydroergotamine, digitoxin, irinotecan, and teniposide were generated by using PRODRG server (http://prodrg1.dyndns.org/submit.html).", [["Sinefungin", "CHEMICAL", 0, 10], ["dihydroergotamine", "CHEMICAL", 12, 29], ["digitoxin", "CHEMICAL", 31, 40], ["irinotecan", "CHEMICAL", 42, 52], ["teniposide", "CHEMICAL", 58, 68], ["Sinefungin", "CHEMICAL", 0, 10], ["dihydroergotamine", "CHEMICAL", 12, 29], ["digitoxin", "CHEMICAL", 31, 40], ["irinotecan", "CHEMICAL", 42, 52], ["teniposide", "CHEMICAL", 58, 68], ["Sinefungin", "SIMPLE_CHEMICAL", 0, 10], ["dihydroergotamine", "SIMPLE_CHEMICAL", 12, 29], ["digitoxin", "SIMPLE_CHEMICAL", 31, 40], ["irinotecan", "SIMPLE_CHEMICAL", 42, 52], ["teniposide", "SIMPLE_CHEMICAL", 58, 68], ["Sinefungin", "TREATMENT", 0, 10], ["dihydroergotamine", "TREATMENT", 12, 29], ["digitoxin", "TREATMENT", 31, 40], ["irinotecan", "TREATMENT", 42, 52], ["teniposide", "TREATMENT", 58, 68]]], ["The apo form and ligand-bound complex was placed in a triclinic box with a distance of 1.2 nm and solvated with a single point charge (SPC) waters.", [["apo", "SIMPLE_CHEMICAL", 4, 7], ["apo form", "PROTEIN", 4, 12], ["ligand-bound complex", "PROTEIN", 17, 37], ["triclinic box", "PROTEIN", 54, 67], ["a triclinic box", "TREATMENT", 52, 67], ["a single point charge (SPC) waters", "TREATMENT", 112, 146]]], ["The system was neutralized by adding 2 Cl\u2212 ions as counterions, and the system was energy minimized by using the Steepest descent method using cut-off up to 239 kcal/mol.", [["Cl\u2212", "CHEMICAL", 39, 42], ["2 Cl\u2212 ions as counterions", "TREATMENT", 37, 62], ["the Steepest descent method", "TREATMENT", 109, 136]]], ["The final MD run was analyzed by using gmx rms for the estimation of root-mean-square deviation (RMSD), gmx rmsf for room mean square function (RMSF) calculation.", [["gmx rms", "PROTEIN", 39, 46], ["root", "ANATOMY", 69, 73], ["square deviation", "OBSERVATION", 79, 95]]], ["The radius of gyration (Rg) and solvent accessible surface area (SASA) were determined by using gmx gyrate, and gmx sasa commands, respectively.", [["surface area", "ANATOMY", 51, 63], ["radius", "OBSERVATION_MODIFIER", 4, 10], ["gyration", "OBSERVATION_MODIFIER", 14, 22]]], ["The XMGRACE software (http://plasma-gate.weizmann.ac.il/Grace/) was used for data plotting and analysis.Sequence analysis of 2\u2032OMTase ::: ResultsThe pairwise sequence alignment analysis of ORF1ab polyprotein of Indian isolate of SARS-CoV-2 with isolate from Wuhan revealed that both the sequences of the 2\u2032-O-ribose methyltransferase domain are identical without any mutation.", [["2\u2032-O-ribose", "CHEMICAL", 304, 315], ["2\u2032-O-ribose", "CHEMICAL", 304, 315], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 189, 195], ["SARS-CoV-2", "ORGANISM", 229, 239], ["2\u2032-O-ribose methyltransferase", "GENE_OR_GENE_PRODUCT", 304, 333], ["XMGRACE software", "DNA", 4, 20], ["ORF1ab polyprotein", "PROTEIN", 189, 207], ["2\u2032-O-ribose methyltransferase domain", "PROTEIN", 304, 340], ["SARS-CoV-2", "SPECIES", 229, 239], ["The XMGRACE software", "TEST", 0, 20], ["data plotting", "TEST", 77, 90], ["analysis", "TEST", 95, 103], ["Sequence analysis", "TEST", 104, 121], ["The pairwise sequence alignment analysis", "TEST", 145, 185], ["ORF1ab polyprotein", "TEST", 189, 207], ["SARS", "TEST", 229, 233], ["CoV", "TEST", 234, 237], ["ribose methyltransferase domain", "TREATMENT", 309, 340], ["any mutation", "PROBLEM", 363, 375], ["ribose methyltransferase", "OBSERVATION", 309, 333]]], ["The PSI-BLAST analysis of 2\u2032OMTase displayed the amino acid sequence identity with previously characterized 2\u2032OMTase of CoV isolated from different strains (Table 1).", [["amino acid", "CHEMICAL", 49, 59], ["amino acid", "CHEMICAL", 49, 59], ["amino acid", "AMINO_ACID", 49, 59], ["CoV", "ORGANISM", 120, 123], ["2\u2032OMTase", "DNA", 26, 34], ["OMTase", "PROTEIN", 110, 116], ["The PSI-BLAST analysis", "TEST", 0, 22], ["the amino acid sequence identity", "PROBLEM", 45, 77], ["CoV", "PROBLEM", 120, 123], ["different strains", "PROBLEM", 138, 155], ["CoV isolated", "OBSERVATION_MODIFIER", 120, 132]]], ["The 2\u2032OMTase sequences from different strains mentioned in Table 1 were retrieved from Uniprot Database and aligned using the T-Coffee program revealed that the catalytic amino acid residues Lys46, Asp130, Lys170, and Glu203 are conserved in all the strains (Fig. 1).Structure modeling of 2\u2032OMTase and validation ::: ResultsThe comparative modeled structure of 2\u2032OMTase (Fig. 2A) displayed the characteristic fold comprising seven stranded \u03b2-sheets surrounded by \u03b1-helices and loops (Fig. 2A).", [["amino acid", "CHEMICAL", 171, 181], ["Asp130, Lys170", "CHEMICAL", 198, 212], ["amino acid", "CHEMICAL", 171, 181], ["Lys46", "CHEMICAL", 191, 196], ["Asp", "CHEMICAL", 198, 201], ["Lys", "CHEMICAL", 206, 209], ["Glu203", "CHEMICAL", 218, 224], ["amino acid", "AMINO_ACID", 171, 181], ["Lys46", "AMINO_ACID", 191, 196], ["Asp130", "AMINO_ACID", 198, 204], ["Lys170", "AMINO_ACID", 206, 212], ["Glu203", "GENE_OR_GENE_PRODUCT", 218, 224], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 361, 369], ["2\u2032OMTase sequences", "DNA", 4, 22], ["Glu203", "PROTEIN", 218, 224], ["OMTase", "PROTEIN", 363, 369], ["2A", "PROTEIN", 376, 378], ["\u03b1-helices", "PROTEIN", 463, 472], ["Fig. 2A", "PROTEIN", 484, 491], ["different strains", "PROBLEM", 28, 45], ["the T-Coffee program", "TREATMENT", 122, 142], ["the catalytic amino acid residues", "TEST", 157, 190], ["Asp", "TEST", 198, 201], ["Lys", "TEST", 206, 209], ["Glu203", "TEST", 218, 224], ["the characteristic fold", "PROBLEM", 390, 413], ["seven", "OBSERVATION_MODIFIER", 425, 430], ["stranded", "OBSERVATION", 431, 439], ["loops", "ANATOMY_MODIFIER", 477, 482]]], ["A similar type of structural organization is conserved and reported for class I MTase family [12,13].", [["class I MTase", "GENE_OR_GENE_PRODUCT", 72, 85], ["class I MTase family", "PROTEIN", 72, 92], ["structural organization", "OBSERVATION", 18, 41]]], ["The different programs available on the SAVES server were used to assess the quality of 2\u2032OMTase energy minimized modeled structure.", [["SAVES server", "DNA", 40, 52], ["the SAVES server", "TEST", 36, 52]]], ["The Ramachandran plot analysis by Procheck server displayed that 266 amino acid residues i.e., non-glycine and proline, follow the stereochemical properties.", [["amino acid", "CHEMICAL", 69, 79], ["non-glycine", "CHEMICAL", 95, 106], ["proline", "CHEMICAL", 111, 118], ["amino acid", "CHEMICAL", 69, 79], ["non-glycine", "CHEMICAL", 95, 106], ["proline", "CHEMICAL", 111, 118], ["amino acid", "AMINO_ACID", 69, 79], ["non-glycine", "SIMPLE_CHEMICAL", 95, 106], ["proline", "AMINO_ACID", 111, 118], ["The Ramachandran plot analysis", "TEST", 0, 30], ["amino acid residues", "TREATMENT", 69, 88], ["non-glycine and proline", "TREATMENT", 95, 118]]], ["The analysis showed that 91.4% amino acid residues of 266 lies in the favored region, and 8.6% amino acid residues accommodate in the allowed region (Fig. 2B).", [["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 95, 105], ["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 95, 105], ["amino acid", "AMINO_ACID", 31, 41], ["amino acid", "AMINO_ACID", 95, 105], ["The analysis", "TEST", 0, 12], ["amino acid residues", "TEST", 31, 50], ["amino acid residues", "TREATMENT", 95, 114]]], ["The absence of amino acid residues in the generously allowed and disallowed regions of the Ramachandran plot demonstrated that the modeled structure of 2\u2032OMTase follows the stereochemical property rule and follows all the possible dihedral, phi (\u03d5) and psi (\u03c8) angle values.", [["amino acid", "CHEMICAL", 15, 25], ["amino acid", "CHEMICAL", 15, 25], ["amino acid", "AMINO_ACID", 15, 25], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 152, 160], ["amino acid residues", "PROBLEM", 15, 34], ["the Ramachandran plot", "TEST", 87, 108], ["psi (\u03c8) angle values", "TEST", 253, 273], ["amino acid residues", "OBSERVATION", 15, 34]]], ["The modeled structure on further evaluation by the VERIFY3D plot, revealed that 92.28% of amino acid residues have an overall average 3D-1D score \u2265 0.2 (Fig. 2C).", [["amino acid", "CHEMICAL", 90, 100], ["amino acid", "CHEMICAL", 90, 100], ["amino acid", "AMINO_ACID", 90, 100], ["further evaluation", "TEST", 25, 43], ["the VERIFY3D plot", "TEST", 47, 64], ["amino acid residues", "PROBLEM", 90, 109]]], ["Similarly, the 2\u2032OMTase energy minimized structure assessed by ERRAT Plot displayed the quality factor of 96.20%, which further confirmed that the modeling of 2\u2032OMTase structure is error-free (Fig. 2D).", [["ERRAT Plot", "TEST", 63, 73], ["the quality factor", "TEST", 84, 102], ["the modeling", "TEST", 143, 155], ["error-free", "OBSERVATION_MODIFIER", 181, 191]]], ["Similarly, ProSA analysis of 2\u2032OMTase displayed the Z score of \u22127.4, confirming the modeled structure accommodated in the X-ray zone (Fig. 2E).", [["ProSA", "PROTEIN", 11, 16], ["ProSA analysis", "TEST", 11, 25], ["the Z score", "TEST", 48, 59], ["the X-ray zone", "TEST", 118, 132]]], ["PDBSum analysis of the modeled structure of 2\u2032OMTase displayed that it contains 13 \u03b1-helices and 13 \u03b2-strands as secondary structure elements (Fig. 2F).", [["OMTase", "SIMPLE_CHEMICAL", 46, 52], ["OMTase", "PROTEIN", 46, 52], ["13 \u03b1-helices", "PROTEIN", 80, 92], ["\u03b2", "PROTEIN", 100, 101], ["secondary structure elements", "DNA", 113, 141], ["PDBSum analysis", "TEST", 0, 15]]], ["The quality assessment parameters of the modeled structure of 2\u2032OMTase were superior to the experimentally determined homologous crystal structure of 2\u2032OMTase, which reveals that the selected modeled structure is the best model for further studies.", [["2\u2032OMTase", "SIMPLE_CHEMICAL", 62, 70], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 150, 158], ["OMTase", "PROTEIN", 152, 158], ["The quality assessment parameters", "TEST", 0, 33], ["further studies", "TEST", 232, 247]]], ["The 2\u2032OMTase and its homologous proteins were subjected to CastP analysis for the determination of active site volume and to predict the open or close conformation.", [["2\u2032OMTase", "PROTEIN", 4, 12], ["CastP", "PROTEIN", 59, 64], ["CastP analysis", "TEST", 59, 73], ["active site volume", "PROBLEM", 99, 117]]], ["The active site volume of 2\u2032OMTase from SARS-CoV-2 was found to be 526.70 \u00c53.", [["SARS", "DISEASE", 40, 44], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["active", "OBSERVATION_MODIFIER", 4, 10], ["site", "OBSERVATION_MODIFIER", 11, 15], ["volume", "OBSERVATION_MODIFIER", 16, 22]]], ["The active site volume of homologous 2\u2032OMTase for PDB ID 3R24_A was 946.75 \u00c53 and for PDB ID 2XYR was 537.38 \u00c53.", [["OMTase", "PROTEIN", 39, 45], ["The active site volume of homologous", "TREATMENT", 0, 36], ["PDB ID 2XYR", "TEST", 86, 97], ["active", "OBSERVATION_MODIFIER", 4, 10], ["site volume", "OBSERVATION", 11, 22]]], ["The Active site volume of 2\u2032OMTase from SARS-CoV-2 matched well with the homologous protein of SARS-CoV and confirmed that the modeled protein has closed conformation.Screening of FDA approved drugs against 2\u2032OMTase ::: ResultsThe high throughput virtual screening analysis of FDA approved drugs library against the 2\u2032-O-methyltransferase (2\u2032OMTase) helps in identifying and selecting the potential FDA approved drugs as an inhibitor or antiviral compounds.", [["2\u2032-O", "CHEMICAL", 316, 320], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 95, 103], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 207, 215], ["2\u2032-O-methyltransferase", "SIMPLE_CHEMICAL", 316, 338], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 340, 348], ["SARS-CoV-2", "DNA", 40, 50], ["SARS-CoV", "PROTEIN", 95, 103], ["2\u2032-O-methyltransferase", "PROTEIN", 316, 338], ["SARS-CoV", "SPECIES", 95, 103], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["virtual screening analysis", "TEST", 247, 273], ["the 2\u2032-O-methyltransferase (2\u2032OMTase)", "TREATMENT", 312, 349], ["drugs", "TREATMENT", 412, 417], ["an inhibitor", "TREATMENT", 421, 433], ["antiviral compounds", "TREATMENT", 437, 456], ["Active", "OBSERVATION_MODIFIER", 4, 10], ["site", "OBSERVATION_MODIFIER", 11, 15], ["volume", "OBSERVATION_MODIFIER", 16, 22], ["closed", "OBSERVATION", 147, 153]]], ["Top twenty molecules displaying the free energy of binding in the range of \u221210.00 to \u22128.7 kcal/mol were selected and considered as top hit compounds and are reported in Table 2.", [["free energy", "OBSERVATION", 36, 47]]], ["Each ligand screened through virtual screening by PyRx displayed nine different conformations, and the ligands forming interaction with catalytic tetrad were selected for further analysis.", [["PyRx", "CHEMICAL", 50, 54], ["PyRx", "SIMPLE_CHEMICAL", 50, 54], ["PyRx", "PROTEIN", 50, 54], ["catalytic tetrad", "PROTEIN", 136, 152], ["virtual screening", "TEST", 29, 46], ["further analysis", "TEST", 171, 187]]], ["These selected top hits included antiviral, alkaloids based drugs, cardiac glycoside, anticancer drugs, steroid-based drugs, and other drugs, etc. These selected FDA approved drugs were further employed for re-docking analysis with the 2\u2032OMTase to discover the potential inhibitor(s) by using Autodock tool.Re-docking analysis of 2\u2032OMTase with identified FDA approved drugs ::: ResultsThe re-docking analysis of the top twenty selected screened FDA approved drugs was carried out by AutoDock 4.2.6.", [["cardiac", "ANATOMY", 67, 74], ["anticancer", "ANATOMY", 86, 96], ["steroid", "CHEMICAL", 104, 111], ["steroid", "CHEMICAL", 104, 111], ["cardiac glycoside", "SIMPLE_CHEMICAL", 67, 84], ["anticancer", "CANCER", 86, 96], ["steroid", "SIMPLE_CHEMICAL", 104, 111], ["OMTase", "SIMPLE_CHEMICAL", 238, 244], ["antiviral", "TREATMENT", 33, 42], ["alkaloids based drugs", "TREATMENT", 44, 65], ["cardiac glycoside", "TREATMENT", 67, 84], ["anticancer drugs", "TREATMENT", 86, 102], ["steroid-based drugs", "TREATMENT", 104, 123], ["other drugs", "TREATMENT", 129, 140], ["drugs", "TREATMENT", 175, 180], ["re-docking analysis", "TEST", 207, 226], ["Re-docking analysis", "TEST", 307, 326], ["The re-docking analysis", "TEST", 385, 408], ["drugs", "TREATMENT", 458, 463], ["AutoDock", "TEST", 483, 491]]], ["The molecular docking analysis revealed that the top ten FDA approved drugs viz. sinefungin, dihydroergotamine, digitoxin, irinotecan, and teniposide displayed the free energy of binding in the range of \u22129.8 kcal/mol to \u22127.8 kcal/mol and predicted inhibitory constant in the range of 20 nM to 3120 nM (Table 3).", [["sinefungin", "CHEMICAL", 81, 91], ["dihydroergotamine", "CHEMICAL", 93, 110], ["digitoxin", "CHEMICAL", 112, 121], ["irinotecan", "CHEMICAL", 123, 133], ["teniposide", "CHEMICAL", 139, 149], ["sinefungin", "CHEMICAL", 81, 91], ["dihydroergotamine", "CHEMICAL", 93, 110], ["digitoxin", "CHEMICAL", 112, 121], ["irinotecan", "CHEMICAL", 123, 133], ["teniposide", "CHEMICAL", 139, 149], ["sinefungin", "SIMPLE_CHEMICAL", 81, 91], ["dihydroergotamine", "SIMPLE_CHEMICAL", 93, 110], ["digitoxin", "SIMPLE_CHEMICAL", 112, 121], ["irinotecan", "SIMPLE_CHEMICAL", 123, 133], ["teniposide", "SIMPLE_CHEMICAL", 139, 149], ["The molecular docking analysis", "TEST", 0, 30], ["drugs viz", "TREATMENT", 70, 79], ["sinefungin", "TREATMENT", 81, 91], ["dihydroergotamine", "TREATMENT", 93, 110], ["digitoxin", "TREATMENT", 112, 121], ["irinotecan", "TREATMENT", 123, 133], ["teniposide", "TREATMENT", 139, 149]]], ["The amino acid residues involved in the formation of hydrogen bonds, other interactions, the free energy of binding and inhibitory constant are shown in Table 3.", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["hydrogen", "CHEMICAL", 53, 61], ["amino acid", "AMINO_ACID", 4, 14], ["hydrogen bonds", "SIMPLE_CHEMICAL", 53, 67], ["The amino acid residues", "TREATMENT", 0, 23], ["hydrogen bonds", "PROBLEM", 53, 67], ["amino", "OBSERVATION", 4, 9], ["acid residues", "OBSERVATION", 10, 23], ["hydrogen bonds", "OBSERVATION", 53, 67]]], ["The protein-ligand complex of selected FDA approved drugs and 2\u2032OMTase were further analyzed by using PyMOL v2.3 software and LigPlot+ software.Re-docking analysis of 2\u2032OMTase with identified FDA approved drugs ::: ResultsThe drug, sinefungin, a natural nucleoside, interacts with 2\u2032OMTase through four hydrogen bonds formed by Gly71, Asp130, Tyr132, and Lys170 (Fig. 3A).", [["sinefungin", "CHEMICAL", 232, 242], ["nucleoside", "CHEMICAL", 254, 264], ["sinefungin", "CHEMICAL", 232, 242], ["nucleoside", "CHEMICAL", 254, 264], ["hydrogen", "CHEMICAL", 303, 311], ["Gly71", "CHEMICAL", 328, 333], ["Asp", "CHEMICAL", 335, 338], ["Tyr132", "CHEMICAL", 343, 349], ["Lys170", "CHEMICAL", 355, 361], ["OMTase", "SIMPLE_CHEMICAL", 64, 70], ["sinefungin", "SIMPLE_CHEMICAL", 232, 242], ["nucleoside", "SIMPLE_CHEMICAL", 254, 264], ["OMTase", "SIMPLE_CHEMICAL", 283, 289], ["Gly71", "SIMPLE_CHEMICAL", 328, 333], ["Asp130", "AMINO_ACID", 335, 341], ["Tyr132", "AMINO_ACID", 343, 349], ["Lys170", "AMINO_ACID", 355, 361], ["protein-ligand complex", "PROTEIN", 4, 26], ["OMTase", "PROTEIN", 64, 70], ["LigPlot", "PROTEIN", 126, 133], ["OMTase", "PROTEIN", 283, 289], ["The protein", "TEST", 0, 11], ["Re-docking analysis", "TEST", 144, 163], ["a natural nucleoside", "TREATMENT", 244, 264], ["Asp", "TEST", 335, 338]]], ["The sinefungin interacts with Tyr47, Gly73, Ser74, Asn99, Leu100, Met131, Asp133, Pro134, and Phe149 amino acid residues and forms hydrophobic/Van der Waals interaction (Fig. 3A).", [["sinefungin", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 101, 111], ["sinefungin", "CHEMICAL", 4, 14], ["Tyr47", "CHEMICAL", 30, 35], ["Gly73", "CHEMICAL", 37, 42], ["Ser74", "CHEMICAL", 44, 49], ["Asn99", "CHEMICAL", 51, 56], ["Leu100", "CHEMICAL", 58, 64], ["Met131", "CHEMICAL", 66, 72], ["Asp", "CHEMICAL", 74, 77], ["Pro", "CHEMICAL", 82, 85], ["Phe149 amino acid", "CHEMICAL", 94, 111], ["sinefungin", "GENE_OR_GENE_PRODUCT", 4, 14], ["Tyr47", "GENE_OR_GENE_PRODUCT", 30, 35], ["Gly73", "GENE_OR_GENE_PRODUCT", 37, 42], ["Ser74", "GENE_OR_GENE_PRODUCT", 44, 49], ["Asn99", "GENE_OR_GENE_PRODUCT", 51, 56], ["Leu100", "GENE_OR_GENE_PRODUCT", 58, 64], ["Met131", "GENE_OR_GENE_PRODUCT", 66, 72], ["Asp133", "AMINO_ACID", 74, 80], ["Pro", "AMINO_ACID", 82, 85], ["134", "AMINO_ACID", 85, 88], ["Phe149", "AMINO_ACID", 94, 100], ["amino acid", "AMINO_ACID", 101, 111], ["sinefungin", "PROTEIN", 4, 14], ["Tyr47", "PROTEIN", 30, 35], ["Gly73", "PROTEIN", 37, 42], ["Ser74", "PROTEIN", 44, 49], ["Asn99", "PROTEIN", 51, 56], ["Leu100", "PROTEIN", 58, 64], ["Met131", "PROTEIN", 66, 72], ["Asp", "TEST", 74, 77], ["Pro", "TEST", 82, 85], ["amino acid residues", "TEST", 101, 120]]], ["The amino acid residue Asp130 and Lys170 forming hydrogen bonds with sinefungin, are the part of catalytic tetrad and plays a key role in the formation of the catalytic cleft.Re-docking analysis of 2\u2032OMTase with identified FDA approved drugs ::: ResultsSimilarly, digitoxin, a cardiac glycoside interacts with 2\u2032OMTase by forming four hydrogen bonds by Lys24, Tyr30, Tyr132 and His174 followed by the formation of hydrophobic interaction through Asn43, Gly71, Gly73, Ser74, Asp75, Asp99, Leu100, Asp130, Met131, Asp133, Pro134, Thr136, Phe149, Lys170, Glu173, Ser202 and Glu203 (Fig. 3B).", [["cardiac", "ANATOMY", 277, 284], ["amino acid", "CHEMICAL", 4, 14], ["Asp", "CHEMICAL", 23, 26], ["sinefungin", "CHEMICAL", 69, 79], ["digitoxin", "CHEMICAL", 264, 273], ["OMTase", "CHEMICAL", 312, 318], ["amino acid", "CHEMICAL", 4, 14], ["Asp", "CHEMICAL", 23, 26], ["Lys170", "CHEMICAL", 34, 40], ["hydrogen", "CHEMICAL", 49, 57], ["sinefungin", "CHEMICAL", 69, 79], ["digitoxin", "CHEMICAL", 264, 273], ["hydrogen", "CHEMICAL", 335, 343], ["Lys24", "CHEMICAL", 353, 358], ["Tyr30", "CHEMICAL", 360, 365], ["Tyr132", "CHEMICAL", 367, 373], ["His", "CHEMICAL", 378, 381], ["Asn43", "CHEMICAL", 446, 451], ["Gly71", "CHEMICAL", 453, 458], ["Gly73", "CHEMICAL", 460, 465], ["Ser74", "CHEMICAL", 467, 472], ["Asp75", "CHEMICAL", 474, 479], ["Asp99", "CHEMICAL", 481, 486], ["Leu100", "CHEMICAL", 488, 494], ["Asp", "CHEMICAL", 496, 499], ["Met", "CHEMICAL", 504, 507], ["Asp", "CHEMICAL", 512, 515], ["Pro", "CHEMICAL", 520, 523], ["Thr", "CHEMICAL", 528, 531], ["Phe", "CHEMICAL", 536, 539], ["Lys170", "CHEMICAL", 544, 550], ["Glu173", "CHEMICAL", 552, 558], ["Ser202", "CHEMICAL", 560, 566], ["Glu203", "CHEMICAL", 571, 577], ["amino acid", "AMINO_ACID", 4, 14], ["residue", "AMINO_ACID", 15, 22], ["Asp130", "AMINO_ACID", 23, 29], ["Lys170", "AMINO_ACID", 34, 40], ["sinefungin", "SIMPLE_CHEMICAL", 69, 79], ["digitoxin", "SIMPLE_CHEMICAL", 264, 273], ["OMTase", "SIMPLE_CHEMICAL", 312, 318], ["Lys24", "SIMPLE_CHEMICAL", 353, 358], ["Tyr30", "GENE_OR_GENE_PRODUCT", 360, 365], ["Tyr132", "AMINO_ACID", 367, 373], ["His174", "GENE_OR_GENE_PRODUCT", 378, 384], ["Asn43", "GENE_OR_GENE_PRODUCT", 446, 451], ["Gly71", "GENE_OR_GENE_PRODUCT", 453, 458], ["Gly73", "GENE_OR_GENE_PRODUCT", 460, 465], ["Ser74", "GENE_OR_GENE_PRODUCT", 467, 472], ["Asp75", "GENE_OR_GENE_PRODUCT", 474, 479], ["Asp99", "GENE_OR_GENE_PRODUCT", 481, 486], ["Leu100", "GENE_OR_GENE_PRODUCT", 488, 494], ["Asp130", "AMINO_ACID", 496, 502], ["Met131", "AMINO_ACID", 504, 510], ["Asp133", "AMINO_ACID", 512, 518], ["Pro134", "AMINO_ACID", 520, 526], ["Thr136", "AMINO_ACID", 528, 534], ["Phe149", "AMINO_ACID", 536, 542], ["Lys170", "GENE_OR_GENE_PRODUCT", 544, 550], ["Glu173", "GENE_OR_GENE_PRODUCT", 552, 558], ["Ser202", "AMINO_ACID", 560, 566], ["catalytic tetrad", "PROTEIN", 97, 113], ["OMTase", "PROTEIN", 312, 318], ["Asn43", "PROTEIN", 446, 451], ["Gly71", "PROTEIN", 453, 458], ["Gly73", "PROTEIN", 460, 465], ["Ser74", "PROTEIN", 467, 472], ["Asp75", "PROTEIN", 474, 479], ["Asp99", "PROTEIN", 481, 486], ["Leu100", "PROTEIN", 488, 494], ["Glu203", "PROTEIN", 571, 577], ["The amino acid residue Asp", "TEST", 0, 26], ["sinefungin", "TREATMENT", 69, 79], ["the catalytic cleft", "PROBLEM", 155, 174], ["Re-docking analysis", "TEST", 175, 194], ["digitoxin", "TREATMENT", 264, 273], ["Asn43", "TEST", 446, 451], ["Gly71", "TEST", 453, 458], ["Gly73", "TEST", 460, 465], ["Asp75", "TEST", 474, 479], ["Asp99", "TEST", 481, 486], ["Leu100", "TEST", 488, 494], ["Asp", "TEST", 496, 499], ["Met", "TEST", 504, 507], ["Asp", "TEST", 512, 515], ["Pro", "TEST", 520, 523], ["Thr", "TEST", 528, 531], ["Phe", "TEST", 536, 539], ["Lys170", "TEST", 544, 550], ["Glu173", "TEST", 552, 558], ["Ser202", "TEST", 560, 566], ["Glu203", "TEST", 571, 577], ["hydrogen bonds", "OBSERVATION", 49, 63], ["catalytic cleft", "OBSERVATION", 159, 174]]], ["The amino acid residues of catalytic tetrad viz., Asp130, Lys170, and Glu203 involved in hydrophobic interactions revealed that these residues are further involved in stabilizing the ligand in the active site region (Fig. 3B).Re-docking analysis of 2\u2032OMTase with identified FDA approved drugs ::: ResultsThe alkaloid drug, dihydroergotamine, forms hydrogen bonds with Tyr47, Gly71, and Lys170 and forms hydrophobic interaction with Asn43, Gly73, Ser74, Asp75, Lys76, Pro80, Asp99, Leu100, Asn101, Asp130, Met131, Tyr132, Pro134 and Glu203 of 2\u2032OMTase (Fig. 3C).", [["amino acid", "CHEMICAL", 4, 14], ["Glu203", "CHEMICAL", 70, 76], ["dihydroergotamine", "CHEMICAL", 323, 340], ["amino acid", "CHEMICAL", 4, 14], ["Asp", "CHEMICAL", 50, 53], ["Lys170", "CHEMICAL", 58, 64], ["Glu203", "CHEMICAL", 70, 76], ["dihydroergotamine", "CHEMICAL", 323, 340], ["hydrogen", "CHEMICAL", 348, 356], ["Tyr47", "CHEMICAL", 368, 373], ["Gly71", "CHEMICAL", 375, 380], ["Lys170", "CHEMICAL", 386, 392], ["Asn43", "CHEMICAL", 432, 437], ["Gly73", "CHEMICAL", 439, 444], ["Ser74", "CHEMICAL", 446, 451], ["Asp75", "CHEMICAL", 453, 458], ["Lys76", "CHEMICAL", 460, 465], ["Pro80", "CHEMICAL", 467, 472], ["Asp99", "CHEMICAL", 474, 479], ["Leu100", "CHEMICAL", 481, 487], ["Asn101", "CHEMICAL", 489, 495], ["Asp", "CHEMICAL", 497, 500], ["Met", "CHEMICAL", 505, 508], ["Tyr132", "CHEMICAL", 513, 519], ["Pro", "CHEMICAL", 521, 524], ["Glu203", "CHEMICAL", 532, 538], ["2\u2032OMTase", "CHEMICAL", 542, 550], ["amino acid", "AMINO_ACID", 4, 14], ["Asp130", "AMINO_ACID", 50, 56], ["Lys170", "AMINO_ACID", 58, 64], ["Glu203", "AMINO_ACID", 70, 76], ["dihydroergotamine", "SIMPLE_CHEMICAL", 323, 340], ["Tyr47", "SIMPLE_CHEMICAL", 368, 373], ["Gly71", "GENE_OR_GENE_PRODUCT", 375, 380], ["Lys170", "AMINO_ACID", 386, 392], ["Asn43", "GENE_OR_GENE_PRODUCT", 432, 437], ["Gly73", "GENE_OR_GENE_PRODUCT", 439, 444], ["Ser74", "GENE_OR_GENE_PRODUCT", 446, 451], ["Asp75", "GENE_OR_GENE_PRODUCT", 453, 458], ["Lys76", "GENE_OR_GENE_PRODUCT", 460, 465], ["Pro80", "GENE_OR_GENE_PRODUCT", 467, 472], ["Asp99", "GENE_OR_GENE_PRODUCT", 474, 479], ["Leu100", "GENE_OR_GENE_PRODUCT", 481, 487], ["Asn101", "GENE_OR_GENE_PRODUCT", 489, 495], ["Asp130", "AMINO_ACID", 497, 503], ["Met131", "AMINO_ACID", 505, 511], ["Tyr132", "AMINO_ACID", 513, 519], ["Pro134", "SIMPLE_CHEMICAL", 521, 527], ["Glu203", "AMINO_ACID", 532, 538], ["active site region", "PROTEIN", 197, 215], ["Asn43", "PROTEIN", 432, 437], ["Ser74", "PROTEIN", 446, 451], ["Asp75", "PROTEIN", 453, 458], ["Lys76", "PROTEIN", 460, 465], ["Pro80", "PROTEIN", 467, 472], ["Asp99", "PROTEIN", 474, 479], ["Leu100", "PROTEIN", 481, 487], ["Asn101", "PROTEIN", 489, 495], ["OMTase", "PROTEIN", 544, 550], ["The amino acid residues", "TEST", 0, 23], ["catalytic tetrad viz.", "TREATMENT", 27, 48], ["Asp", "TEST", 50, 53], ["Lys170", "TEST", 58, 64], ["these residues", "PROBLEM", 128, 142], ["Re-docking analysis", "TEST", 226, 245], ["The alkaloid drug", "TREATMENT", 304, 321], ["dihydroergotamine", "TREATMENT", 323, 340], ["Tyr47", "TREATMENT", 368, 373], ["Asn43", "TEST", 432, 437], ["Asp75", "TEST", 453, 458], ["Pro80", "TEST", 467, 472], ["Asp99", "TEST", 474, 479], ["Leu100", "TEST", 481, 487], ["Asn101", "TEST", 489, 495], ["Asp", "TEST", 497, 500], ["Met", "TEST", 505, 508], ["Pro", "TEST", 521, 524], ["Glu203", "TEST", 532, 538], ["amino acid", "OBSERVATION", 4, 14], ["ligand", "ANATOMY", 183, 189], ["active site", "OBSERVATION", 197, 208], ["alkaloid drug", "OBSERVATION", 308, 321]]], ["The three amino acid residues of catalytic tetrad stabilize the drug in the catalytic cleft by hydrogen bond and hydrophobic interactions.Re-docking analysis of 2\u2032OMTase with identified FDA approved drugs ::: ResultsAnticancer drug irinotecan (Fig. 3D) forms hydrogen bonds with Tyr47 and Ser200 and involved in hydrophobic interactions through Tyr30, Gly31, Asp32, Ser33, Met42, Asn43, Lys46, Gly71, Gly73, Ser74, Asp99, Leu100, Asp130, Met131, Tyr132, Lys170, Val197, Asn198 and Ser201 of 2\u2032OMTase.", [["amino acid", "CHEMICAL", 10, 20], ["irinotecan", "CHEMICAL", 232, 242], ["amino acid", "CHEMICAL", 10, 20], ["hydrogen", "CHEMICAL", 95, 103], ["irinotecan", "CHEMICAL", 232, 242], ["hydrogen", "CHEMICAL", 259, 267], ["Tyr47", "CHEMICAL", 279, 284], ["Ser200", "CHEMICAL", 289, 295], ["Tyr30", "CHEMICAL", 345, 350], ["Gly31", "CHEMICAL", 352, 357], ["Asp32", "CHEMICAL", 359, 364], ["Ser33", "CHEMICAL", 366, 371], ["Met42", "CHEMICAL", 373, 378], ["Asn43", "CHEMICAL", 380, 385], ["Lys46", "CHEMICAL", 387, 392], ["Gly71", "CHEMICAL", 394, 399], ["Gly73", "CHEMICAL", 401, 406], ["Ser74", "CHEMICAL", 408, 413], ["Asp99", "CHEMICAL", 415, 420], ["Leu100", "CHEMICAL", 422, 428], ["Asp", "CHEMICAL", 430, 433], ["Met", "CHEMICAL", 438, 441], ["Tyr132", "CHEMICAL", 446, 452], ["Lys", "CHEMICAL", 454, 457], ["Val", "CHEMICAL", 462, 465], ["Asn198", "CHEMICAL", 470, 476], ["Ser201", "CHEMICAL", 481, 487], ["2\u2032OMTase", "CHEMICAL", 491, 499], ["amino acid", "AMINO_ACID", 10, 20], ["irinotecan", "SIMPLE_CHEMICAL", 232, 242], ["Tyr47", "GENE_OR_GENE_PRODUCT", 279, 284], ["Ser200", "AMINO_ACID", 289, 295], ["Tyr30", "GENE_OR_GENE_PRODUCT", 345, 350], ["Gly31", "GENE_OR_GENE_PRODUCT", 352, 357], ["Asp32", "GENE_OR_GENE_PRODUCT", 359, 364], ["Ser33", "GENE_OR_GENE_PRODUCT", 366, 371], ["Met42", "GENE_OR_GENE_PRODUCT", 373, 378], ["Asn43", "GENE_OR_GENE_PRODUCT", 380, 385], ["Lys46", "GENE_OR_GENE_PRODUCT", 387, 392], ["Gly71", "GENE_OR_GENE_PRODUCT", 394, 399], ["Gly73", "GENE_OR_GENE_PRODUCT", 401, 406], ["Ser74", "GENE_OR_GENE_PRODUCT", 408, 413], ["Asp99", "GENE_OR_GENE_PRODUCT", 415, 420], ["Leu100", "GENE_OR_GENE_PRODUCT", 422, 428], ["Asp130", "AMINO_ACID", 430, 436], ["Met131", "AMINO_ACID", 438, 444], ["Tyr132", "GENE_OR_GENE_PRODUCT", 446, 452], ["Lys170", "AMINO_ACID", 454, 460], ["Val197", "AMINO_ACID", 462, 468], ["Asn198", "AMINO_ACID", 470, 476], ["Ser201", "AMINO_ACID", 481, 487], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 491, 499], ["Ser200", "PROTEIN", 289, 295], ["Asp32", "PROTEIN", 359, 364], ["Ser33", "PROTEIN", 366, 371], ["Met42", "PROTEIN", 373, 378], ["Asn43", "PROTEIN", 380, 385], ["Gly71", "PROTEIN", 394, 399], ["Gly73", "PROTEIN", 401, 406], ["Ser74", "PROTEIN", 408, 413], ["Asp99", "PROTEIN", 415, 420], ["Leu100", "PROTEIN", 422, 428], ["OMTase", "PROTEIN", 493, 499], ["The three amino acid residues of catalytic tetrad", "TREATMENT", 0, 49], ["Re-docking analysis", "TEST", 138, 157], ["ResultsAnticancer drug irinotecan", "TREATMENT", 209, 242], ["hydrogen bonds", "TEST", 259, 273], ["Asp32", "TEST", 359, 364], ["Asn43", "TEST", 380, 385], ["Lys46", "TEST", 387, 392], ["Asp99", "TEST", 415, 420], ["Leu100", "TEST", 422, 428], ["Asp", "TEST", 430, 433], ["Met", "TEST", 438, 441], ["Lys", "TEST", 454, 457], ["Val", "TEST", 462, 465], ["Asn198", "TEST", 470, 476], ["hydrogen bond", "OBSERVATION", 95, 108], ["hydrophobic interactions", "OBSERVATION", 113, 137]]], ["Teniposide interacts with Asp99, Leu100, Asp130, Lys137, and Glu203 and forms hydrogen bond (Fig. 3E).", [["Teniposide", "CHEMICAL", 0, 10], ["Teniposide", "CHEMICAL", 0, 10], ["Asp99", "CHEMICAL", 26, 31], ["Leu100", "CHEMICAL", 33, 39], ["Asp", "CHEMICAL", 41, 44], ["Lys137", "CHEMICAL", 49, 55], ["Glu203", "CHEMICAL", 61, 67], ["hydrogen", "CHEMICAL", 78, 86], ["Teniposide", "SIMPLE_CHEMICAL", 0, 10], ["Asp99", "GENE_OR_GENE_PRODUCT", 26, 31], ["Leu100", "GENE_OR_GENE_PRODUCT", 33, 39], ["Asp130", "AMINO_ACID", 41, 47], ["Lys137", "AMINO_ACID", 49, 55], ["Glu203", "AMINO_ACID", 61, 67], ["Asp99", "PROTEIN", 26, 31], ["Glu203", "PROTEIN", 61, 67], ["Asp99", "TEST", 26, 31], ["Leu100", "TEST", 33, 39], ["Asp", "TEST", 41, 44], ["Lys137", "TEST", 49, 55], ["Glu203", "TEST", 61, 67]]], ["Besides, the amino acid residues Gly71, Gly73, Ser74, Asn101, Met131, Tyr132, Pro134, Lys170, and Thr172 form hydrophobic interaction.", [["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 13, 23], ["Gly71", "CHEMICAL", 33, 38], ["Gly73", "CHEMICAL", 40, 45], ["Ser74", "CHEMICAL", 47, 52], ["Asn101", "CHEMICAL", 54, 60], ["Met", "CHEMICAL", 62, 65], ["Tyr132", "CHEMICAL", 70, 76], ["Pro", "CHEMICAL", 78, 81], ["Lys170", "CHEMICAL", 86, 92], ["Thr", "CHEMICAL", 98, 101], ["amino acid", "AMINO_ACID", 13, 23], ["Gly71", "GENE_OR_GENE_PRODUCT", 33, 38], ["Gly73", "GENE_OR_GENE_PRODUCT", 40, 45], ["Ser74", "GENE_OR_GENE_PRODUCT", 47, 52], ["Asn101", "GENE_OR_GENE_PRODUCT", 54, 60], ["Met131", "GENE_OR_GENE_PRODUCT", 62, 68], ["Tyr132", "GENE_OR_GENE_PRODUCT", 70, 76], ["Pro134", "SIMPLE_CHEMICAL", 78, 84], ["Lys170", "GENE_OR_GENE_PRODUCT", 86, 92], ["Thr172", "AMINO_ACID", 98, 104], ["the amino acid residues", "TEST", 9, 32], ["Gly73", "TEST", 40, 45], ["Asn101", "TEST", 54, 60], ["Met", "TEST", 62, 65], ["Tyr132", "TEST", 70, 76], ["Pro", "TEST", 78, 81], ["Lys170", "TEST", 86, 92], ["Thr", "TEST", 98, 101]]], ["These drugs are stabilized in the catalytic cleft by catalytic residues Asp130, Lys170, and Glu203.Re-docking analysis of 2\u2032OMTase with identified FDA approved drugs ::: ResultsThe selected FDA approved drugs completely accommodated the catalytic cleft and interaction stabilized mainly by three amino acid residues viz.", [["Asp130, Lys170", "CHEMICAL", 72, 86], ["amino acid", "CHEMICAL", 296, 306], ["Asp", "CHEMICAL", 72, 75], ["Lys", "CHEMICAL", 80, 83], ["Glu203", "CHEMICAL", 92, 98], ["amino acid", "CHEMICAL", 296, 306], ["Asp130", "AMINO_ACID", 72, 78], ["Lys170", "AMINO_ACID", 80, 86], ["Glu203", "AMINO_ACID", 92, 98], ["amino acid", "AMINO_ACID", 296, 306], ["These drugs", "TREATMENT", 0, 11], ["catalytic residues Asp", "TEST", 53, 75], ["Lys", "TEST", 80, 83], ["Glu203", "TEST", 92, 98], ["Re-docking analysis", "TEST", 99, 118], ["The selected FDA approved drugs", "TREATMENT", 177, 208], ["the catalytic cleft", "PROBLEM", 233, 252], ["three amino acid residues viz", "TREATMENT", 290, 319], ["acid residues", "OBSERVATION", 302, 315]]], ["Asp130, Lys170, and Glu203 of the catalytic tetrad.", [["Asp", "CHEMICAL", 0, 3], ["Lys170", "CHEMICAL", 8, 14], ["Glu203", "CHEMICAL", 20, 26], ["Asp", "AMINO_ACID", 0, 3], ["Lys170", "AMINO_ACID", 8, 14], ["Glu203", "AMINO_ACID", 20, 26], ["catalytic tetrad", "PROTEIN", 34, 50], ["Asp", "TEST", 0, 3], ["the catalytic tetrad", "TREATMENT", 30, 50]]], ["This may result in preventing the 5\u2032 Cap modification by inhibiting the methyltransferase enzyme activity.Molecular dynamic simulation of the apo and ligand-bound form of 2\u2032OMTase ::: ResultsThe molecular dynamics (MD) simulation analysis of both apo and ligand complex was analyzed for the 50 ns to understand the stability and conformational dynamic behavior.", [["apo", "SIMPLE_CHEMICAL", 142, 145], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 171, 179], ["apo", "SIMPLE_CHEMICAL", 247, 250], ["methyltransferase enzyme", "PROTEIN", 72, 96], ["apo and ligand complex", "PROTEIN", 247, 269], ["Cap modification", "TREATMENT", 37, 53], ["the methyltransferase enzyme activity", "PROBLEM", 68, 105], ["simulation analysis", "TEST", 219, 238], ["apo and ligand complex", "TREATMENT", 247, 269]]], ["The estimated root mean square deviation (RMSD) analysis of apo 2\u2032OMTase (Black color) displayed fluctuation up to eight ns, and thereafter it became stable at 0.24 nm till 50 ns (Fig. 4A).", [["root", "ANATOMY", 14, 18], ["OMTase", "SIMPLE_CHEMICAL", 66, 72], ["The estimated root mean square deviation (RMSD) analysis of apo 2", "PROBLEM", 0, 65], ["root", "OBSERVATION_MODIFIER", 14, 18], ["mean", "OBSERVATION_MODIFIER", 19, 23], ["square deviation", "OBSERVATION", 24, 40], ["fluctuation", "OBSERVATION_MODIFIER", 97, 108], ["stable", "OBSERVATION_MODIFIER", 150, 156]]], ["The drug sinefungin bound 2\u2032OMTase displayed the RMSD at 0.30 nm till 25 ns, but after that, the sudden increase was observed until 50 ns.", [["sinefungin", "CHEMICAL", 9, 19], ["sinefungin", "CHEMICAL", 9, 19], ["OMTase", "SIMPLE_CHEMICAL", 28, 34], ["OMTase", "PROTEIN", 28, 34], ["The drug sinefungin bound", "TREATMENT", 0, 25], ["the sudden increase", "PROBLEM", 93, 112]]], ["Similarly, digitoxin bound 2\u2032OMTase displayed the initial RMSD at 0.32 nm, and after that, a small increase from 0.32 nm to 0.36 nm was observed up to 50 ns.", [["digitoxin", "CHEMICAL", 11, 20], ["digitoxin", "CHEMICAL", 11, 20], ["digitoxin", "SIMPLE_CHEMICAL", 11, 20], ["OMTase", "SIMPLE_CHEMICAL", 29, 35], ["digitoxin bound", "PROBLEM", 11, 26], ["a small increase", "PROBLEM", 91, 107], ["small", "OBSERVATION_MODIFIER", 93, 98], ["increase", "OBSERVATION_MODIFIER", 99, 107]]], ["The drug dihydroergotamine bound 2\u2032OMTase showed an average RMSD value of 0.29 nm.", [["dihydroergotamine", "CHEMICAL", 9, 26], ["dihydroergotamine", "CHEMICAL", 9, 26], ["dihydroergotamine", "SIMPLE_CHEMICAL", 9, 26], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 33, 41], ["The drug dihydroergotamine bound", "TREATMENT", 0, 32], ["an average RMSD value", "TEST", 49, 70], ["0.29 nm", "OBSERVATION_MODIFIER", 74, 81]]], ["The drug irinotecan bound 2\u2032OMTase demonstrated the average RMSD of 0.27 nm up to 40 ns, and thereafter the abrupt increase in RMSD was observed up to 50 ns.", [["irinotecan", "CHEMICAL", 9, 19], ["irinotecan", "CHEMICAL", 9, 19], ["irinotecan", "SIMPLE_CHEMICAL", 9, 19], ["OMTase", "SIMPLE_CHEMICAL", 28, 34], ["The drug irinotecan bound", "TREATMENT", 0, 25], ["the abrupt increase in RMSD", "PROBLEM", 104, 131], ["average", "OBSERVATION_MODIFIER", 52, 59], ["RMSD", "OBSERVATION_MODIFIER", 60, 64], ["abrupt", "OBSERVATION_MODIFIER", 108, 114], ["increase", "OBSERVATION_MODIFIER", 115, 123]]], ["The 2\u2032OMTas-teniposide complex displayed an average RMSD at 0.36 nm from 10 ns to 50 ns.", [["teniposide", "CHEMICAL", 12, 22], ["teniposide", "CHEMICAL", 12, 22], ["teniposide", "SIMPLE_CHEMICAL", 12, 22], ["teniposide complex", "PROTEIN", 12, 30], ["The 2\u2032OMTas-teniposide complex", "TREATMENT", 0, 30], ["average", "OBSERVATION_MODIFIER", 44, 51], ["RMSD", "OBSERVATION_MODIFIER", 52, 56]]], ["The RMSD analysis confirmed that the apo and ligand-bound 2\u2032OMTase attains a stable conformation throughout the MD simulation.", [["apo", "SIMPLE_CHEMICAL", 37, 40], ["OMTase", "SIMPLE_CHEMICAL", 60, 66], ["OMTase", "PROTEIN", 60, 66], ["The RMSD analysis", "TEST", 0, 17], ["stable", "OBSERVATION_MODIFIER", 77, 83]]], ["Similarly, the ligand stability was also determined by estimating the RMSD throughout the simulation.", [["ligand stability", "OBSERVATION", 15, 31], ["RMSD", "OBSERVATION_MODIFIER", 70, 74]]], ["The ligands viz. sinefungin, digitoxin, dihydroergotamine and teniposide showed RMSD value in the range of 0.2\u20130.3 nm confirming the stable conformation (Fig. 4B).", [["sinefungin", "CHEMICAL", 17, 27], ["digitoxin", "CHEMICAL", 29, 38], ["dihydroergotamine", "CHEMICAL", 40, 57], ["teniposide", "CHEMICAL", 62, 72], ["sinefungin", "CHEMICAL", 17, 27], ["digitoxin", "CHEMICAL", 29, 38], ["dihydroergotamine", "CHEMICAL", 40, 57], ["teniposide", "CHEMICAL", 62, 72], ["sinefungin", "SIMPLE_CHEMICAL", 17, 27], ["digitoxin", "SIMPLE_CHEMICAL", 29, 38], ["dihydroergotamine", "SIMPLE_CHEMICAL", 40, 57], ["teniposide", "SIMPLE_CHEMICAL", 62, 72], ["sinefungin", "TREATMENT", 17, 27], ["digitoxin", "TREATMENT", 29, 38], ["dihydroergotamine", "TREATMENT", 40, 57], ["teniposide", "TREATMENT", 62, 72], ["RMSD value", "TEST", 80, 90], ["stable", "OBSERVATION_MODIFIER", 133, 139]]], ["However, the ligand, irinotecan, displayed the RMSD value in the range of 0.5\u20131.2 nm with a high degree of fluctuation, revealing that the ligand is flexible and unstable.", [["irinotecan", "CHEMICAL", 21, 31], ["irinotecan", "CHEMICAL", 21, 31], ["irinotecan", "SIMPLE_CHEMICAL", 21, 31], ["irinotecan", "TREATMENT", 21, 31], ["the RMSD value", "TEST", 43, 57], ["a high degree of fluctuation", "PROBLEM", 90, 118], ["high degree", "OBSERVATION_MODIFIER", 92, 103], ["fluctuation", "OBSERVATION", 107, 118], ["unstable", "OBSERVATION_MODIFIER", 162, 170]]], ["The residue wise analysis of root means square fluctuation (RMSF) for apo and ligand-bound 2\u2032OMTase based on C\u03b1 atoms revealed that the structural changes occur in the loop forming region and displayed the high flexibility (Fig. 4C).", [["root", "ANATOMY", 29, 33], ["C\u03b1", "CHEMICAL", 109, 111], ["apo", "SIMPLE_CHEMICAL", 70, 73], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 91, 99], ["C\u03b1 atoms", "SIMPLE_CHEMICAL", 109, 117], ["apo and ligand-bound 2\u2032OMTase", "PROTEIN", 70, 99], ["C\u03b1 atoms", "PROTEIN", 109, 117], ["loop forming region", "PROTEIN", 168, 187], ["The residue wise analysis", "TEST", 0, 25], ["apo and ligand-bound", "TEST", 70, 90], ["the structural changes", "PROBLEM", 132, 154], ["loop", "ANATOMY_MODIFIER", 168, 172], ["high flexibility", "OBSERVATION", 206, 222]]], ["The protein regions displaying the high fluctuation are ranging from the amino acid 16\u201340, 72\u201380, 99\u2013110, 132\u2013147, 212\u2013219, and 242\u2013268 position shows the deviation up to 0.4 nm, apart from these regions other amino acids are showing variation from 0.1 to 0.25 nm.", [["amino acid", "CHEMICAL", 73, 83], ["amino acids", "CHEMICAL", 210, 221], ["amino acid", "CHEMICAL", 73, 83], ["amino acids", "CHEMICAL", 210, 221], ["amino acid", "AMINO_ACID", 73, 83], ["16\u201340", "AMINO_ACID", 84, 89], ["amino acids", "AMINO_ACID", 210, 221], ["protein regions", "PROTEIN", 4, 19], ["The protein regions", "TEST", 0, 19], ["the amino acid", "TEST", 69, 83], ["the deviation", "PROBLEM", 151, 164], ["amino acids", "TEST", 210, 221], ["high fluctuation", "OBSERVATION", 35, 51], ["amino acids", "OBSERVATION", 210, 221], ["variation", "OBSERVATION_MODIFIER", 234, 243]]], ["The ligand-bound complex viz.", [["ligand-bound complex", "PROTEIN", 4, 24]]], ["2\u2032OMTase-sinefungin, 2\u2032OMTase-dihydroergotamine, 2\u2032OMTase-irinotecan and 2\u2032OMTase-teniposide, when compared with the apo-2\u2032OMTase, displayed the high fluctuation in the temperature factor of the region mentioned above suggesting that these regions are mainly involved in the formation of catalytic cleft.Molecular dynamic simulation of the apo and ligand-bound form of 2\u2032OMTase ::: ResultsThe radius of gyration analysis of apo 2\u2032OMTase for the estimation of global compactness displayed the average Rg values of 1.90 nm up to 50 ns; however, a small increment in the Rg value was observed between 18 ns to 23 ns (Fig. 4D).", [["sinefungin", "CHEMICAL", 9, 19], ["dihydroergotamine", "CHEMICAL", 30, 47], ["2\u2032OMTase-", "CHEMICAL", 49, 58], ["irinotecan", "CHEMICAL", 58, 68], ["2\u2032OMTase-teniposide", "CHEMICAL", 73, 92], ["sinefungin", "CHEMICAL", 9, 19], ["2\u2032OMTase-dihydroergotamine", "CHEMICAL", 21, 47], ["2\u2032OMTase-irinotecan", "CHEMICAL", 49, 68], ["2\u2032OMTase-teniposide", "CHEMICAL", 73, 92], ["2\u2032OMTase-sinefungin", "SIMPLE_CHEMICAL", 0, 19], ["2\u2032OMTase-dihydroergotamine", "SIMPLE_CHEMICAL", 21, 47], ["2\u2032OMTase-irinotecan", "SIMPLE_CHEMICAL", 49, 68], ["2\u2032OMTase-teniposide", "SIMPLE_CHEMICAL", 73, 92], ["apo-2\u2032OMTase", "SIMPLE_CHEMICAL", 117, 129], ["apo", "SIMPLE_CHEMICAL", 340, 343], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 369, 377], ["apo 2\u2032OMTase", "SIMPLE_CHEMICAL", 424, 436], ["apo-2\u2032OMTase", "PROTEIN", 117, 129], ["apo 2\u2032OMTase", "PROTEIN", 424, 436], ["dihydroergotamine", "TREATMENT", 30, 47], ["irinotecan", "TREATMENT", 58, 68], ["2\u2032OMTase-teniposide", "TREATMENT", 73, 92], ["the high fluctuation", "PROBLEM", 141, 161], ["catalytic cleft", "PROBLEM", 288, 303], ["global compactness", "PROBLEM", 459, 477], ["a small increment", "PROBLEM", 543, 560], ["the Rg value", "TEST", 564, 576], ["high fluctuation", "OBSERVATION", 145, 161], ["catalytic cleft", "OBSERVATION", 288, 303], ["radius", "OBSERVATION_MODIFIER", 393, 399], ["small", "OBSERVATION_MODIFIER", 545, 550]]], ["The ligand-bound 2\u2032OMTase complexes displayed the fluctuation in Rg value for an initial 3 ns, and thereafter the Rg value remains stable in the range of 1.85\u20131.89 nm throughout the simulation (Fig. 4D).", [["2\u2032OMTase", "SIMPLE_CHEMICAL", 17, 25], ["ligand-bound 2\u2032OMTase complexes", "PROTEIN", 4, 35], ["The ligand-bound", "TEST", 0, 16], ["an initial 3 ns", "TREATMENT", 78, 93], ["the Rg value", "TEST", 110, 122], ["stable", "OBSERVATION_MODIFIER", 131, 137]]], ["The Rg analysis concludes that the protein remains in stable conformation resulted in achieving global compactness.", [["The Rg analysis", "TEST", 0, 15], ["the protein", "TEST", 31, 42], ["global compactness", "OBSERVATION", 96, 114]]], ["Similarly, the estimated average solvent accessible surface area (SASA) for apo form of 2\u2032OMTase up to 25 ns was 160 nm2 and thereafter, it reduces to 150 nm2 and remained unchanged throughout the MD simulation (Fig. 4E).", [["surface area", "ANATOMY", 52, 64], ["average", "OBSERVATION_MODIFIER", 25, 32], ["solvent", "OBSERVATION_MODIFIER", 33, 40], ["accessible", "OBSERVATION_MODIFIER", 41, 51], ["surface", "OBSERVATION_MODIFIER", 52, 59], ["unchanged", "OBSERVATION_MODIFIER", 172, 181]]], ["The ligand-bound complex of 2\u2032OMTase also displayed a similar type of pattern, and the average SASA was found to be in the range of 133\u2013141 nm2.Molecular dynamic simulation of the apo and ligand-bound form of 2\u2032OMTase ::: ResultsThe ligand-bound complex of 2\u2032OMTase after the MD simulation was further subjected to the estimation of the interaction energy between protein and ligand molecule.", [["2\u2032OMTase", "SIMPLE_CHEMICAL", 28, 36], ["apo", "SIMPLE_CHEMICAL", 180, 183], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 209, 217], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 257, 265], ["ligand-bound complex", "PROTEIN", 4, 24], ["OMTase", "PROTEIN", 30, 36], ["ligand-bound complex", "PROTEIN", 233, 253], ["2\u2032OMTase", "PROTEIN", 257, 265], ["ligand molecule", "PROTEIN", 376, 391], ["The ligand-bound complex", "TEST", 0, 24], ["the average SASA", "TEST", 83, 99], ["ligand molecule", "OBSERVATION", 376, 391]]], ["The interaction energy of 2\u2032OMTase for sinefungin was \u221254.35 kcal/mol, for digitoxin \u221269.47 kcal/mol, for dihydroergotamine \u221292.74 kcal/mol, irinotecan \u221275.34 kcal/mol, and teniposide \u221297.88 kcal/mol.", [["sinefungin", "CHEMICAL", 39, 49], ["digitoxin", "CHEMICAL", 75, 84], ["dihydroergotamine", "CHEMICAL", 106, 123], ["irinotecan", "CHEMICAL", 141, 151], ["teniposide", "CHEMICAL", 173, 183], ["sinefungin", "CHEMICAL", 39, 49], ["digitoxin", "CHEMICAL", 75, 84], ["dihydroergotamine", "CHEMICAL", 106, 123], ["irinotecan", "CHEMICAL", 141, 151], ["teniposide", "CHEMICAL", 173, 183], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 26, 34], ["sinefungin", "SIMPLE_CHEMICAL", 39, 49], ["digitoxin", "SIMPLE_CHEMICAL", 75, 84], ["dihydroergotamine", "SIMPLE_CHEMICAL", 106, 123], ["irinotecan", "SIMPLE_CHEMICAL", 141, 151], ["teniposide", "SIMPLE_CHEMICAL", 173, 183], ["sinefungin", "TREATMENT", 39, 49], ["digitoxin", "TREATMENT", 75, 84], ["dihydroergotamine", "TREATMENT", 106, 123], ["irinotecan", "TREATMENT", 141, 151], ["teniposide", "TREATMENT", 173, 183]]], ["The interaction energy calculation reveals that the digitoxin, dihydroergotamine, irinotecan, and teniposide has more affinity towards 2\u2032OMTase and forms a stable conformation as compared to the reference ligand i.e. sinefungin.DiscussionMethylation of mRNA Cap present at 5\u2032 terminal is a crucial process, which protects its recognition as a foreign particle from the host immune system.", [["immune system", "ANATOMY", 374, 387], ["digitoxin", "CHEMICAL", 52, 61], ["dihydroergotamine", "CHEMICAL", 63, 80], ["irinotecan", "CHEMICAL", 82, 92], ["teniposide", "CHEMICAL", 98, 108], ["sinefungin", "CHEMICAL", 217, 227], ["digitoxin", "CHEMICAL", 52, 61], ["dihydroergotamine", "CHEMICAL", 63, 80], ["irinotecan", "CHEMICAL", 82, 92], ["teniposide", "CHEMICAL", 98, 108], ["sinefungin", "CHEMICAL", 217, 227], ["digitoxin", "SIMPLE_CHEMICAL", 52, 61], ["dihydroergotamine", "SIMPLE_CHEMICAL", 63, 80], ["irinotecan", "SIMPLE_CHEMICAL", 82, 92], ["teniposide", "SIMPLE_CHEMICAL", 98, 108], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 135, 143], ["sinefungin", "SIMPLE_CHEMICAL", 217, 227], ["Cap", "GENE_OR_GENE_PRODUCT", 258, 261], ["immune system", "ANATOMICAL_SYSTEM", 374, 387], ["OMTase", "PROTEIN", 137, 143], ["mRNA Cap", "PROTEIN", 253, 261], ["The interaction energy calculation", "TEST", 0, 34], ["the digitoxin", "TREATMENT", 48, 61], ["dihydroergotamine", "TREATMENT", 63, 80], ["irinotecan", "TREATMENT", 82, 92], ["teniposide", "TREATMENT", 98, 108], ["mRNA Cap", "PROBLEM", 253, 261], ["stable", "OBSERVATION", 156, 162], ["Cap", "OBSERVATION_MODIFIER", 258, 261], ["crucial process", "OBSERVATION", 290, 305], ["foreign particle", "OBSERVATION", 343, 359], ["host immune", "OBSERVATION", 369, 380]]], ["2\u2032OMTase is a crucial enzyme involved in the methylation of 5\u2032capped mRNA, which makes this enzyme a potential drug target for identification and screening of FDA approved drugs for repurposing.", [["2\u2032OMTase", "SIMPLE_CHEMICAL", 0, 8], ["OMTase", "PROTEIN", 2, 8], ["5\u2032capped mRNA", "RNA", 60, 73], ["a crucial enzyme", "PROBLEM", 12, 28], ["screening", "TEST", 146, 155], ["FDA", "TREATMENT", 159, 162], ["drugs", "TREATMENT", 172, 177]]], ["The modeled structure of the 2\u2032OMTase protein displayed the conserved fold of the Class I MTase enzyme [12,13].DiscussionThe quality assessment of the modeled structure by SAVES server reveals that the 100% non-glycine and non-proline residues attain the favorable dihedral, phi (\u03d5), and psi (\u03c8) angles.", [["non-glycine", "CHEMICAL", 207, 218], ["non-proline", "CHEMICAL", 223, 234], ["non-glycine", "CHEMICAL", 207, 218], ["non-proline", "CHEMICAL", 223, 234], ["2\u2032OMTase", "GENE_OR_GENE_PRODUCT", 29, 37], ["non-glycine", "SIMPLE_CHEMICAL", 207, 218], ["non-proline", "SIMPLE_CHEMICAL", 223, 234], ["2\u2032OMTase protein", "PROTEIN", 29, 45], ["Class I MTase enzyme", "PROTEIN", 82, 102], ["MTase enzyme", "TEST", 90, 102], ["The quality assessment", "TEST", 121, 143], ["SAVES server", "TEST", 172, 184], ["the 100% non-glycine", "TREATMENT", 198, 218], ["non-proline residues", "PROBLEM", 223, 243], ["the favorable dihedral, phi (\u03d5), and psi (\u03c8) angles", "PROBLEM", 251, 302], ["favorable dihedral", "OBSERVATION", 255, 273]]], ["The non-bonded interaction analysis of different types of atoms in the modeled structure when compared with the experimentally determined structure also suggested that the modeled structure is of excellent quality and can be used for further analysis.", [["further analysis", "TEST", 234, 250], ["non-bonded interaction", "OBSERVATION", 4, 26], ["different", "OBSERVATION_MODIFIER", 39, 48], ["atoms", "OBSERVATION_MODIFIER", 58, 63]]], ["The multiple sequence alignment analysis of 2\u2032OMTase with other homologous proteins revealed that the residues involved in catalytic tetrad formation i.e., Lys46, Asp130, Lys170, and Glu203, are strictly conserved in all the CoV strains [12,13].", [["Lys46", "CHEMICAL", 156, 161], ["Asp", "CHEMICAL", 163, 166], ["Lys", "CHEMICAL", 171, 174], ["Glu203", "CHEMICAL", 183, 189], ["2\u2032OMTase", "GENE_OR_GENE_PRODUCT", 44, 52], ["Lys46", "GENE_OR_GENE_PRODUCT", 156, 161], ["Asp130", "AMINO_ACID", 163, 169], ["Lys170", "AMINO_ACID", 171, 177], ["Glu203", "GENE_OR_GENE_PRODUCT", 183, 189], ["Glu203", "PROTEIN", 183, 189], ["The multiple sequence alignment analysis", "TEST", 0, 40], ["other homologous proteins", "TEST", 58, 83], ["the residues", "PROBLEM", 98, 110], ["Lys46", "TEST", 156, 161], ["Asp", "TEST", 163, 166], ["Lys", "TEST", 171, 174], ["Glu203", "TEST", 183, 189]]], ["Structure-based screening analysis of 3000 FDA approved drugs against 2\u2032OMTase for repurposing helped in identifying the inhibitor molecules which can block the active site pocket of 2\u2032OMTase enzyme.", [["2\u2032OMTase", "SIMPLE_CHEMICAL", 70, 78], ["2\u2032OMTase enzyme", "GENE_OR_GENE_PRODUCT", 183, 198], ["2\u2032OMTase enzyme", "PROTEIN", 183, 198], ["based screening analysis", "TEST", 10, 34], ["drugs", "TREATMENT", 56, 61], ["repurposing", "TREATMENT", 83, 94], ["the inhibitor molecules", "TREATMENT", 117, 140]]], ["The initial top 20 FDA approved potential drug compounds included antiviral, alkaloid based drugs, cardiac glycoside, anticancer drugs, steroid-based drugs, and other drugs, etc. Five best compounds were selected based on the maximum number of conformations at a particular free energy of binding, ranging from \u22129.8 kcal/mol to \u22128.3 kcal/mol after re-docking analysis of the top 20 FDA approved drugs.", [["cardiac", "ANATOMY", 99, 106], ["anticancer", "ANATOMY", 118, 128], ["steroid", "CHEMICAL", 136, 143], ["steroid", "CHEMICAL", 136, 143], ["alkaloid", "SIMPLE_CHEMICAL", 77, 85], ["cardiac glycoside", "SIMPLE_CHEMICAL", 99, 116], ["anticancer", "CANCER", 118, 128], ["steroid", "SIMPLE_CHEMICAL", 136, 143], ["drug compounds", "TREATMENT", 42, 56], ["antiviral", "TREATMENT", 66, 75], ["alkaloid based drugs", "TREATMENT", 77, 97], ["cardiac glycoside", "TREATMENT", 99, 116], ["anticancer drugs", "TREATMENT", 118, 134], ["steroid-based drugs", "TREATMENT", 136, 155], ["other drugs", "TREATMENT", 161, 172]]], ["These five best drug compounds were sinefungin, digitoxin, dihydroergotamine, irinotecan, and teniposide.", [["sinefungin", "CHEMICAL", 36, 46], ["digitoxin", "CHEMICAL", 48, 57], ["dihydroergotamine", "CHEMICAL", 59, 76], ["irinotecan", "CHEMICAL", 78, 88], ["teniposide", "CHEMICAL", 94, 104], ["sinefungin", "CHEMICAL", 36, 46], ["digitoxin", "CHEMICAL", 48, 57], ["dihydroergotamine", "CHEMICAL", 59, 76], ["irinotecan", "CHEMICAL", 78, 88], ["teniposide", "CHEMICAL", 94, 104], ["sinefungin", "SIMPLE_CHEMICAL", 36, 46], ["digitoxin", "SIMPLE_CHEMICAL", 48, 57], ["dihydroergotamine", "SIMPLE_CHEMICAL", 59, 76], ["irinotecan", "SIMPLE_CHEMICAL", 78, 88], ["teniposide", "SIMPLE_CHEMICAL", 94, 104], ["sinefungin", "TREATMENT", 36, 46], ["digitoxin", "TREATMENT", 48, 57], ["dihydroergotamine", "TREATMENT", 59, 76], ["irinotecan", "TREATMENT", 78, 88], ["teniposide", "TREATMENT", 94, 104]]], ["These compounds interact through hydrogen bond and hydrophobic interactions predominantly with Asp130, Lys170, and Glu203, the amino acid residues involved in the formation of a catalytic tetrad of 2\u2032OMTase.", [["Asp130, Lys170", "CHEMICAL", 95, 109], ["amino acid", "CHEMICAL", 127, 137], ["hydrogen", "CHEMICAL", 33, 41], ["Asp", "CHEMICAL", 95, 98], ["Lys", "CHEMICAL", 103, 106], ["Glu203", "CHEMICAL", 115, 121], ["amino acid", "CHEMICAL", 127, 137], ["Asp130", "AMINO_ACID", 95, 101], ["Lys170", "AMINO_ACID", 103, 109], ["Glu203", "AMINO_ACID", 115, 121], ["amino acid", "AMINO_ACID", 127, 137], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 198, 206], ["catalytic tetrad of 2\u2032OMTase", "PROTEIN", 178, 206], ["Asp", "TEST", 95, 98], ["Lys", "TEST", 103, 106], ["Glu203", "TEST", 115, 121], ["the amino acid residues", "PROBLEM", 123, 146], ["a catalytic tetrad", "TREATMENT", 176, 194], ["hydrogen bond", "OBSERVATION", 33, 46]]], ["These amino acid residues viz.", [["amino acid", "CHEMICAL", 6, 16], ["amino acid", "CHEMICAL", 6, 16], ["amino acid", "AMINO_ACID", 6, 16], ["These amino acid residues viz", "PROBLEM", 0, 29], ["amino", "OBSERVATION", 6, 11], ["acid residues", "OBSERVATION", 12, 25]]], ["Asp130, Lys170, and Glu203 help in accommodating and stabilizing the ligands in the catalytic cleft.", [["Asp", "CHEMICAL", 0, 3], ["Lys170", "CHEMICAL", 8, 14], ["Glu203", "CHEMICAL", 20, 26], ["Asp130", "AMINO_ACID", 0, 6], ["Lys170", "AMINO_ACID", 8, 14], ["Glu203", "AMINO_ACID", 20, 26], ["Asp", "TEST", 0, 3], ["Glu203", "TREATMENT", 20, 26], ["catalytic cleft", "OBSERVATION", 84, 99]]], ["The apo and ligand-bound complexes were analyzed for conformational dynamics and stability by MD simulation studies.", [["apo", "SIMPLE_CHEMICAL", 4, 7], ["apo and ligand-bound complexes", "PROTEIN", 4, 34], ["The apo and ligand-bound complexes", "TEST", 0, 34], ["conformational dynamics", "TEST", 53, 76], ["MD simulation studies", "TEST", 94, 115]]], ["The RMSD analysis of apo and complex form revealed that except 2\u2032OMTase-irinotecan complex, all the conformations attain the stable conformation.", [["irinotecan", "CHEMICAL", 72, 82], ["irinotecan", "CHEMICAL", 72, 82], ["apo", "GENE_OR_GENE_PRODUCT", 21, 24], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 63, 71], ["irinotecan", "SIMPLE_CHEMICAL", 72, 82], ["apo and complex form", "PROTEIN", 21, 41], ["OMTase", "PROTEIN", 65, 71], ["irinotecan complex", "PROTEIN", 72, 90], ["The RMSD analysis", "TEST", 0, 17], ["OMTase-irinotecan complex", "TREATMENT", 65, 90], ["stable", "OBSERVATION_MODIFIER", 125, 131]]], ["The RMSF analysis displayed that the regions of the protein ranging from 16\u201340, 72\u201380, 99\u2013110, 132\u2013147, 212\u2013219, and 242\u2013268 are mainly composed of \u03b2 and \u03b3 turns and provide flexibility.", [["\u03b2", "GENE_OR_GENE_PRODUCT", 148, 149], ["The RMSF analysis", "TEST", 0, 17], ["the protein", "TEST", 48, 59], ["RMSF", "OBSERVATION", 4, 8]]], ["The interaction energy analysis of the selected drugs revealed that digitoxin, dihydroergotamine, irinotecan, and teniposide have more affinity towards 2\u2032OMTase and forms a stable conformation as compared to the earlier known inhibitor, i.e. sinefungin.DiscussionThe nucleoside inhibitor, sinefungin, suppressed the replication of feline herpesvirus type 1 in the host feline kidney cells [17].", [["kidney cells", "ANATOMY", 376, 388], ["digitoxin", "CHEMICAL", 68, 77], ["dihydroergotamine", "CHEMICAL", 79, 96], ["irinotecan", "CHEMICAL", 98, 108], ["teniposide", "CHEMICAL", 114, 124], ["sinefungin", "CHEMICAL", 242, 252], ["nucleoside", "CHEMICAL", 267, 277], ["sinefungin", "CHEMICAL", 289, 299], ["digitoxin", "CHEMICAL", 68, 77], ["dihydroergotamine", "CHEMICAL", 79, 96], ["irinotecan", "CHEMICAL", 98, 108], ["teniposide", "CHEMICAL", 114, 124], ["sinefungin", "CHEMICAL", 242, 252], ["nucleoside", "CHEMICAL", 267, 277], ["sinefungin", "CHEMICAL", 289, 299], ["digitoxin", "SIMPLE_CHEMICAL", 68, 77], ["dihydroergotamine", "SIMPLE_CHEMICAL", 79, 96], ["irinotecan", "SIMPLE_CHEMICAL", 98, 108], ["teniposide", "SIMPLE_CHEMICAL", 114, 124], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 152, 160], ["sinefungin", "SIMPLE_CHEMICAL", 242, 252], ["nucleoside", "SIMPLE_CHEMICAL", 267, 277], ["sinefungin", "SIMPLE_CHEMICAL", 289, 299], ["feline herpesvirus type 1", "ORGANISM", 331, 356], ["feline", "ORGANISM", 369, 375], ["kidney cells", "CELL", 376, 388], ["OMTase", "PROTEIN", 154, 160], ["host feline kidney cells", "CELL_TYPE", 364, 388], ["feline herpesvirus", "SPECIES", 331, 349], ["feline", "SPECIES", 369, 375], ["feline herpesvirus type 1", "SPECIES", 331, 356], ["The interaction energy analysis", "TEST", 0, 31], ["digitoxin", "TREATMENT", 68, 77], ["dihydroergotamine", "TREATMENT", 79, 96], ["irinotecan", "TREATMENT", 98, 108], ["teniposide", "TREATMENT", 114, 124], ["The nucleoside inhibitor", "TREATMENT", 263, 287], ["sinefungin", "TREATMENT", 289, 299], ["stable", "OBSERVATION_MODIFIER", 173, 179], ["feline herpesvirus", "OBSERVATION", 331, 349], ["kidney", "ANATOMY", 376, 382]]], ["The alkaloid based drug, dihydroergotamine was not used as antiviral but for the migraine problems in HIV patients [18].", [["dihydroergotamine", "CHEMICAL", 25, 42], ["migraine", "DISEASE", 81, 89], ["HIV", "DISEASE", 102, 105], ["dihydroergotamine", "CHEMICAL", 25, 42], ["alkaloid", "SIMPLE_CHEMICAL", 4, 12], ["dihydroergotamine", "SIMPLE_CHEMICAL", 25, 42], ["HIV", "ORGANISM", 102, 105], ["patients", "ORGANISM", 106, 114], ["HIV", "SPECIES", 102, 105], ["patients", "SPECIES", 106, 114], ["HIV", "SPECIES", 102, 105], ["The alkaloid based drug", "TREATMENT", 0, 23], ["dihydroergotamine", "TREATMENT", 25, 42], ["antiviral", "TREATMENT", 59, 68], ["the migraine problems", "PROBLEM", 77, 98]]], ["Cardiac glycosides such as digitoxin inhibit the human cytomegalovirus (HCMV) replication by inducing AMP-activated protein kinase (AMPK) activity and autophagy flux through the Na+, K+/ATPase \u03b11 subunit activation [19].", [["Cardiac", "ANATOMY", 0, 7], ["digitoxin", "CHEMICAL", 27, 36], ["AMP", "CHEMICAL", 102, 105], ["K", "CHEMICAL", 183, 184], ["digitoxin", "CHEMICAL", 27, 36], ["AMP", "CHEMICAL", 102, 105], ["K+", "CHEMICAL", 183, 185], ["Cardiac glycosides", "SIMPLE_CHEMICAL", 0, 18], ["digitoxin", "SIMPLE_CHEMICAL", 27, 36], ["human cytomegalovirus", "ORGANISM", 49, 70], ["HCMV", "ORGANISM", 72, 76], ["AMP-activated protein kinase", "GENE_OR_GENE_PRODUCT", 102, 130], ["AMPK", "GENE_OR_GENE_PRODUCT", 132, 136], ["Na+, K+/ATPase \u03b11", "GENE_OR_GENE_PRODUCT", 178, 195], ["AMP-activated protein kinase", "PROTEIN", 102, 130], ["AMPK", "PROTEIN", 132, 136], ["Na+, K+/ATPase \u03b11 subunit", "PROTEIN", 178, 203], ["human", "SPECIES", 49, 54], ["human cytomegalovirus", "SPECIES", 49, 70], ["HCMV", "SPECIES", 72, 76], ["Cardiac glycosides", "TREATMENT", 0, 18], ["digitoxin", "TREATMENT", 27, 36], ["the human cytomegalovirus", "PROBLEM", 45, 70], ["AMP", "TEST", 102, 105], ["activated protein kinase", "TEST", 106, 130], ["autophagy flux", "TEST", 151, 165], ["the Na+", "TEST", 174, 181], ["K", "TEST", 183, 184], ["glycosides", "OBSERVATION", 8, 18]]], ["Similarly, teniposide, the anticancer compound, inhibits the replication of SV40 by blocking the topoisomerase type II activity [20].", [["anticancer", "ANATOMY", 27, 37], ["teniposide", "CHEMICAL", 11, 21], ["teniposide", "CHEMICAL", 11, 21], ["teniposide", "SIMPLE_CHEMICAL", 11, 21], ["anticancer", "CANCER", 27, 37], ["SV40", "ORGANISM", 76, 80], ["topoisomerase type II", "GENE_OR_GENE_PRODUCT", 97, 118], ["topoisomerase type II", "PROTEIN", 97, 118], ["teniposide", "TREATMENT", 11, 21], ["the replication of SV40", "TREATMENT", 57, 80], ["anticancer compound", "OBSERVATION", 27, 46]]], ["To date, all these potential FDA approved drugs are used for different applications and not used for the inhibition of 2\u2032OMTase.", [["drugs", "TREATMENT", 42, 47], ["different applications", "TREATMENT", 61, 83], ["the inhibition of 2\u2032OMTase", "TREATMENT", 101, 127]]], ["The strong predicted binding of these approved drugs at the active site of 2\u2032OMTase displayed that they can be used for inactivating the enzyme.DiscussionThe SARS-CoV-2 infection has created a global pandemic and an urgent need for therapeutics.", [["SARS-CoV-2 infection", "DISEASE", 158, 178], ["2\u2032OMTase", "SIMPLE_CHEMICAL", 75, 83], ["SARS-CoV-2", "ORGANISM", 158, 168], ["enzyme", "PROTEIN", 137, 143], ["SARS-CoV-2", "SPECIES", 158, 168], ["drugs", "TREATMENT", 47, 52], ["the enzyme", "TEST", 133, 143], ["The SARS", "TEST", 154, 162], ["2 infection", "PROBLEM", 167, 178], ["a global pandemic", "PROBLEM", 191, 208], ["therapeutics", "TREATMENT", 232, 244]]], ["Repurposing of an existing drug based on the bioinformatics study could be a fast way to understand its antiviral efficacy against SARS-CoV-2.", [["SARS", "DISEASE", 131, 135], ["SARS-CoV-2", "ORGANISM", 131, 141], ["SARS-CoV", "SPECIES", 131, 139], ["the bioinformatics study", "TEST", 41, 65], ["SARS", "PROBLEM", 131, 135]]], ["Although the understanding of SARS-CoV-2 molecular biology is limited, and there is a pressing need to design some potential therapeutics.", [["SARS", "DISEASE", 30, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["SARS", "PROBLEM", 30, 34]]], ["The identification of some novel drugs that can display significant effect in silico can be further explored to validate its use clinically to control the disease and associated mortality.", [["some novel drugs", "TREATMENT", 22, 38], ["the disease", "PROBLEM", 151, 162]]], ["This study may pave the way in understanding the biology of SARS-CoV-2 and finding new possible drugs.Declaration of competing interestThe authors do not have any potential conflict of interest.", [["SARS", "DISEASE", 60, 64], ["SARS-CoV-2", "ORGANISM", 60, 70], ["SARS-CoV", "SPECIES", 60, 68], ["This study", "TEST", 0, 10]]]], "47042cce544f3acc20025192c34af7a0dcbc172b": [["IntroductionThe new decade of the 21 st century (2020) started with a deadly coronavirus disease 2019 pandemic caused by a novel coronavirus (SARS-CoV-2) in Wuhan, China [1] . .", [["coronavirus disease", "DISEASE", 77, 96], ["pandemic", "DISEASE", 102, 110], ["SARS", "DISEASE", 142, 146], ["coronavirus", "ORGANISM", 77, 88], ["SARS-CoV-2", "ORGANISM", 142, 152], ["coronavirus", "SPECIES", 129, 140], ["SARS-CoV-2", "SPECIES", 142, 152], ["a deadly coronavirus disease", "PROBLEM", 68, 96], ["pandemic", "PROBLEM", 102, 110], ["a novel coronavirus", "PROBLEM", 121, 140], ["new", "OBSERVATION_MODIFIER", 16, 19]]], ["In December 2019, various cases of pneumonia with unknown etiology were reported in Wuhan, China.", [["pneumonia", "DISEASE", 35, 44], ["pneumonia", "PROBLEM", 35, 44], ["pneumonia", "OBSERVATION", 35, 44]]], ["Later, on 10 th January 2020, the disease was confirmed as viral pneumonia and found epidemiologically linked with Huanan seafood market of Wuhan, where wild animals including bats were sold [2, 3] .", [["viral pneumonia", "DISEASE", 59, 74], ["bats", "ORGANISM", 176, 180], ["the disease", "PROBLEM", 30, 41], ["viral pneumonia", "PROBLEM", 59, 74], ["disease", "OBSERVATION", 34, 41], ["viral", "OBSERVATION_MODIFIER", 59, 64], ["pneumonia", "OBSERVATION", 65, 74]]], ["Soon after the Chinese authorities declared an emergency situation in Wuhan, other countries in the world started reporting COVID-19 cases [4] .", [["COVID", "TEST", 124, 129]]], ["Due to high spread, morbidity, mortality, and infectiousness, WHO declared COVID-19 outbreak as a pandemic [5] .", [["high spread", "PROBLEM", 7, 18], ["morbidity", "PROBLEM", 20, 29], ["infectiousness", "PROBLEM", 46, 60], ["high", "OBSERVATION_MODIFIER", 7, 11], ["spread", "OBSERVATION_MODIFIER", 12, 18]]], ["As of June 6, 2020, more than 6.7 millions confirmed cases and more than 3,90000 deaths are reported from J o u r n a l P r e -p r o o f COVID-19 pandemic (Walker, 2020).", [["deaths", "DISEASE", 81, 87], ["COVID", "TEST", 137, 142]]], ["To curb the risk of spread and manage the adverse impacts of virus, it is necessary to know the medical consequences associated with COVID-19 infection.IntroductionIn this article, we briefly describe the consequences of highly infectous human corona viruses, and elaborate the transmission and health consequences (both physical and mental health) of COVID-19 disease.", [["COVID-19", "CHEMICAL", 133, 141], ["infection", "DISEASE", 142, 151], ["COVID-19", "ORGANISM", 133, 141], ["human", "ORGANISM", 238, 243], ["human", "SPECIES", 238, 243], ["COVID-19", "SPECIES", 133, 141], ["human corona viruses", "SPECIES", 238, 258], ["spread", "PROBLEM", 20, 26], ["the adverse impacts of virus", "PROBLEM", 38, 66], ["COVID-19 infection", "PROBLEM", 133, 151], ["highly infectous human corona viruses", "PROBLEM", 221, 258], ["COVID-19 disease", "PROBLEM", 352, 368], ["infection", "OBSERVATION", 142, 151], ["corona viruses", "OBSERVATION", 244, 258]]], ["We further discuss the potential therapeutic and preventive strategies, and required research investigations that may help managing and controlling the spread of COVID-19 disease.SARS CoV2 as one of CoronavirusesBefore COVID-19, severe acute respiratory syndrome (SARS) outbreak caused by SARS-CoV during 2002 in Guangdong, China affected 8098 individuals and killed 774 individuals in 29 different countries [6] .", [["COVID", "DISEASE", 162, 167], ["SARS", "DISEASE", 179, 183], ["acute respiratory syndrome", "DISEASE", 236, 262], ["SARS", "DISEASE", 264, 268], ["SARS", "DISEASE", 289, 293], ["COVID-19", "CANCER", 162, 170], ["SARS-CoV", "ORGANISM", 289, 297], ["CoronavirusesBefore COVID-19", "SPECIES", 199, 227], ["SARS-CoV", "SPECIES", 289, 297], ["preventive strategies", "TREATMENT", 49, 70], ["research investigations", "TEST", 85, 108], ["COVID-19 disease", "PROBLEM", 162, 178], ["CoronavirusesBefore COVID", "TEST", 199, 224], ["severe acute respiratory syndrome", "PROBLEM", 229, 262], ["SARS", "PROBLEM", 289, 293], ["severe", "OBSERVATION_MODIFIER", 229, 235], ["acute", "OBSERVATION_MODIFIER", 236, 241], ["respiratory syndrome", "OBSERVATION", 242, 262]]], ["Only a decade later (during 2012), the world witnessed the Middle East respiratory syndrome (MERS) outbreak caused by MERS-CoV in the Middle East [7] .", [["Middle East respiratory syndrome", "DISEASE", 59, 91], ["MERS", "DISEASE", 93, 97], ["MERS-CoV", "ORGANISM", 118, 126], ["MERS-CoV", "SPECIES", 118, 126], ["the Middle East respiratory syndrome", "PROBLEM", 55, 91], ["Middle", "ANATOMY_MODIFIER", 59, 65], ["respiratory syndrome", "OBSERVATION", 71, 91], ["Middle", "ANATOMY_MODIFIER", 134, 140]]], ["Until 2020, MERS-CoV infected 2468 individuals and caused 851 fatalities worldwide [8] .", [["fatalities", "DISEASE", 62, 72], ["MERS-CoV", "ORGANISM", 12, 20], ["MERS-CoV", "SPECIES", 12, 20]]], ["While researchers were still investigating the mechanisms to develop therapeutic strategies against MERS, another member of coronaviruses called SARS-CoV-2, emerged in Wuhan [9] .", [["MERS", "DISEASE", 100, 104], ["SARS", "DISEASE", 145, 149], ["coronaviruses", "ORGANISM", 124, 137], ["SARS-CoV-2", "ORGANISM", 145, 155], ["MERS", "PROTEIN", 100, 104], ["therapeutic strategies", "TREATMENT", 69, 91], ["MERS", "PROBLEM", 100, 104]]], ["Market civets were thought to be the possible source of SARS-CoV transmission to human, however, the virus strains in civets were found transmitted from horseshoe bats [10] .", [["SARS", "DISEASE", 56, 60], ["SARS-CoV", "ORGANISM", 56, 64], ["human", "ORGANISM", 81, 86], ["civets", "CANCER", 118, 124], ["human", "SPECIES", 81, 86], ["SARS-CoV", "SPECIES", 56, 64], ["human", "SPECIES", 81, 86], ["SARS", "PROBLEM", 56, 60], ["the virus strains in civets", "PROBLEM", 97, 124], ["thought to be the possible", "UNCERTAINTY", 19, 45]]], ["MERS-CoV strains obtained from camels were highly similar to those isolated from humans; with highly prevalent MERS-CoV-specific antibodies in camels from the Middle East, Africa, and Asia [7, [11] [12] [13] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["camels", "ORGANISM", 31, 37], ["humans", "ORGANISM", 81, 87], ["MERS-CoV", "ORGANISM", 111, 119], ["MERS-CoV-specific antibodies", "PROTEIN", 111, 139], ["humans", "SPECIES", 81, 87], ["MERS-CoV", "SPECIES", 0, 8], ["humans", "SPECIES", 81, 87], ["MERS-CoV", "SPECIES", 111, 119], ["CoV strains", "PROBLEM", 5, 16], ["specific antibodies in camels", "PROBLEM", 120, 149], ["Middle", "ANATOMY_MODIFIER", 159, 165]]], ["These observations suggest that MERS-CoV transmitted from camel to human.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["camel", "ORGANISM", 58, 63], ["human", "ORGANISM", 67, 72], ["camel", "SPECIES", 58, 63], ["human", "SPECIES", 67, 72], ["MERS-CoV", "SPECIES", 32, 40], ["camel", "SPECIES", 58, 63], ["human", "SPECIES", 67, 72]]], ["However, genome sequencing analysis revealed that MERS-CoV is phylogenetically related to bat coronaviruses [14] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 50, 58], ["bat coronaviruses", "ORGANISM", 90, 107], ["MERS-CoV", "DNA", 50, 58], ["MERS-CoV", "SPECIES", 50, 58], ["bat coronaviruses", "SPECIES", 90, 107], ["genome sequencing analysis", "TEST", 9, 35], ["MERS", "PROBLEM", 50, 54], ["CoV", "PROBLEM", 55, 58], ["bat coronaviruses", "PROBLEM", 90, 107]]], ["The zoonotic source of SARS-CoV-2 is not confirmed, however, its genome sequence exhibited close relatedness with two bat-derived SARS-like coronaviruses [15, 16] .", [["SARS", "DISEASE", 23, 27], ["SARS", "DISEASE", 130, 134], ["SARS-CoV-2", "ORGANISM", 23, 33], ["bat-derived SARS-like coronaviruses", "ORGANISM", 118, 153], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 23, 27], ["two bat-derived SARS", "PROBLEM", 114, 134], ["coronaviruses", "PROBLEM", 140, 153], ["zoonotic", "OBSERVATION_MODIFIER", 4, 12]]], ["Thus, it is thought that bats are the possible source of origination for SARS-CoV-2.", [["SARS", "DISEASE", 73, 77], ["bats", "ORGANISM", 25, 29], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 73, 83], ["SARS-CoV", "SPECIES", 73, 81], ["SARS", "PROBLEM", 73, 77], ["CoV", "TEST", 78, 81]]], ["Like MERS-CoV and SARS-CoV, SARS-CoV-2 belongs to betacoronavirus (subgenus; Sarbecovirus) [3, 17] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 5, 13], ["SARS-CoV", "ORGANISM", 18, 26], ["SARS-CoV-2", "ORGANISM", 28, 38], ["betacoronavirus", "ORGANISM", 50, 65], ["MERS-CoV", "SPECIES", 5, 13], ["SARS-CoV", "SPECIES", 18, 26], ["SARS-CoV-2", "SPECIES", 28, 38], ["CoV", "PROBLEM", 10, 13], ["SARS", "PROBLEM", 18, 22], ["CoV", "PROBLEM", 23, 26], ["SARS", "PROBLEM", 28, 32], ["CoV", "TEST", 33, 36], ["betacoronavirus", "PROBLEM", 50, 65]]], ["Reportedly, the genome sequencing analysis has revealed over 80% similarity between SARS-CoV-2 and SARS-CoV, however, there are some differences at the structural protein levels.", [["SARS-CoV-2", "ORGANISM", 84, 94], ["SARS-CoV", "ORGANISM", 99, 107], ["SARS-CoV", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 99, 107], ["the genome sequencing analysis", "TEST", 12, 42], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["SARS", "PROBLEM", 99, 103], ["protein levels", "OBSERVATION", 163, 177]]], ["For instance, the 8a protein was reported missing while the aminoacids number in 8b and 3c protein were found fluctuating in SARS-CoV-2 [17] .", [["aminoacids", "CHEMICAL", 60, 70], ["8b", "GENE_OR_GENE_PRODUCT", 81, 83], ["3c", "GENE_OR_GENE_PRODUCT", 88, 90], ["8a protein", "PROTEIN", 18, 28], ["8b and 3c protein", "PROTEIN", 81, 98], ["SARS-CoV", "SPECIES", 125, 133], ["the 8a protein", "TEST", 14, 28], ["the aminoacids number", "TEST", 56, 77], ["3c protein", "TEST", 88, 98], ["SARS", "TEST", 125, 129], ["CoV", "TEST", 130, 133]]], ["These differences can help in studying the infectiousness, transmission, and health impacts of COVID-19 infection.SARS CoV2 as one of CoronavirusesJ o u r n a l P r e -p r o o fTransmission of SARS-CoV-2Although bats are thought to be the source of origin for SARS-CoV-2, the intermediate animal that caused the transmission of virus to humans, is still unknown [3] .", [["COVID-19", "CHEMICAL", 95, 103], ["infection", "DISEASE", 104, 113], ["SARS", "DISEASE", 114, 118], ["SARS", "DISEASE", 193, 197], ["SARS", "DISEASE", 260, 264], ["COVID-19", "ORGANISM", 95, 103], ["SARS-CoV-2Although bats", "ORGANISM", 193, 216], ["SARS-CoV-2", "ORGANISM", 260, 270], ["humans", "ORGANISM", 337, 343], ["humans", "SPECIES", 337, 343], ["COVID-19", "SPECIES", 95, 103], ["SARS-CoV-2Although bats", "SPECIES", 193, 216], ["SARS-CoV", "SPECIES", 260, 268], ["humans", "SPECIES", 337, 343], ["the infectiousness", "PROBLEM", 39, 57], ["COVID-19 infection", "PROBLEM", 95, 113], ["fTransmission", "PROBLEM", 176, 189], ["SARS", "PROBLEM", 193, 197], ["CoV", "PROBLEM", 198, 201], ["bats", "PROBLEM", 212, 216], ["SARS", "PROBLEM", 260, 264], ["CoV", "TEST", 265, 268], ["virus", "PROBLEM", 328, 333], ["infection", "OBSERVATION", 104, 113]]], ["Once SARS-COV-2 transfers from zoonotic source to human, it can potentially transmit from human-to-human, mainly through respiratory droplets from an infected individual via coughing or sneezing [18] .", [["respiratory droplets", "ANATOMY", 121, 141], ["SARS", "DISEASE", 5, 9], ["coughing", "DISEASE", 174, 182], ["sneezing", "DISEASE", 186, 194], ["human", "ORGANISM", 50, 55], ["human", "ORGANISM", 90, 95], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 99, 104], ["SARS", "PROBLEM", 5, 9], ["respiratory droplets", "PROBLEM", 121, 141], ["coughing", "PROBLEM", 174, 182], ["sneezing", "PROBLEM", 186, 194]]], ["The virus can also transmit from an asymptomatic infected individual to infect healthy individual [19] .", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["asymptomatic", "OBSERVATION_MODIFIER", 36, 48], ["infected", "OBSERVATION", 49, 57]]], ["The entry of virus to host cell occurs in several steps including binding to a target host cell via cellular receptors, fusing the envelope with a cellular membrane, and forking over its genetic material inside the cell [20, 21] .", [["cell", "ANATOMY", 27, 31], ["cell", "ANATOMY", 91, 95], ["cellular", "ANATOMY", 100, 108], ["cellular membrane", "ANATOMY", 147, 164], ["cell", "ANATOMY", 215, 219], ["host cell", "CELL", 22, 31], ["cell", "CELL", 91, 95], ["cellular", "CELL", 100, 108], ["cellular membrane", "CELLULAR_COMPONENT", 147, 164], ["cell", "CELL", 215, 219], ["cellular receptors", "PROTEIN", 100, 118], ["a cellular membrane", "PROBLEM", 145, 164], ["virus", "OBSERVATION", 13, 18], ["host cell", "OBSERVATION", 22, 31], ["host cell", "OBSERVATION", 86, 95], ["cellular receptors", "OBSERVATION", 100, 118], ["cellular membrane", "OBSERVATION", 147, 164]]], ["This process is highly dependent upon binding specificity to receptors, proteolytic activation, and endocytosis efficiency.", [["proteolytic activation", "PROBLEM", 72, 94], ["endocytosis efficiency", "PROBLEM", 100, 122], ["endocytosis efficiency", "OBSERVATION", 100, 122]]], ["This entry process is facilitated by glycosylated spike (S) fusion protein, which is capable of significant structural rearrangement, thus plays an important role in fusing the viral membrane with the host cell membrane [15] .", [["membrane", "ANATOMY", 183, 191], ["cell membrane", "ANATOMY", 206, 219], ["glycosylated spike (S)", "GENE_OR_GENE_PRODUCT", 37, 59], ["membrane", "CELLULAR_COMPONENT", 183, 191], ["cell membrane", "CELLULAR_COMPONENT", 206, 219], ["glycosylated spike (S) fusion protein", "PROTEIN", 37, 74], ["glycosylated spike (S) fusion protein", "PROBLEM", 37, 74], ["significant structural rearrangement", "PROBLEM", 96, 132], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["structural rearrangement", "OBSERVATION", 108, 132], ["viral membrane", "OBSERVATION", 177, 191], ["host cell membrane", "OBSERVATION", 201, 219]]], ["The spike glycoproteins are comprised of two subunits known as S1 and S2, where S2 subunit contains fusion peptide [22] .", [["S1", "GENE_OR_GENE_PRODUCT", 63, 65], ["S2", "GENE_OR_GENE_PRODUCT", 70, 72], ["S2", "GENE_OR_GENE_PRODUCT", 80, 82], ["spike glycoproteins", "PROTEIN", 4, 23], ["S1", "PROTEIN", 63, 65], ["S2", "PROTEIN", 70, 72], ["S2 subunit", "PROTEIN", 80, 90], ["The spike glycoproteins", "PROBLEM", 0, 23], ["fusion peptide", "TREATMENT", 100, 114], ["S2", "ANATOMY", 70, 72]]], ["This fusion process is the key to virus entry into a cell, however, the fusion process is linked with the accessibility of the receptor determined by hinge-like conformational movements of the receptor-binding domain (RBD) of S1.", [["cell", "ANATOMY", 53, 57], ["cell", "CELL", 53, 57], ["hinge", "PROTEIN", 150, 155], ["receptor-binding domain", "PROTEIN", 193, 216], ["RBD", "PROTEIN", 218, 221], ["S1", "PROTEIN", 226, 228], ["This fusion process", "PROBLEM", 0, 19], ["the fusion process", "PROBLEM", 68, 86], ["fusion", "OBSERVATION", 5, 11], ["fusion", "OBSERVATION", 72, 78], ["S1", "ANATOMY", 226, 228]]], ["The RBD can transiently hide or expose the determinants of receptor binding [23] .", [["RBD", "PROTEIN", 4, 7], ["receptor binding", "PROBLEM", 59, 75]]], ["Soon after the entrance of the virus to the host cell, transcription of polyprotein 1a/1ab (pp1a/pp1ab) is initiated by the activity of the replicationtranscription complex (RTC) [22] .", [["cell", "ANATOMY", 49, 53], ["host cell", "CELL", 44, 53], ["/1", "GENE_OR_GENE_PRODUCT", 86, 88], ["pp1a", "GENE_OR_GENE_PRODUCT", 92, 96], ["pp1ab", "GENE_OR_GENE_PRODUCT", 97, 102], ["polyprotein 1a", "PROTEIN", 72, 86], ["pp1a", "PROTEIN", 92, 96], ["pp1ab", "PROTEIN", 97, 102], ["replicationtranscription complex", "PROTEIN", 140, 172], ["RTC", "PROTEIN", 174, 177], ["polyprotein 1a/1ab (pp1a/pp1ab)", "TREATMENT", 72, 103], ["the replicationtranscription complex (RTC)", "TREATMENT", 136, 178], ["host cell", "OBSERVATION", 44, 53]]], ["Binding of S protein to the cellular receptor ACE2 initiates the life cycle of SARS-CoV-2 in host cells [22] .Transmission of SARS-CoV-2Studying the infectiousness mechanism further can help to understand the source of origination and transmission.", [["cellular", "ANATOMY", 28, 36], ["cells", "ANATOMY", 98, 103], ["S protein", "GENE_OR_GENE_PRODUCT", 11, 20], ["cellular", "CELL", 28, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 79, 89], ["host cells", "CELL", 93, 103], ["SARS-CoV", "ORGANISM", 126, 134], ["S protein", "PROTEIN", 11, 20], ["cellular receptor", "PROTEIN", 28, 45], ["ACE2", "PROTEIN", 46, 50], ["host cells", "CELL_TYPE", 93, 103], ["the cellular receptor ACE2", "TREATMENT", 24, 50], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["SARS-CoV", "TEST", 126, 134], ["the infectiousness mechanism", "PROBLEM", 145, 173]]], ["Knowing the intermediate sources of transmission is important in disease control.", [["disease control", "TREATMENT", 65, 80]]], ["A recently report indicated pangolin as the possible intermediate source that might have transferred the virus to humans after receiving it from bat [24] .", [["pangolin", "CHEMICAL", 28, 36], ["pangolin", "GENE_OR_GENE_PRODUCT", 28, 36], ["humans", "ORGANISM", 114, 120], ["humans", "SPECIES", 114, 120], ["humans", "SPECIES", 114, 120], ["pangolin", "TREATMENT", 28, 36]]], ["The main reasons for the high rate of transmission are not well documented however, the higher affinity of RBD for binding to ACE2 receptors is considered to be one of the possibilities for the high rate of infectiousness [17, 25] .", [["RBD", "DISEASE", 107, 110], ["RBD", "GENE_OR_GENE_PRODUCT", 107, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 126, 130], ["RBD", "PROTEIN", 107, 110], ["ACE2 receptors", "PROTEIN", 126, 140], ["RBD", "PROBLEM", 107, 110], ["ACE2 receptors", "TEST", 126, 140], ["the high rate of infectiousness", "PROBLEM", 190, 221], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The RBD amino acids (L455, F486, Q493, S494, N501, and Y505) in SARS-CoV-2 can play a role in the determination of the host range [25] .", [["amino acids", "CHEMICAL", 8, 19], ["amino acids", "CHEMICAL", 8, 19], ["L455, F486, Q493, S494, N501, and Y505", "CHEMICAL", 21, 59], ["RBD", "SIMPLE_CHEMICAL", 4, 7], ["amino acids", "AMINO_ACID", 8, 19], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["RBD", "PROTEIN", 4, 7], ["SARS-CoV", "SPECIES", 64, 72], ["The RBD amino acids", "TEST", 0, 19], ["F486", "TEST", 27, 31], ["S494", "TEST", 39, 43], ["N501", "TEST", 45, 49], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72]]], ["Further research is required to investigate these RBD amino-acids in a wide range of animal species.", [["amino-acids", "CHEMICAL", 54, 65], ["amino-acids", "CHEMICAL", 54, 65], ["RBD amino-acids", "AMINO_ACID", 50, 65], ["RBD", "PROTEIN", 50, 53], ["these RBD amino-acids", "TEST", 44, 65], ["animal species", "PROBLEM", 85, 99], ["animal species", "OBSERVATION", 85, 99]]], ["Despite the RBD aminoacids, proteases associated with infectiousness such as furin, can also help to determine host range.", [["aminoacids", "CHEMICAL", 16, 26], ["furin", "GENE_OR_GENE_PRODUCT", 77, 82], ["RBD aminoacids", "PROTEIN", 12, 26], ["proteases", "PROTEIN", 28, 37], ["furin", "PROTEIN", 77, 82], ["the RBD aminoacids", "TREATMENT", 8, 26], ["proteases", "TREATMENT", 28, 37], ["infectiousness", "PROBLEM", 54, 68]]], ["This J o u r n a l P r e -p r o o f determination can further be facilitated by studying the higher genetic variation in spike glycoproteins [3, 25] .", [["P", "DNA", 19, 20], ["spike glycoproteins", "PROTEIN", 121, 140], ["spike glycoproteins", "PROBLEM", 121, 140]]], ["It has been reported that the mutation found in polybasic cleavage site in SARS-CoV-2 from humans was dissimilar to that in bat and pangolin viruses [25] , suggesting its association transmission and infection in humans.", [["SARS", "DISEASE", 75, 79], ["infection", "DISEASE", 200, 209], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 75, 85], ["humans", "ORGANISM", 91, 97], ["bat", "ORGANISM", 124, 127], ["pangolin viruses", "ORGANISM", 132, 148], ["humans", "ORGANISM", 213, 219], ["polybasic cleavage site", "PROTEIN", 48, 71], ["humans", "SPECIES", 91, 97], ["humans", "SPECIES", 213, 219], ["SARS-CoV", "SPECIES", 75, 83], ["humans", "SPECIES", 91, 97], ["humans", "SPECIES", 213, 219], ["the mutation", "PROBLEM", 26, 38], ["polybasic cleavage site", "PROBLEM", 48, 71], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83], ["pangolin viruses", "PROBLEM", 132, 148], ["infection in humans", "PROBLEM", 200, 219], ["polybasic cleavage", "OBSERVATION", 48, 66], ["bat", "ANATOMY", 124, 127], ["infection", "OBSERVATION", 200, 209]]], ["These observations indicate the need for further research on understanding the impact of polybasic cleavage on transmissibility and pathogenesis.Transmission of SARS-CoV-2Without knowing the zoonotic source of transmission, range of animals hosts, and source of origination, it may be impossible to eradicate the virus.Health consequences COVID-19COVID-19 disease has caused millions of morbidities and hundred of thousands of mortalities worldwide (Walker, 2020). .", [["COVID-19COVID-19 disease", "DISEASE", 339, 363], ["SARS-CoV", "ORGANISM", 161, 169], ["polybasic cleavage", "PROBLEM", 89, 107], ["pathogenesis", "PROBLEM", 132, 144], ["SARS-CoV", "TEST", 161, 169], ["the virus", "PROBLEM", 309, 318], ["COVID", "TEST", 339, 344], ["disease", "PROBLEM", 356, 363], ["polybasic cleavage", "OBSERVATION", 89, 107], ["virus", "OBSERVATION", 313, 318]]], ["The clinical manifestations of COVID-19 are characterized by fever, cough, dyspnea, and bilateral infiltrates on chest imaging [26] .", [["chest", "ANATOMY", 113, 118], ["fever", "DISEASE", 61, 66], ["cough", "DISEASE", 68, 73], ["dyspnea", "DISEASE", 75, 82], ["COVID", "TEST", 31, 36], ["fever", "PROBLEM", 61, 66], ["cough", "PROBLEM", 68, 73], ["dyspnea", "PROBLEM", 75, 82], ["bilateral infiltrates", "PROBLEM", 88, 109], ["chest imaging", "TEST", 113, 126], ["fever", "OBSERVATION", 61, 66], ["cough", "OBSERVATION", 68, 73], ["bilateral", "ANATOMY_MODIFIER", 88, 97], ["infiltrates", "OBSERVATION", 98, 109], ["chest", "ANATOMY", 113, 118]]], ["After infection, the majority of individuals show moderate symptoms whereas approximately, 20% of the infected patients show severe illness of respiratory failure, septic shock [26] , gastrointestinal complications [26, 27] , myalgias, lymphopenia, and parenchymal lung abnormalities [2] .", [["respiratory", "ANATOMY", 143, 154], ["gastrointestinal", "ANATOMY", 184, 200], ["parenchymal lung", "ANATOMY", 253, 269], ["infection", "DISEASE", 6, 15], ["illness", "DISEASE", 132, 139], ["respiratory failure", "DISEASE", 143, 162], ["septic shock", "DISEASE", 164, 176], ["gastrointestinal complications", "DISEASE", 184, 214], ["myalgias", "DISEASE", 226, 234], ["lymphopenia", "DISEASE", 236, 247], ["parenchymal lung abnormalities", "DISEASE", 253, 283], ["individuals", "ORGANISM", 33, 44], ["patients", "ORGANISM", 111, 119], ["gastrointestinal", "ORGAN", 184, 200], ["lung", "ORGAN", 265, 269], ["patients", "SPECIES", 111, 119], ["infection", "PROBLEM", 6, 15], ["moderate symptoms", "PROBLEM", 50, 67], ["severe illness", "PROBLEM", 125, 139], ["respiratory failure", "PROBLEM", 143, 162], ["septic shock", "PROBLEM", 164, 176], ["gastrointestinal complications", "PROBLEM", 184, 214], ["myalgias", "PROBLEM", 226, 234], ["lymphopenia", "PROBLEM", 236, 247], ["parenchymal lung abnormalities", "PROBLEM", 253, 283], ["infection", "OBSERVATION", 6, 15], ["moderate", "OBSERVATION_MODIFIER", 50, 58], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["respiratory failure", "OBSERVATION", 143, 162], ["septic shock", "OBSERVATION", 164, 176], ["gastrointestinal", "ANATOMY", 184, 200], ["complications", "OBSERVATION", 201, 214], ["lymphopenia", "OBSERVATION", 236, 247], ["parenchymal", "ANATOMY_MODIFIER", 253, 264], ["lung", "ANATOMY", 265, 269], ["abnormalities", "OBSERVATION", 270, 283]]], ["The severity of symptoms and death causing ability of the virus are highly dependent on underlying diseases such as cancer, hypertension, and cardiopulmonary diseases [3, 26] .", [["cancer", "ANATOMY", 116, 122], ["cardiopulmonary", "ANATOMY", 142, 157], ["death", "DISEASE", 29, 34], ["cancer", "DISEASE", 116, 122], ["hypertension", "DISEASE", 124, 136], ["cardiopulmonary diseases", "DISEASE", 142, 166], ["cancer", "CANCER", 116, 122], ["symptoms", "PROBLEM", 16, 24], ["death", "PROBLEM", 29, 34], ["the virus", "PROBLEM", 54, 63], ["underlying diseases", "PROBLEM", 88, 107], ["cancer", "PROBLEM", 116, 122], ["hypertension", "PROBLEM", 124, 136], ["cardiopulmonary diseases", "PROBLEM", 142, 166], ["diseases", "OBSERVATION", 99, 107], ["cancer", "OBSERVATION", 116, 122], ["hypertension", "OBSERVATION", 124, 136], ["cardiopulmonary", "ANATOMY", 142, 157], ["diseases", "OBSERVATION", 158, 166]]], ["The infection has been reported to cause high mortalities in older people [28] and individuals with blood group A [29] .", [["blood", "ANATOMY", 100, 105], ["infection", "DISEASE", 4, 13], ["people", "ORGANISM", 67, 73], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["people", "SPECIES", 67, 73], ["The infection", "PROBLEM", 0, 13], ["high mortalities", "PROBLEM", 41, 57], ["blood group A", "TEST", 100, 113], ["infection", "OBSERVATION", 4, 13]]], ["Moreover, pregnant women with confirmed COVID-19 pneumonia can face adverse pregnancy and neonatal impacts [30] .", [["pneumonia", "DISEASE", 49, 58], ["women", "ORGANISM", 19, 24], ["COVID-19", "ORGANISM", 40, 48], ["women", "SPECIES", 19, 24], ["COVID", "TEST", 40, 45], ["pneumonia", "PROBLEM", 49, 58], ["face adverse pregnancy", "PROBLEM", 63, 85], ["neonatal impacts", "PROBLEM", 90, 106], ["pneumonia", "OBSERVATION", 49, 58]]], ["The individuals at higher risk of developing severe disease after contracting the infection should be give the priority for treatment and providing the mangeemtn and health servicesConsidering the importance of COVID-19 in the aspects of the asymptomatic spread of the virus and adverse health impacts, it is deemed necessary to investigate the factors associated with the rate of infectiousness and severity of symptoms.COVID-19 infection and mental illnessesCOVID-19 outbreak is affecting physical health as well as mental health, however, the primary attention is given to physical health [9] .", [["infection", "DISEASE", 82, 91], ["COVID-19", "CHEMICAL", 421, 429], ["infection", "DISEASE", 430, 439], ["developing severe disease", "PROBLEM", 34, 59], ["the infection", "PROBLEM", 78, 91], ["treatment", "TREATMENT", 124, 133], ["COVID", "TREATMENT", 211, 216], ["the virus", "PROBLEM", 265, 274], ["infectiousness", "PROBLEM", 381, 395], ["severity of symptoms", "PROBLEM", 400, 420], ["COVID", "TEST", 421, 426], ["infection", "PROBLEM", 430, 439], ["mental illnessesCOVID", "PROBLEM", 444, 465], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["disease", "OBSERVATION", 52, 59], ["infection", "OBSERVATION", 82, 91], ["infection", "OBSERVATION", 430, 439]]], ["Fear of being infected due to close contact with infected patients, prolonged working schedules without proper rest, and disturbed wake and sleep routines have increased the risk of stress and anxiety in the healthcare workers [9] .", [["anxiety", "DISEASE", 193, 200], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["prolonged working schedules", "TREATMENT", 68, 95], ["sleep routines", "TREATMENT", 140, 154], ["stress", "PROBLEM", 182, 188], ["anxiety", "PROBLEM", 193, 200], ["infected", "OBSERVATION", 14, 22]]], ["The consequences can be alarming as mental illnesses have been reported to alter immunity, thus J o u r n a l P r e -p r o o f increasing the vulnerability to diseases [31] .", [["mental illnesses", "PROBLEM", 36, 52], ["the vulnerability to diseases", "PROBLEM", 138, 167]]], ["Therefore, a large number of people rely on electronic and social media, in an attempt to win the race, share forged news also termed as infodemia, thereby, increasing the risk of stress, fear, and anxiety [32, 33] .mediated morbidity among medical staff and clinical workers.", [["anxiety", "DISEASE", 198, 205], ["people", "ORGANISM", 29, 35], ["people", "SPECIES", 29, 35], ["stress", "PROBLEM", 180, 186], ["anxiety", "PROBLEM", 198, 205], ["large", "OBSERVATION_MODIFIER", 13, 18]]], ["Although, the risk communication team of WHO has already launched an information platform (WHO InformationNormal daily routines are inevitable to maintain normal rhythms, however, due to the current restrictions to outdoor activities, millions of people rely on indoor activities.", [["people", "ORGANISM", 247, 253], ["people", "SPECIES", 247, 253]]], ["These individuals may experience disturbance in eating routines, exposure to irregular light-dark cycles and disturbed sleep-wake behaviors which may dysregulate circadian rhythms and mood [34] .mediated morbidity among medical staff and clinical workers.", [["disturbance in eating routines", "PROBLEM", 33, 63], ["irregular light-dark cycles", "PROBLEM", 77, 104], ["disturbed sleep", "PROBLEM", 109, 124], ["wake behaviors", "PROBLEM", 125, 139]]], ["Although, the risk communication team of WHO has already launched an information platform (WHO InformationWhile, mistimed exposure to light and disrupted sleep perturb the circadian rhythm that may lead to mental illnesses including stress and anxiety [35, 36] .", [["anxiety", "DISEASE", 244, 251], ["mental illnesses", "PROBLEM", 206, 222], ["stress", "PROBLEM", 233, 239], ["anxiety", "PROBLEM", 244, 251]]], ["Notably, children have no or limited exposure to the open environment and playgrounds, indicating that they may have more access to electronic devices or smartphones.", [["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17], ["electronic devices", "TREATMENT", 132, 150]]], ["These situations can lead to severe mental illnesses in the future [37, 38] . .", [["severe mental illnesses", "PROBLEM", 29, 52], ["severe", "OBSERVATION_MODIFIER", 29, 35]]], ["Nonetheless, the researchers should conduct psychological investigations and identify the mental health concerns if any, not only in children but also in women, elder individuals, and healthcare workers, so that timely treatment and psychological assistance are providedPotential therapeutic and vaccines options available against the COVID-19 infectionCurrently, no promising treatment options are available against the COVID-19.", [["children", "ORGANISM", 133, 141], ["women", "ORGANISM", 154, 159], ["COVID-19", "DNA", 421, 429], ["children", "SPECIES", 133, 141], ["women", "SPECIES", 154, 159], ["psychological investigations", "TEST", 44, 72], ["psychological assistance", "TREATMENT", 233, 257], ["therapeutic and vaccines options", "TREATMENT", 280, 312], ["the COVID", "TEST", 331, 340], ["promising treatment options", "TREATMENT", 367, 394], ["the COVID", "TEST", 417, 426]]], ["However, to contain the COVID-19, several therapeutic strategies have been evaluated.", [["COVID-19", "DNA", 24, 32], ["the COVID", "TEST", 20, 29], ["several therapeutic strategies", "TREATMENT", 34, 64]]], ["Among the trialed antiviral drugs, remdesivir alone or in combination with chloroquine or interferon beta showed effectiveness against the COVID-19 infection [39] .", [["remdesivir", "CHEMICAL", 35, 45], ["chloroquine", "CHEMICAL", 75, 86], ["interferon beta", "CHEMICAL", 90, 105], ["infection", "DISEASE", 148, 157], ["remdesivir", "CHEMICAL", 35, 45], ["chloroquine", "CHEMICAL", 75, 86], ["remdesivir", "SIMPLE_CHEMICAL", 35, 45], ["chloroquine", "SIMPLE_CHEMICAL", 75, 86], ["interferon beta", "GENE_OR_GENE_PRODUCT", 90, 105], ["COVID-19", "ORGANISM", 139, 147], ["interferon beta", "PROTEIN", 90, 105], ["COVID-19", "SPECIES", 139, 147], ["antiviral drugs", "TREATMENT", 18, 33], ["remdesivir", "TREATMENT", 35, 45], ["chloroquine", "TREATMENT", 75, 86], ["interferon beta", "TREATMENT", 90, 105], ["the COVID-19 infection", "PROBLEM", 135, 157]]], ["Chloroquine efficacy against the COVID-19 may be linked with its ability to prevent binding and cellular entry of the SARS-CoV-2 through interfering with ACE2.", [["cellular", "ANATOMY", 96, 104], ["Chloroquine", "CHEMICAL", 0, 11], ["COVID-19", "CHEMICAL", 33, 41], ["SARS", "DISEASE", 118, 122], ["Chloroquine", "CHEMICAL", 0, 11], ["COVID-19", "CHEMICAL", 33, 41], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["COVID-19", "GENE_OR_GENE_PRODUCT", 33, 41], ["cellular", "CELL", 96, 104], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 118, 128], ["ACE2", "GENE_OR_GENE_PRODUCT", 154, 158], ["COVID-19", "DNA", 33, 41], ["ACE2", "PROTEIN", 154, 158], ["Chloroquine efficacy", "TREATMENT", 0, 20], ["the COVID", "TREATMENT", 29, 38], ["the SARS", "TEST", 114, 122], ["CoV", "TEST", 123, 126]]], ["While remdesivir inhibits the action of viral RNA polymerase to prevent viral replication [40] .", [["remdesivir", "CHEMICAL", 6, 16], ["remdesivir", "CHEMICAL", 6, 16], ["remdesivir", "SIMPLE_CHEMICAL", 6, 16], ["viral RNA polymerase", "PROTEIN", 40, 60], ["viral RNA polymerase", "TREATMENT", 40, 60], ["viral replication", "PROBLEM", 72, 89]]], ["Currently, clinical clinical trials are underway in different regions of the world, while China based preliminary data has demonstrated benefits of chloroquine in patients with pneumonia, as the drug significantly eliminatied the virus and improved recovery from COVID-19 disease [41] .", [["chloroquine", "CHEMICAL", 148, 159], ["pneumonia", "DISEASE", 177, 186], ["chloroquine", "CHEMICAL", 148, 159], ["chloroquine", "SIMPLE_CHEMICAL", 148, 159], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["chloroquine", "TREATMENT", 148, 159], ["pneumonia", "PROBLEM", 177, 186], ["the virus", "PROBLEM", 226, 235], ["COVID-19 disease", "PROBLEM", 263, 279], ["pneumonia", "OBSERVATION", 177, 186]]], ["Thus, it was included in the Guidelines for the Prevention, Diagnosis, and Treatment of COVID-19 disease, Chinese National Health Commission [41, 42] .", [["COVID-19 disease", "DISEASE", 88, 104], ["COVID-19 disease", "PROBLEM", 88, 104]]], ["However, J o u r n a l P r e -p r o o f chloroquine is also known to have toxicity and side effects to central nervious system [42] .", [["chloroquine", "CHEMICAL", 40, 51], ["toxicity", "DISEASE", 74, 82], ["chloroquine", "CHEMICAL", 40, 51], ["chloroquine", "SIMPLE_CHEMICAL", 40, 51], ["chloroquine", "TREATMENT", 40, 51], ["toxicity", "PROBLEM", 74, 82]]], ["On the other hand, a multi-center trial of remdesivir showed serious side effects in 12 out of the 53 COVID-19 patients, although 36 of them were reported clinically recovered [43] .", [["remdesivir", "CHEMICAL", 43, 53], ["remdesivir", "CHEMICAL", 43, 53], ["remdesivir", "SIMPLE_CHEMICAL", 43, 53], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["remdesivir", "TREATMENT", 43, 53], ["serious side effects", "PROBLEM", 61, 81]]], ["Therfore, both remdesivir and chloroquine should further be evaluated for their suitability against COVID-19.Potential therapeutic and vaccines options available against the COVID-19 infectionBaricitinib an approved drug for the treatment of rheumatoid arthritis has been considered as the potential candidate to treat COVID-19.", [["remdesivir", "CHEMICAL", 15, 25], ["chloroquine", "CHEMICAL", 30, 41], ["COVID-19", "CHEMICAL", 174, 182], ["infection", "DISEASE", 183, 192], ["Baricitinib", "CHEMICAL", 192, 203], ["rheumatoid arthritis", "DISEASE", 242, 262], ["remdesivir", "CHEMICAL", 15, 25], ["chloroquine", "CHEMICAL", 30, 41], ["COVID-19", "CHEMICAL", 319, 327], ["remdesivir", "SIMPLE_CHEMICAL", 15, 25], ["chloroquine", "SIMPLE_CHEMICAL", 30, 41], ["COVID-19", "ORGANISM", 174, 182], ["Baricitinib", "SIMPLE_CHEMICAL", 192, 203], ["chloroquine", "TREATMENT", 30, 41], ["COVID", "TEST", 100, 105], ["therapeutic and vaccines options", "TREATMENT", 119, 151], ["the COVID-19 infectionBaricitinib", "TREATMENT", 170, 203], ["rheumatoid arthritis", "PROBLEM", 242, 262], ["COVID", "TEST", 319, 324], ["rheumatoid arthritis", "OBSERVATION", 242, 262]]], ["This drug inhibits the endocytosis regulating enzymes (AP2-associated protein kinase 1) [44] , thus, can inhibit endocytosis of SARS-CoV-2 into the cell.Potential therapeutic and vaccines options available against the COVID-19 infectionThus, it could be another potential candidate to treat COVID-19 [42] , however, wide range of clinical trials are necessary to evaluate its effectiveness Furthermore, ritonavir and lopinavir are promising protease inhibitors, which have been included in the list of anti-COVID-19 drugs.Potential therapeutic and vaccines options available against the COVID-19 infectionAlthough, earlier treatment of COVID-19 patients with ritonavir and lopinavir in Wuhan, China, did not indicate sufficient benefits of these drugs [45] , however, their combination may successfully inhibit both protease cytochrome P4503A4 which can reduce metabolism and inhibit viral replication [46] .", [["cell", "ANATOMY", 148, 152], ["infection", "DISEASE", 227, 236], ["ritonavir", "CHEMICAL", 403, 412], ["lopinavir", "CHEMICAL", 417, 426], ["ritonavir", "CHEMICAL", 659, 668], ["lopinavir", "CHEMICAL", 673, 682], ["P4503A4", "CHEMICAL", 836, 843], ["COVID-19", "CHEMICAL", 291, 299], ["ritonavir", "CHEMICAL", 403, 412], ["lopinavir", "CHEMICAL", 417, 426], ["anti-COVID-19", "CHEMICAL", 502, 515], ["ritonavir", "CHEMICAL", 659, 668], ["lopinavir", "CHEMICAL", 673, 682], ["AP2-associated protein kinase 1", "GENE_OR_GENE_PRODUCT", 55, 86], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 128, 138], ["cell", "CELL", 148, 152], ["COVID-19", "ORGANISM", 218, 226], ["ritonavir", "SIMPLE_CHEMICAL", 403, 412], ["lopinavir", "SIMPLE_CHEMICAL", 417, 426], ["anti-COVID-19 drugs", "SIMPLE_CHEMICAL", 502, 521], ["COVID-19", "ORGANISM", 587, 595], ["patients", "ORGANISM", 645, 653], ["ritonavir", "SIMPLE_CHEMICAL", 659, 668], ["lopinavir", "SIMPLE_CHEMICAL", 673, 682], ["cytochrome P4503A4", "GENE_OR_GENE_PRODUCT", 825, 843], ["endocytosis regulating enzymes", "PROTEIN", 23, 53], ["AP2", "PROTEIN", 55, 58], ["protein kinase 1", "PROTEIN", 70, 86], ["protease cytochrome P4503A4", "PROTEIN", 816, 843], ["patients", "SPECIES", 645, 653], ["COVID-19", "SPECIES", 218, 226], ["the endocytosis regulating enzymes", "PROBLEM", 19, 53], ["AP2", "TEST", 55, 58], ["protein kinase", "TEST", 70, 84], ["endocytosis of SARS", "PROBLEM", 113, 132], ["CoV", "TEST", 133, 136], ["therapeutic and vaccines options", "TREATMENT", 163, 195], ["the COVID-19 infection", "PROBLEM", 214, 236], ["COVID", "TEST", 291, 296], ["ritonavir", "TREATMENT", 403, 412], ["lopinavir", "TREATMENT", 417, 426], ["promising protease inhibitors", "TREATMENT", 431, 460], ["anti-COVID-19 drugs", "TREATMENT", 502, 521], ["therapeutic and vaccines options", "TREATMENT", 532, 564], ["the COVID", "TEST", 583, 592], ["COVID", "TREATMENT", 636, 641], ["ritonavir", "TREATMENT", 659, 668], ["lopinavir", "TREATMENT", 673, 682], ["these drugs", "TREATMENT", 740, 751], ["both protease cytochrome P4503A4", "TREATMENT", 811, 843], ["cell", "ANATOMY", 148, 152]]], ["Therefore, further clincal trials with combination of these drugs are required to evaluate their effectiveness.", [["further clincal trials", "TREATMENT", 11, 33], ["these drugs", "TREATMENT", 54, 65]]], ["Recently another antiviral drug known as favipiravir designed for influenza that inhibits RNA-dependent RNA polymerase, was found effective against the COVID-19.", [["favipiravir", "CHEMICAL", 41, 52], ["influenza", "DISEASE", 66, 75], ["favipiravir", "CHEMICAL", 41, 52], ["favipiravir", "SIMPLE_CHEMICAL", 41, 52], ["RNA-dependent RNA polymerase", "PROTEIN", 90, 118], ["COVID-19", "DNA", 152, 160], ["another antiviral drug", "TREATMENT", 9, 31], ["favipiravir", "TREATMENT", 41, 52], ["influenza", "PROBLEM", 66, 75], ["RNA-dependent RNA polymerase", "PROBLEM", 90, 118], ["the COVID", "TEST", 148, 157]]], ["However, further studies are required to find its broad term efficacy and associated side effects [47] .Potential therapeutic and vaccines options available against the COVID-19 infectionMoreover, some antiviral drugs in combination with traditional Chinese medicines are currently being evaluated in COVID-19 patients.", [["infection", "DISEASE", 178, 187], ["COVID-19", "ORGANISM", 169, 177], ["patients", "ORGANISM", 310, 318], ["patients", "SPECIES", 310, 318], ["COVID-19", "SPECIES", 169, 177], ["further studies", "TEST", 9, 24], ["therapeutic and vaccines options", "TREATMENT", 114, 146], ["the COVID", "TREATMENT", 165, 174], ["some antiviral drugs", "TREATMENT", 197, 217], ["traditional Chinese medicines", "TREATMENT", 238, 267]]], ["It is thought that lower mortality and higher recovery rate from COVID-19 disease in China may be linked to the treatment with tradiations Chinese medicines in combined with Western medicines, as approximately 85% patients in China received these combinations [42, 48] .", [["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["lower mortality", "PROBLEM", 19, 34], ["COVID-19 disease", "PROBLEM", 65, 81], ["tradiations", "TREATMENT", 127, 138], ["Chinese medicines", "TREATMENT", 139, 156], ["Western medicines", "TREATMENT", 174, 191], ["lower", "OBSERVATION_MODIFIER", 19, 24], ["mortality", "OBSERVATION", 25, 34]]], ["However, we did not find convincing evidence to conclude that traditional Chinese medicines are siginifanclty effective, thereore, further investigations are required to determine their effects against COVID-19 disease.", [["traditional Chinese medicines", "TREATMENT", 62, 91], ["further investigations", "TEST", 131, 153], ["COVID-19 disease", "PROBLEM", 202, 218]]], ["Despite the afore-mentioned therapeutic options, further studies are necessary to develop promising therapeutic strategies against COVID-19 infection.", [["COVID-19", "CHEMICAL", 131, 139], ["infection", "DISEASE", 140, 149], ["COVID-19", "ORGANISM", 131, 139], ["COVID-19", "SPECIES", 131, 139], ["therapeutic options", "TREATMENT", 28, 47], ["further studies", "TEST", 49, 64], ["COVID-19 infection", "PROBLEM", 131, 149], ["infection", "OBSERVATION", 140, 149]]], ["The serious concern with coronaviruses is the ability to suppress counteracting response from the host innate interferons [6] , thus, utilizing interferon inducers or recombinant interferons may help to treat COVID-19 pneumonia.", [["pneumonia", "DISEASE", 218, 227], ["coronaviruses", "ORGANISM", 25, 38], ["interferon", "PROTEIN", 144, 154], ["recombinant interferons", "PROTEIN", 167, 190], ["coronaviruses", "PROBLEM", 25, 38], ["counteracting response", "PROBLEM", 66, 88], ["the host innate interferons", "TREATMENT", 94, 121], ["interferon inducers", "TREATMENT", 144, 163], ["recombinant interferons", "TREATMENT", 167, 190], ["COVID", "TEST", 209, 214], ["pneumonia", "PROBLEM", 218, 227], ["pneumonia", "OBSERVATION", 218, 227]]], ["Surface structural spike protein (S) and ACE2 play a critical role in the process of pathogenicity through facilitating SARS-CoV-2 entry into the host cells [6, 16] .", [["cells", "ANATOMY", 151, 156], ["Surface structural spike protein (S)", "GENE_OR_GENE_PRODUCT", 0, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 120, 130], ["host cells", "CELL", 146, 156], ["Surface structural spike protein", "PROTEIN", 0, 32], ["S", "PROTEIN", 34, 35], ["ACE2", "PROTEIN", 41, 45], ["host cells", "CELL_TYPE", 146, 156], ["Surface structural spike protein", "TEST", 0, 32], ["pathogenicity", "PROBLEM", 85, 98], ["CoV", "TEST", 125, 128], ["spike protein", "OBSERVATION", 19, 32]]], ["Targeting these regions through monoclonal antibodies or fusion J o u r n a l P r e -p r o o f inhibitors [6] may be effective therapeutic options against coronaviruses.", [["o f inhibitors [6]", "SIMPLE_CHEMICAL", 91, 109], ["coronaviruses", "ORGANISM", 155, 168], ["monoclonal antibodies", "PROTEIN", 32, 53], ["these regions", "TEST", 10, 23], ["monoclonal antibodies", "TEST", 32, 53], ["a l P r e -p r o o f inhibitors", "TREATMENT", 74, 105], ["coronaviruses", "PROBLEM", 155, 168]]], ["Therefore, antiviral peptides such as HP2P-M2 that target S protein [6] should be evaluated against the SARS-CoV-2.Potential therapeutic and vaccines options available against the COVID-19 infectionEffective vaccines are important to prevent and control sporadic epidemics of emerging viruses.", [["HP2P-M2", "GENE_OR_GENE_PRODUCT", 38, 45], ["SARS-CoV-2", "ORGANISM", 104, 114], ["COVID-19", "ORGANISM", 180, 188], ["HP2P", "PROTEIN", 38, 42], ["M2", "PROTEIN", 43, 45], ["S protein", "PROTEIN", 58, 67], ["SARS-CoV", "SPECIES", 104, 112], ["antiviral peptides", "TREATMENT", 11, 29], ["HP2P", "TEST", 38, 42], ["the SARS", "TEST", 100, 108], ["CoV", "TEST", 109, 112], ["therapeutic and vaccines options", "TREATMENT", 125, 157], ["the COVID-19 infectionEffective vaccines", "TREATMENT", 176, 216]]], ["Although SARS-CoV was fully controlled during 2003, and MERS-CoV spreads poorly, yet the SARS-CoV-2 is spreading efficiently, thus the availability of vaccine is necessary to control further spread of the disease.", [["SARS", "DISEASE", 9, 13], ["SARS", "DISEASE", 89, 93], ["SARS-CoV", "ORGANISM", 9, 17], ["MERS-CoV", "ORGANISM", 56, 64], ["SARS-CoV-2", "ORGANISM", 89, 99], ["SARS-CoV", "SPECIES", 9, 17], ["MERS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 89, 97], ["SARS", "PROBLEM", 9, 13], ["CoV", "PROBLEM", 14, 17], ["the SARS", "TEST", 85, 93], ["vaccine", "TREATMENT", 151, 158], ["the disease", "PROBLEM", 201, 212], ["disease", "OBSERVATION", 205, 212]]], ["Viral vectors, recombinant protein, viral-like particles, rhesus\u03b8defensin-1, and protein cage-nanoparticles are generally effective in prevention against coronaviruses [6] , therefore such vaccination strategies can be developed for individuals at high risk of COVID-19 infection, to control the ongoing pandemics [49] .Conclusion and PerspectiveCOVID-19 disesae has created an alarming situation worldwide and therefore, it requires serious attention from healthcare authorities and research communities in the aspects of transmission, treatment and prevention.", [["infection", "DISEASE", 270, 279], ["PerspectiveCOVID-19 disesae", "CHEMICAL", 335, 362], ["rhesus\u03b8defensin-1", "GENE_OR_GENE_PRODUCT", 58, 75], ["coronaviruses", "ORGANISM", 154, 167], ["PerspectiveCOVID-19 disesae", "ORGANISM", 335, 362], ["recombinant protein", "PROTEIN", 15, 34], ["COVID-19", "SPECIES", 261, 269], ["PerspectiveCOVID-19 disesae", "SPECIES", 335, 362], ["Viral vectors", "TREATMENT", 0, 13], ["recombinant protein", "TEST", 15, 34], ["viral", "TEST", 36, 41], ["rhesus\u03b8defensin", "TEST", 58, 73], ["protein cage-nanoparticles", "TREATMENT", 81, 107], ["coronaviruses", "PROBLEM", 154, 167], ["such vaccination strategies", "TREATMENT", 184, 211], ["COVID-19 infection", "PROBLEM", 261, 279], ["PerspectiveCOVID", "TEST", 335, 351], ["treatment", "TREATMENT", 537, 546], ["prevention", "TREATMENT", 551, 561], ["infection", "OBSERVATION", 270, 279]]], ["After originating in bats, SARS-CoV-2 emerged in Wuhan, spread all over the world through human to human transmission, and infected millions of individuals.", [["SARS", "DISEASE", 27, 31], ["SARS-CoV-2", "ORGANISM", 27, 37], ["human", "ORGANISM", 90, 95], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 99, 104], ["SARS-CoV", "SPECIES", 27, 35], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 99, 104], ["infected millions of individuals", "PROBLEM", 123, 155]]], ["Currently, each pasing day, the virus is causing deaths in thousands of COVID-19 infected individuals across the globe.", [["deaths", "DISEASE", 49, 55], ["the virus", "PROBLEM", 28, 37], ["COVID", "TEST", 72, 77], ["virus", "OBSERVATION", 32, 37], ["infected", "OBSERVATION", 81, 89], ["globe", "ANATOMY", 113, 118]]], ["Although, the virus mainly affects lungs to cause severe to moderate pneumonia, it may adversely impact mental health to develop stress, anxiety and depression.", [["lungs", "ANATOMY", 35, 40], ["pneumonia", "DISEASE", 69, 78], ["anxiety", "DISEASE", 137, 144], ["depression", "DISEASE", 149, 159], ["lungs", "ORGAN", 35, 40], ["the virus", "PROBLEM", 10, 19], ["severe to moderate pneumonia", "PROBLEM", 50, 78], ["stress", "PROBLEM", 129, 135], ["anxiety", "PROBLEM", 137, 144], ["depression", "PROBLEM", 149, 159], ["virus", "OBSERVATION", 14, 19], ["lungs", "ANATOMY", 35, 40], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["moderate", "OBSERVATION_MODIFIER", 60, 68], ["pneumonia", "OBSERVATION", 69, 78]]], ["To control the spread of COVID-19 infection, there is a need for developing therapeutic options, vaccines and proper management of daily activities and human to human interactions.", [["infection", "DISEASE", 34, 43], ["COVID-19", "CELL", 25, 33], ["human", "ORGANISM", 152, 157], ["human", "ORGANISM", 161, 166], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 161, 166], ["COVID-19", "SPECIES", 25, 33], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 161, 166], ["COVID-19 infection", "PROBLEM", 25, 43], ["developing therapeutic options", "TREATMENT", 65, 95], ["vaccines", "TREATMENT", 97, 105], ["proper management", "TREATMENT", 110, 127], ["spread", "OBSERVATION_MODIFIER", 15, 21], ["infection", "OBSERVATION", 34, 43]]], ["Given the importance of the COVID-19 pandemic, further studies are necessary to understand replication, pathogenesis, and biological properties in order to control COVID-19 disease and prevent novel emerging diseases in future.", [["the COVID", "TEST", 24, 33], ["further studies", "TEST", 47, 62], ["pathogenesis", "PROBLEM", 104, 116], ["COVID-19 disease", "PROBLEM", 164, 180], ["novel emerging diseases", "PROBLEM", 193, 216]]], ["The research work should focus on identifying or designing therapeutic agents and developing effective vaccines.", [["therapeutic agents", "TREATMENT", 59, 77], ["developing effective vaccines", "TREATMENT", 82, 111]]], ["Testing the drugs for coronaviruses requires suitable animal models prior to their use in humans.", [["coronaviruses", "ORGANISM", 22, 35], ["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["coronaviruses", "PROBLEM", 22, 35]]], ["However, the J o u r n a l P r e -p r o o f currently established models for SARS and MERS are not promising except few small animals such as transgenic mice expressing human ACE2 and mouse-adapted SARS-CoV strains [6] .Conclusion and PerspectiveTherefore, more animal models from mouse to non-human primates are needed to be developed.Conclusion and PerspectiveNeverthelesss, healthcareworkers and medical professionals should focus on helping the public to cope with the mental health concerns.", [["SARS", "DISEASE", 77, 81], ["mice", "ORGANISM", 153, 157], ["human", "ORGANISM", 169, 174], ["ACE2", "GENE_OR_GENE_PRODUCT", 175, 179], ["mouse", "ORGANISM", 184, 189], ["SARS-CoV", "ORGANISM", 198, 206], ["mouse", "ORGANISM", 281, 286], ["non-human", "ORGANISM", 290, 299], ["primates", "ORGANISM", 300, 308], ["human ACE2", "PROTEIN", 169, 179], ["mice", "SPECIES", 153, 157], ["human", "SPECIES", 169, 174], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 281, 286], ["mice", "SPECIES", 153, 157], ["human", "SPECIES", 169, 174], ["mouse", "SPECIES", 184, 189], ["SARS-CoV", "SPECIES", 198, 206], ["mouse", "SPECIES", 281, 286], ["SARS", "PROBLEM", 77, 81], ["MERS", "PROBLEM", 86, 90], ["CoV strains", "PROBLEM", 203, 214]]], ["They should further educate the people to understand the spread mechanisms, infection consequences and required management to control the spread. mental health.", [["infection", "DISEASE", 76, 85], ["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38], ["infection consequences", "PROBLEM", 76, 98], ["management", "TREATMENT", 112, 122]]]], "e8af0f841423e1b46204d8d6383c8f3cf0074588": [["therapies that have saved innumerable lives.", [["therapies", "TREATMENT", 0, 9]]], ["The success of antiretroviral drug development is now being recapitulated by the latest generation of potent diseaseeradicating anti-Hepatitis C virus (HCV) drugs that target specific HCV proteins.", [["diseaseeradicating anti-Hepatitis C virus", "ORGANISM", 109, 150], ["HCV", "ORGANISM", 152, 155], ["HCV", "ORGANISM", 184, 187], ["HCV proteins", "PROTEIN", 184, 196], ["anti-Hepatitis C virus", "SPECIES", 128, 150], ["anti-Hepatitis C virus", "SPECIES", 128, 150], ["HCV", "SPECIES", 152, 155], ["HCV", "SPECIES", 184, 187], ["antiretroviral drug development", "TREATMENT", 15, 46], ["potent diseaseeradicating anti-Hepatitis C virus (HCV) drugs", "TREATMENT", 102, 162], ["target specific HCV proteins", "PROBLEM", 168, 196], ["antiretroviral drug", "OBSERVATION", 15, 34]]], ["These successes showcase the power of the traditional pathogen-specific drug development paradigm that is so well practised by the pharmaceutical industry.", [["the traditional pathogen", "PROBLEM", 38, 62], ["power", "OBSERVATION_MODIFIER", 29, 34]]]], "c0b9b9426c31014372750fb2818f5a1de6b1c6d4": [["IntroductionEpidemiological data suggest that more than one billion people worldwide, as well as numerous groups of livestock, are infected with at least one species of gastrointestinal (GI) nematode [1] .", [["gastrointestinal", "ANATOMY", 169, 185], ["gastrointestinal (GI) nematode", "DISEASE", 169, 199], ["people", "ORGANISM", 68, 74], ["gastrointestinal", "ORGANISM_SUBDIVISION", 169, 185], ["people", "SPECIES", 68, 74], ["Epidemiological data", "TEST", 12, 32], ["livestock", "OBSERVATION", 116, 125], ["infected", "OBSERVATION", 131, 139], ["gastrointestinal", "ANATOMY", 169, 185]]], ["These parasitic species have evolved sophisticated and highly integrated mechanisms to reside in the GI tract of the hosts [2] .", [["GI tract", "ANATOMY", 101, 109], ["GI tract", "ORGANISM_SUBDIVISION", 101, 109], ["These parasitic species", "PROBLEM", 0, 23], ["parasitic species", "OBSERVATION", 6, 23], ["GI tract", "ANATOMY", 101, 109]]], ["GI nematodes can release certain factors, generally termed excretorysecretory (ES) products or proteins, by actively exporting or passively diffusing into the host environment to ensure survival [2, 3] .", [["GI nematodes", "ORGANISM", 0, 12], ["excretorysecretory (ES) products", "PROTEIN", 59, 91], ["GI nematodes", "TREATMENT", 0, 12], ["nematodes", "OBSERVATION", 3, 12]]], ["To date, the investigation of nematode ES proteins has been incorporated into taxonomic composition analysis, immunodiagnostic applications, and vaccine development [4] .", [["nematode ES proteins", "PROTEIN", 30, 50], ["nematode ES proteins", "TREATMENT", 30, 50], ["taxonomic composition analysis", "TEST", 78, 108], ["immunodiagnostic applications", "TREATMENT", 110, 139]]], ["Importantly, increasing attention has been paid to the immunomodulatory properties of ES proteins, with multitudinous findings demonstrating the selective immunosuppressive or regulatory effects of certain nematode products on host immune cells [5] .IntroductionThe barber's pole worm, Haemonchus contortus, is a voraciously blood-feeding and highly pathogenic GI nematode inhabiting the abomasum of small ruminants (mainly sheep and goats) [6] .", [["immune cells", "ANATOMY", 232, 244], ["blood", "ANATOMY", 325, 330], ["abomasum", "ANATOMY", 388, 396], ["Haemonchus contortus", "DISEASE", 286, 306], ["host immune cells", "CELL", 227, 244], ["barber's pole worm", "ORGANISM", 266, 284], ["Haemonchus contortus", "ORGANISM", 286, 306], ["blood", "ORGANISM_SUBSTANCE", 325, 330], ["GI nematode", "ORGANISM", 361, 372], ["abomasum", "ORGANISM_SUBDIVISION", 388, 396], ["sheep", "ORGANISM_SUBDIVISION", 424, 429], ["ES proteins", "PROTEIN", 86, 97], ["host immune cells", "CELL_TYPE", 227, 244], ["Haemonchus contortus", "SPECIES", 286, 306], ["sheep", "SPECIES", 424, 429], ["goats", "SPECIES", 434, 439], ["Haemonchus contortus", "SPECIES", 286, 306], ["sheep", "SPECIES", 424, 429], ["goats", "SPECIES", 434, 439], ["the selective immunosuppressive", "TREATMENT", 141, 172], ["certain nematode products", "TREATMENT", 198, 223], ["host immune cells", "TREATMENT", 227, 244], ["Haemonchus contortus", "PROBLEM", 286, 306], ["highly pathogenic GI nematode", "PROBLEM", 343, 372], ["small ruminants", "PROBLEM", 400, 415], ["selective", "OBSERVATION_MODIFIER", 145, 154], ["immunosuppressive", "OBSERVATION", 155, 172], ["Haemonchus contortus", "OBSERVATION", 286, 306], ["GI", "ANATOMY", 361, 363], ["nematode", "OBSERVATION", 364, 372], ["abomasum", "ANATOMY", 388, 396], ["small ruminants", "OBSERVATION", 400, 415]]], ["Given its widespread occurrence and substantial morbidity among affected animals, haemonecrosis is one of the most economically important parasite diseases, representing a major constraint on the livestock industry worldwide, especially in tropical, subtropical and warm climatic zones [7] .", [["haemonecrosis", "DISEASE", 82, 95], ["parasite diseases", "DISEASE", 138, 155], ["substantial morbidity among affected animals", "PROBLEM", 36, 80], ["haemonecrosis", "PROBLEM", 82, 95], ["parasite diseases", "PROBLEM", 138, 155], ["widespread", "OBSERVATION_MODIFIER", 10, 20], ["substantial", "OBSERVATION_MODIFIER", 36, 47], ["morbidity", "OBSERVATION", 48, 57], ["parasite diseases", "OBSERVATION", 138, 155], ["major", "OBSERVATION_MODIFIER", 172, 177], ["subtropical", "OBSERVATION_MODIFIER", 250, 261], ["warm", "OBSERVATION_MODIFIER", 266, 270], ["climatic", "OBSERVATION_MODIFIER", 271, 279], ["zones", "OBSERVATION_MODIFIER", 280, 285]]], ["H. contortus is transmitted via a complex life cycle involving three Open Access P < 0.05, ***P < 0.0001 vs the control group.HcESPs suppressed cell proliferation and induced cell cycle arrestAs apoptosis, proliferation and the cell cycle are interconnected cellular movements, we next explored the influence of HcESP stimuli on the cell proliferation and cell cycle of host T cells.", [["cell", "ANATOMY", 144, 148], ["cell", "ANATOMY", 175, 179], ["cell", "ANATOMY", 228, 232], ["cellular", "ANATOMY", 258, 266], ["cell", "ANATOMY", 333, 337], ["cell", "ANATOMY", 356, 360], ["T cells", "ANATOMY", 375, 382], ["HcESPs", "CHEMICAL", 126, 132], ["H. contortus", "ORGANISM", 0, 12], ["HcESPs", "SIMPLE_CHEMICAL", 126, 132], ["cell", "CELL", 144, 148], ["cell", "CELL", 175, 179], ["cell", "CELL", 228, 232], ["cellular", "CELL", 258, 266], ["HcESP", "GENE_OR_GENE_PRODUCT", 312, 317], ["cell", "CELL", 333, 337], ["cell", "CELL", 356, 360], ["host T cells", "CELL", 370, 382], ["HcESPs", "PROTEIN", 126, 132], ["HcESP", "PROTEIN", 312, 317], ["host T cells", "CELL_TYPE", 370, 382], ["H. contortus", "SPECIES", 0, 12], ["H. contortus", "SPECIES", 0, 12], ["H. contortus", "PROBLEM", 0, 12], ["HcESPs", "PROBLEM", 126, 132], ["cell proliferation", "PROBLEM", 144, 162], ["induced cell cycle arrest", "PROBLEM", 167, 192], ["apoptosis", "PROBLEM", 195, 204], ["proliferation", "PROBLEM", 206, 219], ["the cell cycle", "PROBLEM", 224, 238], ["HcESP stimuli", "TEST", 312, 325], ["the cell proliferation", "TREATMENT", 329, 351], ["cell proliferation", "OBSERVATION", 144, 162], ["cell cycle arrest", "OBSERVATION", 175, 192], ["proliferation", "OBSERVATION_MODIFIER", 206, 219], ["cell cycle", "OBSERVATION", 228, 238], ["interconnected", "OBSERVATION_MODIFIER", 243, 257], ["cellular movements", "OBSERVATION", 258, 276], ["cell proliferation", "OBSERVATION", 333, 351], ["host T cells", "OBSERVATION", 370, 382]]], ["In a dose-dependent manner, treatment with HcESPs significantly inhibited the proliferation of T cells in vitro, as indicated by the decreasing percentage of cells in S phase compared with control cells (P < 0.05) ( Figure 4A ).", [["T cells", "ANATOMY", 95, 102], ["cells", "ANATOMY", 158, 163], ["cells", "ANATOMY", 197, 202], ["HcESPs", "CHEMICAL", 43, 49], ["HcESPs", "CHEMICAL", 43, 49], ["HcESPs", "SIMPLE_CHEMICAL", 43, 49], ["T cells", "CELL", 95, 102], ["cells", "CELL", 158, 163], ["cells", "CELL", 197, 202], ["T cells", "CELL_TYPE", 95, 102], ["control cells", "CELL_TYPE", 189, 202], ["treatment", "TREATMENT", 28, 37], ["HcESPs", "TREATMENT", 43, 49], ["T cells", "PROBLEM", 95, 102]]], ["Given that the treatment with 20 \u03bcg/mL HcESPs had significant biological effects on cell viability, apoptosis and proliferation, as well as the transcription of certain key genes, we next treated T cells with 20 \u00b5g/mL HcESPs for cell cycle determination.", [["cell", "ANATOMY", 84, 88], ["T cells", "ANATOMY", 196, 203], ["cell", "ANATOMY", 229, 233], ["HcESPs", "CHEMICAL", 39, 45], ["HcESPs", "CHEMICAL", 39, 45], ["HcESPs", "SIMPLE_CHEMICAL", 39, 45], ["cell", "CELL", 84, 88], ["T cells", "CELL", 196, 203], ["HcESPs", "SIMPLE_CHEMICAL", 218, 224], ["cell", "CELL", 229, 233], ["T cells", "CELL_TYPE", 196, 203], ["the treatment", "TREATMENT", 11, 24], ["cell viability", "PROBLEM", 84, 98], ["apoptosis", "PROBLEM", 100, 109], ["T cells", "TREATMENT", 196, 203], ["cell cycle determination", "TEST", 229, 253], ["cell viability", "OBSERVATION", 84, 98]]], ["Flow cytometry analysis with PI staining revealed that HcESP stimuli induced cell cycle arrest at G1 phase in a time-dependent manner, as indicated by the increasing percentage of cells in G1 phase (P < 0.01) and the decreasing percentage of cells in S phase (P < 0.01) (Figure 4B) .", [["cell", "ANATOMY", 77, 81], ["cells", "ANATOMY", 180, 185], ["cells", "ANATOMY", 242, 247], ["PI", "SIMPLE_CHEMICAL", 29, 31], ["HcESP", "SIMPLE_CHEMICAL", 55, 60], ["cell", "CELL", 77, 81], ["cells", "CELL", 180, 185], ["cells", "CELL", 242, 247], ["HcESP", "PROTEIN", 55, 60], ["Flow cytometry analysis", "TEST", 0, 23], ["PI staining", "TEST", 29, 40], ["HcESP stimuli", "TEST", 55, 68], ["cell cycle arrest", "PROBLEM", 77, 94], ["S phase", "TEST", 251, 258], ["cell cycle arrest", "OBSERVATION", 77, 94], ["decreasing", "OBSERVATION_MODIFIER", 217, 227]]], ["Consistent with the above findings, real-time PCR analysis of key genes in G1/S checkpoints and G2/M checkpoints showed that the transcription of CCND1 (P < 0.05), CCNE1 (P < 0.05), CDK4 (P < 0.05), CDK6 (P < 0.05) and CDK2 (P < 0.05) was significantly downregulated, whereas no significant transcriptional changes in CCNB1 or CDK1 were observed ( Figure 4C ).", [["CCND1", "GENE_OR_GENE_PRODUCT", 146, 151], ["CCNE1", "GENE_OR_GENE_PRODUCT", 164, 169], ["CDK4", "GENE_OR_GENE_PRODUCT", 182, 186], ["CDK6", "GENE_OR_GENE_PRODUCT", 199, 203], ["CDK2", "GENE_OR_GENE_PRODUCT", 219, 223], ["CCNB1", "GENE_OR_GENE_PRODUCT", 318, 323], ["CDK1", "GENE_OR_GENE_PRODUCT", 327, 331], ["CCND1", "PROTEIN", 146, 151], ["CCNE1", "PROTEIN", 164, 169], ["CDK4", "PROTEIN", 182, 186], ["CDK6", "PROTEIN", 199, 203], ["CDK2", "PROTEIN", 219, 223], ["CCNB1", "PROTEIN", 318, 323], ["CDK1", "PROTEIN", 327, 331], ["the above findings", "TEST", 16, 34], ["real-time PCR analysis", "TEST", 36, 58], ["G1/S checkpoints", "TEST", 75, 91], ["G2/M checkpoints", "TEST", 96, 112], ["CCND1", "TEST", 146, 151], ["P", "TEST", 153, 154], ["CCNE1", "TEST", 164, 169], ["P", "TEST", 171, 172], ["CDK4", "TEST", 182, 186], ["P", "TEST", 188, 189], ["CDK6", "TEST", 199, 203], ["P", "TEST", 205, 206], ["CDK2", "TEST", 219, 223], ["P", "TEST", 225, 226], ["significant transcriptional changes in CCNB1", "PROBLEM", 279, 323], ["CDK1", "PROBLEM", 327, 331], ["no", "UNCERTAINTY", 276, 278], ["significant", "OBSERVATION_MODIFIER", 279, 290], ["transcriptional changes", "OBSERVATION", 291, 314]]], ["In addition, the transcription of essential genes in the Akt/PKB pathway that regulate cell proliferation and cell growth was also detected in this study.", [["cell", "ANATOMY", 87, 91], ["cell", "ANATOMY", 110, 114], ["Akt", "GENE_OR_GENE_PRODUCT", 57, 60], ["PKB", "GENE_OR_GENE_PRODUCT", 61, 64], ["cell", "CELL", 87, 91], ["cell", "CELL", 110, 114], ["essential genes", "DNA", 34, 49], ["Akt", "PROTEIN", 57, 60], ["PKB", "PROTEIN", 61, 64], ["the Akt/PKB pathway", "TEST", 53, 72], ["regulate cell proliferation", "PROBLEM", 78, 105], ["cell growth", "PROBLEM", 110, 121], ["this study", "TEST", 143, 153], ["essential genes", "OBSERVATION", 34, 49], ["PKB", "ANATOMY", 61, 64], ["regulate cell proliferation", "OBSERVATION", 78, 105], ["cell", "OBSERVATION", 110, 114], ["growth", "OBSERVATION_MODIFIER", 115, 121]]], ["The transcripts of FoxO1 (P < 0.05), p21 (P < 0.05) and p27 (P < 0.05) were dramatically enhanced, while Akt1 transcription was significantly suppressed (P < 0.05) ( Figure 4C ).", [["FoxO1", "GENE_OR_GENE_PRODUCT", 19, 24], ["p21", "GENE_OR_GENE_PRODUCT", 37, 40], ["p27", "GENE_OR_GENE_PRODUCT", 56, 59], ["Akt1", "GENE_OR_GENE_PRODUCT", 105, 109], ["FoxO1", "PROTEIN", 19, 24], ["p21", "PROTEIN", 37, 40], ["p27", "PROTEIN", 56, 59], ["Akt1", "PROTEIN", 105, 109], ["FoxO1", "TEST", 19, 24], ["p21", "TEST", 37, 40], ["P", "TEST", 42, 43], ["p27", "TEST", 56, 59], ["Akt1 transcription", "TEST", 105, 123]]], ["Collectively, HcESP stimuli restrained T cell proliferation and caused T cell cycle stalling at the G1 phase.ELISA assaysTo investigate the modulatory effects of HcESPs on T cell cytokine production, the secretion of IL-2, IL-4, IL-10, IL-17A, IFN-\u03b3, and TGF-\u03b21 was examined by ELISA in this study.", [["T cell", "ANATOMY", 39, 45], ["T cell", "ANATOMY", 71, 77], ["T cell", "ANATOMY", 172, 178], ["HcESPs", "CHEMICAL", 162, 168], ["HcESP", "SIMPLE_CHEMICAL", 14, 19], ["T cell", "CELL", 39, 45], ["T cell", "CELL", 71, 77], ["HcESPs", "SIMPLE_CHEMICAL", 162, 168], ["T cell", "CELL", 172, 178], ["IL-2", "GENE_OR_GENE_PRODUCT", 217, 221], ["IL-4", "GENE_OR_GENE_PRODUCT", 223, 227], ["IL-10", "GENE_OR_GENE_PRODUCT", 229, 234], ["IL-17A", "GENE_OR_GENE_PRODUCT", 236, 242], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 244, 249], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 255, 261], ["HcESP", "PROTEIN", 14, 19], ["HcESPs", "PROTEIN", 162, 168], ["cytokine", "PROTEIN", 179, 187], ["IL", "PROTEIN", 236, 238], ["IFN", "PROTEIN", 244, 247], ["TGF-\u03b21", "PROTEIN", 255, 261], ["HcESP stimuli", "TEST", 14, 27], ["T cell proliferation", "PROBLEM", 39, 59], ["T cell cycle stalling", "PROBLEM", 71, 92], ["ELISA assays", "TEST", 109, 121], ["HcESPs", "PROBLEM", 162, 168], ["T cell cytokine production", "TREATMENT", 172, 198], ["the secretion of IL", "TEST", 200, 219], ["IL", "TEST", 223, 225], ["IL", "TEST", 229, 231], ["IL", "TEST", 236, 238], ["IFN", "TEST", 244, 247], ["TGF", "TEST", 255, 258], ["this study", "TEST", 287, 297], ["cell proliferation", "OBSERVATION", 41, 59]]], ["The results showed that goat T cells exposed to HcESPs changed their cytokine production profile ( Figure 5 ).", [["T cells", "ANATOMY", 29, 36], ["HcESPs", "CHEMICAL", 48, 54], ["HcESPs", "CHEMICAL", 48, 54], ["goat", "ORGANISM", 24, 28], ["T cells", "CELL", 29, 36], ["HcESPs", "SIMPLE_CHEMICAL", 48, 54], ["goat T cells", "CELL_TYPE", 24, 36], ["cytokine", "PROTEIN", 69, 77], ["goat", "SPECIES", 24, 28], ["goat", "SPECIES", 24, 28], ["goat T cells", "PROBLEM", 24, 36], ["HcESPs", "TEST", 48, 54]]], ["The production of IL-2 was predominantly inhibited by stimulation with 10 \u03bcg/mL (P < 0.05), 20 \u03bcg/mL (P < 0.001), 40 \u03bcg/mL (P < 0.0001) and 80 \u03bcg/ mL (P < 0.0001) HcESPs.", [["IL-2", "GENE_OR_GENE_PRODUCT", 18, 22], ["IL", "PROTEIN", 18, 20], ["IL-2", "TREATMENT", 18, 22], ["P", "TEST", 151, 152], ["HcESPs", "TEST", 163, 169]]], ["IL-17A secretion was significantly promoted by treatment with 20 \u03bcg/mL (P < 0.05), 40 \u03bcg/mL (P < 0.01) and 80 \u03bcg/mL (P < 0.001) HcESPs.", [["IL-17A", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL", "PROTEIN", 0, 2], ["HcESPs", "TEST", 128, 134]]], ["Meanwhile, treatment with 40 \u03bcg/mL and 80 \u03bcg/mL HcESPs dramatically inhibited IL-4 (P < 0.01 and P < 0.01, respectively) and IFN-\u03b3 production (P < 0.01 and P < 0.05, respectively).", [["HcESPs", "CHEMICAL", 48, 54], ["HcESPs", "CHEMICAL", 48, 54], ["HcESPs", "SIMPLE_CHEMICAL", 48, 54], ["IL-4", "GENE_OR_GENE_PRODUCT", 78, 82], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 125, 130], ["IL-4", "PROTEIN", 78, 82], ["IFN", "PROTEIN", 125, 128], ["treatment", "TREATMENT", 11, 20], ["HcESPs", "TEST", 48, 54], ["IL", "TEST", 78, 80], ["P", "TEST", 97, 98], ["IFN", "TEST", 125, 128], ["P", "TEST", 143, 144], ["P", "TEST", 156, 157]]], ["Importantly, a high dose of HcESPs (80 \u03bcg/ mL) promoted the secretion of IL-10 (P < 0.01) and TGF-\u03b21 (P < 0.001) ( Figure 5 ).", [["HcESPs", "CHEMICAL", 28, 34], ["HcESPs", "CHEMICAL", 28, 34], ["HcESPs", "SIMPLE_CHEMICAL", 28, 34], ["IL-10", "GENE_OR_GENE_PRODUCT", 73, 78], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 94, 100], ["IL-10", "PROTEIN", 73, 78], ["TGF", "PROTEIN", 94, 97], ["HcESPs", "TEST", 28, 34], ["the secretion of IL", "TEST", 56, 75], ["TGF", "TEST", 94, 97]]], ["Taken together, the results show that HcESP stimuli mainly played an immunosuppressive role in the T cell immune response via alteration of cytokine secretion profiles.DiscussionFor decades, significant efforts have been made to identify the composition and structure of HcESPs from different developmental stages to better understand the pathophysiology and develop novel controls.", [["T cell", "ANATOMY", 99, 105], ["HcESP", "GENE_OR_GENE_PRODUCT", 38, 43], ["T cell", "CELL", 99, 105], ["HcESPs", "GENE_OR_GENE_PRODUCT", 271, 277], ["HcESP", "PROTEIN", 38, 43], ["cytokine", "PROTEIN", 140, 148], ["HcESPs", "PROTEIN", 271, 277], ["HcESP stimuli", "PROBLEM", 38, 51], ["an immunosuppressive role", "TREATMENT", 66, 91], ["the T cell immune response", "TREATMENT", 95, 121], ["cytokine secretion profiles", "PROBLEM", 140, 167], ["HcESPs", "PROBLEM", 271, 277], ["different developmental stages", "PROBLEM", 283, 313], ["cytokine secretion", "OBSERVATION", 140, 158]]], ["Yatsuda et al. identified 107 adult HcESPs recognized by anti-H. contortus serum for the first time [39] , whereas Wang et al. recently characterized 878 unique proteins in ES products from different life-cycle stages [40] .", [["serum", "ANATOMY", 75, 80], ["ES", "ANATOMY", 173, 175], ["HcESPs", "CANCER", 36, 42], ["anti-H. contortus", "ORGANISM", 57, 74], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["ES products", "CELL", 173, 184], ["878 unique proteins", "PROTEIN", 150, 169], ["ES products", "PROTEIN", 173, 184], ["anti-H. contortus", "SPECIES", 57, 74], ["anti-H. contortus", "SPECIES", 57, 74], ["anti-H. contortus serum", "TEST", 57, 80], ["unique proteins in ES products", "TREATMENT", 154, 184]]], ["Here, we identified 114 adult ES proteins that interacted with goat T cells through co-IP and LC-MS/MS analysis.", [["T cells", "ANATOMY", 68, 75], ["goat", "ORGANISM", 63, 67], ["T cells", "CELL", 68, 75], ["co-IP", "GENE_OR_GENE_PRODUCT", 84, 89], ["adult ES proteins", "PROTEIN", 24, 41], ["goat T cells", "CELL_TYPE", 63, 75], ["goat", "SPECIES", 63, 67], ["goat", "SPECIES", 63, 67], ["co-IP", "TEST", 84, 89], ["LC", "TEST", 94, 96], ["MS/MS analysis", "TEST", 97, 111], ["LC", "ANATOMY", 94, 96]]], ["Notably, a cascade of proteolytic peptidases, including aspartic peptidases and metallopeptidases, was identified from these interacting ES proteins and is postulated to play crucial roles in larval development, adult survival and reproduction via the digestion or degradation of host haemoglobin [41, 42] .", [["metallopeptidases", "GENE_OR_GENE_PRODUCT", 80, 97], ["larval", "DEVELOPING_ANATOMICAL_STRUCTURE", 192, 198], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 285, 296], ["proteolytic peptidases", "PROTEIN", 22, 44], ["aspartic peptidases", "PROTEIN", 56, 75], ["metallopeptidases", "PROTEIN", 80, 97], ["interacting ES proteins", "PROTEIN", 125, 148], ["proteolytic peptidases", "PROBLEM", 22, 44], ["aspartic peptidases and metallopeptidases", "PROBLEM", 56, 97], ["the digestion", "PROBLEM", 248, 261], ["host haemoglobin", "TEST", 280, 296]]], ["Similarly, comparable expression of these peptidase family members in ES products was reported in a series of blood-feeding nematodes, such as A. caninum [43] , Necator americanus [44] , and Ancylostoma ceylanicum [45] .", [["ES products", "ANATOMY", 70, 81], ["blood", "ANATOMY", 110, 115], ["Ancylostoma ceylanicum", "DISEASE", 191, 213], ["ES products", "CELL", 70, 81], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["A. caninum", "ORGANISM", 143, 153], ["Necator americanus", "ORGANISM", 161, 179], ["Ancylostoma ceylanicum", "ORGANISM", 191, 213], ["peptidase family members", "PROTEIN", 42, 66], ["ES products", "PROTEIN", 70, 81], ["A. caninum", "SPECIES", 143, 153], ["Necator americanus", "SPECIES", 161, 179], ["Ancylostoma ceylanicum", "SPECIES", 191, 213], ["A. caninum", "SPECIES", 143, 153], ["Necator americanus", "SPECIES", 161, 179], ["Ancylostoma ceylanicum", "SPECIES", 191, 213]]], ["Simultaneously, other essential molecules, e.g., C-type lectins (CLECs) and venom allergen-like proteins (VALs), were detected in the current study.", [["C-type lectins", "GENE_OR_GENE_PRODUCT", 49, 63], ["CLECs", "GENE_OR_GENE_PRODUCT", 65, 70], ["venom allergen-like proteins", "GENE_OR_GENE_PRODUCT", 76, 104], ["VALs", "GENE_OR_GENE_PRODUCT", 106, 110], ["C-type lectins", "PROTEIN", 49, 63], ["CLECs", "PROTEIN", 65, 70], ["venom allergen-like proteins", "PROTEIN", 76, 104], ["VALs", "PROTEIN", 106, 110], ["C-type lectins (CLECs)", "PROBLEM", 49, 71], ["venom allergen", "TEST", 76, 90], ["the current study", "TEST", 130, 147], ["essential", "OBSERVATION_MODIFIER", 22, 31], ["molecules", "OBSERVATION", 32, 41], ["venom", "ANATOMY", 76, 81]]], ["As members of the lectin superfamily, CLECs engage in a diverse set of immune regulation processes by glycan binding and are as indispensable to nematode survival as the secretome [46, 47] .", [["CLECs", "ANATOMY", 38, 43], ["lectin", "GENE_OR_GENE_PRODUCT", 18, 24], ["CLECs", "GENE_OR_GENE_PRODUCT", 38, 43], ["lectin superfamily", "PROTEIN", 18, 36], ["CLECs", "PROTEIN", 38, 43]]], ["Given their wide distribution and potential binding with the host, CLECs have been speculated to be immunomodulators in parasite-host interactions or parasitic immune evasion [47] .", [["CLECs", "ANATOMY", 67, 72], ["CLECs", "GENE_OR_GENE_PRODUCT", 67, 72], ["CLECs", "PROTEIN", 67, 72], ["immunomodulators", "TREATMENT", 100, 116], ["parasitic immune evasion", "PROBLEM", 150, 174]]], ["In addition, recent studies reported abundantly secreted VALs in ES products that caused severe damage to host tissue, favouring the establishment of persistent infections during parasitism, and VALs could inhibit innate immune responses and remodel the extracellular matrix [48] .DiscussionIn this study, our preliminary bioinformatics analysis revealed that HcESP stimuli might affect T cell growth and survival, based on the identification of FasL, a binding ligand of Fas.", [["ES", "ANATOMY", 65, 67], ["tissue", "ANATOMY", 111, 117], ["extracellular matrix", "ANATOMY", 254, 274], ["T cell", "ANATOMY", 387, 393], ["infections", "DISEASE", 161, 171], ["VALs", "CHEMICAL", 195, 199], ["VALs", "GENE_OR_GENE_PRODUCT", 57, 61], ["ES products", "CELL", 65, 76], ["tissue", "TISSUE", 111, 117], ["VALs", "SIMPLE_CHEMICAL", 195, 199], ["extracellular matrix", "CELLULAR_COMPONENT", 254, 274], ["HcESP", "GENE_OR_GENE_PRODUCT", 360, 365], ["T cell", "CELL", 387, 393], ["FasL", "GENE_OR_GENE_PRODUCT", 446, 450], ["Fas", "GENE_OR_GENE_PRODUCT", 472, 475], ["VALs", "PROTEIN", 57, 61], ["HcESP", "PROTEIN", 360, 365], ["FasL", "PROTEIN", 446, 450], ["Fas", "PROTEIN", 472, 475], ["recent studies", "TEST", 13, 27], ["severe damage to host tissue", "PROBLEM", 89, 117], ["persistent infections during parasitism", "PROBLEM", 150, 189], ["this study", "TEST", 294, 304], ["our preliminary bioinformatics analysis", "TEST", 306, 345], ["HcESP stimuli", "PROBLEM", 360, 373], ["T cell growth", "PROBLEM", 387, 400], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["damage", "OBSERVATION", 96, 102], ["host tissue", "OBSERVATION", 106, 117], ["persistent", "OBSERVATION_MODIFIER", 150, 160], ["infections", "OBSERVATION", 161, 171]]], ["Apoptosis can be induced through the activation of death receptors, including Fas, TNF\u03b1R, DR3, DR4, and DR5, by their respective ligands [49] .", [["death", "DISEASE", 51, 56], ["Fas", "GENE_OR_GENE_PRODUCT", 78, 81], ["TNF\u03b1R", "GENE_OR_GENE_PRODUCT", 83, 88], ["DR3", "GENE_OR_GENE_PRODUCT", 90, 93], ["DR4", "GENE_OR_GENE_PRODUCT", 95, 98], ["DR5", "GENE_OR_GENE_PRODUCT", 104, 107], ["death receptors", "PROTEIN", 51, 66], ["Fas", "PROTEIN", 78, 81], ["TNF\u03b1R", "PROTEIN", 83, 88], ["DR3", "PROTEIN", 90, 93], ["DR4", "PROTEIN", 95, 98], ["DR5", "PROTEIN", 104, 107], ["Apoptosis", "PROBLEM", 0, 9], ["death receptors", "TEST", 51, 66], ["Fas", "TEST", 78, 81], ["TNF", "TEST", 83, 86], ["DR3", "TEST", 90, 93], ["DR4", "TEST", 95, 98], ["DR5", "TEST", 104, 107]]], ["Consistent with the GO annotation, our data proved that HcESP stimuli dramatically inhibited T cell viability and induced cell apoptosis.", [["T cell", "ANATOMY", 93, 99], ["cell", "ANATOMY", 122, 126], ["HcESP", "SIMPLE_CHEMICAL", 56, 61], ["T cell", "CELL", 93, 99], ["cell", "CELL", 122, 126], ["our data", "TEST", 35, 43], ["HcESP stimuli", "TEST", 56, 69], ["T cell viability", "PROBLEM", 93, 109], ["induced cell apoptosis", "PROBLEM", 114, 136], ["cell viability", "OBSERVATION", 95, 109], ["cell apoptosis", "OBSERVATION", 122, 136]]], ["Generally, death receptor ligands initiate signalling via receptor oligomerization, which in turn results in the recruitment of specialized adaptor proteins and activation of caspase cascades [31] .", [["death", "DISEASE", 11, 16], ["caspase", "GENE_OR_GENE_PRODUCT", 175, 182], ["death receptor ligands", "PROTEIN", 11, 33], ["adaptor proteins", "PROTEIN", 140, 156], ["caspase", "PROTEIN", 175, 182], ["death receptor ligands", "PROBLEM", 11, 33], ["receptor oligomerization", "TEST", 58, 82], ["specialized adaptor proteins", "TREATMENT", 128, 156], ["activation of caspase cascades", "TREATMENT", 161, 191]]], ["Regarding Fas-mediated signalling, Fas trimerization resulting from binding to FasL leads to recruitment of the initiator Caspase-8 via the adaptor protein FADD, inducing Caspase-8 oligomerization and activation via autocatalysis.", [["Fas", "GENE_OR_GENE_PRODUCT", 35, 38], ["FasL", "GENE_OR_GENE_PRODUCT", 79, 83], ["Caspase-8", "GENE_OR_GENE_PRODUCT", 122, 131], ["FADD", "GENE_OR_GENE_PRODUCT", 156, 160], ["Caspase-8", "GENE_OR_GENE_PRODUCT", 171, 180], ["Fas", "PROTEIN", 35, 38], ["FasL", "PROTEIN", 79, 83], ["initiator Caspase-8", "PROTEIN", 112, 131], ["adaptor protein", "PROTEIN", 140, 155], ["FADD", "PROTEIN", 156, 160], ["Caspase-8", "PROTEIN", 171, 180], ["Fas-mediated signalling", "PROBLEM", 10, 33], ["Fas trimerization", "PROBLEM", 35, 52], ["the initiator Caspase", "TREATMENT", 108, 129], ["the adaptor protein FADD", "TREATMENT", 136, 160], ["Caspase-8 oligomerization", "TREATMENT", 171, 196], ["activation via autocatalysis", "TREATMENT", 201, 229]]], ["Subsequently, activated Caspase-8 stimulates apoptosis by directly cleaving and activating Caspase-3 or alternatively cleaving Bid, which is a pro-apoptotic Bcl-2 family protein.", [["Caspase-8", "GENE_OR_GENE_PRODUCT", 24, 33], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 91, 100], ["Bid", "GENE_OR_GENE_PRODUCT", 127, 130], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 157, 162], ["Caspase-8", "PROTEIN", 24, 33], ["Caspase-3", "PROTEIN", 91, 100], ["Bid", "PROTEIN", 127, 130], ["pro-apoptotic Bcl-2 family protein", "PROTEIN", 143, 177], ["activated Caspase-8 stimulates apoptosis", "TREATMENT", 14, 54], ["activating Caspase", "TREATMENT", 80, 98]]], ["Then, truncated Bid (tBid) translocates to mitochondria, facilitating the release of cytochrome c to activate Caspase-9 and Caspase-3 sequentially [50, 51] .", [["mitochondria", "ANATOMY", 43, 55], ["Bid", "GENE_OR_GENE_PRODUCT", 16, 19], ["Bid", "GENE_OR_GENE_PRODUCT", 22, 25], ["mitochondria", "CELLULAR_COMPONENT", 43, 55], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 85, 97], ["Caspase-9", "GENE_OR_GENE_PRODUCT", 110, 119], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 124, 133], ["truncated Bid (tBid)", "PROTEIN", 6, 26], ["cytochrome c", "PROTEIN", 85, 97], ["Caspase-9", "PROTEIN", 110, 119], ["Caspase", "PROTEIN", 124, 131], ["cytochrome c", "TREATMENT", 85, 97], ["Caspase", "TEST", 110, 117], ["Caspase", "TREATMENT", 124, 131]]], ["In this study, HcESPs exerted modulatory effects on the transcript levels of several essential genes in the Fas-mediated death receptor pathway.", [["HcESPs", "CHEMICAL", 15, 21], ["death", "DISEASE", 121, 126], ["HcESPs", "CHEMICAL", 15, 21], ["HcESPs", "SIMPLE_CHEMICAL", 15, 21], ["Fas-mediated death receptor", "PROTEIN", 108, 135], ["this study", "TEST", 3, 13]]], ["The mRNA transcription of FasL, Fas, FADD, Bid, Caspase-3, Caspase-8 and Caspase-9 was notably upregulated due to HcESP stimulation, indicating a potential mechanism of HcESPinduced intrinsic and extrinsic apoptosis of T cells.DiscussionCell apoptosis, the cell cycle, and cell proliferation are fundamental and ultimately linked processes.", [["T cells", "ANATOMY", 219, 226], ["cell", "ANATOMY", 257, 261], ["cell", "ANATOMY", 273, 277], ["FasL", "GENE_OR_GENE_PRODUCT", 26, 30], ["Fas", "GENE_OR_GENE_PRODUCT", 32, 35], ["FADD", "GENE_OR_GENE_PRODUCT", 37, 41], ["Bid", "GENE_OR_GENE_PRODUCT", 43, 46], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 48, 57], ["Caspase-8", "GENE_OR_GENE_PRODUCT", 59, 68], ["Caspase-9", "GENE_OR_GENE_PRODUCT", 73, 82], ["HcESP", "GENE_OR_GENE_PRODUCT", 114, 119], ["HcESPinduced", "SIMPLE_CHEMICAL", 169, 181], ["T cells", "CELL", 219, 226], ["cell", "CELL", 257, 261], ["cell", "CELL", 273, 277], ["FasL", "PROTEIN", 26, 30], ["Fas", "PROTEIN", 32, 35], ["FADD", "PROTEIN", 37, 41], ["Bid", "PROTEIN", 43, 46], ["Caspase-3", "PROTEIN", 48, 57], ["Caspase-8", "PROTEIN", 59, 68], ["Caspase-9", "PROTEIN", 73, 82], ["HcESP", "PROTEIN", 114, 119], ["T cells", "CELL_TYPE", 219, 226], ["Fas", "TEST", 32, 35], ["FADD", "TEST", 37, 41], ["Caspase", "TEST", 48, 55], ["Caspase", "TREATMENT", 59, 66], ["Caspase", "TREATMENT", 73, 80], ["HcESP stimulation", "PROBLEM", 114, 131], ["HcESPinduced intrinsic", "PROBLEM", 169, 191], ["extrinsic apoptosis of T cells", "PROBLEM", 196, 226], ["DiscussionCell apoptosis", "PROBLEM", 227, 251], ["the cell cycle", "TEST", 253, 267], ["extrinsic apoptosis", "OBSERVATION", 196, 215], ["T cells", "OBSERVATION", 219, 226], ["cell cycle", "OBSERVATION", 257, 267], ["cell proliferation", "OBSERVATION", 273, 291]]], ["Analogous to its pro-apoptotic effects, HcESP stimuli repressed cell proliferation in a dose-dependent manner.", [["cell", "ANATOMY", 64, 68], ["HcESP", "SIMPLE_CHEMICAL", 40, 45], ["cell", "CELL", 64, 68], ["HcESP", "PROTEIN", 40, 45], ["its pro-apoptotic effects", "PROBLEM", 13, 38], ["HcESP stimuli repressed cell proliferation", "PROBLEM", 40, 82], ["pro-apoptotic effects", "OBSERVATION", 17, 38], ["repressed cell proliferation", "OBSERVATION", 54, 82]]], ["In eukaryotic cells, cell cycle progression is controlled by the G1/S checkpoint via CDK4/6-Cyclin D and CDK2-Cyclin E kinase complexes and the G2/M checkpoint via the Cyclin B-cdc2 (CDK1) complex [52, 53] .", [["cells", "ANATOMY", 14, 19], ["cell", "ANATOMY", 21, 25], ["cells", "CELL", 14, 19], ["cell", "CELL", 21, 25], ["CDK4/6", "GENE_OR_GENE_PRODUCT", 85, 91], ["Cyclin D", "GENE_OR_GENE_PRODUCT", 92, 100], ["CDK2-Cyclin E", "GENE_OR_GENE_PRODUCT", 105, 118], ["Cyclin B-cdc2", "GENE_OR_GENE_PRODUCT", 168, 181], ["CDK1", "GENE_OR_GENE_PRODUCT", 183, 187], ["eukaryotic cells", "CELL_TYPE", 3, 19], ["CDK4/6", "PROTEIN", 85, 91], ["Cyclin D", "PROTEIN", 92, 100], ["CDK2", "PROTEIN", 105, 109], ["Cyclin E kinase complexes", "PROTEIN", 110, 135], ["Cyclin B-cdc2 (CDK1) complex", "PROTEIN", 168, 196], ["cell cycle progression", "PROBLEM", 21, 43], ["CDK4", "TEST", 85, 89], ["CDK2", "TEST", 105, 109], ["Cyclin E kinase complexes", "TREATMENT", 110, 135], ["the Cyclin B-cdc2 (CDK1) complex", "TEST", 164, 196], ["eukaryotic cells", "OBSERVATION", 3, 19], ["cell cycle", "OBSERVATION", 21, 31]]], ["Here, PI/RNase staining results revealed that HcESP stimuli induced cell cycle arrest at the G1 phase in a time-dependent manner.", [["cell", "ANATOMY", 68, 72], ["PI", "GENE_OR_GENE_PRODUCT", 6, 8], ["RNase", "GENE_OR_GENE_PRODUCT", 9, 14], ["HcESP", "SIMPLE_CHEMICAL", 46, 51], ["cell", "CELL", 68, 72], ["RNase", "PROTEIN", 9, 14], ["HcESP", "PROTEIN", 46, 51], ["PI/RNase staining", "TEST", 6, 23], ["HcESP stimuli", "PROBLEM", 46, 59], ["cell cycle arrest", "PROBLEM", 68, 85], ["cell cycle arrest", "OBSERVATION", 68, 85]]], ["Furthermore, the commitment of T cells to enter from the G1/S phase into G2/M phase was prevented by HcESPs through the downregulation of CCND1, CDK4/6, CCNE1, and CDK2 transcription.", [["T cells", "ANATOMY", 31, 38], ["T cells", "CELL", 31, 38], ["HcESPs", "GENE_OR_GENE_PRODUCT", 101, 107], ["CCND1", "GENE_OR_GENE_PRODUCT", 138, 143], ["CDK4/6", "GENE_OR_GENE_PRODUCT", 145, 151], ["CCNE1", "GENE_OR_GENE_PRODUCT", 153, 158], ["CDK2", "GENE_OR_GENE_PRODUCT", 164, 168], ["T cells", "CELL_TYPE", 31, 38], ["HcESPs", "PROTEIN", 101, 107], ["CCND1", "PROTEIN", 138, 143], ["CDK4", "PROTEIN", 145, 149], ["CCNE1", "PROTEIN", 153, 158], ["CDK2", "PROTEIN", 164, 168], ["CCND1", "TEST", 138, 143], ["CDK4", "TEST", 145, 149], ["CCNE1", "TEST", 153, 158], ["CDK2 transcription", "TREATMENT", 164, 182], ["CDK2 transcription", "OBSERVATION", 164, 182]]], ["The serine/ threonine kinase Akt contributes to cell proliferation by phosphorylating the CDK inhibitors p21 and p27, both of which have direct inhibitory modification effects on CDK2 [54] .", [["cell", "ANATOMY", 48, 52], ["serine", "CHEMICAL", 4, 10], ["threonine", "CHEMICAL", 12, 21], ["serine", "AMINO_ACID", 4, 10], ["threonine", "AMINO_ACID", 12, 21], ["Akt", "GENE_OR_GENE_PRODUCT", 29, 32], ["cell", "CELL", 48, 52], ["CDK", "GENE_OR_GENE_PRODUCT", 90, 93], ["p21", "GENE_OR_GENE_PRODUCT", 105, 108], ["p27", "GENE_OR_GENE_PRODUCT", 113, 116], ["CDK2", "GENE_OR_GENE_PRODUCT", 179, 183], ["serine/ threonine kinase", "PROTEIN", 4, 28], ["Akt", "PROTEIN", 29, 32], ["CDK inhibitors", "PROTEIN", 90, 104], ["p21", "PROTEIN", 105, 108], ["p27", "PROTEIN", 113, 116], ["CDK2", "PROTEIN", 179, 183], ["The serine/ threonine kinase Akt", "TREATMENT", 0, 32], ["cell proliferation", "PROBLEM", 48, 66], ["phosphorylating the CDK inhibitors p21", "TEST", 70, 108], ["p27", "TEST", 113, 116], ["CDK2", "TEST", 179, 183], ["cell proliferation", "OBSERVATION", 48, 66]]], ["Akt also has multistep inhibitory modifying effects on Cyclin D via GSK-3\u03b2 [55] .", [["Akt", "GENE_OR_GENE_PRODUCT", 0, 3], ["Cyclin D", "GENE_OR_GENE_PRODUCT", 55, 63], ["GSK-3", "GENE_OR_GENE_PRODUCT", 68, 73], ["Akt", "PROTEIN", 0, 3], ["Cyclin D", "PROTEIN", 55, 63], ["GSK-3\u03b2", "PROTEIN", 68, 74], ["Cyclin D via GSK", "TEST", 55, 71]]], ["Importantly, Akt is a major mediator of cell survival through direct inhibition of pro-apoptotic proteins such as Bad or inhibition of pro-apoptotic signals generated by transcription factors such as FoxO [56] .", [["cell", "ANATOMY", 40, 44], ["Akt", "GENE_OR_GENE_PRODUCT", 13, 16], ["cell", "CELL", 40, 44], ["Bad", "GENE_OR_GENE_PRODUCT", 114, 117], ["FoxO [56]", "GENE_OR_GENE_PRODUCT", 200, 209], ["Akt", "PROTEIN", 13, 16], ["pro-apoptotic proteins", "PROTEIN", 83, 105], ["Bad", "PROTEIN", 114, 117], ["transcription factors", "PROTEIN", 170, 191], ["FoxO [56]", "PROTEIN", 200, 209], ["pro-apoptotic proteins", "TREATMENT", 83, 105], ["pro-apoptotic signals", "PROBLEM", 135, 156], ["cell survival", "OBSERVATION", 40, 53]]], ["Based on these associations, we found that Akt1 transcription was significantly suppressed, whereas p21, p27 and FoxO1 transcription was strongly promoted, in HcESP-treated T cells.", [["T cells", "ANATOMY", 173, 180], ["Akt1", "GENE_OR_GENE_PRODUCT", 43, 47], ["p21", "GENE_OR_GENE_PRODUCT", 100, 103], ["p27", "GENE_OR_GENE_PRODUCT", 105, 108], ["FoxO1", "GENE_OR_GENE_PRODUCT", 113, 118], ["HcESP", "SIMPLE_CHEMICAL", 159, 164], ["T cells", "CELL", 173, 180], ["Akt1", "PROTEIN", 43, 47], ["p21", "PROTEIN", 100, 103], ["p27", "PROTEIN", 105, 108], ["FoxO1", "PROTEIN", 113, 118], ["HcESP-treated T cells", "CELL_LINE", 159, 180], ["Akt1 transcription", "PROBLEM", 43, 61], ["p21", "TEST", 100, 103], ["p27", "TEST", 105, 108], ["FoxO1 transcription", "TEST", 113, 132]]], ["Given that FoxO1 induces apoptosis by upregulating the pro-apoptotic molecule FasL and CDK2 directly phosphorylates FoxO1 [57] , the associations among FasL, FoxO1, CDKs, Cyclin proteins and Akt represent complex regulation by HcESP stimuli that can act via the alteration of mRNA transcription of key genes in the AKT/PKB pathway to mediate cell cycle arrest and apoptosis.", [["cell", "ANATOMY", 342, 346], ["FoxO1", "GENE_OR_GENE_PRODUCT", 11, 16], ["FasL", "GENE_OR_GENE_PRODUCT", 78, 82], ["CDK2", "GENE_OR_GENE_PRODUCT", 87, 91], ["FoxO1 [57]", "GENE_OR_GENE_PRODUCT", 116, 126], ["FasL", "GENE_OR_GENE_PRODUCT", 152, 156], ["FoxO1", "GENE_OR_GENE_PRODUCT", 158, 163], ["CDKs", "GENE_OR_GENE_PRODUCT", 165, 169], ["Cyclin", "GENE_OR_GENE_PRODUCT", 171, 177], ["Akt", "GENE_OR_GENE_PRODUCT", 191, 194], ["HcESP", "GENE_OR_GENE_PRODUCT", 227, 232], ["AKT", "GENE_OR_GENE_PRODUCT", 315, 318], ["PKB", "GENE_OR_GENE_PRODUCT", 319, 322], ["cell", "CELL", 342, 346], ["FoxO1", "PROTEIN", 11, 16], ["pro-apoptotic molecule", "PROTEIN", 55, 77], ["FasL", "PROTEIN", 78, 82], ["CDK2", "PROTEIN", 87, 91], ["FoxO1", "PROTEIN", 116, 121], ["FasL", "PROTEIN", 152, 156], ["FoxO1", "PROTEIN", 158, 163], ["CDKs", "PROTEIN", 165, 169], ["Cyclin proteins", "PROTEIN", 171, 186], ["Akt", "PROTEIN", 191, 194], ["HcESP", "PROTEIN", 227, 232], ["AKT", "PROTEIN", 315, 318], ["PKB", "PROTEIN", 319, 322], ["FoxO1 induces apoptosis", "PROBLEM", 11, 34], ["CDK2 directly phosphorylates FoxO1", "TEST", 87, 121], ["Cyclin proteins", "TREATMENT", 171, 186], ["HcESP stimuli", "TEST", 227, 240], ["cell cycle arrest", "PROBLEM", 342, 359], ["apoptosis", "PROBLEM", 364, 373], ["PKB", "ANATOMY", 319, 322], ["cell cycle arrest", "OBSERVATION", 342, 359]]], ["Collectively, this could be the mechanism by which HcESPs regulate cell apoptosis, the cell cycle and the proliferation of goat T cells.", [["cell", "ANATOMY", 67, 71], ["cell", "ANATOMY", 87, 91], ["T cells", "ANATOMY", 128, 135], ["HcESPs", "GENE_OR_GENE_PRODUCT", 51, 57], ["cell", "CELL", 67, 71], ["cell", "CELL", 87, 91], ["goat", "ORGANISM", 123, 127], ["T cells", "CELL", 128, 135], ["HcESPs", "PROTEIN", 51, 57], ["goat T cells", "CELL_TYPE", 123, 135], ["goat", "SPECIES", 123, 127], ["goat", "SPECIES", 123, 127], ["HcESPs regulate cell apoptosis", "PROBLEM", 51, 81], ["the cell cycle", "TEST", 83, 97], ["the proliferation of goat T cells", "PROBLEM", 102, 135], ["cell apoptosis", "OBSERVATION", 67, 81], ["proliferation", "OBSERVATION_MODIFIER", 106, 119]]], ["However, due to the lack of available goat immune reagents, we only checked the expression of several key molecules at the transcription level in this study.", [["goat", "ORGANISM", 38, 42], ["goat", "SPECIES", 38, 42], ["goat", "SPECIES", 38, 42], ["available goat immune reagents", "TREATMENT", 28, 58], ["this study", "TEST", 146, 156]]], ["Details regarding the regulation of these molecules at the protein level, along with the associated pathways, merit further investigation.", [["merit further investigation", "TEST", 110, 137]]], ["As there is currently no literature revealing the physiological dose range of HcESPs, we employed serial dilutions of HcESPs (0, 10, 20, 40 and 80 \u00b5g/mL) for functional studies and demonstrated that 20 \u00b5g/mL was the best reference concentration that had a significant impact on cell viability, apoptosis, proliferation and the cell cycle.", [["cell", "ANATOMY", 278, 282], ["cell", "ANATOMY", 327, 331], ["HcESPs", "CHEMICAL", 118, 124], ["HcESPs", "SIMPLE_CHEMICAL", 78, 84], ["HcESPs", "SIMPLE_CHEMICAL", 118, 124], ["cell", "CELL", 278, 282], ["cell", "CELL", 327, 331], ["HcESPs", "TEST", 118, 124], ["functional studies", "TEST", 158, 176], ["cell viability", "PROBLEM", 278, 292], ["apoptosis", "PROBLEM", 294, 303], ["significant", "OBSERVATION_MODIFIER", 256, 267], ["impact", "OBSERVATION_MODIFIER", 268, 274], ["cell viability", "OBSERVATION", 278, 292], ["proliferation", "OBSERVATION_MODIFIER", 305, 318], ["cell cycle", "OBSERVATION", 327, 337]]], ["However, under the circumstance of natural infection, whether the accumulation of HcESPs in H. contortus-infected goats could reach this relevant dose (20 \u00b5g/mL) to induce notable suppression effects on T cells is still unclear, and further efforts are needed to validate this hypothesis.DiscussionGenerally, immunomodulation by ES proteins of parasitic helminths has several predominant features: mediating Th2 responses as exemplified by the secretion of IL-4; inducing the generation of anti-inflammatory cytokines, including IL-10 and TGF-\u03b2; inhibiting lymphocyte activation; blocking pro-inflammatory and Th1 cytokines such as IL-2 and IFN-\u03b3; and regulating Treg and Th17 responses [4, 58] .", [["T cells", "ANATOMY", 203, 210], ["lymphocyte", "ANATOMY", 557, 567], ["Treg", "ANATOMY", 663, 667], ["infection", "DISEASE", 43, 52], ["HcESPs", "CHEMICAL", 82, 88], ["parasitic helminths", "DISEASE", 344, 363], ["HcESPs", "GENE_OR_GENE_PRODUCT", 82, 88], ["H. contortus", "ORGANISM", 92, 104], ["goats", "ORGANISM", 114, 119], ["T cells", "CELL", 203, 210], ["Th2", "GENE_OR_GENE_PRODUCT", 408, 411], ["IL-4", "GENE_OR_GENE_PRODUCT", 457, 461], ["IL-10", "GENE_OR_GENE_PRODUCT", 529, 534], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 539, 544], ["lymphocyte", "CELL", 557, 567], ["IL-2", "GENE_OR_GENE_PRODUCT", 632, 636], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 641, 646], ["Treg", "CELL", 663, 667], ["Th17", "CELL", 672, 676], ["T cells", "CELL_TYPE", 203, 210], ["ES proteins", "PROTEIN", 329, 340], ["IL-4", "PROTEIN", 457, 461], ["anti-inflammatory cytokines", "PROTEIN", 490, 517], ["IL-10", "PROTEIN", 529, 534], ["TGF-\u03b2", "PROTEIN", 539, 544], ["pro-inflammatory and Th1 cytokines", "PROTEIN", 589, 623], ["IL-2", "PROTEIN", 632, 636], ["IFN-\u03b3", "PROTEIN", 641, 646], ["Treg", "CELL_TYPE", 663, 667], ["H. contortus", "SPECIES", 92, 104], ["goats", "SPECIES", 114, 119], ["H. contortus", "SPECIES", 92, 104], ["goats", "SPECIES", 114, 119], ["natural infection", "PROBLEM", 35, 52], ["HcESPs", "PROBLEM", 82, 88], ["H. contortus", "PROBLEM", 92, 104], ["infected goats", "PROBLEM", 105, 119], ["notable suppression effects on T cells", "PROBLEM", 172, 210], ["this hypothesis", "PROBLEM", 272, 287], ["parasitic helminths", "PROBLEM", 344, 363], ["anti-inflammatory cytokines", "TREATMENT", 490, 517], ["IL", "TEST", 529, 531], ["TGF", "TEST", 539, 542], ["inhibiting lymphocyte activation", "PROBLEM", 546, 578], ["blocking pro-inflammatory", "PROBLEM", 580, 605], ["Th1 cytokines", "TEST", 610, 623], ["IL", "TEST", 632, 634], ["IFN", "TEST", 641, 644], ["natural", "OBSERVATION_MODIFIER", 35, 42], ["infection", "OBSERVATION", 43, 52], ["notable", "OBSERVATION_MODIFIER", 172, 179], ["suppression", "OBSERVATION", 180, 191], ["anti-inflammatory cytokines", "OBSERVATION", 490, 517], ["lymphocyte activation", "OBSERVATION", 557, 578], ["Treg", "ANATOMY", 663, 667]]], ["Consistent with these findings, HcESPs significantly suppressed the secretion of IL-2, IL-4 and IFN-\u03b3, indicating that HcESP stimuli exerted critical control effects on Th2 and Th1 responses.", [["HcESPs", "CHEMICAL", 32, 38], ["HcESPs", "CHEMICAL", 32, 38], ["HcESPs", "SIMPLE_CHEMICAL", 32, 38], ["IL-2", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-4", "GENE_OR_GENE_PRODUCT", 87, 91], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 96, 101], ["HcESP", "SIMPLE_CHEMICAL", 119, 124], ["Th2", "CELL", 169, 172], ["Th1", "GENE_OR_GENE_PRODUCT", 177, 180], ["IL-2, IL-4", "PROTEIN", 81, 91], ["IFN-\u03b3", "PROTEIN", 96, 101], ["HcESPs", "TEST", 32, 38], ["IL", "TEST", 81, 83], ["IFN", "TREATMENT", 96, 99], ["HcESP stimuli", "TEST", 119, 132]]], ["Although the reduced IL-2, IL-4 and IFN-\u03b3 secretion might be associated with the inhibition of cell viability and proliferation, we could not precisely determine IL-2/IL-4/IFN-\u03b3 production on a per cell basis here, and we could not determine the exact proportion of IL-2 + /IL-4 + /IFN-\u03b3 + T cells among total T cells.", [["cell", "ANATOMY", 95, 99], ["cell", "ANATOMY", 198, 202], ["IL-2 + /IL-4 + /IFN-\u03b3 + T cells", "ANATOMY", 266, 297], ["T cells", "ANATOMY", 310, 317], ["IL-2", "GENE_OR_GENE_PRODUCT", 21, 25], ["IL-4", "GENE_OR_GENE_PRODUCT", 27, 31], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 36, 41], ["cell", "CELL", 95, 99], ["IL-2", "GENE_OR_GENE_PRODUCT", 162, 166], ["IL-4", "GENE_OR_GENE_PRODUCT", 167, 171], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 172, 177], ["cell", "CELL", 198, 202], ["IL-2", "GENE_OR_GENE_PRODUCT", 266, 270], ["IL-4", "GENE_OR_GENE_PRODUCT", 274, 278], ["T cells", "CELL", 310, 317], ["IFN", "PROTEIN", 36, 39], ["IFN", "PROTEIN", 172, 175], ["IFN", "PROTEIN", 282, 285], ["T cells", "CELL_TYPE", 290, 297], ["total T cells", "CELL_TYPE", 304, 317], ["the reduced IL", "TEST", 9, 23], ["IL", "TEST", 27, 29], ["IFN", "TREATMENT", 36, 39], ["cell viability", "PROBLEM", 95, 109], ["IL", "TEST", 162, 164], ["IL", "TEST", 167, 169], ["IFN", "PROBLEM", 172, 175], ["IL", "TEST", 266, 268], ["IL", "TEST", 274, 276], ["IFN", "PROBLEM", 282, 285], ["T cells", "PROBLEM", 290, 297], ["total T cells", "PROBLEM", 304, 317], ["reduced", "OBSERVATION_MODIFIER", 13, 20], ["IL", "OBSERVATION_MODIFIER", 21, 23], ["cell viability", "OBSERVATION", 95, 109]]], ["Thus, whether the reduction in IL-2/IL-4/IFN-\u03b3 production resulted from HcESP stimuli causing reduced numbers of live IL-2 + /IL-4 + /IFN-\u03b3 + T cells, reduced numbers of differentiated IL-2 + /IL-4 + / IFN-\u03b3 + T cells, or increased numbers of hyporesponsive IL-2 + /IL-4 + /IFN-\u03b3 + T cells remains unclear, and further efforts are needed to address this issue.", [["IL-2 + /IL-4 + /IFN-\u03b3 + T cells", "ANATOMY", 118, 149], ["IL-2 + /IL-4 + / IFN-\u03b3 + T cells", "ANATOMY", 185, 217], ["IL-2 + /IL-4 + /IFN-\u03b3 + T cells", "ANATOMY", 258, 289], ["IL-2", "GENE_OR_GENE_PRODUCT", 31, 35], ["IL-4", "GENE_OR_GENE_PRODUCT", 36, 40], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 41, 46], ["HcESP", "GENE_OR_GENE_PRODUCT", 72, 77], ["IL-2", "GENE_OR_GENE_PRODUCT", 118, 122], ["IL-4", "GENE_OR_GENE_PRODUCT", 126, 130], ["IFN", "GENE_OR_GENE_PRODUCT", 134, 137], ["IL-2", "GENE_OR_GENE_PRODUCT", 185, 189], ["IL-4", "GENE_OR_GENE_PRODUCT", 193, 197], ["IFN", "GENE_OR_GENE_PRODUCT", 202, 205], ["IL-2", "GENE_OR_GENE_PRODUCT", 258, 262], ["IL-4", "GENE_OR_GENE_PRODUCT", 266, 270], ["IFN", "PROTEIN", 41, 44], ["IFN", "PROTEIN", 134, 137], ["T cells", "CELL_TYPE", 142, 149], ["IFN", "PROTEIN", 202, 205], ["T cells", "CELL_TYPE", 210, 217], ["IFN", "PROTEIN", 274, 277], ["T cells", "CELL_TYPE", 282, 289], ["the reduction in IL", "TREATMENT", 14, 33], ["IL", "TEST", 36, 38], ["IFN", "TREATMENT", 41, 44], ["HcESP stimuli", "TEST", 72, 85], ["reduced numbers", "PROBLEM", 94, 109], ["live IL", "TEST", 113, 120], ["IL", "TEST", 126, 128], ["IFN", "TEST", 134, 137], ["T cells", "PROBLEM", 142, 149], ["IL", "TEST", 185, 187], ["IL", "TEST", 193, 195], ["IFN", "TEST", 202, 205], ["T cells", "PROBLEM", 210, 217], ["increased numbers", "PROBLEM", 222, 239], ["hyporesponsive IL", "TEST", 243, 260], ["IL", "TEST", 266, 268], ["IFN", "PROBLEM", 274, 277], ["T cells", "PROBLEM", 282, 289], ["reduction", "OBSERVATION_MODIFIER", 18, 27]]], ["In a previous study, a Galectin-9 homologue derived from adult Toxascaris leonina restrained inflammatory reactions by inhibiting Th1 and Th2 cytokine production by enhancing TGF-\u03b2 and IL-10 production [59] .", [["Galectin-9", "CHEMICAL", 23, 33], ["Galectin-9", "GENE_OR_GENE_PRODUCT", 23, 33], ["Toxascaris leonina", "ORGANISM", 63, 81], ["Th1", "CELL", 130, 133], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 175, 180], ["IL-10", "GENE_OR_GENE_PRODUCT", 185, 190], ["Galectin-9 homologue", "DNA", 23, 43], ["cytokine", "PROTEIN", 142, 150], ["TGF", "PROTEIN", 175, 178], ["Toxascaris leonina", "SPECIES", 63, 81], ["Toxascaris leonina", "SPECIES", 63, 81], ["a previous study", "TEST", 3, 19], ["a Galectin", "TEST", 21, 31], ["inflammatory reactions", "PROBLEM", 93, 115], ["enhancing TGF", "TEST", 165, 178], ["IL", "TEST", 185, 187], ["inflammatory", "OBSERVATION_MODIFIER", 93, 105]]], ["Similarly, a high dose of HcESPs also upregulated IL-10 and TGF-\u03b21 secretion to inhibit the host inflammatory response.", [["HcESPs", "CHEMICAL", 26, 32], ["HcESPs", "CHEMICAL", 26, 32], ["HcESPs", "SIMPLE_CHEMICAL", 26, 32], ["IL-10", "GENE_OR_GENE_PRODUCT", 50, 55], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 60, 66], ["TGF-\u03b21", "PROTEIN", 60, 66], ["HcESPs", "TEST", 26, 32], ["IL", "TEST", 50, 52], ["TGF", "TEST", 60, 63], ["the host inflammatory response", "PROBLEM", 88, 118], ["host", "OBSERVATION_MODIFIER", 92, 96], ["inflammatory response", "OBSERVATION", 97, 118]]], ["Additionally, TGF-\u03b2 induces apoptosis via death-associated protein 6 (DAXX), another binding receptor of Fas [60] .", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 14, 19], ["death-associated protein 6", "GENE_OR_GENE_PRODUCT", 42, 68], ["DAXX", "GENE_OR_GENE_PRODUCT", 70, 74], ["Fas", "GENE_OR_GENE_PRODUCT", 105, 108], ["TGF-\u03b2", "PROTEIN", 14, 19], ["death-associated protein 6", "PROTEIN", 42, 68], ["DAXX", "PROTEIN", 70, 74], ["binding receptor", "PROTEIN", 85, 101], ["Fas", "PROTEIN", 105, 108], ["TGF", "TEST", 14, 17], ["apoptosis via death", "PROBLEM", 28, 47], ["protein", "TEST", 59, 66], ["Fas", "TEST", 105, 108]]], ["Therefore, increased TGF-\u03b21 secretion may exacerbate Fas-mediated apoptosis via a separate apoptotic pathway.", [["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 21, 27], ["TGF-\u03b21", "PROTEIN", 21, 27], ["increased TGF", "TEST", 11, 24], ["Fas-mediated apoptosis", "PROBLEM", 53, 75], ["a separate apoptotic pathway", "TREATMENT", 80, 108], ["increased", "OBSERVATION_MODIFIER", 11, 20], ["TGF", "OBSERVATION_MODIFIER", 21, 24]]], ["Recent studies demonstrated the inhibition of Th17 differentiation and IL-17 secretion by Echinococcus granulosus and Acanthocheilonema viteae ES proteins [61, 62] .", [["Th17", "ANATOMY", 46, 50], ["Echinococcus granulosus", "DISEASE", 90, 113], ["Th17", "CELL", 46, 50], ["IL-17", "GENE_OR_GENE_PRODUCT", 71, 76], ["Echinococcus granulosus", "ORGANISM", 90, 113], ["Acanthocheilonema viteae ES", "ORGANISM", 118, 145], ["Echinococcus granulosus", "SPECIES", 90, 113], ["Acanthocheilonema viteae", "SPECIES", 118, 142], ["Echinococcus granulosus", "SPECIES", 90, 113], ["Acanthocheilonema viteae", "SPECIES", 118, 142], ["Recent studies", "TEST", 0, 14], ["Th17 differentiation", "TEST", 46, 66], ["IL", "TEST", 71, 73], ["Echinococcus granulosus", "TEST", 90, 113], ["Acanthocheilonema viteae ES proteins", "TEST", 118, 154]]], ["Instead, the secretion of the pro-inflammatory cytokine IL-17A was notably promoted by HcESP stimuli in this study, indicating that HcESPs may not induce apoptosis of the Th17 subset.", [["Th17", "ANATOMY", 171, 175], ["HcESPs", "CHEMICAL", 132, 138], ["IL-17A", "GENE_OR_GENE_PRODUCT", 56, 62], ["HcESP", "SIMPLE_CHEMICAL", 87, 92], ["HcESPs", "SIMPLE_CHEMICAL", 132, 138], ["Th17", "CELL", 171, 175], ["pro-inflammatory cytokine IL-17A", "PROTEIN", 30, 62], ["Th17 subset", "CELL_TYPE", 171, 182], ["HcESP stimuli", "TEST", 87, 100], ["this study", "TEST", 104, 114]]], ["In addition, TGF-\u03b2 contributes to Th17 formation and IL-17 secretion [63, 64] , and it is likely that increased TGF-\u03b21 production may function as the key factor to facilitate IL-17A production.DiscussionAs one of the most intensive research areas, a pleiotropic range of immunomodulatory activities of ES proteins has been determined in numerous species of GIhelminths, including H. polygyrus [65] , Teladorsagia circumcincta [66] , A. caninum [67] , and N. americanus [68] .", [["Th17", "ANATOMY", 34, 38], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 13, 18], ["Th17", "CELL", 34, 38], ["IL-17", "GENE_OR_GENE_PRODUCT", 53, 58], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 112, 118], ["IL-17A", "GENE_OR_GENE_PRODUCT", 175, 181], ["GIhelminths", "GENE_OR_GENE_PRODUCT", 357, 368], ["H. polygyrus", "ORGANISM", 380, 392], ["[65]", "ORGANISM", 393, 397], ["Teladorsagia circumcincta", "ORGANISM", 400, 425], ["[66]", "ORGANISM", 426, 430], ["A. caninum", "ORGANISM", 433, 443], ["N. americanus", "ORGANISM", 455, 468], ["TGF-\u03b2", "PROTEIN", 13, 18], ["TGF-\u03b21", "PROTEIN", 112, 118], ["IL", "PROTEIN", 175, 177], ["17A", "PROTEIN", 178, 181], ["ES proteins", "PROTEIN", 302, 313], ["H. polygyrus", "SPECIES", 380, 392], ["Teladorsagia circumcincta", "SPECIES", 400, 425], ["A. caninum", "SPECIES", 433, 443], ["N. americanus", "SPECIES", 455, 468], ["H. polygyrus", "SPECIES", 380, 392], ["Teladorsagia circumcincta", "SPECIES", 400, 425], ["A. caninum", "SPECIES", 433, 443], ["N. americanus", "SPECIES", 455, 468], ["TGF", "TEST", 13, 16], ["Th17 formation", "TEST", 34, 48], ["IL", "TEST", 53, 55], ["increased TGF", "PROBLEM", 102, 115], ["ES proteins", "PROBLEM", 302, 313], ["H. polygyrus", "PROBLEM", 380, 392], ["Teladorsagia circumcincta", "PROBLEM", 400, 425], ["is likely", "UNCERTAINTY", 87, 96], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["TGF", "OBSERVATION", 112, 115]]], ["In our previous work, two novel ES proteins, namely, Y75B8A.8 and HcTTR, were validated as binding partners and novel antagonists of goat IL-2 and IL-4, respectively, and were shown to block downstream effectors [69, 70] .", [["Y75B8A.8", "GENE_OR_GENE_PRODUCT", 53, 61], ["HcTTR", "GENE_OR_GENE_PRODUCT", 66, 71], ["goat IL-2", "GENE_OR_GENE_PRODUCT", 133, 142], ["IL-4", "GENE_OR_GENE_PRODUCT", 147, 151], ["ES proteins", "PROTEIN", 32, 43], ["Y75B8A.8", "PROTEIN", 53, 61], ["HcTTR", "PROTEIN", 66, 71], ["goat IL-2 and IL-4", "PROTEIN", 133, 151], ["goat", "SPECIES", 133, 137], ["HcTTR", "TEST", 66, 71], ["goat IL", "TEST", 133, 140]]], ["Although we employed proteomic approaches to identify a variety of potential immunomodulators, such as kinases, hydrolases, proteases, lipases, phosphatases and CLECs, in this study, the exact molecules that regulate/interact with T cell FasL directly/indirectly at the parasite-host interface, along with the cascade of cellular responses, still need to be further investigated.", [["T cell", "ANATOMY", 231, 237], ["cellular", "ANATOMY", 321, 329], ["lipases", "GENE_OR_GENE_PRODUCT", 135, 142], ["CLECs", "GENE_OR_GENE_PRODUCT", 161, 166], ["T cell FasL", "GENE_OR_GENE_PRODUCT", 231, 242], ["cellular", "CELL", 321, 329], ["kinases", "PROTEIN", 103, 110], ["hydrolases", "PROTEIN", 112, 122], ["proteases", "PROTEIN", 124, 133], ["lipases", "PROTEIN", 135, 142], ["phosphatases", "PROTEIN", 144, 156], ["CLECs", "PROTEIN", 161, 166], ["FasL", "PROTEIN", 238, 242], ["proteomic approaches", "TREATMENT", 21, 41], ["potential immunomodulators", "TREATMENT", 67, 93], ["hydrolases", "TEST", 112, 122], ["proteases", "TEST", 124, 133], ["lipases", "TEST", 135, 142], ["phosphatases", "TEST", 144, 156], ["CLECs", "TEST", 161, 166], ["this study", "TEST", 171, 181], ["host interface", "OBSERVATION", 279, 293]]]], "986a3b759ee133ad544b92b6de91647414d55132": [["INTRODUCTIONHuman metapneumovirus (hMPV) was discovered in 2001 in the Netherlands from a nasopharyngeal aspirate of young children with acute respiratory tract infection [Van den Hoogen et al., 2001] .", [["nasopharyngeal aspirate", "ANATOMY", 90, 113], ["respiratory tract", "ANATOMY", 143, 160], ["INTRODUCTIONHuman metapneumovirus (hMPV)", "DISEASE", 0, 40], ["acute respiratory tract infection", "DISEASE", 137, 170], ["INTRODUCTIONHuman metapneumovirus", "ORGANISM", 0, 33], ["hMPV", "ORGANISM", 35, 39], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 90, 113], ["children", "ORGANISM", 123, 131], ["children", "SPECIES", 123, 131], ["INTRODUCTIONHuman metapneumovirus", "SPECIES", 0, 33], ["hMPV", "SPECIES", 35, 39], ["INTRODUCTIONHuman metapneumovirus (hMPV", "PROBLEM", 0, 39], ["acute respiratory tract infection", "PROBLEM", 137, 170], ["nasopharyngeal", "ANATOMY", 90, 104], ["aspirate", "OBSERVATION", 105, 113], ["acute", "OBSERVATION_MODIFIER", 137, 142], ["respiratory tract", "ANATOMY", 143, 160]]], ["Since then, hMPV has been identified frequently in respiratory tract infections worldwide [Kahn, 2006] , and lately recognized as a major cause of lower respiratory tract infections in infants, elderly, and immunocompromised patients [Bao et al., 2008] .", [["respiratory tract", "ANATOMY", 51, 68], ["lower respiratory tract", "ANATOMY", 147, 170], ["respiratory tract infections", "DISEASE", 51, 79], ["respiratory tract infections", "DISEASE", 153, 181], ["hMPV", "ORGANISM", 12, 16], ["lower", "ORGANISM", 147, 152], ["respiratory tract", "ORGANISM_SUBDIVISION", 153, 170], ["infants", "ORGANISM", 185, 192], ["patients", "ORGANISM", 225, 233], ["infants", "SPECIES", 185, 192], ["patients", "SPECIES", 225, 233], ["hMPV", "SPECIES", 12, 16], ["hMPV", "PROBLEM", 12, 16], ["respiratory tract infections", "PROBLEM", 51, 79], ["lower respiratory tract infections", "PROBLEM", 147, 181], ["hMPV", "OBSERVATION", 12, 16], ["respiratory tract", "ANATOMY", 51, 68], ["lower", "ANATOMY_MODIFIER", 147, 152], ["respiratory tract", "ANATOMY", 153, 170], ["infections", "OBSERVATION", 171, 181]]], ["Around 12% of all respiratory tract infections in children are caused by hMPV [Kahn, 2006] , and almost all children are infected by the age of 5 [ Van den Hoogen et al., 2001] .", [["respiratory tract", "ANATOMY", 18, 35], ["respiratory tract infections", "DISEASE", 18, 46], ["respiratory tract", "ORGANISM_SUBDIVISION", 18, 35], ["children", "ORGANISM", 50, 58], ["hMPV", "ORGANISM", 73, 77], ["children", "ORGANISM", 108, 116], ["children", "SPECIES", 50, 58], ["children", "SPECIES", 108, 116], ["hMPV", "SPECIES", 73, 77], ["all respiratory tract infections", "PROBLEM", 14, 46], ["respiratory tract", "ANATOMY", 18, 35], ["infections", "OBSERVATION", 36, 46]]], ["Human metapneumovirus also accounts for 10% of all hospitalizations of elderly patients with respiratory tract infections [Falsey et al., 2003] , and is a significant pathogen in immunocompromised patients [Muir and Pillay, 1998; Williams et al., 2005] .INTRODUCTIONThe clinical symptoms associated with hMPV infections are very similar to those symptoms observed in respiratory syncytial virus (RSV) infection.", [["respiratory tract", "ANATOMY", 93, 110], ["Human metapneumovirus", "DISEASE", 0, 21], ["respiratory tract infections", "DISEASE", 93, 121], ["hMPV infections", "DISEASE", 304, 319], ["respiratory syncytial virus (RSV) infection", "DISEASE", 367, 410], ["Human", "ORGANISM", 0, 5], ["metapneumovirus", "ORGANISM", 6, 21], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 197, 205], ["hMPV", "ORGANISM", 304, 308], ["respiratory syncytial virus", "ORGANISM", 367, 394], ["RSV", "ORGANISM", 396, 399], ["Human", "SPECIES", 0, 5], ["metapneumovirus", "SPECIES", 6, 21], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 197, 205], ["syncytial virus (RSV", "SPECIES", 379, 399], ["Human metapneumovirus", "SPECIES", 0, 21], ["hMPV", "SPECIES", 304, 308], ["respiratory syncytial virus", "SPECIES", 367, 394], ["RSV", "SPECIES", 396, 399], ["Human metapneumovirus", "PROBLEM", 0, 21], ["respiratory tract infections", "PROBLEM", 93, 121], ["The clinical symptoms", "PROBLEM", 266, 287], ["hMPV infections", "PROBLEM", 304, 319], ["those symptoms", "PROBLEM", 340, 354], ["respiratory syncytial virus (RSV) infection", "PROBLEM", 367, 410], ["metapneumovirus", "OBSERVATION", 6, 21], ["respiratory tract", "ANATOMY", 93, 110], ["significant", "OBSERVATION_MODIFIER", 155, 166], ["pathogen", "OBSERVATION", 167, 175], ["respiratory", "ANATOMY", 367, 378], ["syncytial virus", "OBSERVATION", 379, 394], ["infection", "OBSERVATION", 401, 410]]], ["Human metapneumovirus can cause both upper and lower respiratory tract infections, such as bronchitis, bronchiolitis, and pneumonia [Boivin et al., 2002] , as well as asthma exacerbation [Kahn, 2003] .", [["lower respiratory tract", "ANATOMY", 47, 70], ["Human metapneumovirus", "DISEASE", 0, 21], ["respiratory tract infections", "DISEASE", 53, 81], ["bronchitis", "DISEASE", 91, 101], ["bronchiolitis", "DISEASE", 103, 116], ["pneumonia", "DISEASE", 122, 131], ["asthma", "DISEASE", 167, 173], ["Human", "ORGANISM", 0, 5], ["metapneumovirus", "ORGANISM", 6, 21], ["upper", "ORGANISM_SUBDIVISION", 37, 42], ["lower", "ORGANISM_SUBDIVISION", 47, 52], ["respiratory tract", "ORGANISM_SUBDIVISION", 53, 70], ["Human", "SPECIES", 0, 5], ["metapneumovirus", "SPECIES", 6, 21], ["Human metapneumovirus", "SPECIES", 0, 21], ["Human metapneumovirus", "PROBLEM", 0, 21], ["both upper and lower respiratory tract infections", "PROBLEM", 32, 81], ["bronchitis", "PROBLEM", 91, 101], ["bronchiolitis", "PROBLEM", 103, 116], ["pneumonia", "PROBLEM", 122, 131], ["asthma exacerbation", "PROBLEM", 167, 186], ["metapneumovirus", "OBSERVATION", 6, 21], ["upper", "ANATOMY_MODIFIER", 37, 42], ["lower", "ANATOMY_MODIFIER", 47, 52], ["respiratory tract", "ANATOMY", 53, 70], ["infections", "OBSERVATION", 71, 81], ["bronchitis", "OBSERVATION", 91, 101], ["bronchiolitis", "OBSERVATION", 103, 116], ["pneumonia", "OBSERVATION", 122, 131], ["asthma", "OBSERVATION", 167, 173]]], ["Symptoms such as fever, cough, tachypnea, wheezing, and hypoxia are frequently observed in infected children, and in children with a clinical syndrome consistent with bronchiolitis, hyperinflation, as well as focal infiltrates and peribronchial cuffing [Williams et al., 2004] .", [["focal infiltrates", "ANATOMY", 209, 226], ["peribronchial", "ANATOMY", 231, 244], ["fever", "DISEASE", 17, 22], ["cough", "DISEASE", 24, 29], ["tachypnea", "DISEASE", 31, 40], ["wheezing", "DISEASE", 42, 50], ["hypoxia", "DISEASE", 56, 63], ["bronchiolitis", "DISEASE", 167, 180], ["hyperinflation", "DISEASE", 182, 196], ["children", "ORGANISM", 100, 108], ["children", "ORGANISM", 117, 125], ["children", "SPECIES", 100, 108], ["children", "SPECIES", 117, 125], ["Symptoms", "PROBLEM", 0, 8], ["fever", "PROBLEM", 17, 22], ["cough", "PROBLEM", 24, 29], ["tachypnea", "PROBLEM", 31, 40], ["wheezing", "PROBLEM", 42, 50], ["hypoxia", "PROBLEM", 56, 63], ["a clinical syndrome", "PROBLEM", 131, 150], ["bronchiolitis", "PROBLEM", 167, 180], ["hyperinflation", "PROBLEM", 182, 196], ["focal infiltrates", "PROBLEM", 209, 226], ["peribronchial cuffing", "PROBLEM", 231, 252], ["wheezing", "OBSERVATION", 42, 50], ["hypoxia", "OBSERVATION", 56, 63], ["consistent with", "UNCERTAINTY", 151, 166], ["bronchiolitis", "OBSERVATION", 167, 180], ["hyperinflation", "OBSERVATION", 182, 196], ["focal", "OBSERVATION_MODIFIER", 209, 214], ["infiltrates", "OBSERVATION", 215, 226], ["peribronchial", "ANATOMY", 231, 244], ["cuffing", "OBSERVATION", 245, 252]]], ["Some reports have shown that hMPV infection is associated with encephalitis, and there is at least one example where hMPV was detected in a patient who died of complications associated with encephalitis [Schildgen et al., 2005] .", [["hMPV infection", "DISEASE", 29, 43], ["encephalitis", "DISEASE", 63, 75], ["hMPV", "DISEASE", 117, 121], ["encephalitis", "DISEASE", 190, 202], ["hMPV", "ORGANISM", 29, 33], ["hMPV", "ORGANISM", 117, 121], ["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 140, 147], ["hMPV", "SPECIES", 29, 33], ["hMPV", "SPECIES", 117, 121], ["hMPV infection", "PROBLEM", 29, 43], ["encephalitis", "PROBLEM", 63, 75], ["hMPV", "PROBLEM", 117, 121], ["complications", "PROBLEM", 160, 173], ["encephalitis", "PROBLEM", 190, 202], ["hMPV", "OBSERVATION_MODIFIER", 29, 33], ["infection", "OBSERVATION", 34, 43], ["associated with", "UNCERTAINTY", 47, 62], ["encephalitis", "OBSERVATION", 63, 75], ["hMPV", "OBSERVATION", 117, 121], ["encephalitis", "OBSERVATION", 190, 202]]], ["In addition, some studies have reported a hospital-acquired hMPV infection in infants, children, and elderly patients in long-term care facilities [Chano et al., 2005; Honda et al., 2006; Boivin et al., 2007; Kim et al., 2009] .INTRODUCTIONGenetic analysis revealed a relatively high degree of sequence variability between different hMPV isolates, and two major subgroups A and B were identified.", [["hMPV infection", "DISEASE", 60, 74], ["hMPV", "ORGANISM", 60, 64], ["infants", "ORGANISM", 78, 85], ["children", "ORGANISM", 87, 95], ["patients", "ORGANISM", 109, 117], ["hMPV", "ORGANISM", 333, 337], ["B", "CANCER", 378, 379], ["infants", "SPECIES", 78, 85], ["children", "SPECIES", 87, 95], ["patients", "SPECIES", 109, 117], ["hMPV", "SPECIES", 60, 64], ["hMPV", "SPECIES", 333, 337], ["some studies", "TEST", 13, 25], ["acquired hMPV infection", "PROBLEM", 51, 74], [".INTRODUCTIONGenetic analysis", "TEST", 227, 256], ["a relatively high degree of sequence variability", "PROBLEM", 266, 314], ["different hMPV isolates", "PROBLEM", 323, 346], ["infection", "OBSERVATION", 65, 74], ["hMPV isolates", "OBSERVATION", 333, 346]]], ["Subsequent genetic analysis led to a further subdivision of the hMPV A and B subgroups into the subtypes 1A, 2A, 1B, and 2B [Biacchesi et al., 2003] .", [["hMPV", "ORGANISM", 64, 68], ["B", "GENE_OR_GENE_PRODUCT", 75, 76], ["1B", "GENE_OR_GENE_PRODUCT", 113, 115], ["Subsequent genetic analysis", "TEST", 0, 27], ["hMPV", "OBSERVATION", 64, 68]]], ["Moreover, subgroup A2 was further subdivided into two minor subgroups A2a and A2b [Huck et al., 2006] .", [["subgroup A2", "GENE_OR_GENE_PRODUCT", 10, 21], ["A2", "PROTEIN", 19, 21]]], ["Although viral respiratory tract infections are very common in Kuwait and responsible of acute respiratory diseases and pneumonia [Hijazi et al., 1996 [Hijazi et al., , 1997 , the prevalence of hMPV infection is not yet documented in Kuwait.", [["respiratory tract", "ANATOMY", 15, 32], ["respiratory", "ANATOMY", 95, 106], ["viral respiratory tract infections", "DISEASE", 9, 43], ["acute respiratory diseases", "DISEASE", 89, 115], ["pneumonia", "DISEASE", 120, 129], ["hMPV infection", "DISEASE", 194, 208], ["viral respiratory tract", "ORGANISM", 9, 32], ["hMPV", "ORGANISM", 194, 198], ["hMPV", "SPECIES", 194, 198], ["viral respiratory tract infections", "PROBLEM", 9, 43], ["acute respiratory diseases", "PROBLEM", 89, 115], ["pneumonia", "PROBLEM", 120, 129], ["hMPV infection", "PROBLEM", 194, 208], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["respiratory tract", "ANATOMY", 15, 32], ["responsible of", "UNCERTAINTY", 74, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory diseases", "OBSERVATION", 95, 115], ["pneumonia", "OBSERVATION", 120, 129], ["hMPV infection", "OBSERVATION", 194, 208]]], ["The aims of this study were therefore to determine the prevalence of hMPV infection in Kuwait in patients with respiratory tract infections with respect to the other respiratory viruses, to identify the type of circulating hMPV, and to determine the seasonal distribution of hMPV infection.Specimen CollectionAll respiratory samples were collected during January-December, 2009 from different hospitals in Kuwait; 236 (51%) were from the Mubarak Al-Kabir Hospital, 136 (30%) from the Al-Sabah Hospital, 31 (7%) from the Farwanya Hospital, 23 (5%) from the Amiri Hospital, 11 (2.5%) from the Abdul-Aziz Al-Rashed Allergy Center, 9 (2%) from the Organ Transplant Center, 4 (1%) from the Adan Hospital, 4 (1%) from the Ibn-Sina Hospital, 4 (1%) from the Jahra Hospital, 1 (0.3%) from the Infectious Diseases Hospital, and 1 (0.3%) from the Kuwait Cancer Center.Specimen CollectionSince the year of 2009 had witnessed the H1N1 pandemic, respiratory samples that were H1N1 positive starting from August to December have been excluded.", [["respiratory tract", "ANATOMY", 111, 128], ["respiratory samples", "ANATOMY", 313, 332], ["respiratory samples", "ANATOMY", 933, 952], ["hMPV infection", "DISEASE", 69, 83], ["respiratory tract infections", "DISEASE", 111, 139], ["hMPV infection", "DISEASE", 275, 289], ["Infectious Diseases", "DISEASE", 785, 804], ["Cancer", "DISEASE", 844, 850], ["hMPV", "ORGANISM", 69, 73], ["patients", "ORGANISM", 97, 105], ["tract", "ORGANISM_SUBDIVISION", 123, 128], ["hMPV", "ORGANISM", 223, 227], ["hMPV", "ORGANISM", 275, 279], ["patients", "SPECIES", 97, 105], ["hMPV", "SPECIES", 69, 73], ["hMPV", "SPECIES", 223, 227], ["hMPV", "SPECIES", 275, 279], ["this study", "TEST", 12, 22], ["hMPV infection", "PROBLEM", 69, 83], ["respiratory tract infections", "PROBLEM", 111, 139], ["the other respiratory viruses", "PROBLEM", 156, 185], ["circulating hMPV", "PROBLEM", 211, 227], ["hMPV infection", "PROBLEM", 275, 289], ["Specimen Collection", "TEST", 290, 309], ["All respiratory samples", "TEST", 309, 332], ["Specimen", "TEST", 858, 866], ["the H1N1 pandemic", "PROBLEM", 914, 931], ["respiratory samples", "TEST", 933, 952], ["H1N1", "PROBLEM", 963, 967], ["hMPV", "OBSERVATION_MODIFIER", 69, 73], ["infection", "OBSERVATION", 74, 83], ["respiratory tract", "ANATOMY", 111, 128], ["respiratory", "ANATOMY", 166, 177], ["viruses", "OBSERVATION", 178, 185], ["hMPV", "OBSERVATION", 223, 227], ["hMPV infection", "OBSERVATION", 275, 289], ["Collection", "OBSERVATION_MODIFIER", 299, 309], ["respiratory", "ANATOMY", 313, 324], ["Organ", "ANATOMY", 644, 649], ["Transplant", "OBSERVATION", 650, 660], ["Infectious", "OBSERVATION_MODIFIER", 785, 795], ["Cancer", "OBSERVATION", 844, 850]]], ["The 460 respiratory samples were obtained from 388 patients, 210 (54%) were males and 178 (46%) were females, with either upper (n \u00bc 94, 24%) or lower (n \u00bc 294, 76%) respiratory tract infections of all age groups, from 0 day up to 80 years, and from different nationalities.", [["respiratory samples", "ANATOMY", 8, 27], ["respiratory tract", "ANATOMY", 166, 183], ["respiratory tract infections", "DISEASE", 166, 194], ["respiratory samples", "CANCER", 8, 27], ["patients", "ORGANISM", 51, 59], ["upper", "ORGANISM_SUBDIVISION", 122, 127], ["respiratory tract", "ORGANISM_SUBDIVISION", 166, 183], ["patients", "SPECIES", 51, 59], ["The 460 respiratory samples", "TEST", 0, 27], ["respiratory tract infections", "PROBLEM", 166, 194], ["upper", "ANATOMY_MODIFIER", 122, 127], ["respiratory tract", "ANATOMY", 166, 183]]], ["The respiratory samples included bronchoalveolar lavage, endotracheal tube secretions, tracheal aspirate, throat swab, nasopharyngeal aspirate, nasopharyngeal swab, nasal swab, nasal and throat swabs, and pleural fluid.", [["respiratory samples", "ANATOMY", 4, 23], ["bronchoalveolar lavage", "ANATOMY", 33, 55], ["endotracheal tube secretions", "ANATOMY", 57, 85], ["tracheal aspirate", "ANATOMY", 87, 104], ["throat swab", "ANATOMY", 106, 117], ["nasopharyngeal aspirate", "ANATOMY", 119, 142], ["nasopharyngeal swab", "ANATOMY", 144, 163], ["nasal swab", "ANATOMY", 165, 175], ["nasal", "ANATOMY", 177, 182], ["throat swabs", "ANATOMY", 187, 199], ["pleural fluid", "ANATOMY", 205, 218], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 33, 55], ["endotracheal tube secretions", "ORGANISM_SUBSTANCE", 57, 85], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 87, 104], ["throat swab", "ORGANISM_SUBSTANCE", 106, 117], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 119, 142], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 144, 163], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 165, 175], ["nasal", "ORGANISM_SUBDIVISION", 177, 182], ["throat", "ORGANISM_SUBDIVISION", 187, 193], ["swabs", "ORGANISM_SUBSTANCE", 194, 199], ["pleural fluid", "ORGANISM_SUBSTANCE", 205, 218], ["The respiratory samples", "TEST", 0, 23], ["bronchoalveolar lavage", "TEST", 33, 55], ["endotracheal tube secretions", "TEST", 57, 85], ["tracheal aspirate", "TEST", 87, 104], ["throat swab", "TEST", 106, 117], ["nasopharyngeal aspirate", "TEST", 119, 142], ["nasopharyngeal swab", "TEST", 144, 163], ["nasal swab", "TEST", 165, 175], ["nasal and throat swabs", "TEST", 177, 199], ["pleural fluid", "PROBLEM", 205, 218], ["respiratory", "ANATOMY", 4, 15], ["bronchoalveolar lavage", "OBSERVATION", 33, 55], ["endotracheal tube", "OBSERVATION", 57, 74], ["secretions", "OBSERVATION", 75, 85], ["tracheal", "ANATOMY", 87, 95], ["aspirate", "OBSERVATION", 96, 104], ["throat", "ANATOMY", 106, 112], ["nasopharyngeal", "ANATOMY", 119, 133], ["aspirate", "OBSERVATION", 134, 142], ["nasopharyngeal", "ANATOMY", 144, 158], ["nasal", "ANATOMY", 165, 170], ["nasal", "ANATOMY", 177, 182], ["throat", "ANATOMY", 187, 193], ["pleural", "ANATOMY", 205, 212], ["fluid", "OBSERVATION", 213, 218]]], ["All respiratory samples were collected after obtaining written informed consent from patients.", [["respiratory samples", "ANATOMY", 4, 23], ["respiratory samples", "CANCER", 4, 23], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["All respiratory samples", "TEST", 0, 23], ["respiratory", "ANATOMY", 4, 15]]], ["The ethical permission on this research study was granted by the Ethical Decision Committee of the Research Administration, Faculty of Medicine, Kuwait University.Viral RNA ExtractionThe hMPV RNA extraction was done using the automated nucleic acid extraction method, MagNA Pure LC 2.0 (Roche Diagnostics Ltd, Rotkreuz, Switzerland).", [["nucleic acid", "CHEMICAL", 236, 248], ["hMPV", "ORGANISM", 187, 191], ["Viral RNA", "RNA", 163, 172], ["hMPV RNA", "RNA", 187, 195], ["hMPV", "SPECIES", 187, 191], ["this research study", "TEST", 26, 45], ["Viral RNA Extraction", "TREATMENT", 163, 183], ["The hMPV RNA extraction", "TREATMENT", 183, 206], ["the automated nucleic acid extraction method", "TREATMENT", 222, 266], ["MagNA Pure LC", "TEST", 268, 281], ["RNA Extraction", "OBSERVATION", 169, 183]]], ["All 460 respiratory samples were extracted using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Applied Science, Mannheim, Germany) according to the manufacturer's instruction.Real-Time RT-PCR for Detection of hMPV RNAThe hMPV RNA was detected using a commercial real-time PCR detection assay that amplifies the hMPV nucleoprotein gene (PrimerDesign, Primer-Design TM Ltd, Southampton, Hants, UK), in combination with the AgPath-ID TM one-step RT-PCR mix reagent (Ambion, Applied Biosystems, Austin, TX).", [["respiratory samples", "ANATOMY", 8, 27], ["hMPV", "ORGANISM", 221, 225], ["hMPV", "ORGANISM", 233, 237], ["hMPV", "ORGANISM", 323, 327], ["UK", "GENE_OR_GENE_PRODUCT", 404, 406], ["hMPV RNAThe hMPV RNA", "RNA", 221, 241], ["hMPV nucleoprotein gene", "DNA", 323, 346], ["AgPath", "DNA", 433, 439], ["hMPV", "SPECIES", 221, 225], ["hMPV", "SPECIES", 233, 237], ["hMPV", "SPECIES", 323, 327], ["the MagNA Pure LC", "TREATMENT", 49, 66], ["Total Nucleic Acid Isolation", "TREATMENT", 67, 95], ["hMPV RNAThe hMPV RNA", "PROBLEM", 221, 241], ["PCR detection assay", "TEST", 284, 303], ["the AgPath", "TREATMENT", 429, 439], ["ID TM", "TREATMENT", 440, 445], ["PCR mix reagent", "TREATMENT", 458, 473]]], ["RT-PCR master mix was prepared on ice by adding 12.5 ml of 2\u00c2 RT-PCR buffer, 1.5 ml of the pathogen specific primer/probe mix, 1 ml of 25\u00c2 RT-PCR enzyme mix, 4 ml nuclease-free water, and 6 ml of the extracted RNA sample.", [["nuclease", "PROTEIN", 163, 171], ["RT-PCR master mix", "TREATMENT", 0, 17], ["2\u00c2 RT-PCR buffer", "TREATMENT", 59, 75], ["the pathogen specific primer/probe mix", "TREATMENT", 87, 125], ["RT-PCR enzyme mix", "TREATMENT", 139, 156]]], ["The Applied Biosystem 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) was used for hMPV detection according to the following cycling: 458C for 10 min, 958C for 10 min, 50 cycles of 958C for 15 sec, and 608C for 60 sec.Detection of Other Respiratory Viruses by PCRIn addition to the hMPV detection, all samples were also tested for other respiratory viruses as described elsewhere [Khadadah et al., 2010] .", [["samples", "ANATOMY", 323, 330], ["respiratory viruses", "DISEASE", 358, 377], ["hMPV", "ORGANISM", 104, 108], ["hMPV", "ORGANISM", 303, 307], ["samples", "CANCER", 323, 330], ["hMPV", "SPECIES", 104, 108], ["hMPV", "SPECIES", 303, 307], ["Biosystem", "TEST", 12, 21], ["hMPV detection", "TEST", 104, 118], ["Other Respiratory Viruses", "PROBLEM", 252, 277], ["the hMPV detection", "TEST", 299, 317], ["all samples", "TEST", 319, 330], ["other respiratory viruses", "PROBLEM", 352, 377], ["Respiratory Viruses", "OBSERVATION", 258, 277], ["respiratory viruses", "OBSERVATION", 358, 377]]], ["Briefly, a single PCR was used to detect adenovirus and parainfluenza virus-2 (PIV-2); duplex PCR was carried out to detect influenza A and B viruses; triplex PCR was carried out to detect respiratory syncytial virus (RSV), parainfluenza viruses (PIV) -1 and -3, and another triplex PCR was performed to detect human rhinovirus, human coronaviruses-229E and -OC43 [Khadadah et al., 2010] .Genotyping of Detected hMPV RNAA set of degenerate primers was selected on the basis of sequences published by Mackay et al. [2003] (forward primer hMPVF; 5 0 -AAYMGWGTRYTAAG-TGATGCRCTC-3 0 , nucleotide position 601-624, and reverse primer hMPVR; 5 0 -CAKTGTYTGRCCRGCH-CCRTAA-3 0 , nucleotide position 792-813) to amplify the N gene (hMPV isolate 00-1, GenBank accession number under AF371337).", [["respiratory syncytial virus", "DISEASE", 189, 216], ["parainfluenza viruses", "DISEASE", 224, 245], ["nucleotide", "CHEMICAL", 671, 681], ["adenovirus", "ORGANISM", 41, 51], ["parainfluenza virus-2", "ORGANISM", 56, 77], ["PIV-2", "ORGANISM", 79, 84], ["B viruses", "ORGANISM", 140, 149], ["respiratory syncytial virus", "ORGANISM", 189, 216], ["RSV", "ORGANISM", 218, 221], ["parainfluenza viruses", "ORGANISM", 224, 245], ["(PIV) -1", "GENE_OR_GENE_PRODUCT", 246, 254], ["-3", "GENE_OR_GENE_PRODUCT", 259, 261], ["human", "ORGANISM", 311, 316], ["rhinovirus", "ORGANISM", 317, 327], ["human", "ORGANISM", 329, 334], ["coronaviruses-229E", "ORGANISM", 335, 353], ["hMPV", "ORGANISM", 412, 416], ["TGATGCRCTC-3 0", "DNA", 564, 578], ["nucleotide position 601-624", "DNA", 581, 608], ["reverse primer hMPVR", "DNA", 614, 634], ["CCRTAA-3 0", "DNA", 658, 668], ["nucleotide position 792-813", "DNA", 671, 698], ["N gene", "DNA", 715, 721], ["parainfluenza virus-2", "SPECIES", 56, 77], ["respiratory syncytial virus", "SPECIES", 189, 216], ["parainfluenza", "SPECIES", 224, 237], ["human", "SPECIES", 311, 316], ["rhinovirus", "SPECIES", 317, 327], ["human", "SPECIES", 329, 334], ["parainfluenza virus-2", "SPECIES", 56, 77], ["influenza A", "SPECIES", 124, 135], ["B viruses", "SPECIES", 140, 149], ["respiratory syncytial virus", "SPECIES", 189, 216], ["RSV", "SPECIES", 218, 221], ["parainfluenza viruses", "SPECIES", 224, 245], ["human rhinovirus", "SPECIES", 311, 327], ["human coronaviruses-229E", "SPECIES", 329, 353], ["hMPV", "SPECIES", 412, 416], ["a single PCR", "TEST", 9, 21], ["adenovirus", "PROBLEM", 41, 51], ["parainfluenza virus", "PROBLEM", 56, 75], ["PIV", "TEST", 79, 82], ["duplex PCR", "TEST", 87, 97], ["influenza A and B viruses", "PROBLEM", 124, 149], ["triplex PCR", "TEST", 151, 162], ["respiratory syncytial virus", "PROBLEM", 189, 216], ["RSV", "TEST", 218, 221], ["parainfluenza viruses", "PROBLEM", 224, 245], ["PIV", "TEST", 247, 250], ["another triplex PCR", "TEST", 267, 286], ["human rhinovirus", "PROBLEM", 311, 327], ["human coronaviruses", "TEST", 329, 348], ["Genotyping", "TEST", 389, 399], ["degenerate primers", "PROBLEM", 429, 447], ["hMPVF", "TEST", 537, 542], ["AAYMGWGTRYTAAG", "TEST", 549, 563], ["TGATGCRCTC", "TEST", 564, 574], ["nucleotide position", "TEST", 581, 600], ["hMPVR", "TEST", 629, 634], ["CAKTGTYTGRCCRGCH", "TEST", 641, 657], ["CCRTAA", "TEST", 658, 664], ["nucleotide position", "TEST", 671, 690], ["the N gene (hMPV isolate", "TREATMENT", 711, 735], ["respiratory syncytial", "ANATOMY", 189, 210]]], ["The RT-PCR was performed using the Qiagen One-Step RT-PCR Kit (Qiagen, Hilden, Germany).", [["The RT-PCR", "TEST", 0, 10], ["the Qiagen", "TREATMENT", 31, 41]]], ["The reaction mixture was exposed to a 30 min, 458C reverse transcription incubation, and then 40 cycles of 948C for 20 sec, 508C for 20 sec, and 688C for 20 sec, with a final 688C extension for 7 min using the GeneAmp 1 PCR System 9700 (Applied Biosystems).", [["948C", "CHEMICAL", 107, 111], ["The reaction mixture", "TREATMENT", 0, 20]]], ["The RT-PCR amplification reaction resulted in a 213-bp PCR product when separated by 2% agarose gel electrophoresis and visualized by ethidium bromide staining.Genotyping of Detected hMPV RNAThe PCR fragments were purified with QIAquick PCR purification columns as described by the manufacturer (Qiagen, Suite, Valencia), and both strands were directly sequenced with both hMPVF and hMPVR primers using the ABI PRISM 1 BigDye 1 Terminator Cycle Sequencing v3.1 Ready Reaction kit (Applied Biosystems).", [["ethidium bromide", "CHEMICAL", 134, 150], ["ethidium bromide", "CHEMICAL", 134, 150], ["agarose", "SIMPLE_CHEMICAL", 88, 95], ["ethidium bromide", "SIMPLE_CHEMICAL", 134, 150], ["hMPV", "ORGANISM", 183, 187], ["hMPV RNAThe PCR fragments", "DNA", 183, 208], ["hMPVF and hMPVR primers", "DNA", 373, 396], ["hMPV", "SPECIES", 183, 187], ["The RT-PCR amplification reaction", "TEST", 0, 33], ["bp PCR product", "TREATMENT", 52, 66], ["2% agarose gel electrophoresis", "TREATMENT", 85, 115], ["ethidium bromide staining", "PROBLEM", 134, 159], ["Genotyping", "TEST", 160, 170], ["Detected hMPV RNAThe PCR fragments", "PROBLEM", 174, 208], ["QIAquick PCR purification columns", "PROBLEM", 228, 261], ["hMPVR primers", "TREATMENT", 383, 396], ["the ABI PRISM", "TEST", 403, 416], ["Sequencing", "TEST", 445, 455]]], ["Labeled DNA fragments were separated and detected using ABI genetic analyzer 3130 (Applied Biosystems).", [["fragments", "ANATOMY", 12, 21], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["DNA fragments", "DNA", 8, 21], ["Labeled DNA fragments", "PROBLEM", 0, 21], ["ABI genetic analyzer", "TEST", 56, 76], ["fragments", "OBSERVATION", 12, 21]]], ["The obtained sequences were then analyzed for genotype identification using Basic Local Alignment Search Tool (BLAST) alignment from GenBank (http://www.ncbi.nlm.nih.gov/ Blast.cgi) and compared to sequences available from the GenBank database (GenBank accession numbers were as follows: Subgroup A1, AF371337; subgroup A2a, NC_004148, FJ168779, and AB503857; subgroup A2b, DQ843659, and GQ153651; subgroup B1, AY525843; and subgroup B2, DQ843658, AY297748, and FJ168778).Statistical AnalysisThe difference in the hMPV viral load between different groups of patients was assessed using Mann-Whitney and Kruskal-Wallis tests.", [["FJ168778", "CHEMICAL", 462, 470], ["FJ168778", "CHEMICAL", 462, 470], ["hMPV", "ORGANISM", 514, 518], ["patients", "ORGANISM", 558, 566], ["patients", "SPECIES", 558, 566], ["hMPV", "SPECIES", 514, 518], ["The obtained sequences", "TEST", 0, 22], ["genotype identification", "TEST", 46, 69], ["subgroup A2a", "TEST", 311, 323], ["NC", "TEST", 325, 327], ["subgroup A2b", "TEST", 360, 372], ["DQ843659", "TEST", 374, 382], ["Statistical Analysis", "TEST", 472, 492], ["the hMPV viral load", "PROBLEM", 510, 529], ["Kruskal-Wallis tests", "TEST", 603, 623]]], ["The significance of the difference in categorical variables among various groups was tested using the x 2 -test and Fisher exact test, as appropriate.", [["the difference in categorical variables", "PROBLEM", 20, 59], ["Fisher exact test", "TEST", 116, 133], ["difference", "OBSERVATION_MODIFIER", 24, 34]]], ["The statistical analysis was performed using SPSS v17.0 software (SPSS Inc., Chicago, IL).RESULTSThe clinical data of the study population is shown in Table I .", [["The statistical analysis", "TEST", 0, 24], ["SPSS v", "TEST", 45, 51], ["the study population", "TEST", 118, 138]]], ["All H1N1-negative respiratory samples were screened for hMPV and other respiratory viruses.", [["respiratory samples", "ANATOMY", 18, 37], ["respiratory viruses", "DISEASE", 71, 90], ["hMPV", "ORGANISM", 56, 60], ["hMPV", "SPECIES", 56, 60], ["All H1N1", "TEST", 0, 8], ["respiratory samples", "TEST", 18, 37], ["hMPV", "PROBLEM", 56, 60], ["other respiratory viruses", "PROBLEM", 65, 90], ["H1N1", "OBSERVATION", 4, 8], ["respiratory", "ANATOMY", 71, 82], ["viruses", "OBSERVATION", 83, 90]]], ["Table II shows that rhinovirus was the most detected virus in clinical respiratory specimens of patients with respiratory symptoms (6.3%), followed by hMPV (5%), respiratory syncytial virus (3%), and adenovirus (2.8%).", [["respiratory specimens", "ANATOMY", 71, 92], ["respiratory", "ANATOMY", 110, 121], ["respiratory symptoms", "DISEASE", 110, 130], ["hMPV", "DISEASE", 151, 155], ["respiratory syncytial virus", "DISEASE", 162, 189], ["rhinovirus", "ORGANISM", 20, 30], ["patients", "ORGANISM", 96, 104], ["hMPV", "ORGANISM", 151, 155], ["respiratory syncytial virus", "ORGANISM", 162, 189], ["adenovirus", "ORGANISM", 200, 210], ["patients", "SPECIES", 96, 104], ["respiratory syncytial virus", "SPECIES", 162, 189], ["hMPV", "SPECIES", 151, 155], ["respiratory syncytial virus", "SPECIES", 162, 189], ["adenovirus", "SPECIES", 200, 210], ["rhinovirus", "PROBLEM", 20, 30], ["respiratory symptoms", "PROBLEM", 110, 130], ["hMPV", "TEST", 151, 155], ["respiratory syncytial virus", "TEST", 162, 189], ["adenovirus", "PROBLEM", 200, 210], ["rhinovirus", "OBSERVATION", 20, 30], ["respiratory syncytial", "ANATOMY", 162, 183]]], ["Coronavirus-OC43 and parainfluenza virus type 2 were not detected.", [["Coronavirus-OC43", "ORGANISM", 0, 16], ["parainfluenza virus type 2", "ORGANISM", 21, 47], ["parainfluenza virus", "SPECIES", 21, 40], ["Coronavirus", "TEST", 0, 11], ["OC43", "PROBLEM", 12, 16], ["parainfluenza virus type 2", "PROBLEM", 21, 47], ["parainfluenza virus", "OBSERVATION", 21, 40]]], ["The prevalence of hMPV infection in patients with respiratory tract infections was 5.4%.", [["respiratory tract", "ANATOMY", 50, 67], ["hMPV infection", "DISEASE", 18, 32], ["respiratory tract infections", "DISEASE", 50, 78], ["hMPV", "ORGANISM", 18, 22], ["patients", "ORGANISM", 36, 44], ["tract", "ORGANISM_SUBDIVISION", 62, 67], ["patients", "SPECIES", 36, 44], ["hMPV", "SPECIES", 18, 22], ["hMPV infection", "PROBLEM", 18, 32], ["respiratory tract infections", "PROBLEM", 50, 78], ["hMPV", "OBSERVATION_MODIFIER", 18, 22], ["infection", "OBSERVATION", 23, 32], ["respiratory tract", "ANATOMY", 50, 67]]], ["Human metapneumovirus was also found in the presence of rhinovirus in three patients (1%), and adenovirus in one patient (0.3%), with a co-infection rate of 1%.RESULTSThe hMPV-positive patients were segregated according to their sex, age, and intensive care unit/ ward admission (Table III) .", [["Human metapneumovirus", "DISEASE", 0, 21], ["Human", "ORGANISM", 0, 5], ["metapneumovirus", "ORGANISM", 6, 21], ["rhinovirus", "ORGANISM", 56, 66], ["patients", "ORGANISM", 76, 84], ["adenovirus", "ORGANISM", 95, 105], ["patient", "ORGANISM", 113, 120], ["hMPV", "ORGANISM", 171, 175], ["patients", "ORGANISM", 185, 193], ["Human", "SPECIES", 0, 5], ["metapneumovirus", "SPECIES", 6, 21], ["patients", "SPECIES", 76, 84], ["patient", "SPECIES", 113, 120], ["patients", "SPECIES", 185, 193], ["Human metapneumovirus", "SPECIES", 0, 21], ["adenovirus", "SPECIES", 95, 105], ["Human metapneumovirus", "PROBLEM", 0, 21], ["rhinovirus", "PROBLEM", 56, 66], ["adenovirus", "PROBLEM", 95, 105], ["a co-infection rate", "TEST", 134, 153], ["RESULTSThe hMPV", "TEST", 160, 175], ["metapneumovirus", "OBSERVATION", 6, 21], ["rhinovirus", "OBSERVATION", 56, 66], ["co-infection", "OBSERVATION", 136, 148]]], ["The overall proportion of hMPV infection in females was 7% (n \u00bc 13) and that in males was 4% (n \u00bc 8) (P \u00bc 0.13).", [["hMPV infection", "DISEASE", 26, 40], ["hMPV", "ORGANISM", 26, 30], ["hMPV", "SPECIES", 26, 30], ["hMPV infection", "PROBLEM", 26, 40], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["proportion", "OBSERVATION_MODIFIER", 12, 22], ["hMPV", "OBSERVATION_MODIFIER", 26, 30], ["infection", "OBSERVATION", 31, 40]]], ["Most of the hMPV-positive patients (76%) were infants having less than 2 years, while 24% of them were patients having 59 years and above, and the overall prevalence of hMPV infection in infants and elderly was 11 and 8%, respectively.", [["hMPV infection", "DISEASE", 169, 183], ["hMPV", "ORGANISM", 12, 16], ["patients", "ORGANISM", 26, 34], ["infants", "ORGANISM", 46, 53], ["patients", "ORGANISM", 103, 111], ["hMPV", "ORGANISM", 169, 173], ["infants", "ORGANISM", 187, 194], ["patients", "SPECIES", 26, 34], ["infants", "SPECIES", 46, 53], ["patients", "SPECIES", 103, 111], ["infants", "SPECIES", 187, 194], ["hMPV", "SPECIES", 169, 173], ["the hMPV", "TEST", 8, 16], ["hMPV infection", "PROBLEM", 169, 183], ["hMPV", "OBSERVATION_MODIFIER", 169, 173], ["infection", "OBSERVATION", 174, 183]]], ["The hMPV infection was not detected among children aged more than 2 years and adults aged less than 59 years.", [["hMPV infection", "DISEASE", 4, 18], ["hMPV", "ORGANISM", 4, 8], ["children", "ORGANISM", 42, 50], ["children", "SPECIES", 42, 50], ["hMPV", "SPECIES", 4, 8], ["The hMPV infection", "PROBLEM", 0, 18], ["hMPV", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 9, 18]]], ["Most of the hMPV-positive patients (90%) were admitted to the intensive care unit; the overall proportion of hMPV infection in patients admitted to intensive care unit was 8%.", [["hMPV infection", "DISEASE", 109, 123], ["hMPV", "ORGANISM", 12, 16], ["patients", "ORGANISM", 26, 34], ["hMPV", "ORGANISM", 109, 113], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 127, 135], ["hMPV", "SPECIES", 109, 113], ["the hMPV", "TEST", 8, 16], ["hMPV infection", "PROBLEM", 109, 123], ["hMPV infection", "OBSERVATION", 109, 123]]], ["The hMPV was only detected in the following types of respiratory samples: Endotracheal tube secretions (30%), tracheal aspirate (30%), nasopharyngeal aspirate (30%), and nasopharyngeal swab (10%).", [["respiratory samples", "ANATOMY", 53, 72], ["Endotracheal tube secretions", "ANATOMY", 74, 102], ["tracheal aspirate", "ANATOMY", 110, 127], ["nasopharyngeal aspirate", "ANATOMY", 135, 158], ["nasopharyngeal swab", "ANATOMY", 170, 189], ["hMPV", "ORGANISM", 4, 8], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 110, 127], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 135, 158], ["nasopharyngeal swab", "CANCER", 170, 189], ["hMPV", "SPECIES", 4, 8], ["The hMPV", "PROBLEM", 0, 8], ["respiratory samples", "TEST", 53, 72], ["Endotracheal tube secretions", "TEST", 74, 102], ["tracheal aspirate", "TEST", 110, 127], ["nasopharyngeal aspirate", "TEST", 135, 158], ["nasopharyngeal swab", "TEST", 170, 189], ["hMPV", "OBSERVATION", 4, 8], ["Endotracheal tube", "OBSERVATION", 74, 91], ["tracheal", "ANATOMY", 110, 118], ["aspirate", "OBSERVATION", 119, 127], ["nasopharyngeal", "ANATOMY", 135, 149], ["aspirate", "OBSERVATION", 150, 158], ["nasopharyngeal swab", "ANATOMY", 170, 189]]], ["The difference in the hMPV RNA load among different types of respiratory samples was not significant.", [["respiratory samples", "ANATOMY", 61, 80], ["hMPV", "ORGANISM", 22, 26], ["hMPV RNA", "RNA", 22, 30], ["hMPV", "SPECIES", 22, 26], ["the hMPV RNA load", "PROBLEM", 18, 35], ["respiratory samples", "TEST", 61, 80], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["hMPV RNA load", "OBSERVATION", 22, 35], ["respiratory samples", "OBSERVATION", 61, 80]]], ["All hMPV-positive patients had lower respiratory tract infections with high detectable RNA load.", [["lower respiratory tract", "ANATOMY", 31, 54], ["respiratory tract infections", "DISEASE", 37, 65], ["hMPV", "ORGANISM", 4, 8], ["patients", "ORGANISM", 18, 26], ["respiratory tract", "ORGANISM_SUBDIVISION", 37, 54], ["patients", "SPECIES", 18, 26], ["hMPV", "SPECIES", 4, 8], ["All hMPV", "TEST", 0, 8], ["lower respiratory tract infections", "PROBLEM", 31, 65], ["high detectable RNA load", "PROBLEM", 71, 95], ["hMPV", "OBSERVATION", 4, 8], ["positive", "OBSERVATION_MODIFIER", 9, 17], ["lower", "ANATOMY_MODIFIER", 31, 36], ["respiratory tract", "ANATOMY", 37, 54], ["infections", "OBSERVATION", 55, 65], ["high detectable", "OBSERVATION_MODIFIER", 71, 86], ["RNA load", "OBSERVATION", 87, 95]]], ["All elderly patients (n \u00bc 5) had pneumonia, while 50% (n \u00bc 8) of infants less than 2 years had bronchopneumonia, 25% (n \u00bc 4) had pneumonia, and 13% (n \u00bc 2) had acute exacerbation of bronchial asthma.", [["bronchial", "ANATOMY", 182, 191], ["pneumonia", "DISEASE", 33, 42], ["bronchopneumonia", "DISEASE", 95, 111], ["pneumonia", "DISEASE", 129, 138], ["bronchial asthma", "DISEASE", 182, 198], ["patients", "ORGANISM", 12, 20], ["infants", "ORGANISM", 65, 72], ["patients", "SPECIES", 12, 20], ["infants", "SPECIES", 65, 72], ["pneumonia", "PROBLEM", 33, 42], ["bronchopneumonia", "PROBLEM", 95, 111], ["pneumonia", "PROBLEM", 129, 138], ["acute exacerbation", "PROBLEM", 160, 178], ["bronchial asthma", "PROBLEM", 182, 198], ["pneumonia", "OBSERVATION", 33, 42], ["bronchopneumonia", "OBSERVATION", 95, 111], ["pneumonia", "OBSERVATION", 129, 138], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["exacerbation", "OBSERVATION", 166, 178], ["bronchial", "ANATOMY", 182, 191], ["asthma", "OBSERVATION", 192, 198]]], ["The median hMPV RNA load for each group of patients according to their clinical data was as the following: 1.76 \u00c2 10 6 copies/ml for patients with pneumonia, 4.08 \u00c2 10 7 copies/ml for patients with bronchopneumonia, and 2.31 \u00c2 10 8 copies/ml for patients presented with acute exacerbation of bronchial asthma.", [["bronchial", "ANATOMY", 292, 301], ["pneumonia", "DISEASE", 147, 156], ["bronchopneumonia", "DISEASE", 198, 214], ["bronchial asthma", "DISEASE", 292, 308], ["hMPV", "ORGANISM", 11, 15], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 184, 192], ["patients", "ORGANISM", 246, 254], ["hMPV RNA", "RNA", 11, 19], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 184, 192], ["patients", "SPECIES", 246, 254], ["hMPV", "SPECIES", 11, 15], ["The median hMPV RNA load", "TREATMENT", 0, 24], ["pneumonia", "PROBLEM", 147, 156], ["bronchopneumonia", "PROBLEM", 198, 214], ["acute exacerbation", "PROBLEM", 270, 288], ["bronchial asthma", "PROBLEM", 292, 308], ["pneumonia", "OBSERVATION", 147, 156], ["bronchopneumonia", "OBSERVATION", 198, 214], ["acute", "OBSERVATION_MODIFIER", 270, 275], ["exacerbation", "OBSERVATION", 276, 288], ["bronchial", "ANATOMY", 292, 301], ["asthma", "OBSERVATION", 302, 308]]], ["In addition, one patient with bronchiolitis had hMPV RNA load of 7.68 \u00c2 10 7 copies/ml, and one with respiratory distress had 4.48 \u00c2 10 6 copies/ml.", [["respiratory", "ANATOMY", 101, 112], ["bronchiolitis", "DISEASE", 30, 43], ["respiratory distress", "DISEASE", 101, 121], ["patient", "ORGANISM", 17, 24], ["hMPV", "ORGANISM", 48, 52], ["patient", "SPECIES", 17, 24], ["hMPV", "SPECIES", 48, 52], ["bronchiolitis", "PROBLEM", 30, 43], ["hMPV RNA load", "TEST", 48, 61], ["respiratory distress", "PROBLEM", 101, 121], ["bronchiolitis", "OBSERVATION", 30, 43], ["respiratory distress", "OBSERVATION", 101, 121]]], ["The difference in the viral load between each group of patients with lower respiratory tract infection was not significant (P \u00bc 0.55).", [["lower respiratory tract", "ANATOMY", 69, 92], ["respiratory tract infection", "DISEASE", 75, 102], ["patients", "ORGANISM", 55, 63], ["lower", "ORGANISM_SUBDIVISION", 69, 74], ["respiratory tract", "ORGANISM_SUBDIVISION", 75, 92], ["patients", "SPECIES", 55, 63], ["the viral load", "TEST", 18, 32], ["lower respiratory tract infection", "PROBLEM", 69, 102], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["viral load", "OBSERVATION", 22, 32], ["lower", "ANATOMY_MODIFIER", 69, 74], ["respiratory tract", "ANATOMY", 75, 92], ["infection", "OBSERVATION", 93, 102]]], ["The median hMPV RNA load in infants aged 2 years and below (9.48 \u00c2 10 6 copies/ml) was not statistically different from that in old patients aged 59 years and above (1.31 \u00c2 10 7 copies/ml) (P \u00bc 0.89).", [["hMPV", "ORGANISM", 11, 15], ["infants", "ORGANISM", 28, 35], ["patients", "ORGANISM", 132, 140], ["hMPV RNA", "RNA", 11, 19], ["infants", "SPECIES", 28, 35], ["patients", "SPECIES", 132, 140], ["hMPV", "SPECIES", 11, 15], ["The median hMPV RNA load", "PROBLEM", 0, 24], ["median hMPV", "OBSERVATION", 4, 15], ["RNA load", "OBSERVATION", 16, 24]]], ["The genotype of hMPV RNA detected was identified by direct sequencing.", [["hMPV", "ORGANISM", 16, 20], ["hMPV RNA", "RNA", 16, 24], ["hMPV", "SPECIES", 16, 20], ["hMPV RNA", "PROBLEM", 16, 24], ["direct sequencing", "TEST", 52, 69], ["hMPV RNA", "OBSERVATION", 16, 24]]], ["Eleven hMPV RT-PCR products could be sequenced showing high similarity with hMPV sequences available in the GenBank database.", [["hMPV", "ORGANISM", 7, 11], ["hMPV", "ORGANISM", 76, 80], ["hMPV RT-PCR products", "DNA", 7, 27], ["hMPV sequences", "DNA", 76, 90], ["hMPV", "SPECIES", 7, 11], ["hMPV", "SPECIES", 76, 80], ["Eleven hMPV RT-PCR products", "TEST", 0, 27], ["hMPV sequences", "TEST", 76, 90]]], ["Two hMPV genotypes were detected, A subgroup 2b and B subgroup 2; although genotype B2 was more prevalent than A2b (Table IV) .", [["hMPV", "ORGANISM", 4, 8], ["Two hMPV genotypes", "PROBLEM", 0, 18], ["genotype B2", "TEST", 75, 86], ["hMPV", "OBSERVATION", 4, 8]]], ["The hMPV infection was detected during winter and spring seasons ( Fig. 1) , with high incidence rate in spring, and with very low incidence during summer (P \u00bc 0.005).DISSCUSSIONThis is the first study in Kuwait exploring the importance of hMPV infection among patients with respiratory tract infections in hospitals.", [["respiratory tract", "ANATOMY", 275, 292], ["hMPV infection", "DISEASE", 4, 18], ["hMPV infection", "DISEASE", 240, 254], ["respiratory tract infections", "DISEASE", 275, 303], ["hMPV", "ORGANISM", 4, 8], ["hMPV", "ORGANISM", 240, 244], ["patients", "ORGANISM", 261, 269], ["tract", "ORGANISM_SUBDIVISION", 287, 292], ["patients", "SPECIES", 261, 269], ["hMPV", "SPECIES", 4, 8], ["hMPV", "SPECIES", 240, 244], ["The hMPV infection", "PROBLEM", 0, 18], ["hMPV infection", "PROBLEM", 240, 254], ["respiratory tract infections", "PROBLEM", 275, 303], ["hMPV", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 9, 18], ["hMPV infection", "OBSERVATION", 240, 254], ["respiratory tract", "ANATOMY", 275, 292]]], ["Previous studies on hMPV infection have been published in the Middle East area however, most of them have focused on one age group, children less than 5 years [Al-Sonboli et al., 2005; Regev et al., 2006; Arabpour et al., 2008; Kaplan et al., 2008; Ali et al., 2010; Moattari et al., 2010] .", [["hMPV infection", "DISEASE", 20, 34], ["hMPV", "ORGANISM", 20, 24], ["children", "ORGANISM", 132, 140], ["children", "SPECIES", 132, 140], ["hMPV", "SPECIES", 20, 24], ["Previous studies", "TEST", 0, 16], ["hMPV infection", "PROBLEM", 20, 34], ["infection", "OBSERVATION", 25, 34], ["Middle", "ANATOMY_MODIFIER", 62, 68], ["Ali", "ANATOMY", 249, 252]]], ["Not surprising, most of respiratory samples collected in this study were from infants less than 2 years, showing that the most affected age group vulnerable for respiratory infections is infants.", [["respiratory samples", "ANATOMY", 24, 43], ["respiratory", "ANATOMY", 161, 172], ["respiratory infections", "DISEASE", 161, 183], ["infants", "ORGANISM", 78, 85], ["infants", "ORGANISM", 187, 194], ["infants", "SPECIES", 78, 85], ["infants", "SPECIES", 187, 194], ["respiratory samples", "TEST", 24, 43], ["this study", "TEST", 57, 67], ["respiratory infections", "PROBLEM", 161, 183], ["infections", "OBSERVATION", 173, 183]]], ["Infants are considered to be at high risk for respiratory infections, since their immunity system is being progressively developed during their first 2 years [File, 2000] .", [["respiratory", "ANATOMY", 46, 57], ["respiratory infections", "DISEASE", 46, 68], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["respiratory infections", "PROBLEM", 46, 68], ["respiratory", "ANATOMY", 46, 57], ["infections", "OBSERVATION", 58, 68]]], ["Respiratory infections are considered as a major cause of morbidity and mortality in developing countries [Campbell, 1995] , and this agrees with our observation that most of the respiratory samples (65%) were collected from patients admitted to the intensive care unit for acute lower respiratory tract infections.DISSCUSSIONIn the current study, rhinovirus was found to be the major cause of acute respiratory infections followed by hMPV and then respiratory syncytial virus.", [["Respiratory", "ANATOMY", 0, 11], ["respiratory samples", "ANATOMY", 179, 198], ["lower respiratory tract", "ANATOMY", 280, 303], ["respiratory", "ANATOMY", 400, 411], ["Respiratory infections", "DISEASE", 0, 22], ["lower respiratory tract infections", "DISEASE", 280, 314], ["respiratory infections", "DISEASE", 400, 422], ["respiratory syncytial virus", "DISEASE", 449, 476], ["respiratory samples", "CANCER", 179, 198], ["patients", "ORGANISM", 225, 233], ["lower", "ORGANISM_SUBDIVISION", 280, 285], ["respiratory tract", "ORGANISM_SUBDIVISION", 286, 303], ["rhinovirus", "ORGANISM", 348, 358], ["hMPV", "ORGANISM", 435, 439], ["respiratory syncytial virus", "ORGANISM", 449, 476], ["patients", "SPECIES", 225, 233], ["hMPV", "SPECIES", 435, 439], ["respiratory syncytial virus", "SPECIES", 449, 476], ["Respiratory infections", "PROBLEM", 0, 22], ["morbidity", "PROBLEM", 58, 67], ["the respiratory samples", "TEST", 175, 198], ["acute lower respiratory tract infections", "PROBLEM", 274, 314], ["the current study", "TEST", 329, 346], ["rhinovirus", "PROBLEM", 348, 358], ["acute respiratory infections", "PROBLEM", 394, 422], ["hMPV", "PROBLEM", 435, 439], ["respiratory syncytial virus", "PROBLEM", 449, 476], ["infections", "OBSERVATION", 12, 22], ["morbidity", "OBSERVATION", 58, 67], ["acute", "OBSERVATION_MODIFIER", 274, 279], ["lower", "ANATOMY_MODIFIER", 280, 285], ["respiratory tract", "ANATOMY", 286, 303], ["infections", "OBSERVATION", 304, 314], ["acute", "OBSERVATION_MODIFIER", 394, 399], ["respiratory", "ANATOMY", 400, 411], ["infections", "OBSERVATION", 412, 422], ["syncytial virus", "OBSERVATION", 461, 476]]], ["These results are in agreement with a previous study done in Kuwait showing that respiratory syncytial virus and human rhinovirus were the major cause of severe lower respiratory tract infections in Kuwait [Khadadah et al., 2010] .", [["lower respiratory tract", "ANATOMY", 161, 184], ["respiratory syncytial virus", "DISEASE", 81, 108], ["lower respiratory tract infections", "DISEASE", 161, 195], ["respiratory syncytial virus", "ORGANISM", 81, 108], ["human", "ORGANISM", 113, 118], ["rhinovirus", "ORGANISM", 119, 129], ["lower", "ORGANISM_SUBDIVISION", 161, 166], ["respiratory tract", "ORGANISM_SUBDIVISION", 167, 184], ["human", "SPECIES", 113, 118], ["rhinovirus", "SPECIES", 119, 129], ["respiratory syncytial virus", "SPECIES", 81, 108], ["human rhinovirus", "SPECIES", 113, 129], ["a previous study", "TEST", 36, 52], ["respiratory syncytial virus", "PROBLEM", 81, 108], ["human rhinovirus", "PROBLEM", 113, 129], ["severe lower respiratory tract infections", "PROBLEM", 154, 195], ["respiratory", "ANATOMY", 81, 92], ["syncytial virus", "OBSERVATION", 93, 108], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["lower", "ANATOMY_MODIFIER", 161, 166], ["respiratory tract", "ANATOMY", 167, 184], ["infections", "OBSERVATION", 185, 195]]], ["In addition, the best respiratory samples for hMPV detection were endotracheal tube secretions, tracheal aspirate, nasopharyngeal aspirate followed by nasopharyngeal swab, whereas hMPV RNA was not detected in throat swab, nasal swab, bronchoalveolar lavage and pleural fluid.", [["respiratory samples", "ANATOMY", 22, 41], ["endotracheal tube secretions", "ANATOMY", 66, 94], ["tracheal aspirate", "ANATOMY", 96, 113], ["nasopharyngeal aspirate", "ANATOMY", 115, 138], ["nasopharyngeal swab", "ANATOMY", 151, 170], ["throat swab", "ANATOMY", 209, 220], ["nasal swab", "ANATOMY", 222, 232], ["bronchoalveolar lavage", "ANATOMY", 234, 256], ["pleural fluid", "ANATOMY", 261, 274], ["hMPV", "ORGANISM", 46, 50], ["tube secretions", "ORGANISM_SUBSTANCE", 79, 94], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 96, 113], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 115, 138], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 151, 170], ["hMPV", "ORGANISM", 180, 184], ["throat swab", "ORGANISM_SUBSTANCE", 209, 220], ["nasal swab", "ORGANISM_SUBSTANCE", 222, 232], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 234, 256], ["pleural fluid", "ORGANISM_SUBSTANCE", 261, 274], ["hMPV RNA", "RNA", 180, 188], ["hMPV", "SPECIES", 46, 50], ["hMPV", "SPECIES", 180, 184], ["the best respiratory samples", "TEST", 13, 41], ["hMPV detection", "TEST", 46, 60], ["endotracheal tube secretions", "PROBLEM", 66, 94], ["tracheal aspirate", "TEST", 96, 113], ["nasopharyngeal aspirate", "TEST", 115, 138], ["nasopharyngeal swab", "TEST", 151, 170], ["hMPV RNA", "TEST", 180, 188], ["throat swab", "TEST", 209, 220], ["nasal swab", "TEST", 222, 232], ["bronchoalveolar lavage", "TEST", 234, 256], ["pleural fluid", "PROBLEM", 261, 274], ["endotracheal tube", "OBSERVATION", 66, 83], ["tracheal", "ANATOMY", 96, 104], ["aspirate", "OBSERVATION", 105, 113], ["nasopharyngeal", "ANATOMY", 115, 129], ["aspirate", "OBSERVATION", 130, 138], ["nasopharyngeal", "ANATOMY", 151, 165], ["nasal", "ANATOMY", 222, 227], ["bronchoalveolar lavage", "OBSERVATION", 234, 256], ["pleural", "ANATOMY", 261, 268], ["fluid", "OBSERVATION", 269, 274]]], ["This support earlier studies which recommended nasopharyngeal aspirate and swabs specimens for hMPV detection [Van den Hoogen et al., 2001 , 2004a .", [["nasopharyngeal aspirate", "ANATOMY", 47, 70], ["swabs specimens", "ANATOMY", 75, 90], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 47, 70], ["hMPV", "ORGANISM", 95, 99], ["hMPV", "SPECIES", 95, 99], ["earlier studies", "TEST", 13, 28], ["nasopharyngeal aspirate", "TEST", 47, 70], ["swabs specimens", "TEST", 75, 90], ["nasopharyngeal", "ANATOMY", 47, 61]]], ["The prevalence of hMPV infection among the study population was 5.4%.", [["hMPV infection", "DISEASE", 18, 32], ["hMPV", "ORGANISM", 18, 22], ["hMPV", "SPECIES", 18, 22], ["hMPV infection", "PROBLEM", 18, 32], ["the study population", "TEST", 39, 59], ["hMPV", "OBSERVATION_MODIFIER", 18, 22], ["infection", "OBSERVATION", 23, 32]]], ["Previous studies have reported that it accounts for at least 5 to 7% of the respiratory tract infections in hospitalized children, and at least 3% in the general community of patients who visit a general practitioner for respiratory tract infections [Van den Hoogen et al., 2004b] .", [["respiratory tract", "ANATOMY", 76, 93], ["respiratory tract", "ANATOMY", 221, 238], ["respiratory tract infections", "DISEASE", 76, 104], ["respiratory tract infections", "DISEASE", 221, 249], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["children", "ORGANISM", 121, 129], ["patients", "ORGANISM", 175, 183], ["tract", "ORGANISM_SUBDIVISION", 233, 238], ["children", "SPECIES", 121, 129], ["patients", "SPECIES", 175, 183], ["Previous studies", "TEST", 0, 16], ["the respiratory tract infections", "PROBLEM", 72, 104], ["respiratory tract infections", "PROBLEM", 221, 249], ["respiratory tract", "ANATOMY", 76, 93], ["infections", "OBSERVATION", 94, 104], ["respiratory tract", "ANATOMY", 221, 238]]], ["Most of the hMPV-positive patients were of age 2 years and less (76%), and of age 59 years and above (24%), and these results parallel most if not all studies that have shown that hMPV is a common disease in children and can cause severe infections in the elderly [Falsey et al., 2003; Wolf et al., 2003; Principi et al., 2006; Hermos et al., 2010] .", [["hMPV", "DISEASE", 180, 184], ["infections", "DISEASE", 238, 248], ["hMPV", "ORGANISM", 12, 16], ["patients", "ORGANISM", 26, 34], ["hMPV", "ORGANISM", 180, 184], ["children", "ORGANISM", 208, 216], ["patients", "SPECIES", 26, 34], ["children", "SPECIES", 208, 216], ["hMPV", "SPECIES", 180, 184], ["the hMPV", "TEST", 8, 16], ["all studies", "TEST", 147, 158], ["hMPV", "PROBLEM", 180, 184], ["severe infections", "PROBLEM", 231, 248], ["hMPV", "OBSERVATION", 180, 184], ["severe", "OBSERVATION_MODIFIER", 231, 237], ["infections", "OBSERVATION", 238, 248]]], ["In Qatar the hMPV virus was the most commonly detected virus, accounting for 74% of all respiratory infections among pediatric patients aged 1 month to 5 years, and this result is very similar to the current study finding that most of hMPV-positive patients were of age 2 years and less than 76% [Al-Thani et al., 2010] .", [["respiratory", "ANATOMY", 88, 99], ["respiratory infections", "DISEASE", 88, 110], ["hMPV-positive", "DISEASE", 235, 248], ["hMPV virus", "ORGANISM", 13, 23], ["patients", "ORGANISM", 127, 135], ["hMPV", "ORGANISM", 235, 239], ["patients", "ORGANISM", 249, 257], ["hMPV virus", "SPECIES", 13, 23], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 249, 257], ["hMPV virus", "SPECIES", 13, 23], ["hMPV", "SPECIES", 235, 239], ["the hMPV virus", "PROBLEM", 9, 23], ["all respiratory infections", "PROBLEM", 84, 110], ["the current study", "TEST", 196, 213], ["hMPV", "TEST", 235, 239], ["hMPV virus", "OBSERVATION", 13, 23], ["respiratory", "ANATOMY", 88, 99], ["infections", "OBSERVATION", 100, 110]]], ["Our results highlight the importance to introduce a screening test for hMPV infection in routine diagnosis, and to have appropriate medical management for hMPV-positive cases as other studies have recommended previously [Deffrasnes et al., 2007] .", [["hMPV infection", "DISEASE", 71, 85], ["hMPV", "ORGANISM", 71, 75], ["hMPV", "ORGANISM", 155, 159], ["hMPV", "SPECIES", 71, 75], ["hMPV", "SPECIES", 155, 159], ["a screening test", "TEST", 50, 66], ["hMPV infection", "PROBLEM", 71, 85], ["appropriate medical management", "TREATMENT", 120, 150], ["hMPV", "PROBLEM", 155, 159], ["other studies", "TEST", 178, 191]]], ["Moreover, the clinical data of hMPV-positive patients have shown that all elderly people presented with pneumonia mainly, while infants presented with a variety of clinical syndromes such as bronchopneumonia, pneumonia, acute exacerbation of bronchial asthma and bronchiolitis, a finding which has also been observed in previous studies [Boivin et al., 2002; Williams et al., 2004] .", [["bronchial", "ANATOMY", 242, 251], ["hMPV-positive", "DISEASE", 31, 44], ["pneumonia", "DISEASE", 104, 113], ["bronchopneumonia", "DISEASE", 191, 207], ["pneumonia", "DISEASE", 209, 218], ["bronchial asthma", "DISEASE", 242, 258], ["bronchiolitis", "DISEASE", 263, 276], ["hMPV", "ORGANISM", 31, 35], ["patients", "ORGANISM", 45, 53], ["people", "ORGANISM", 82, 88], ["infants", "ORGANISM", 128, 135], ["patients", "SPECIES", 45, 53], ["people", "SPECIES", 82, 88], ["infants", "SPECIES", 128, 135], ["the clinical data", "TEST", 10, 27], ["hMPV", "TEST", 31, 35], ["pneumonia", "PROBLEM", 104, 113], ["clinical syndromes", "PROBLEM", 164, 182], ["bronchopneumonia", "PROBLEM", 191, 207], ["pneumonia", "PROBLEM", 209, 218], ["acute exacerbation", "PROBLEM", 220, 238], ["bronchial asthma", "PROBLEM", 242, 258], ["bronchiolitis", "PROBLEM", 263, 276], ["previous studies", "TEST", 320, 336], ["pneumonia", "OBSERVATION", 104, 113], ["bronchopneumonia", "OBSERVATION", 191, 207], ["pneumonia", "OBSERVATION", 209, 218], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["exacerbation", "OBSERVATION_MODIFIER", 226, 238], ["bronchial", "ANATOMY", 242, 251], ["asthma", "OBSERVATION", 252, 258], ["bronchiolitis", "OBSERVATION", 263, 276]]], ["In this context, a study conducted on 10 elderly patients with underlying illness, has shown that four patients had developed pneumonitis and two have died due to hMPV infection [Boivin et al., 2002] .DISSCUSSIONOf the 23 hMPV-positive patients, three (1%) were also positive for rhinovirus and one (0.3%) was positive for adenovirus, with total co-infection rate of 1%.", [["pneumonitis", "DISEASE", 126, 137], ["hMPV infection", "DISEASE", 163, 177], ["hMPV-positive", "DISEASE", 222, 235], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 103, 111], ["hMPV", "ORGANISM", 163, 167], ["hMPV", "ORGANISM", 222, 226], ["patients", "ORGANISM", 236, 244], ["rhinovirus", "ORGANISM", 280, 290], ["adenovirus", "ORGANISM", 323, 333], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 236, 244], ["hMPV", "SPECIES", 163, 167], ["adenovirus", "SPECIES", 323, 333], ["a study", "TEST", 17, 24], ["underlying illness", "PROBLEM", 63, 81], ["pneumonitis", "PROBLEM", 126, 137], ["hMPV infection", "PROBLEM", 163, 177], ["hMPV", "TEST", 222, 226], ["rhinovirus", "PROBLEM", 280, 290], ["adenovirus", "PROBLEM", 323, 333], ["total co-infection rate", "TEST", 340, 363], ["pneumonitis", "OBSERVATION", 126, 137], ["infection", "OBSERVATION", 168, 177]]], ["Some previous reports have shown a co-infection of hMPV/respiratory syncytial virus, which correlated with the severity of infection [Greensill et al., 2003; Semple et al., 2005] .", [["hMPV/respiratory syncytial virus", "DISEASE", 51, 83], ["infection", "DISEASE", 123, 132], ["hMPV/respiratory syncytial virus", "ORGANISM", 51, 83], ["respiratory syncytial virus", "SPECIES", 56, 83], ["hMPV/respiratory syncytial virus", "SPECIES", 51, 83], ["a co-infection of hMPV/respiratory syncytial virus", "PROBLEM", 33, 83], ["infection", "PROBLEM", 123, 132], ["co-infection", "OBSERVATION", 35, 47], ["hMPV", "OBSERVATION", 51, 55], ["respiratory", "ANATOMY", 56, 67], ["syncytial virus", "OBSERVATION", 68, 83], ["infection", "OBSERVATION", 123, 132]]], ["On the other hand, other studies have shown that hMPV/respiratory syncytial virus coinfection may normally be rare in most populations [Mackay et al., 2006] , while some publications have failed to detect this co-infection [Esper et al., 2003; Al-Sonboli et al., 2006; Van Woensel et al., 2006 ].", [["hMPV/respiratory syncytial virus coinfection", "DISEASE", 49, 93], ["hMPV/respiratory syncytial virus", "ORGANISM", 49, 81], ["respiratory syncytial virus", "SPECIES", 54, 81], ["hMPV/respiratory syncytial virus", "SPECIES", 49, 81], ["other studies", "TEST", 19, 32], ["hMPV", "PROBLEM", 49, 53], ["respiratory syncytial virus coinfection", "PROBLEM", 54, 93], ["this co-infection", "PROBLEM", 205, 222], ["hMPV", "OBSERVATION", 49, 53], ["respiratory", "ANATOMY", 54, 65], ["syncytial virus", "OBSERVATION", 66, 81]]], ["Furthermore, some recent studies have found co-infection of hMPV with SARS-coronavirus and human bocavirus [Choi et al., 2006; Lee et al., 2007] .", [["hMPV", "DISEASE", 60, 64], ["SARS-coronavirus", "DISEASE", 70, 86], ["hMPV", "ORGANISM", 60, 64], ["SARS-coronavirus", "ORGANISM", 70, 86], ["human", "ORGANISM", 91, 96], ["bocavirus", "ORGANISM", 97, 106], ["coronavirus", "SPECIES", 75, 86], ["human", "SPECIES", 91, 96], ["hMPV", "SPECIES", 60, 64], ["SARS-coronavirus", "SPECIES", 70, 86], ["human", "SPECIES", 91, 96], ["some recent studies", "TEST", 13, 32], ["co-infection", "PROBLEM", 44, 56], ["hMPV", "PROBLEM", 60, 64], ["SARS", "PROBLEM", 70, 74], ["coronavirus", "PROBLEM", 75, 86]]], ["The coinfection of hMPV/rhinovirus might be responsible for the severe symptoms presented by our patients.", [["hMPV/rhinovirus", "DISEASE", 19, 34], ["hMPV", "ORGANISM", 19, 23], ["rhinovirus", "ORGANISM", 24, 34], ["patients", "ORGANISM", 97, 105], ["hMPV/rhinovirus", "SPECIES", 19, 34], ["patients", "SPECIES", 97, 105], ["hMPV/rhinovirus", "SPECIES", 19, 34], ["hMPV", "PROBLEM", 19, 23], ["rhinovirus", "PROBLEM", 24, 34], ["the severe symptoms", "PROBLEM", 60, 79], ["coinfection", "OBSERVATION", 4, 15], ["hMPV", "OBSERVATION", 19, 23], ["rhinovirus", "OBSERVATION", 24, 34]]], ["Indeed, one 2-years-old female had high hMPV RNA load (4.62 \u00c2 10 8 copies/ml) and presented with acute exacerbation of bronchial asthma.", [["bronchial", "ANATOMY", 119, 128], ["bronchial asthma", "DISEASE", 119, 135], ["female", "ORGANISM", 24, 30], ["hMPV", "ORGANISM", 40, 44], ["hMPV RNA", "RNA", 40, 48], ["hMPV", "SPECIES", 40, 44], ["high hMPV RNA load", "PROBLEM", 35, 53], ["acute exacerbation", "PROBLEM", 97, 115], ["bronchial asthma", "PROBLEM", 119, 135], ["high", "OBSERVATION_MODIFIER", 35, 39], ["hMPV RNA load", "OBSERVATION", 40, 53], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["exacerbation", "OBSERVATION", 103, 115], ["bronchial", "ANATOMY", 119, 128], ["asthma", "OBSERVATION", 129, 135]]], ["A male infant aged 2 months had recurrent chest infection with frequent intensive care unit admission, and his hMPV viral load was high (1.76 \u00c2 10 6 copies/ml).", [["chest", "ANATOMY", 42, 47], ["chest infection", "DISEASE", 42, 57], ["infant", "ORGANISM", 7, 13], ["chest", "ORGANISM_SUBDIVISION", 42, 47], ["hMPV", "ORGANISM", 111, 115], ["infant", "SPECIES", 7, 13], ["hMPV", "SPECIES", 111, 115], ["recurrent chest infection", "PROBLEM", 32, 57], ["his hMPV viral load", "TEST", 107, 126], ["chest", "ANATOMY", 42, 47], ["infection", "OBSERVATION", 48, 57]]], ["The last patient was a 1-year-old female with recurrent chest infection and frequent intensive care unit admission, and her hMPV RNA load was high (5.73 \u00c2 10 8 copies/ml).", [["chest", "ANATOMY", 56, 61], ["chest infection", "DISEASE", 56, 71], ["patient", "ORGANISM", 9, 16], ["female", "ORGANISM", 34, 40], ["chest", "ORGANISM_SUBDIVISION", 56, 61], ["hMPV", "ORGANISM", 124, 128], ["patient", "SPECIES", 9, 16], ["hMPV", "SPECIES", 124, 128], ["recurrent chest infection", "PROBLEM", 46, 71], ["her hMPV RNA load", "TEST", 120, 137], ["chest", "ANATOMY", 56, 61], ["infection", "OBSERVATION", 62, 71]]], ["This suggests that the presence of hMPV infection with other respiratory virus may complicate the clinical condition and prolong patient stay in the hospital, as it has been reported earlier [Greensill et al., 2003; Semple et al., 2005; Xiao et al., 2010] .", [["hMPV infection", "DISEASE", 35, 49], ["respiratory virus", "DISEASE", 61, 78], ["hMPV", "ORGANISM", 35, 39], ["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136], ["hMPV", "SPECIES", 35, 39], ["hMPV infection", "PROBLEM", 35, 49], ["other respiratory virus", "PROBLEM", 55, 78], ["hMPV", "OBSERVATION_MODIFIER", 35, 39], ["infection", "OBSERVATION", 40, 49], ["respiratory virus", "OBSERVATION", 61, 78]]], ["The high viral load of hMPV detected in our patients with lower respiratory tract infection may suggest a correlation between the severity of clinical symptoms and the virus replication rate, as described elsewhere [Boivin et al., 2002; Gerna et al., 2007; Bosis et al., 2008; Peng et al., 2010] .DISSCUSSIONThe detection of hMPV in the respiratory samples was confirmed by RT-PCR and sequencing of the hMPV N gene as described earlier [Mackay et al., 2003] .", [["lower respiratory tract", "ANATOMY", 58, 81], ["respiratory samples", "ANATOMY", 337, 356], ["hMPV", "DISEASE", 23, 27], ["respiratory tract infection", "DISEASE", 64, 91], ["hMPV", "ORGANISM", 23, 27], ["patients", "ORGANISM", 44, 52], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 58, 81], ["hMPV", "ORGANISM", 325, 329], ["hMPV", "ORGANISM", 403, 407], ["hMPV N gene", "DNA", 403, 414], ["patients", "SPECIES", 44, 52], ["hMPV", "SPECIES", 23, 27], ["hMPV", "SPECIES", 325, 329], ["The high viral load of hMPV", "PROBLEM", 0, 27], ["lower respiratory tract infection", "PROBLEM", 58, 91], ["clinical symptoms", "PROBLEM", 142, 159], ["the virus replication rate", "PROBLEM", 164, 190], ["hMPV", "PROBLEM", 325, 329], ["the respiratory samples", "TEST", 333, 356], ["RT-PCR", "TEST", 374, 380], ["high", "OBSERVATION_MODIFIER", 4, 8], ["viral load", "OBSERVATION", 9, 19], ["hMPV", "OBSERVATION", 23, 27], ["lower", "ANATOMY_MODIFIER", 58, 63], ["respiratory tract", "ANATOMY", 64, 81], ["infection", "OBSERVATION", 82, 91], ["hMPV", "OBSERVATION", 325, 329], ["respiratory", "ANATOMY", 337, 348]]], ["Sequence analysis has shown that both genotypes A and B circulate in Kuwait, with predominance of B2 subgroup.", [["B", "GENE_OR_GENE_PRODUCT", 54, 55], ["Sequence analysis", "TEST", 0, 17]]], ["Genotype A has been reported as the predominant genotype in respiratory samples [Bastien et al., 2003; Boivin et al., 2003; Maggi et al., 2003; Peiris et al., 2003] , but other studies have documented the presence of both genotypes A and B [Huck et al., 2006; Regev et al., 2006; Matsuzaki et al., 2008] .", [["respiratory samples", "ANATOMY", 60, 79], ["respiratory samples", "TEST", 60, 79], ["other studies", "TEST", 171, 184], ["respiratory", "ANATOMY", 60, 71]]], ["The seasonal distribution of hMPV infection during the year 2009 indicates that hMPV infection incidence is high in winter and peaks during spring with almost no infection detected during summer.", [["hMPV infection", "DISEASE", 29, 43], ["hMPV infection", "DISEASE", 80, 94], ["infection", "DISEASE", 162, 171], ["hMPV", "ORGANISM", 29, 33], ["hMPV", "ORGANISM", 80, 84], ["hMPV", "SPECIES", 29, 33], ["hMPV", "SPECIES", 80, 84], ["hMPV infection", "PROBLEM", 29, 43], ["hMPV infection incidence", "PROBLEM", 80, 104], ["infection", "PROBLEM", 162, 171], ["seasonal", "OBSERVATION_MODIFIER", 4, 12], ["distribution", "OBSERVATION_MODIFIER", 13, 25], ["hMPV infection", "OBSERVATION", 29, 43], ["hMPV", "OBSERVATION_MODIFIER", 80, 84], ["infection", "OBSERVATION", 85, 94], ["high", "OBSERVATION_MODIFIER", 108, 112], ["infection", "OBSERVATION", 162, 171]]], ["These results are not different from those of previous observations that have found high level of hMPV detection in the spring and winter months [Sugrue et al., 2008; Ali et al., 2010] .", [["hMPV", "ORGANISM", 98, 102], ["hMPV", "SPECIES", 98, 102], ["previous observations", "TEST", 46, 67], ["hMPV detection", "PROBLEM", 98, 112], ["hMPV", "OBSERVATION", 98, 102]]]]}